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Abstract 
Human papillomavirus (HPV) is a small double-stranded DNA (dsDNA) virus that 
infects mucosal and cutaneous epithelial tissues. Persistent infection with high-risk (HR) 
HPV is the main etiological agent in the development of cervical cancer worldwide. 
Although prophylactic vaccines against HPV are available, these preventative measures 
are type-specific and are ineffective against existing infections. Thus, there is a pressing 
need for antiviral drugs with a broad-spectrum activity against HPV to eradicate existing 
infections, no matter the subtype.  
Our group and collaborators have synthesized an extensive library of novel N-
methylpyrrole/N-methylimidazole (Py/Im) hairpin polyamides (PAs) with broad-
spectrum activities against three prevalent HR-HPV types (HPV16, HPV18 and HPV31) 
without apparent cytotoxicity. Py/Im hairpin polyamides are cell-permeable, synthetic 
DNA ligands and higher homologues of the natural antibiotics netropsin and distamycin 
A. Because Py/Im polyamides can be rationally designed to bind the minor groove of 
double-stranded DNA (dsDNA) in a sequence-dependent manner, these small molecules 
are attractive candidates as modulators of gene expression, as molecular probes for 
diagnostics and as antiviral agents for the selective elimination of dsDNA viruses. 
Despite the promise of applying these agents to treat HPV infections, much regarding 
their mechanism of action remains unexplained. Therefore, the overall goal of this 
dissertation is to investigate the DNA-binding properties of potent anti-HPV PAs under 
cell-free conditions and in HPV-harboring keratinocytes.  
Because PA-binding events impart structural perturbations to DNA, these DNA-
targeting agents can disrupt viral protein-DNA interactions in the viral genome and thus 
inhibit their functions. Consequently, displacement of viral proteins, as well as cellular 
transcription factors (TFs) and replication machinery, from their canonical binding sites 
on HPV would presumably lead to episomal instability followed by the elimination of the 
viral genome. Chapter 2 describes biophysical studies of anti-HPV hairpin polyamides 
(PA1 and PA25) using deoxyribonuclease I (DNase I) footprinting and affinity cleavage 
(AC) to interrogate the sequence specificity, binding sites and dissociation constants 
within the HPV18 Long Control Region (LCR). Analysis of the DNA-binding properties 
of PA1 and PA25 demonstrated that these anti-HPV polyamides bind avidly to the minor 
groove of A/T-rich sequences in the LCR of HPV18 with dissociation constants in the 
nanomolar range, and tolerate PA-DNA mismatches without a significant decrease in 
binding affinity. Chapter 3 extends these analyses to a new structural class of hairpin 
polyamides with tetramethylguanidinium (PA30) and guanidinium (PA31) substitutions 
on the N-terminus of PA1. In contrast to PA1 and PA30/PA31, PA25 has the ability to 
tolerate a higher number of PA-DNA mismatches and exhibits a more extended coverage 
of the LCR. Because the HPV LCR harbors the early promoter and regulatory sequences 
vital to HPV’s lifecycle, the improved antiviral activity of PA25 against HPV18 may 
arise from more abundant PA occupancy within vital protein binding sites in the LCR. 
Chapter 4 presents a detailed procedure to determine the genome-wide binding events of 
DNA-binding molecules in cell-free conditions using hydroxyl radical footprinting 
coupled to massively parallel DNA sequencing (·OH-Seq). As a proof of concept, a 
genome-wide binding map of PA1 across the supercoiled HPV16 episome is presented 
and compared against previously reported binding sites within the HPV16 LCR using 
DNase I footprinting with an automated capillary electrophoresis. The binding sites 
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obtained with ·OH-Seq are nearly identical to those observed in the capillary 
electrophoresis DNase I method within the HPV16 LCR. 
Because the viral genome is negatively supercoiled, compacted into a chromatin-like 
structure and associated with numerous viral and host proteins in vivo, some of the 
potential DNA-binding sequences may be inaccessible by polyamides. To this end, ·OH-
Seq and COSMIC-Seq (Chapter 5) have been employed to assess the binding 
occupancies of anti-HPV hairpin polyamides across the viral genomes in keratinocytes 
harboring HPV16 episomes.   
A deeper understanding of the molecular underpinnings of the ability of antiviral 
hairpin PAs to eliminate the HPV viral load may facilitate the development of a new 
generation of broad-spectrum antiviral treatments against this deadly virus.  
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Introduction to Human Papillomavirus and N-Methylpyrrole/N-Methylimidazole 
Hairpin Polyamides 
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1.1  HUMAN PAPILLOMAVIRUS (HPV) 
 
Human papillomavirus (HPV) is a small dsDNA virus with a predilection (tropism) 
toward basal keratinocytes of cutaneous and mucosal tissues.1 HPV is classified into five 
genera (α-, β-, γ-, μ-, ν-papillomavirus) within the Papillomaviridae family, and sub-
divided into types based on the genomic sequence of the major capsid protein.2,3 HPV 
infections remain a major health concern with most clinically important types belonging 
to the α-, β-, and γ-papillomavirus genera.3 HPV infections can lead to proliferative 
epithelial lesions, ranging from benign skin and genital warts to cancer development of 
the penis, anus, vagina, oropharynx, mouth and cervix.4-6 Accordingly, HPV types are 
classified as low- and high-risk (HR) based on their propensity to develop into malignant 
tumors.2,3 To date, over 180 types have been isolated of which approximately 15 
oncogenic types have been identified.7-9 The development of cervical cancer, the second 
most prevalent cancer affecting women worldwide, is closely associated with persistent 
infections of HR-HPV types.10-12 Specifically, HR-HPV DNA has been detected in 99.7 
% of cervical cancers, as well as in ~90 % of anal cancers and ~60 % of oropharyngeal 
(mouth and throat) cancers.5 In particular, HPV types 16 and 18 account for ~70 % of 
cervical cancer cases worldwide.13 Infection with HR-HPV is required, but not solely 
responsible, for the development of cervical cancer (Figure 1.1).6,10  
 
 
  
Most HPV infections are asymptomatic and are cleared by the immune system.14 In 
developed countries, the prevention of cervical cancer has benefited from screening 
programs and prophylactic vaccines,15 yet more than 35,000 HPV-related cancer cases 
were reported in 2009 in the United States alone.5 In third world countries, where these 
preventive measures are less available, HPV infections remain a significant health 
burden; the approximately 500,000 new cases diagnosed annually contribute to 290,000 
deaths within the same time frame.12  
 
Figure 1.1. Stages of Cervical Cancer Development and HPV Types Associated with Each Stage. The
development of cervical cancer, the second most prevalent cancer affecting women worldwide, is closely associated
with persistent infections of HPV types 16 and 18. Figure adapted from Crow 2012 (permission # 4087191013835). 
Nature 488, (7413) S2‐S3 
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1.2 HPV LIFECYCLE 
 
At the cellular level, infection is initiated through microlesions of cutaneous or 
mucosal epithelia, where the viral capsid can bind to its host receptor and gain entry to 
the basal cells.16 Entry of the virion is believed to occur through clathrin-dependent 
endocytosis by interactions of the viral L1 capsid protein with heparan sulfate and a 
second unidentified receptor (co-receptor) on the surface of basal epithelial cells.16,17    
Structurally, HPV is a non-enveloped virus whose closed-circular genome consists of 
roughly 8,000 base pairs of dsDNA that encode for eight well-characterized proteins. 
Based on their function within the lifecycle, the HPV genome can be divided into three 
regions: a late region (L), a non-coding region (LCR; long control region) and an early 
region (E) (Figure 1.2).18 The encoded non-structural proteins from the early region 
primarily serve regulatory functions including DNA replication, transcription, cell 
signaling and immune evasion. The HPV episome is protected by an icosahedral capsid 
composed of the late-region major capsid protein L1 and minor protein L2.19 L1 is 
necessary for the assembly of the virion and its genomic sequence serves as the basis for 
HPV type classification; L2 alone cannot assemble into a virion.19 Nonetheless, L2 is 
essential for viral infection as cleavage at its C-terminus allows for both endosomal 
escape and nuclear targeting of the viral DNA.17  
 
 
  
In its infectious cycle, HPV benefits from the normal differentiation of keratinocytes 
(Figure 1.3).20 Once the viral genome reaches the nucleus, it is maintained as a low-copy 
circular extrachromosomal DNA (episome) of ~50-100 copies/cell in an E1 and E2 
Figure 1.2. Characteristic Organization of the Mucosal High-Risk HPV Genome. Coding regions and functions for
each gene are given with their relative positions in the genome. The origin of replication (oriR), E2 (E2BS) and E1
(E1BS) binding sites within the LCR are illustrated above the map.          
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dependent manner.20 HPV DNA is compacted into a chromatin-like structure that is not 
as condensed as human chromatin, though the actual structure is a topic of active 
investigation. Expression of the early proteins (E6, E7, E1, E2, E4, E5) is minimal until 
the HPV-carrying keratinocytes begin differentiation, upon which expression is 
upregulated.18 This is advantageous to the virus because it allows HPV to remain 
undetected by the host immune system in the primitive compartment of the epithelium, as 
this compartment is in close proximity to stromal dendritic cells.20 As basal keratinocytes 
migrate to upper layers of the epithelium, where they terminally differentiate, they carry 
the viral payload which is amplified to a high-copy number of at least a thousand copies 
per cell.18,20 Because the viral infection is strictly intraepithelial, it produces no event that 
can be detected by the cell-mediated immune system such as inflammation21 or blood-
circulating antigens (viremia);22 thus, it has the ability to migrate and proliferate amongst 
the immediate epithelial tissue.20,22 In addition to these passive immunoevasion strategies, 
HPV has also evolved several active strategies to thwart the host immune system. For 
example, HPV infections inhibit the presentation of human leukocyte antigen (HLA) 
class I viral peptide complexes and dampen several pathways of the innate immune 
system.23-28 
The small genome of HPV only encodes for one enzyme, E1.29 The nuclear-localized 
E1 protein is the essential ATPase helicase of papillomaviruses that binds to HPV LCR 
after it is recruited by the DNA-binding E2 protein. The latter binds the major groove of 
the palindromic sequence ACCgN4cGGT (upper case designates required nucleotides, 
lower case represents preferred nucleotides, and N denotes no nucleotide preference) near 
the viral origin of replication (oriR).30,31 There, E1 recruits the host replication machinery 
to initiate viral DNA replication.1 E2 is also a transcription factor that tightly regulates, 
both positively and negatively, the expression of E6 and E7 oncoproteins.32 In addition, 
E2 is also important for proper viral episome segregation during cell division of infected 
cells.30,33 Because HPV has a tropism for basal keratinocytes, which eventually 
differentiate and exit the cell cycle, the oncogenic proteins E6 and E7 permit the reentry 
to S-phase which is necessary for proliferation and the synthesis of infectious particles.30 
To achieve this result, E6 orchestrates the ubiquitin-proteasomal degradation of p53, 
which evades the induction of apoptosis as a result of unscheduled S-phase reentry. The 
latter is promoted by the sequestration of the retinoblastoma (pRb) family of tumor 
suppressors upon E7 binding.16 Thus, integration of the E6 and E7 ORF into the host 
chromosome along with the loss of their transcription regulator (E2) leads to the 
overexpression of these oncoproteins, culminating in cancerous growth.12,16,34 
Virion packaging occurs in the upper layers of the epithelium, as the capsid-
associated L1 gene expression relies on the usage of rare mammalian codons.35,36 
Moreover, the late promoter region becomes more accessible to transcriptional factors as 
HPV31-infected cells differentiate.37 The release of progeny virions coincides with 
desquamation of keratinocytes; hence, virion release is not associated with a lytic phase.38 
These features are advantageous for immunoevasion as virion release occurs far from 
immunosurveillance compartments and circumvents the requirement of a viremic phase.36 
In this manner, the HPV lifecycle terminates with the release of new infectious particles 
that can infect naïve individuals (Figure 1.3).1  
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1.3 PREVENTATIVE MEASURES AND TREATMENTS AGAINST HPV 
INFECTIONS 
 
The late region capsid proteins, in particular L1, are the focus in the development of 
HPV vaccines.19,39 Three prophylactic vaccines have been successfully implemented to 
immunize at-risk individuals against HR-HPV16 and HR-HPV18 (Cervarix® developed 
by GlaxoSmith-Kline), these high-risk types plus low-risk HPV6 and HPV11 (Gardasil® 
developed by Merck)19,39,40 or all of these plus the HR-HPV types 31, 33, 45, 52 and 58 
(Gardasil 9® developed by Merck). With the addition of these five HR-HPV types, 
Gardasil 9® has the potential to prevent over 90 % of HPV-induced cancers.41 However, 
these preventative measures are type-specific and ineffective against existing infections.42 
Moreover, the prevention of cervical cancer has also benefited from Papanicolau (Pap) 
screening, which is responsible for an approximately 50 % reduction of cases in the 
developed world.15,43 Currently, the available therapies against HPV infections rely on 
the surgical excision and cryogenic destruction of infected tissues. Additionally, non-
surgical treatments that are exclusively approved against cutaneous infections are 
available. These include topical formulations with cytotoxic chemicals like 
trichloroacetic acid, anti-proliferative natural products such as podophyllotoxin, or 
immunomodulatory agents like imiquimod. However, these treatments are not HPV-
specific and are often associated with numerous negative side-effects including pain, 
bleeding, tissue scarring, and severe irritation of the treated area. Also, these therapeutic 
approaches are cytodestructive and relatively inefficient with high frequencies of viral 
recurrence.44  
Figure 1.3. HPV Lifecycle. HPV infection is initiated through microlesions of cutaneous or mucosal epithelia, where
the viral capsid binds to its host receptor. In the nucleus, it is maintained as a low-copy circular extrachromosomal
DNA of ~50-100 copies/cell in an E1 and E2 dependent manner, although replication mechanisms have also been
shown to not require these proteins. Expression of the early proteins (E6, E7, E1, E2, E4, E5) is minimal until the HPV-
carrying keratinocytes begin differentiation, upon which expression is upregulated. Virion packaging occurs in the
upper layers of the epithelium upon E4, L1 and L2 expression, and the released infectious particles can then infect
naïve individuals. Figure adapted from Stanley 2012 (permission to account #3001138983).  
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There is a pressing need for antiviral drugs with a broad-spectrum activity against the 
various HPV types that lack cytotoxicity. Most antiviral agents primarily target viral 
enzymes; however, HPV only encodes one enzyme (E1)29 and hijacks the host replication 
machinery to establish a productive infection. As a result, the development of novel 
HPV-specific antiviral therapies has been hindered due to the limited number of 
conventional targets. Therefore, our group and collaborators have pursued a novel 
strategy to eliminate viral loads of episome-harboring keratinocytes by targeting the HPV 
genome with hairpin polyamides.  
1.4 N-METHYLPYRROLE/N-METHYLIMIDAZOLE HAIRPIN POLYAMIDES 
(Py/Im PAs) 
 
The rational design of small molecules to selectively target predetermined DNA 
sequences is a major goal in the development of novel therapeutics. The ability to 
selectively regulate gene expression and DNA replication with limited toxicity has 
potential applications in the treatment of cancer and virus-associated diseases. N-
methylpyrrole/N-methylimidazole (Py/Im) hairpin polyamides (PAs) are synthetic 
heteroaromatic compounds inspired by the chemical structures of the natural antibiotics 
netropsin and distamycin A.45-50 These crescent-shaped molecules, collectively known as 
polyamides, bind with high affinity (nano- to picomolar dissociation constants) to the 
minor groove of dsDNA in a sequence-selective fashion.51-53  
The pioneering work from the Dickerson, Wemmer and Dervan groups, among 
others, provided the impetus and paved the way in the research area of sequence-selective 
DNA recognition by polyamide molecules. Initial efforts were focused on explaining the 
molecular origin of the specificity toward A/T-rich sequences exhibited by distamycin A 
and netropsin. These natural DNA ligands are composed of repeating N-methylpyrrole 
heterocycles linked by amide bonds and display a broad-spectrum of antibacterial, 
antiviral and antitumor activities. However, unlike their synthetic counterparts, they 
exhibit dramatic cytotoxicity, rendering them unfit for therapeutic applications.54-56 
Nonetheless, their ability to preferentially bind A/T-rich sequences in a non-intercalative 
manner has received considerable attention.46  
In the mid-1970s, Wells et al. proposed that the sequence preference of netropsin for 
A/T-rich DNA sequences was governed by steric interactions generated by the 2-amino 
group of guanine and stabilized by specific hydrogen bond interactions.57 About a decade 
later, these molecular interactions were confirmed by separate structural studies of 
netropsin-DNA complexes conducted by Dickerson and Patel; Dickerson et al. solved the 
X-ray crystal structure of a 1:1 complex of netropsin and DNA, whereas Patel et al. 
investigated this complex using NMR.46,58 These structural studies suggested that the 
crescent shape of netropsin provided the optimum fit with the inherent curvature of the 
minor groove of B-DNA, affording favorable van der Waals and hydrogen bond 
interactions. The narrowness of the minor groove in A/T-rich sequences and the optimal 
spacing of netropsin’s N-methylpyrrole building blocks were found to provide for 
specific bifurcated H-bonds to form between the amide NHs with the N3 of adenine and 
O2 of thymine in the floor of the minor groove of B-DNA (Figure 1.4). These 
interactions were suggested to be further stabilized by the electrostatic interactions 
afforded by the positive termini of netropsin and the negatively charged phosphates in the 
DNA backbone. However, the exclusion of G·C base pairs in the canonical recognition 
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sequence of netropsin and distamycin A was proposed to be governed mainly by the 
steric hindrance that arises by the exocyclic amino group of guanine in the minor groove 
of G·C base pairs, impeding hydrogen bonding between the ligand and DNA.  
 
Additionally, Dickerson et al. proposed that replacing N-methylpyrrole with N-
methylimidazole would furnish a H-bond acceptor and remove the steric hindrance 
generated by the exocyclic amino group of guanine, allowing for the expansion of the 
permitted targeting sequences to include G·C pairs (Figure 1.5).46  
 
 
 
Figure 1.4. Chemical Scheme of a Netropsin Recognizing an A/T-Rich Binding Site. The minor groove atoms
that interact with netropsin are shown in the DNA ladder. Standard distances of H-bonds are shown as dot-dash
lines, while distances longer than 3.2 Å are indicated as dotted lines. Figure adapted from Dickerson et al. 1985.
Figure 1.5. Chemical Scheme of a Lexitropsin Ligand Recognizing a G·C Base Pair as Proposed by Dickerson 
et al. The replacement of N-methylpyrrole with N-methylimidazole provides an H-bond acceptor and relieves the 
steric hindrance with guanine’s exocyclic amino group, affording the recognition of G·C base pairs. The minor groove 
of DNA is represented in the bottom of the figure. H-bonds are shown as filled in arrows, while van der Waals 
contacts are indicated as short parallel lines. Figure adapted from Dickerson et al. 1985.     
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In the breakthrough findings by Wemmer et al., it was demonstrated that in addition 
to the 1:1 ratio of ligand to DNA complex, distamycin A, a close relative of netropsin, 
could also bind DNA with a 2:1 stoichiometry.59 Using NMR spectroscopy, the authors 
showed that the two ligands bound side-by-side in an anti-parallel fashion in the minor 
groove of an AAATT duplex, allowing each distamycin A molecule to interact 
independently with each anti-parallel strand of DNA (Figure 1.6).59  
 
 
  
Consistent with these observations, Dervan et al. confirmed that the introduction of a 
N-methylimidazole subunit into a synthetic PA (ImPyPy) bound the 5’-WGWCW-3’ 
(where W represents A or T) sequence as a dimer, suggesting that the antiparallel pairing 
of Im/Py could discriminate G·C from C·G base pairs.60-62 Additionally, Dervan 
demonstrated that linking the C-terminus of a PA with the N-terminus of a second PA by 
γ-aminobutyric acid (GABA) preserved the appropriate ring pairing, and thus improved 
binding affinity and sequence specificity.45,63  
The novel hairpin motif introduced by Dervan’s group established the paradigm of 
antiparallel side-by-side ring pairing to recognize the sequence-dependent H-bonds 
presented by the Watson-Crick bases in the minor groove of B-DNA (Figure 1.7).45 
Specifically, a binary code has been established where a Py/Py pair H-bonds to the 
degenerate A·T and T·A base pairs, as each Py heterocycle recognizes nucleotides (A, T, 
or C) that present H-bond acceptors to the minor groove.60-62,64 An Im/Py or Py/Im pair 
preferentially binds G·C or C·G base pairs, respectively. This selectivity arises from the 
steric hindrance between pyrrole substituents and the exocyclic amino group of guanine 
found in the minor groove, and is relieved by imidazole substituents which provide both 
room and an H-bond acceptor to this NH2 group.60-62,64 Notably, substitution of Py 
heterocycles with the flexible β-alanine (β) substituent relieves the inherent overcurvature 
observed in polyamides with four or more contiguous heterocycles and resets the H-bond 
Figure 1.6. Chemical Scheme of the 2:1 Distamycin-DNA Complex. Each distamycin A molecule recognizes the 
DNA strands independently in an antiparallel manner. Figure adapted from Dervan et al. 2001 (permission # 
4087220270140). 
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register between the ligand and DNA.65,66 The GABA hairpin turn recognizes the 
degenerate A·T and T·A base pairs preferentially due to steric factors.67 The C-terminal 
positively-charged tail recognizes A·T and T·A base pairs and mimics the cationic 
moieties found in distamycin A and netropsin.46,67 Furthermore, hairpin polyamides have 
been shown to bind B-form DNA exclusively, with little or no affinity for dsRNA, A-
DNA or Z-DNA.46,57,68 
 
 
  
Because of their modular nature, hairpin PAs afford the rational design of different 
contiguous combinations of their building blocks, linked by amide bonds, to target 
predetermined sequences for the control of gene expression and DNA replication. As a 
result, these small, cell-permeable molecules are attractive novel candidates as 
modulators of gene expression,69-74 as molecular probes for diagnostics in living cells75-78 
and as antiviral agents for the selective elimination of dsDNA viruses.32,79-81 Gene 
transcription is orchestrated by the intricate interplay between chromatin accessibility37 
and the recruitment of RNA polymerases by DNA-TF (transcription factor) complexes in 
canonical regulatory elements found in gene promoters.47 Hairpin polyamides exhibit 
binding affinities similar to transcription factors.67 Thus, polyamides can be designed to 
downregulate specific gene transcripts by direct or allosteric competition with TFs for 
DNA sites, depending on whether the DNA-binding protein recognizes the major or 
minor groove of DNA, respectively.67 PAs have been shown to inhibit numerous DNA-
binding proteins, including Ets-1,70 TFIIIA,82 HTLV-1 Tax,83 EBNA179 and HPV18 E2.32 
Because gene expression and DNA replication are regulated via specific DNA-binding 
proteins,84 hairpin polyamides are adept at specifically downregulating the propagation of 
viral genomes and related gene products, while avoiding toxicity to both infected and 
adjacent healthy cells.80,81 
Adapted from Ansari et al. 2007,  
C&EN Volume 85, Number 8, pp. 34-35 
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Figure 1.7. Sequence-Dependent Recognition in the Minor Groove of dsDNA by Hairpin Py/Im Polyamides.
Pyrrole/imidazole hairpin polyamides can be synthesized to recognize specific DNA sequences by following the
reported PA-DNA pairing rules, which delineate the Watson-Crick base pairs recognized by each heterocycle pair in a
hairpin polyamide. (A) Model of a pyrrole/imidazole hairpin polyamide bound in the minor groove of dsDNA (Figure
adapted from Ansari et al. 2007). (B) Chemical structure of the Watson-Crick base pairs with H-bond acceptors
(circled in blue) and donors (circled in red). Binding model of anti-HPV PA1 in the minor groove of dsDNA to its
canonical binding sequence. Dashed lines represent H-bonds between DNA and polyamide.  
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Our group and collaborators have synthesized an extensive library of hairpin PAs 
with broad-spectrum activities against three prevalent HR-HPV types (HPV16, HPV18 
and HPV31).80,85 Compared to the reported short hairpin polyamides, anti-PAs exhibit 
greater binding promiscuity.81,86,87 Specifically, these large anti-HPV PAs tolerate PA-
DNA mismatches without a significant decrease in binding affinity and require a binding 
site of >10 base pairs.86,87 Recent findings by our collaborators at NanoVir revealed that 
effective episomal elimination by anti-HPV PAs is accompanied by a significant change 
in expression of members from the DNA Damage Response (DDR) pathways.81 Most 
notably, the authors demonstrated that modulation of DDR pathways was dependent on 
the presence of HPV in the episomal form, as SiHa cells harboring integrated copies of 
HPV16 and HPV-negative cells did not elicit such response. Likewise, the inactive eight-
ring hairpin polyamide PA11 had no effect on the DDR transcripts studied.81 Thus, the 
mode of action by which antiviral PAs eliminate HPV episomes is more complex than a 
simple allosteric inhibition of DNA-binding proteins, and it may comprise the concerted 
interplay of multiple cellular pathways. 
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Chapter 2 
 
Determination of the DNA-Binding Properties of Antiviral Hairpin Polyamides PA1 
and PA25 on Natural DNA Sequences Corresponding to the Long Control Region 
(LCR) of HPV18 Genome 
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2.1 ABSTRACT 
 
Human papillomavirus (HPV) is the main etiological agent in the development of 
cervical cancer worldwide, with HPV18 accounting for approximately 20 % of the 
reported cases. N-methylpyrrole/N-imidazole hairpin polyamides PA1 and PA25 are 
among a large library of antiviral compounds capable of significantly decreasing HPV18 
episomes in cell culture (PA1 IC50 = 0.7 µM; PA25 IC50 = 0.06 µM) without 
cytotoxicity. To establish whether the basis of the antiviral activity differences is a result 
of dissimilar DNA-binding properties, the sequence specificity, binding sites and 
equilibrium dissociation constants were interrogated by DNase I footprinting and affinity 
cleavage experiments using DNA sequences corresponding to the HPV18 regulatory 
regions under cell-free conditions. Although these DNA-ligands were designed to target 
specific A/T-rich sequences (PA1 = W2GW7 and PA25 = W2GW5GW4, where W can be 
A or T), we find an extensive coverage of the studied DNA sequences with a population 
of binding sites with multiple polyamide-DNA mismatches. Specifically, both large 
hairpin polyamides tolerate as many as 2 (PA1) or 3 (PA25) DNA-polyamide 
mismatches without a significant change in binding affinity. We also report that these 
minor groove binders bind avidly to A/T-rich sequences corresponding to the HPV18 
genome with equilibrium dissociation constants ranging from 1.1 nM to 2.6 nM for PA1 
and 0.4 nM to 1.2 nM for PA25.  
2.2 INTRODUCTION 
 
2.2.1 Human Papillomavirus (HPV) 
 
Human papillomavirus (HPV) is a small double-stranded DNA virus with a tropism 
for mucosal and cutaneous epithelial tissues.1 HPV is the most prevalent sexually 
transmitted infection in the United States,2 and remains a significant health concern as 
persistent infections with an oncogenic HPV type can lead to the development of cervical 
cancer, in addition to oral and other head and neck cancers.3-5 To date, over 180 types 
have been isolated of which approximately 15 oncogenic types have been identified.6-8 Of 
these types, HPV16 and HPV18 are the most prevalent and together account for 
approximately 70 % of the reported cervical cancers worldwide.9  
At the molecular level, the dsDNA genome of HPV18 consists of 7,857 base pairs 
that encode for eight well-characterized proteins. Based on their function within the 
lifecycle, the HPV18 genome can be divided into three regions: a late region (L; 4244-
7136 bp), a non-coding region (LCR, long control region; 7137-104 bp) and an early 
region (E; 105-4157 bp) (Figure 2.1).10 The encoded non-structural proteins from the 
early region primarily serve regulatory functions including DNA replication, 
transcription, immune evasion and cell signaling. The proteins encoded from the late 
region are necessary for the assembly of infectious virions that can infect naïve 
individuals.11 On the other hand, the LCR genomic region does not encode for any 
proteins, but it harbors the early promoter and regulatory sequences vital to HPV’s 
lifecycle.10 Thus, the DNA sequences studied here correspond to the LCR region of the 
HPV18 genome. 
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Prevention of HPV-related cervical cancer has benefited from Pap smears and related 
screening programs.12,13 Although prophylactic vaccines introduced about ten years ago 
have also made an impact, vaccines are ineffective against existing infections. 
Furthermore, levels of vaccination have not yet achieved projected values.11,14,15  
Most HPV infections are asymptomatic and are cleared by the immune system.16 
However, more than 35,000 HPV-related cancer cases were reported in 2009 in the 
United States alone.5 In third world countries, where these preventive measures are less 
available, HPV infections remain a significant health burden; the approximately 500,000 
new cases diagnosed annually contribute to 290,000 deaths within the same time frame.17 
Therefore, a need for antivirals against HPV is dramatic and such drugs would be 
lifesaving. Toward this goal, we have designed and synthesized an extensive library of 
large N-methylpyrrole/N-methylimidazole hairpin polyamides with broad-spectrum 
activities against three prevalent HR-HPV types (HPV16, HPV18 and HPV31).18,19  
 
2.2.2 N-Methylpyrrole/N-Methylimidazole  Hairpin Polyamides (Py/Im PAs) 
 
N-methylpyrrole/N-methylimidazole (Py/Im) hairpin polyamides (PAs) are synthetic 
heteroaromatic compounds inspired by the chemical structures of the natural antibiotics 
distamycin A and netropsin, which bind to the minor groove of A/T-rich DNA 
sequences.20-23 These crescent-shaped molecules, collectively known as polyamides, bind 
with high affinity (nano- to picomolar dissociation constants) to the minor groove of 
dsDNA in a sequence-selective fashion.24-26 According to the literature, Py/Im PAs can 
E7 (590-907)E6 (105-581)
E1 (914-2887)
E2 (2817-3914)
E4 (3418-3684)
E5 (3936-4157)
L2 (4244-5632)
L1 (5430-7136)
HPV-18
X05015
7857 bp
LCR (7137-104)
E2BS-3 (7822-7833)
E1BS (3-18)
E2BS-2 (42-53)
E2BS-1 (58-69)
LCR
Promoter and enhancer
elements (oriR)
Late genes
L1 - Major capsid protein
L2 - Minor capsid protein
Early genes
E1 - Helicase for viral replication
E2 - Viral transcription factor
E4 - Viral assembly
E5 - Weak transforming activity
and immune evasion
E6 - Binds p53 (ubiquitin-mediated
degradation)
E7 - Binds pRb (S-phase reentry)
E2BS-4 (7458-7469)
OriR
Figure 2.1. Structure of the HPV18 Genome. The circular genome of HPV18 (GenBank Accession No. X05015)
encodes for early (E) and late (L) genes and consists of 7857 bp of dsDNA. Coding regions for each gene are annotated
with their respective positions in the genome. The E2 and E1 binding sites within the long control region (LCR) are
illustrated above the map. The functions for the HPV18 encoded genes are also given below the map. 
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be rationally designed to target predetermined DNA sequences based on the established 
PA-DNA recognition rules.27-31 These recognition rules delineate the Watson-Crick base 
pairs recognized by each antiparallel side-by-side ring pairing in a hairpin polyamide. A 
Py/Im pair H-bonds to a G·C (but not a C·G), whereas a Py/Py H-bonds to the degenerate 
A·T and T·A base pairs. While replacing a Py heterocycle with the flexible β-alanine 
substituent relieves the inherent overcurvature observed in polyamides with four or more 
contiguous heterocycles and resets the H-bond register between the ligand and DNA.27,28 
The gamma-aminobutyric turn recognizes the degenerate A·T and T·A base pairs 
preferentially due to steric factors.29 The C-terminal positively-charged tail recognizes 
A·T and T·A base pairs and mimics the cationic moieties found in distamycin A and 
netropsin.29,30 This reported specificity is achieved by the optimal positioning of the H-
bond acceptors and donors, van der Waals interactions with the walls of the minor groove 
and appropriate curvature of the polyamide with respect to the minor groove of B-DNA.31   
Because of their modular nature, hairpin PAs afford the rational design to target 
predetermined sequences for the control of gene expression and DNA replication. As a 
result, these small, cell-permeable molecules are attractive novel candidates as 
modulators of gene expression,32-37 as molecular probes for diagnostics in living cells38-41 
and as antiviral agents for the selective elimination of dsDNA viruses.18,42-44 Because 
polyamide-binding events impart significant structural perturbations to DNA,45 these 
synthetic DNA-ligands can allosterically repress gene transcription and DNA replication 
by competing with the endogenous DNA-binding proteins and transcription factors.29 Of 
interest, Yasuda et al. designed Py-Im hairpin polyamides targeting the Epstein-Barr 
Nuclear Antigen 1 (EBNA1) binding sites in the origin of plasmid replication (oriP) 
within the viral genome and demonstrated an efficient inhibition of EBNA1-binding and 
reduced recruitment of host replication machinery to the oriP in chromatin 
immunoprecipitation (ChIP) assays.42 Schaal et al. showed that tandem hairpin 
polyamides were able to displace the HPV18 E2, a major groove binding protein, from its 
canonical E2BS4 (E2 Binding Site 4) DNA binding site. Consistent with the allosteric 
model, the authors suggested that these tandem hairpin polyamides prevented the bending 
of DNA structure required for E2 binding.43  
Displacement of viral proteins as well as cellular transcription factors and the 
replication machinery from their viral, canonical binding sites by anti-HPV PAs would 
presumably cause episomal instability followed by the elimination of the HPV genome. 
In fact, the multifunctional E2 protein forms a complex with E1 to initiate viral DNA 
replication within the HPV LCR,1 while E2 alone tightly regulates transcription of viral 
proteins43 and ensures proper episomal segregation during cell division of infected 
cells.46,47 Because the HPV LCR harbors the early promoter and regulatory sequences 
vital to HPV’s lifecycle, our group designed PA1 to target specific viral DNA sequences 
near the origin of replication in the LCR of HPV16. Despite the heterogeneity of the 
DNA sequences among these types, PA1 and PA25 exhibit broad-spectrum antiviral 
activities against these prevalent high-risk types (Table 2.1). Our novel anti-HPV 
polyamides potentiate a substantial and rapid decrease in episomal levels in human 
keratinocytes and tissue cultures without measurable cytotoxicity via MTT assays.18,19,48 
Remarkably, the loss of episomal DNA is not associated with viral integration into the 
host genome.18 Specifically, PA1 and PA25 exhibit IC50 values of 0.7 µM and 0.06 µM 
against HPV18, respectively.  
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Table 2.1. IC50 and IC90 Values of PA1 and PA25 Against High-Risk HPV16, HPV18 and HPV31 Types. 
 HPV16 HPV18 HPV31 
 IC50 (µM) IC90 (µM) N IC50 (µM) 
IC90 
(µM) n IC50 (µM) 
IC90 
(µM) n 
PA1 0.1(1) 1.1(8) 4 0.7(4) >10 3 0.1(1) 1.0(5) 4 
PA25 0.036(1) 0.351 3 0.056(5) 1.462 6 0.030(1) 0.510 3 
The numbers in parentheses are standard deviations; n is the number of independent measurements. 
Py/Im PA1 has the sequence dIm-Py-Py-β-Py-Py-Py-γ-Py-Py-β-Py-Py-Py-Py-β-Ta 
(dIm = desamino-imidazole, Py = pyrrole, β = β-alanine, γ = γ-aminobutyric acid and Ta 
= CH3N(CH2CH2CH2NH2)2).49 According to the prediction rules, PA1 recognizes the 
DNA sequence 5’-W2GW7-3’, where W (Weak) can be A or T. On the other hand, Py/Im 
PA25 has the sequence dIm-Py-Py-β-Py-Py-Im-β-Py-Py-γ-Py-Py-β-Py-Py-Py-β-Py-Py-
Py-β-Ta and a cognate DNA binding motif of 5’-W2GW5GW4-3’.44 The chemical 
structures and cognate binding sites for PA1 and PA25 are shown in Figure 2.2. 
 
 
 
To establish whether the basis of these antiviral activity differences between PA1 and 
PA25 is a result of dissimilar DNA-binding properties, the sequence specificity, binding 
orientation and dissociation constants were interrogated under cell-free conditions for the 
HPV18 LCR genomic region (7479-157 bp) by quantitative DNase I (deoxyribonuclease 
I) footprinting and affinity cleavage. Binding events to the specific regulatory sequences 
(i.e., E1-BS, E2BS, oriR; see Figure 2.1) in the LCR will be assessed to investigate 
potential allosteric competition with DNA-binding proteins. Because the anti-HPV 
polyamides are much larger than those reported in the literature, it is of considerable 
Figure 2.2. Chemical Structures for PA1 and PA25. Chemical structure of anti-HPV (A) PA1 and (B) PA25 are
provided. According to the PA-DNA recognition rules, PA1 targets the DNA sequence 5’-W2GW7-3’, where W
(Weak) can be A or T. On the other hand, the cognate DNA binding motif for PA25 is 5’-W2GW5GW4-3’. The
polyamide building blocks are represented by open circles for N-methylpyrrole, filled circles for N-methylimidazole,
diamonds for β-alanine, + for the Ta tail and  for γ-aminobutyric acid. 
A 
B 
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interest to determine whether the pairing rules established with small eight-ring PAs also 
apply to our large hairpin PAs. 
2.2.3 Deoxyribonuclease I (DNase I) Footprinting 
 
DNase I footprinting pioneered by Galas and Schmitz50 provides a powerful yet 
simple technique for deciphering the specific contacts in DNA-ligand complexes. DNase 
I footprinting measures the protection of DNA by a ligand from the enzymatic cleavage 
by DNase I endonuclease.50,51 This method has been successfully employed to determine 
the sequence selectivity of numerous DNA-ligands including intercalators,52-55 
transcription factors,56-58 and minor groove DNA binders.52,53,55,59,60  
The principle of DNase I footprinting is summarized schematically in Figure 2.3. A 
dsDNA fragment harboring the sequence of interest is end-labelled, either radioactively 
with 32P or fluorescently for visualization purposes. The choice of the end-labelling 
depends on the method of detection of the generated fragments. In this chapter, we have 
relied on separation and visualization by automated capillary electrophoresis using two 
different fluorescent dyes covalently attached to the 5’-ends of the strands in the DNA 
duplex. The dual fluorescently-labeled DNA fragment is then incubated in the presence 
and absence of the DNA-binding ligand (e.g., polyamide). For quantitative DNase I 
footprinting, multiple solutions of DNA are incubated with increasing concentrations of 
the DNA-binding ligand. After equilibration of the ligand-DNA complex, the ensemble 
of DNA molecules are subjected to mild digestion by DNase I endonuclease under 
conditions of single-hit kinetics, that is, one cut per DNA molecule on average.51 DNase I 
binds to the minor groove and cleaves the phosphodiester backbone of DNA, leading to 
the formation of cleavage products with a 3’-hydroxyl group and a 5’-phosphate.61 The 
fragmented DNA is then separated by automated capillary electrophoresis and the 
cleavage patterns are compared between the naked and ligand-bound DNA samples. 
Binding of the ligand to its recognition site, or cognate sequence, leads to increased 
protection of DNA at that particular location, providing a ‘footprint’ (Figure 2.3A).51,61 
In the case of quantitative DNase I footprinting, monitoring the decrease of cleavage 
products at the particular fragment length where the polyamide binds as a function of 
increasing ligand concentrations allows for the determination of the equilibrium 
dissociation constants (Figure 2.3B).62 
Although this technique can reveal both the binding sites and the binding constants of 
DNA-binding ligands, DNase I footprinting has some disadvantages. Specifically, the 
cleavage agent exhibits sequence-dependent structural motifs of the DNA duplex, leading 
to low signal-to-noise ratio at some regions of the DNA fragment, precluding the 
determination of binding constants at these sites. In addition, DNase I is relatively large, 
with a DNA-binding surface of approximately 10 bp, which causes overestimation of 
ligand binding site sizes and poor resolution of multiple ligands bound in close proximity 
of each other.51,61,63 
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Figure 2.3. Experimental Scheme for DNase I Footprinting by Automated Capillary Electrophoresis. (A) For
reasons of clarity, only one 5’ end of the DNA fragments is shown as fluorescently-labeled in this illustration. Briefly,
the dual fluorescently-labeled DNA fragment is incubated in the absence and presence of different PA amounts for at
least 4 hours at 37 oC. At the end of the incubation period, treatment with the appropriate concentration of DNase I is
performed to yield single-hit kinetics or one cut per DNA molecule on average. (B) Quantitative analysis of polyamide
footprints. Because the bound polyamides protect the DNA from endonuclease cleavage, automated capillary
electrophoresis analysis of the control and polyamide-treated samples permits for the determination of polyamide
binding sites and equilibrium dissociation constants. Green arrow – integration peak within polyamide footprint; red
arrow – integration peak not bound by polyamide, thereby, it is used to normalize the data. nt – nucleotide. 
A 
B 
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2.2.4 Affinity Cleavage 
 
The affinity cleavage method relies on the sequence-specific cleavage of DNA by a 
DNA-binding molecule (e.g., polyamide) that has been conjugated with EDTA-Fe2+. In 
the case of hairpin polyamides, the EDTA moiety is covalently attached onto its C-
terminus (i.e., Ta tail) via an amide bond. In the presence of ferrous iron, oxygen and the 
reducing agent dithiothreitol (DTT), the catalytic formation of diffusible hydroxyl 
radicals occurs at the C-terminal EDTA and leads to oxidative cleavage of DNA near this 
position (Figure 2.4A). The cleavage pattern yields multiple neighboring cleavage sites 
with a Gaussian-like distribution due to the ability of the hydroxyl radicals to diffuse 
along the DNA backbone. Furthermore, the pattern is also asymmetrical compared to the 
opposite strand, exhibiting a 3’ shift from the location of the EDTA-Fe2+ moiety. The 3’ 
shift is a result of a 2 bp offset of the deoxyribose to its complement on the 3’ side of the 
minor groove of B-form DNA (Figure 2.4B).64 Affinity cleavage experiments were 
performed to decipher the polyamide binding sites and relative orientations in the 
fragments corresponding to the HPV18 LCR. 
 
 
 
 
Figure 2.4. Cartoon Representation of PA-EDTA-Fe2+ Analog in the Minor Groove of DNA and Representative
Electropherograms. (A) Affinity cleavage is performed using PA-EDTA conjugates. Sequence-specific cleavage of
DNA by a hairpin polyamide covalently attached with EDTA onto its C-terminus (i.e. Ta tail). In the presence of
ferrous iron, oxygen and the reducing agent dithiothreitol (DTT), the catalytic formation of diffusible hydroxyl radicals
occurs at the C-terminal EDTA and leads to oxidative cleavage of the DNA near this position (Figure adapted from Uil
et al. 2003; permission # 4087221444733). (B) Representative FAM/HEX channel electropherograms. Cleavage
pattern yields multiple neighboring cleavage sites with a Gaussian-like distribution due to the ability of the hydroxyl
radical to diffuse along the backbone of the DNA. Asymmetrical pattern is generated compared to the opposite strand
with a 3’ shift from the location of the EDTA-Fe2+ moiety.      
A 
B 
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2.3 MATERIALS AND METHODS 
 
2.3.1 Buffers and Reagents  
 
Starting reagents were used without further purification, unless specifically noted. 
Autoclaved MilliQ H2O (18.2 MΩ·cm at 25 °C, Millipore Integral 10) was used in the 
preparation of all reagents. HPV18/pBR322 plasmid was purchased from ATCC, Catalog 
# 45152. Lysogenic Broth (LB) Agar was obtained from Sigma, Catalog # L7533-
6X500ML. Glucose was purchased from Aldrich, Catalog # 158968-1KG. Ampicillin 
was purchased from Fisher Scientific, Catalog #BP1760-25. Calcium chloride was 
obtained from Alfa Aesar, Catalog # 10680. BamHI and EcoRI restriction enzymes 
(Catalog # R0136S, 20,000 U/mL / Catalog # R0101S, 20,000 U/mL), 1X NEBuffer 3.1 
(Catalog # R7203S, 10X concentration), Gel Loading Dye, Blue (6X, Catalog # B7021S), 
1 kb DNA ladder (Catalog # N3232S, 500 µg/mL) and 100 bp DNA ladder (Catalog # 
N3231S, 500 µg/mL) were purchased from New England Biolabs. 
Ethylenediaminetetraacetic acid (EDTA) was purchased from Sigma, Catalog # E5134-
100G. 1X TAE buffer consisted of 40 mM Tris-acetate, 1 M EDTA, pH 8.0. Ethidium 
bromide was obtained from Spectrum (Catalog # E1031, 1 % solution). Oligonucleotides 
for DNase I footprinting, affinity cleavage and circular dichroism experiments were 
purchased from Integrated DNA Technologies. Oligonucleotides for X-ray 
crystallography screening were obtained from Midland Certified Reagent Company. 
Deoxynucleotide (dNTP) Solution Mix (Catalog # N0447S, 10 mM), 10X Standard Taq 
Reaction Buffer (Catalog # B9014S) and Taq DNA Polymerase (Catalog # M0273L, 
5,000 U/mL) were purchased from New England Biolabs. Sodium acetate (Catalog # 
S7545-250G) was obtained from Sigma. Isopropanol (Catalog # BP2618-1) was 
purchased from Fisher Scientific. Thermo Sequence Dye Primer Manual Cycle 
Sequencing Kit USB (Catalog # 79260 1 KT) was obtained from Affymetrix. DNase I 
endonuclease (Catalog # M610A, 1,000 units) was purchased from Promega. QIAGEN 
QIAprep Spin Miniprep Kit (Catalog # 27104) and QIAquick PCR Purification Kit 
(Catalog # 28106) was purchased from QIAGEN. Dimethyl sulfoxide was purchased 
from Sigma Life Science, Catalog # D2650. TKMC buffer consisted of 10 mM Tris, 10 
mM KCl, 5 mM MgCl2 and 5 mM CaCl2. Ammonium iron(II) sulfate hexahydrate was 
obtained from Aldrich, Catalog # 203505-25G. 0.22 µm MILLEX-GP filters were 
purchased from Merck Millipore Ltd. 100 % ethanol was obtained from Decon 
Laboratories, Inc., Catalog # 2716. Agarose was obtained from Sigma, Catalog # A9539-
100G. Natrix HT crystallization matrix (Catalog # HR2-131) was purchased from 
Hampton Research. 
2.3.2 Polyamide Synthesis 
 
Hairpin polyamide synthesis was performed by Dr. K. J. Koeller and Dr. G. D. 
Harris, Jr. PA1, PA25 and their EDTA conjugates were synthesized by Boc solid-phase 
methods65 as previously reported in the literature.18,66  
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2.3.3 HPV18/pBR322 Plasmid DNA Amplification and Purification 
 
2.3.3.1 Transformation of Escherichia coli JM109 Cells with HPV18/pBR322 Plasmid 
 
HPV18 DNA amplification was accomplished by transforming E. coli JM109 cells 
with a plasmid construct consisting of the full HPV18 genome (GenBank Accession No. 
X05015) cloned into the EcoRI restriction site of the pBR322 vector (ATCC, Catalog # 
45152, total length = 12,219 bp). Because the EcoRI restriction site (which cleaves the 5’ 
adenine on each DNA strand of the sequence 5’-GAATTC-3’) occurs within the open 
reading frame of E1, cloning of the HPV18 genome into the pBR322 vector leads to the 
disruption of the E1 coding region.67,68 
In order to avoid contamination, aseptic techniques were implemented when handling 
media and bacterial colonies. In particular, surfaces and disposable gloves were treated 
with 70 % ethanol, as well as the equipment (i.e., inoculation loop) was sterilized with 70 
% ethanol followed by heating with an open flame. Sterile Lysogenic Broth (LB) agar 
(Sigma, Catalog # L7533-6X500ML) was melted in a microwave and poured into three 
plates (approximately half full). The LB agar was allowed to solidify and the plates were 
labeled 1 JM109, 2 JM109 and Control. 1 JM109 and 2 JM109 were each divided into 
two sections. In one of the halves from 1 JM109, an E. coli JM109 stab was plated 
followed by serial dilution of the bacterial colonies into the three remaining halves 
(Figure 2.5). The plates were placed upside-down in a Thermo Scientific MaxQ 4000 
incubator and incubated overnight at 37 °C. There were no cells in the Control plate after 
the overnight incubation period. 
 
The following day, a single colony from 1 JM109 plate Section 2 was inoculated into 
a single sterile test tube containing 3 mL of LB solution and labeled CHC 01-14-13 
JM109. Similarly, a control was prepared and labeled CHC 01-14-13 CTL. Both test 
tubes were placed in a Brunswick G Series 25 incubator shaker at 37 °C and 250 RPM 
overnight. The next morning, 1 mL of LB solution was transferred into a sterile flask 
containing 50 mL sterile LB media. The E. coli cells were allowed to grow in a 
Brunswick G Series 25 incubator at 37 °C and 250 RPM until an optical density of 0.4 + 
0.05 at 590 nm was achieved. Once the optical density was reached, the LB medium 
harboring the E. coli cells was poured into a sterile 50 mL conical centrifuge tube and 
placed on ice for 40 min. The cells were pelleted by centrifugation for 10 min at 2,800 
RPM, 4 °C in a Thermo Scientific Sorvall ST16R centrifuge. The supernatant was 
Figure 2.5. Streaking LB Agar Plates. Illustration of the streaking procedure. The E. coli JM109 stab was streaked
directly onto Section 1 of Plate 1 JM109 followed by sterilization of the inoculation loop. Some colonies were then
transferred onto Section 2 of Plate 1 JM109 by gently touching the sterile inoculation loop to a streaked region of
Section 1 followed by streaking onto Section 2. This procedure was then repeated for Section 3 (using colonies from
Section 2) and Section 4 (using colonies from Section 3) of Plate 2 JM109. Individual colonies were obtained from
Section 2 of Plate 1 JM109. CONTROL = no E. coli plated. 
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decanted and the tube was placed upside down for ~1 min to remove any remaining 
media. The cell pellet was gently resuspended in 10 mL of sterile 0.1 M CaCl2 (Alfa 
Aesar, Catalog # 10680) and placed in an ice bath. After three minutes of cold shock, the 
suspended E. coli cells were spun for 10 min at 2,800 RPM, 4 °C in a Thermo Scientific 
Sorvall ST16R centrifuge. The supernatant was decanted and 2 mL of sterile 0.1 M CaCl2 
were added to the cell pellet. Four separate 200 µL aliquots were transferred into 
individual autoclaved 1.5 mL microcentrifuge tubes. These were then placed on ice and 
stored at 4 °C. 
After about three hours at 4 °C, competent cells and HPV18/pBR322 (ATCC Catalog 
No. 45152; stock concentration = 1.10 µg/µL) were thawed on ice. A 40X dilution was 
prepared by diluting 2 µL of the DNA plasmid stock in 78 µL of autoclaved MilliQ H2O. 
A 1 µL aliquot of this solution was then added to one of the 1.5 mL microcentrifuge 
tubes containing 200 µL of competent cells, while a separate tube without DNA plasmid 
was used as a control. These tubes were labeled CHC 01-15-13 (+) and CHC 01-15-13 (-) 
respectively and incubated on ice for 30 min. In the meantime, ampicillin/LB agar plates 
were prepared. Briefly, 30 µL of 150 mg/mL ampicillin (Fisher Scientific, Catalog # 
BP1760-25) solution was separately added to three LB agar plates and evenly spread 
aseptically. Upon completion of the 30 min incubation on ice, the tubes containing the 
competent E. coli cells were transferred into a 42 °C water bath for 45 s, followed by 90 s 
in an ice bath. The cells were inoculated in growth media consisting of 1 % glucose 
(Aldrich 158968-1KG) in LB media. In order for the cured cells to develop ampicillin 
resistance, the control (competent cells without HPV18/pBR322) and the tubes 
containing competent cells with DNA plasmid were incubated for 1 hour and 15 min at 
37 °C and 250 RPM in a Brunswick G Series 25 incubator. A 100 µL aliquot from each 
of the control and competent cells subjected to HPV18/pBR322 were plated out 
separately onto individual ampicillin/LB agar plates. On a third plate, a 200 µL aliquot of 
the competent cells with HPV18/pBR322 was also plated out. These three plates were 
incubated overnight at 37 °C in a Thermo Scientific MaxQ 4000 incubator. 
The next morning, the ampicillin/LB agar plates were inspected for bacterial growth. 
The control plate did not grow any colonies and minimal growth was observed on the 
plate with 100 µL aliquot of JM109. Single colonies covered the plate with 200 µL 
aliquot of JM109. A single colony from the 200 µL plate was inoculated into a sterile 
flask with 50 mL of LB solution supplemented with 50 µL of 150 mg/mL ampicillin 
solution. This was repeated once to yield two separate cell suspensions. The flasks were 
labeled CHC 01-16-13 HPV18-1 and CHC 01-16-13 HPV18-2. Both samples were 
incubated overnight at 37 °C and 250 RPM in a Brunswick G Series incubator. 
2.3.3.2 HPV18/pBR322 Plasmid Purification Using QIAprep Spin Miniprep Kit 
 
HPV18/pBR322 plasmid DNA67,68 purification from transformed E. coli JM109 cells 
was achieved with a QIAGEN QIAprep Spin Miniprep Kit (Catalog # 27104) as 
recommended by the manufacturer. Briefly, after overnight incubation, a 15 mL aliquot 
from each flask (CHC 01-16-13 HPV18-1 and CHC 01-16-13 HPV18-2) was separately 
centrifuged for 15 min at 4,000x g. The supernatant was discarded and each cell pellet 
was resuspended in 2 mL of Buffer P1. Each sample was separately aliquoted into five 
1.5 mL microcentrifuge tubes (400 µL per tube). Cell lysis was performed by adding 400 
µL of Buffer P2 to each tube and was mixed by inverting the samples gently 4-6 times. 
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To each sample, a 560 µL aliquot of Buffer N3 was added and the resulting slurry was 
mixed immediately by inverting the tube 4-6 times. The samples were centrifuged for 10 
min at 17,900x g.  
The resulting supernatants were applied to QIAprep spin columns (3 columns per 
sample; 6 columns total) and centrifuged for 60 s at 17,900x g. The flow-through was 
discarded, followed by washing of the columns with 750 µL of Buffer PE and were 
centrifuged for 60 s at 17,900x g. The flow-through was discarded and the columns were 
centrifuged for an additional minute at 17,900x g to remove the residual Buffer PE. Each 
column was then placed into a clean 1.5 mL microcentrifuge tube and the DNA was 
eluted by adding 50 µL of Buffer EB onto the center of the column. The columns were 
allowed to stand for 1 min, followed by centrifugation at 17,900x g for 60 s. The eluted 
plasmid DNA in Buffer EB were pooled together into two different samples (HPV18-1 
CHC1007-1 and HPV18-2 CHC1007-2) and stored at -20 °C. Plasmid DNA 
concentrations were determined by measuring the absorbance at 260 nm using a 
Shimadzu UV1800 UV spectrophotometer. 
 
2.3.3.3 Entry of HPV18/pBR322 Clones into Plasmid Library and Stabs 
 
In order to ensure that the plasmid library and stabs in Dr. Dupureur’s lab are 
maintained, 20 µL of HPV18-1 CHC1007-1 DNA were entered into the plasmid library 
and 1 mL of LB agar stabbed with E. coli JM109 cells. 
2.3.3.4 Restriction Digests of HPV18/pBR322 Clones 
 
The purified HPV18/pBR322 DNA from transformed E. coli JM109 cells was 
subjected to restriction digests using BamHI (NEB Catalog # R0136S, 20,000 U/mL) and 
EcoRI (NEB Catalog # R0101S, 20,000 U/mL) as recommended by the manufacturer. 
Briefly, a 30 µL aliquot of purified HPV18/pBR322 DNA was diluted with 48 µL of 
autoclaved MilliQ H2O to make a working standard (WS). The BamHI restriction digest 
was performed by incubating 26 µL aliquot of the HPV18/pBR322 WS with 3 µL 10X 
NE Buffer 3, 1 µL BamHI and 0.3 µL 100X bovine serum albumin (BSA; NEB) at 37 °C 
for 1 hour. The EcoRI restriction digest was performed by incubating 26 µL aliquot of 
the HPV18/pBR322 WS with 3 µL 10X NE Buffer 3, 1 µL EcoRI and 0.3 µL 100X BSA 
at 37 °C for 1 hour. The restriction digest fragments were electrophoresed on a 1 % 
agarose gel. To prepare the agarose gel, 1 gram of agarose powder (Sigma-Aldrich, 
Catalog # A9539-100G) was added to 100 mL of autoclaved MilliQ H2O and 
microwaved for 1 min. The solution was mixed well, allowed to cool to ~70 °C and 
poured onto a Thermo Scientific Owl Easycast B1-BP casting plate with 10-well comb. 
The reaction products produced by restriction enzyme treatments were separately mixed 
with Gel Loading Dye, Blue (6X, NEB, Catalog # B7021S) and loaded onto the agarose 
gel. After sample loading, gel electrophoresis was performed in 1X TAE buffer (40 mM 
Tris-acetate, 1 M EDTA, pH 8.0) at 110 V, room temperature for 1 h. After 
electrophoresis, the gel was stained with 0.5 µg/mL ethidium bromide (Spectrum E1031, 
1 % solution) for 20 min and washed with autoclaved MilliQ H2O for 5 min in a staining 
box. The fragmented DNA and 1 kb DNA ladder (NEB, Catalog # N3232S, 500 µg/mL) 
were imaged using a FOTO/Convertible UV-light box equipped with an ethidium 
bromide filter (FOTODYNE Incorporated). Molecular weights of linearized DNA 
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fragments were estimated using NEB 1 kb DNA ladder (NEB N3232S, 500 µg/mL). The 
agarose gel was imaged and analyzed with FOTO/Analyst PC Image version 5.00. 
2.3.4 Polymerase Chain Reaction (PCR): Amplification of HPV18 LCR Fragments 
Corresponding to Positions 7479-7783 (305 bp) and 7647-157 (368 bp) 
  
2.3.4.1 PCR Reagent Amounts and Parameters 
 
Two DNA fragments corresponding to 7479-7783 (305 bp) and 7647-157 (368 bp) 
from the HPV18 LCR were PCR-amplified for subsequent quantitative DNase I 
footprinting and affinity cleavage experiments with anti-HPV hairpin polyamides PA1 
and PA25. The LCR region is important for both viral transcription and replication,10 and 
as a result it was chosen to study polyamide binding. The 368 bp fragment harbors 
HPV18’s origin of replication, the E2 binding sites (E2BS-1 7822-7833; E2BS-2 42-53; 
E2BS-3 58-69) and the E1 binding site (E1BS 3-18) (Figure 2.6). The viral E1 protein is 
a helicase that unwinds DNA using its ATPase activity. While the viral E2 protein can 
repress or activate transcription depending on the viral infection stage, its interaction with 
E1 leads to the initiation of DNA replication by the host cell machinery.69  
 
 
  
Two different fluorescent dyes were attached to the 5’-end of each primer to visualize 
the fragmentation patterns obtained from quantitative DNase I footprinting and affinity 
cleavage experiments using capillary electrophoresis (CE). The top strand was labeled 
with 6-carboxyfluorescein (6-FAM) and the bottom strand with hexachloro-fluorescein 
(HEX). These oligonucleotides were purchased from Integrated DNA Technologies. The 
primer sequences with their respective fluorescein dyes are provided below: 
 
Primers used to amplify the LCR region covering HPV18 7479-7783: 
          Forward Primer (SLE1004F FAM): 5’-/56-FAM/CT TAT GTC TGT GGT TTT CTG   
                    20 base pairs, 40 % GC content, Tm 55.9 °C  
          Reverse Primer (SLE1004R HEX): 5’-/5HEX/TT CAT GTT AAG GGT AGA CAG  
                    20 base pairs, 40 % GC content, Tm 56.3 °C 
 
Figure 2.6. Map of HPV18 DNA Fragments Used in DNA-Binding Studies. Top duplex represents entire HPV18
LCR (Genbank Accession number X05015). Two fragments corresponding to 7479-7783 (305 bp) and 7647-157 (368
bp) from HPV18 LCR were used for quantitative DNase I footprinting and affinity cleavage experiments. The 368 bp
fragment harbors HPV18’s origin of replication, three out of four E2 binding sites (red) and the E1 binding site (black).
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Primers used to amplify the LCR/E6 region covering HPV18 7647-157: 
          Forward Primer (CHC1017FD): 5’-/56-FAM/TG CAT AAC TAT ATC CAC TCC   
               20 base pairs, 40 % GC content, Tm 56 °C  
          Reverse Primer (CHC1017RD): 5’-/5HEX/CA CAG ATC AGG TAG CTT GTA  
              20 base pairs, 45 % GC content, Tm 58.3 °C 
 
(Tm values were determined using OligoAnalyzer 3.1 
http://www.idtdna.com/analyzer/Applications/OligoAnalyzer/ with Na+ concentration 
of 50 mM and Mg++ concentration of 1.5 mM) 
 
PCR reactions were performed on a Mastercycler Nexus Thermal Gradient 
(Eppendorf) using Carlos/mid frag.cyc for 7479-7783 or Carlos/HPV18 CHC1020.cyc 
for 7647-157. The cocktail and parameters used for the PCR reactions are given in Table 
2.2. 
 
Table 2.2. PCR Reagent Amounts and Run Parameters. The amounts given are for a 50 µL reaction of PCR.  
Program Reagent Volume (µL) PCR Step 
Time 
(min)  
Carlos/mid frag.cyc 
(7479-7783 fragment) 
MilliQ H2O 41.45 Polymerase Activation at 95 °C 3 
10X Standard Taq Buffer 5.0 Denaturation at 95 °C 0.5 
30 X 10 mM dNTP Mix 1.0 Annealing at 48 °C 0.5 
10 µM Forward Primer 1.0 Extension at 68 °C 0.5 
10 µM Reverse Primer 1.0 Extension at 68 °C 10 
 Template DNA (200X 
HPV18-1) 0.3 Hold at 6 °C ∞ 
Taq DNA Polymerase 0.25   
Carlos/HPV18 
CHC1020.cyc  
(7647-157 fragment) 
MilliQ H2O 41.45 Polymerase Activation at 95 °C 3  
10X Standard Taq Buffer 5.0 Denaturation at 95 °C 0.5  
10 mM dNTP Mix 1.0 Annealing at 55 °C 1 30 X
10 µM Forward Primer 1.0 Extension at 68 °C 0.5  
10 µM Reverse Primer 1.0 Extension at 68 °C 10  
Template DNA (200X 
HPV18-1) 0.3 Hold at 6 °C ∞  
Taq DNA Polymerase 0.25   
Deoxynucleotide (dNTP) Solution Mix (Catalog # N0447S, 10 mM), 10X Standard Taq Reaction Buffer (Catalog # 
B9014S) and Taq DNA Polymerase (Catalog # M0273L, 5,000 U/mL) were purchased from New England Biolabs. 
 
Upon completion of PCR, aliquots from the reactions were verified by gel 
electrophoresis using a 1 % agarose gel in 1X TAE buffer at 100 V, room temperature for 
about 1 hour or until the gel loading dye had migrated approximately ¾ of the gel length. 
The gel was stained with 0.5 µg/mL ethidium bromide for 20 min and washed with 
MilliQ H2O for 5 min in a staining box. The PCR-amplified DNA and 100 bp DNA 
ladder (NEB, Catalog # N3231S, 500 µg/mL) were visualized with a FOTO/Convertible 
UV-light box equipped with an ethidium bromide filter (FOTODYNE Incorporated). The 
agarose gel was imaged and analyzed with FOTO/Analyst PC Image version 5.00.  
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2.3.4.2 Purification of PCR-Amplified LCR Fragments 
 
Purification of the PCR-amplified fragments was initiated by precipitating the DNA. 
Briefly, 1/10 volume of 3 M sodium acetate, pH 5.2 was added to the PCR reaction and 
mixed well by inverting the vial ~ 6 times. To this solution, 3X volume of cold 100 % 
ethanol was added and mixed again by inversion. The DNA sample was then placed in a -
20 °C freezer overnight. The next morning, the microcentrifuge vial was centrifuged at 
17,900x g and 4 °C for 30 min. The supernatant was carefully removed using a pipettor, 
being careful not to disturb the DNA pellet. The pellet was washed with 400 µL of cold 
(4 oC) 70 % ethanol without mixing. This solution was centrifuged at 17,900x g and 4 °C 
for 15 min. The supernatant was again removed and the pellet was allowed to air dry until 
no solvent was observed (~20 min). The DNA pellet was dissolved in 30 µL of Buffer 
EB (10 mM Tris·Cl, pH 8.5; QIAGEN) and subjected to 1 % agarose gel electrophoresis 
as previously discussed. The PCR-amplified DNA fragments were then excised from the 
agarose gel using a clean razor blade and each lane was purified using a QIAGEN Gel 
Extraction Kit (Catalog # 28706). Briefly, 3X volume of Buffer QG were added to 1X 
volume of the gel (volume determined by weight of gel, where 100 µL is equivalent to 
approximately 100 mg of gel). The suspension was then heated to 50 °C for 10 min, 
vortexing every 2 min to ensure complete dissolution of agarose gel. After ensuring that 
the color of the solution remained yellow upon dissolution, 1X volume of isopropanol 
(Fisher BioReagents, Catalog # BP2618-1) was added and mixed by vortexing. This 
solution was carefully transferred into a QIAquick spin column. The column was then 
centrifuged for 60 s at 17,900x g and the flow-through was discarded. A 500 µL aliquot 
of Buffer QG was then added to the column, centrifuged for 60 s at 17,900x g and the 
flow-through was discarded. The column was then washed with 750 µL of Buffer PE, 
allowed to stand for 2 min and centrifuged for 60 s at 17,900x g. The flow-through was 
discarded and the wash step was repeated once. The column was centrifuged for an extra 
60 s at 17,900x g to remove any residual Buffer PE. The QIAquick column was then 
placed in a clean 1.5 mL microcentrifuge tube. The DNA was eluted from the column by 
adding 50 µL of Buffer EB to the center of the column membrane and the column was 
allowed to incubate for 5 min at room temperature. The column was then centrifuged for 
60 s at 17,900x g. The purified DNA fragments were aliquoted and stored at -20 °C. 
2.3.4.3 Sanger DNA Sequencing  
 
To ensure that the PCR-amplified fragments corresponded to the HPV 18 LCR 
regions from 7479 to 7783 bp and from 7647 to 157 bp, Sanger DNA sequencing was 
performed. In this sequencing method, four different reactions are prepared with the four 
2’-deoxynucleotide triphosphates plus one of the four 2’, 3’-dideoxynucleotide 
triphosphates in each reaction at the proper ratio. Since DNA polymerization requires a 
hydroxyl group on the 3’ carbon of the sugar ring, the DNA polymerase will irreversibly 
terminate upon insertion of the particular 2’, 3’-dideoxynucleotide yielding a population 
of fragments terminating with each nucleotide that can then be separated and sequenced 
using electrophoresis.70 With the advancements in capillary electrophoresis and dye 
chemistry, the sequencing of a DNA fragment can be deduced from a single reaction with 
2’, 3’-dideoxynucleotide triphosphate terminators with different fluorescent dyes and 
detected via automated capillary electrophoresis.71  
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The two HPV18 fragments (305 bp, 7479-7783 and 368 bp, 7647-157) without 5’ 
dyes were submitted to the DNA Core Facility at University of Missouri for Sanger DNA 
sequencing to ensure that the correct fragments were PCR-amplified. Submission 
guidelines can be found at http://biotech.missouri.edu/dnacore/sangersequencing.html. 
The procedure is delineated below: 
1. Samples are submitted in a 1.5 mL microcentrifuge tube. 
2. The total volume of the template and primer mix in the 1.5 mL 
microcentrifuge tube must be 16 µL. MilliQ H2O is used as the diluent. 
3. For PCR products, the total amount of DNA is 50-275 ng. 
4. An aliquot of 15-26 pmol of a single primer (without 5’ dye) is added to each 
reaction. 
 
The sequencing data were processed using FinchTV version 1.4.0 (Geospiza Inc.).   
 
2.3.5 Biophysical Analysis of DNA-PA Interactions in the HPV18 LCR 
 
Quantitative DNase I footprinting experiments with PA1 and PA25, as well as 
affinity cleavage experiments with the EDTA conjugates of PA1 and PA25, were 
performed on the 305 bp and 368 bp fragments corresponding to 7479-7783 bp and 7647-
157 bp of the HPV18 LCR, respectively. Capillary electrophoresis analysis was 
conducted by MU DNA Core using an ABI 3730XI DNA Analyzer with an internal size 
standard consisting of Genescan 600 LIZ. 
 
2.3.5.1 CE Size Indexing for the 305 bp (7479-7783) and 368 bp (7647-157) Using 
Sanger Sequencing Chemistry 
 
In order to accurately map the PA1 and PA25 binding sites on the HPV18 fragments 
(7479-7783 and 7647-157), the correct nucleotide position on the HPV18 genome must 
be accurately correlated to the relative CE mobility of the fragment terminating with the 
nucleotide in question. Both the sequencing chemistry and the nature of 5’ dye influence 
the CE mobility of the DNA, and as a result the appropriate indexing method must be 
chosen. Particularly for quantitative DNase I footprinting, the cleavage products have a 
neutral hydroxyl group on the 3’ end and display a similar CE mobility to the neutral 
fragments generated by Sanger chemistry (Figure 2.7A and C).72 
Indexing was performed for both the top and bottom strands of the duplex since the 
former bears a 5’ FAM dye and the latter has a 5’ HEX dye. Sanger sequencing was 
conducted using a Thermo Sequence Dye Primer Manual Cycle Sequencing Kit USB 
(Affymetrix, Catalog # 79260 1 KT) as per the manufacturer’s instructions. The 
sequencing reactions were performed at two different DNA template concentrations: 20 
ng/µL and 2 ng/µL. Briefly, 4 sets of four 0.2 mL PCR tubes were labeled G, A, T or C 
and placed on ice. Master reaction mix stocks for both DNA concentrations and both the 
fluorescently labeled forward and reverse primers were prepared (Table 2.3). USB 
sequencing was performed at both 20 ng/µL and 2 ng/µL in order to optimize the output 
signal. 
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Figure 2.7. Chemical Structures of the Cleavage Products Generated by Various Sequencing and Footprinting
Chemistries. DNA fragments are 5’ end-labelled with fluorescent dyes and cleavage is only shown for the top strand
of the DNA duplex. (A & C) DNase I cleavage products generate neutral hydroxyl group on the 3’ end and display a
similar CE mobility to the neutral fragments generated by Sanger chemistry. (D) In radical chemistry, abstraction of a
deoxyribose hydrogen atom by a hydroxyl radical produces single-stranded nicks and gaps along the DNA duplex.
Depending on the site of hydroxyl radical attack, the resulting reaction products consist of a single-nucleoside gap with
a 3’ phosphate (Top) or a single-nucleoside gap with a 3’ phosphoglycolate (Middle), or a single-stranded nick with a
3’ phosphate (Bottom). (B & D) Because Maxam-Gilbert and hydroxyl radical chemistries lead to the generation of
negatively charged 3’ phosphates, their cleavage products display similar CE mobility. P = phosphate, PG =
phosphoglycolate, OH = hydroxyl. 
A  B
C  D
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Table 2.3. USB Sequencing Reagents and Amounts for Master Reaction Mix Stocks.  
Reagent 
Volumes for 20 ng/µL DNA 
Template Master RXN Mix 
(µL) 
Volumes for 2 ng/µL DNA 
Template Master RXN Mix 
(µL) 
5’-FAM 
Primer 
5’-HEX 
Primer 
5’-FAM 
Primer 
5’-HEX 
Primer 
HPV18 7479-7783 (305 bp) no dye             
OR  
HPV18 7647-157 (368 bp) no dye  
1.0 1.0 1.0 1.0 
Reaction Buffer (conc.) 2.2 2.2 2.2 2.2 
2 µM CHC1017 FD  1.0 NA 1.0 NA 
2 µM CHC1017 RD NA 1.0 NA 1.0 
MilliQ H2O 12.8 12.8 12.8 12.8 
Thermo Sequenase (20 U/µL) 1.0 1.0 1.0 1.0 
TOTAL 18.0 18.0 18.0 18.0 
A total of four master reaction mix stocks were prepared. Each DNA template concentration was prepared twice 
containing either the 5’-FAM primer (top strand) or the 5’-HEX primer (bottom strand).   
 
Next, 4 µL aliquots from each of the master reaction mix stocks were transferred into 
the 0.2 mL PCR tubes labeled G, A, T or C, previously cooled on ice. To each of these 
tubes, 1 µL of the respective termination mix was added (i.e., ddGTP termination mix 
was added to the tubes labeled G). Immediately, the reactions were placed in a 
Mastercycler Nexus Thermal Gradient and the PCR program Carlos/DNA Index CE.cyc 
was started. Table 2.4 provides the PCR parameters. The samples were submitted to MU 
DNA Core for fragmentation analysis and the results were analyzed using GeneMarker 
Version 2.4.0 (SoftGenetics LLC.). 
 
Table 2.4. USB Sequencing PCR Thermal Profile.  
PCR Step Time (min)  Polymerase Activation at 95 °C 3 
Denaturation at 95 °C 0.5 
30 X Annealing at 55 °C 0.5 
Extension at 72 °C 1 
Extension at 68 °C 10  Hold at 6 °C ∞ 
 
2.3.5.2 CE Size Indexing for the 305 bp (7479-7783) and 368 bp (7647-157) Using 
Maxam-Gilbert Sequencing Chemistry 
 
As previously discussed, it is imperative to accurately index the CE fragment size to 
the actual nucleotide on the sequence of interest in order to correctly map the binding site 
of DNA-binding ligands. To accurately determine the cleavage sites in affinity cleavage 
experiments, the DNA fragment must be indexed by Maxam-Gilbert sequencing 
chemistry. In this technique, the DNA is cleaved by specific base modifications, followed 
by eviction of the modified bases and strand cleavage at these positions.73 The cleavage 
products from the Maxam-Gilbert sequencing reactions have a 3’-phosphate group. 
Similarly, the cleavage products for affinity cleavage experiments and hydroxyl radical 
footprinting have a negatively charged phosphate group or a negatively charged 
phosphoglycolate group on their 3’ end, and display a similar CE mobility to the 
fragments generated by Maxam-Gilbert chemistry (Figure 2.7B and D).72 
Indexing was performed for both the top and bottom strands of the duplex. Indexing 
of the HVP18 fragments (7647-157 and 7479-7783) were determined using the Maxam-
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Gilbert protocol found in Molecular Cloning 2nd Edition.74 Briefly, two separate reactions 
were prepared for each HPV 18 fragment and subjected to either piperidine formate (pH 
2.0) or hydrazine. The former will react with purines and the latter will react with 
pyrimidines. After incubation with these chemicals, phosphate bond cleavage at the 
modified base is accomplished by the addition of hot 1 M piperidine solution. These two 
reactions were also performed at different DNA concentrations and incubation times (see 
Section 2.71). The samples were submitted to MU DNA Core for fragmentation analysis 
and the results were processed with GeneMarker Version 2.4.0.   
 
2.3.5.3 Quantitative DNase I Footprinting  
 
Quantitative DNase I footprinting experiments were performed to determine the PA1 
and PA25 binding sites in the HPV18 LCR, as well as the respective equilibrium 
dissociation constants associated with the observed binding events.   
PA1 (KG1068) and PA25 (KTK6006) polyamides were first lyophilized into single-
use aliquots by accurately weighing 1 mg of powder, diluting in 1 mL of 50 % H2O (0.1 
% TFA) : 50 % ACN (0.1 % TFA) and transferring a 100 µL aliquot of this solution into 
9 different 1.5 mL Eppendorf microcentrifuge tubes. The 10 vials were lyophilized 
overnight and stored at -20 °C. The concentration was then determined prior to use. 
Briefly, a lyophilized aliquot was dissolved in 100 µL of 100 % DMSO and the 
absorbance was measured at the λmax (~305 nm) using a Thermo Scientific Evolution 260 
Bio UV-visible spectrophotometer, and molar extinction coefficients used were 88,235 
M-1cm-1 and 147,400 M-1cm-1 for PA1 and PA25, respectively.  
2.3.5.3.1  Control DNase I Fragmentation Reaction 
 
To determine the appropriate DNase I concentration for subsequent footprinting 
experiments, a DNase I endonuclease (Promega RQ1 RNase-free DNase I, Catalog # 
M610A) titration from 0-0.08 Activity Units (AU) was carried out. Quantitative DNase I 
footprinting reactions must be conducted under conditions of single-hit kinetics, that is, 
one cut per DNA molecule on average.51 The control fragmentation reactions were 
performed at 200 pM of DNA in TKMC buffer (10 mM Tris, 10 mM KCl, 5 mM MgCl2 
and 5 mM CaCl2), 2 % v/v DMSO and 10 mM 3-[(3-
Cholamidopropyl)dimethylammonio]-1-propanesulfonate (CHAPS) for a total reaction 
volume of 250 μL. Eight aliquots from this solution were transferred into separate 1.5 mL 
microcentrifuge tubes and the respective DNase I in QIAGEN Buffer EB (10 mM Tris-
HCl, pH 8.5) amount was added into each. The reactions were incubated for 5 min at 37 
°C and followed by quenching the reaction by the addition of 10 µL 200 mM 
ethylenediaminetetraacetic acid (EDTA) and denaturation of the endonuclease at 100 °C 
for 2 min. The fragments were purified with a QIAquick PCR Purification Kit following 
the manufacturer’s instructions with a slight modification. Because salt anions compete 
with DNA during electrokinetic injection into the capillary,75 the filter-bound DNA 
samples were always washed twice with Buffer PE, allowing the buffer to stand for one 
minute before discarding. Furthermore, DNA elution was always performed by 
incubating the Buffer EB in the column membrane for 5 min. The samples were 
submitted to MU DNA Core for fragment analysis and the data were processed with 
GeneMarker Version 2.4.0.   
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2.3.5.3.2 PA1 Quantitative DNase I Footprinting 
 
Quantitative DNase I footprinting experiments were performed on the 368 bp 
(HPV18 7647-157) fragment to determine the PA1 binding sites and equilibrium binding 
constants in this region of the viral genome. To determine the equilibrium dissociation 
constant (Kd) values for PA1, quantitative DNase I footprinting reactions were performed 
at 200 pM DNA at 250 μL per reaction. Briefly, HPV18 DNA fragment stock was 
prepared in TKMC buffer and 10 mM CHAPS to yield a final DNA concentration of 200 
pM. Eight aliquots from this solution were transferred into separate 1.5 mL Eppendorf 
microcentrifuge tubes. A titration was then performed by increasing the concentration 
from 0 to 40 nM PA1 per tube, keeping the total DMSO concentration per reaction at 2 % 
v/v. Polyamide binding to the DNA fragment was carried out at 37 °C for 4 h to 
overnight. 
After the polyamide-DNA incubation period, DNase I digestion was performed at 37 
°C for 5 min with 0.01 AU of DNase I (as determined by a control DNase I 
fragmentation reaction). Each reaction was quenched by adding 10 µL of 200 mM 
EDTA, followed by denaturation of the enzyme at 100 °C for 2 min. The fragments were 
purified with a QIAquick PCR Purification Kit (Catalog # 28106) and submitted to MU 
DNA Core for fragment analysis. The data were processed with GeneMarker Version 
2.4.0. Quantitative DNase I footprinting was repeated at least three times. Equilibrium 
dissociation constants were determined separately per binding site and reported as the 
average of the separate trials.    
 
2.3.5.3.3 PA25 Quantitative DNase I Footprinting 
 
Quantitative DNase I footprinting experiments were performed on both the 305 bp 
(HPV18 7479-7783) and 368 bp (HPV18 7647-157) DNA fragments to determine the 
PA25 binding sites and equilibrium dissociation constants in the LCR region of the viral 
genome. To determine the equilibrium dissociation constants for PA25, quantitative 
DNase I footprinting reactions were performed at 200 pM of DNA (250 μL/reaction), as 
well as at 50 pM (1000 μL/reaction) due to the observed low Kd values at 200 pM DNA. 
Experiments at 10 pM DNA were also carried out; however, DNase I cutting displayed 
significant uneven cleavage throughout the DNA fragment (data not shown). PA25 
quantitative DNase I footprinting experiment were performed by preparing HPV18 DNA 
fragment stocks in TKMC buffer and 10 mM CHAPS to yield final DNA concentrations 
of 200 pM and 50 pM. Twelve aliquots from each solution were transferred into separate 
1.5 mL microcentrifuge tubes. Titrations were then performed by increasing the 
concentration from 0 to 40 nM PA25 per tube for samples containing 200 pM DNA, or 0 
to 10 nM PA25 for 50 pM DNA, keeping the total DMSO concentration per reaction at 2 
% v/v. Polyamide binding to the DNA fragment was carried out at 37 °C for 2.5 h to 
overnight.  
After the polyamide-DNA incubation period, DNase I digestion was performed at 37 
°C for 5 min with 0.06 AU of DNase I for the 305 bp fragment at 200 pM DNA and 0.01 
AU of DNase I for the 368 bp fragment (as determined by a control DNase I 
fragmentation reaction). For experiments conducted at 50 pM, 0.2 AU DNase I for the 
305 bp fragment and 0.1 AU of DNase I for the 368 bp fragment were used. Each 
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reaction was quenched by adding 50 µL of 200 mM EDTA, followed by denaturation of 
the enzyme at 100 °C for 2 min. Because the experiments at the lower 50 pM DNA 
concentration were carried out at 1000 μL per reaction, each sample was lyophilized 
overnight to reduce the sample volume prior to column purification. The fragments were 
purified with a QIAquick PCR Purification Kit and submitted to MU DNA Core for 
fragment analysis. The data were processed with GeneMarker Version 2.4.0. The analysis 
was repeated at least three times. Equilibrium dissociation constants were determined 
separately per binding site and reported as the average of the separate trials.   
 
2.3.5.3.4  Determination of Equilibrium Dissociation Constants (Kd Values) 
 
Increasing the ligand concentration and monitoring the decrease of cleavage product 
(as the integrated area under the curve) at particular nucleotide positions along the 305 bp 
and 368 bp HPV18 DNA fragments reveals the polyamide binding sites. Once these 
binding sites were established, a reference peak on the electropherogram was chosen in 
order to normalize the cleavage data. This reference peak must not fall within a 
polyamide binding site or a DNase I hypersensitive site. For the 305 bp DNA fragment 
corresponding to 7479-7783 bp of the HPV18 LCR, the reference peak at nucleotide 
7629 and nucleotide 7625 were chosen as the reference peaks for the 5’-FAM- and 5’-
HEX-labelled strands, respectively. For the 368 bp DNA fragment corresponding to 
7647-157 bp of the HPV18 LCR, the reference peak at nucleotide 7840 and nucleotide 
7837 were chosen as the reference peaks for the 5’-FAM- and 5’-HEX-labelled strands, 
respectively. 
In order to calculate the Kd values of the observed PA-binding events, the integrated 
area of at least one peak within a polyamide binding site—preferably one with a high 
signal-to-noise ratio found in the middle of the protected region—and the area of the 
respective reference peak were tabulated at each polyamide concentration. The ratio of 
the sample peak area (polyamide binding site peak) to the reference peak area was 
calculated. Since each sample was submitted as technical triplicates, the average of these 
ratios was used to calculate the normalized bound fraction of polyamide to DNA. The 
data were fit to both Langmuir and Hill equations (Equations 2.1 and 2.2) using 
Kaleidagraph 4.1.1 (Synergy Software).   
    (2.1) 
 
 
       
             (2.2) 
 
 
(θ = fraction bound, Ka = equilibrium association constant,  
n = Hill coefficient, [PA] = polyamide concentration) 
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2.3.5.4 Affinity Cleavage Experiments 
 
In order to determine the correct binding orientation of the polyamides within the 
protected regions on the HPV18 DNA fragments, affinity cleavage experiments were 
conducted using the EDTA conjugates of PA1 and PA25. This method relies on the 
sequence-specific cleavage of DNA by a hairpin polyamide covalently attached with 
EDTA onto its C-terminus (i.e., Ta tail) (Figure 2.8). In the presence of ferrous iron, 
oxygen and the reducing agent dithiothreitol (DTT), the catalytic formation of diffusible 
hydroxyl radicals occurs at the C-terminal EDTA and leads to oxidative cleavage of the 
DNA near this position. This cleavage pattern yields multiple neighboring cleavage sites 
with a Gaussian-like distribution due to the ability of the hydroxyl radicals to diffuse 
along the backbone of the DNA. Furthermore, the pattern is also asymmetrical compared 
to the opposite strand, exhibiting a 3’ shift from the location of the EDTA-Fe2+ when 
hydroxyl radicals are generated in the minor groove. The 3’ shift is a result of a 2 bp 
offset of the deoxyribose to its complement on the 3’ side of the minor groove of B-form 
DNA (Figure 2.9).64  
 
  
  
 
Figure 2.8. Chemical Structures of the PA1- and PA25-EDTA Affinity Cleavage (AC) Agents. Sequence-specific
DNA-binding polyamides PA1 and PA25 covalently modified at the C-terminus with EDTA moiety (red).
36 
 
 
 
  
Affinity cleavage experiments were performed using PA1-EDTA and PA25-EDTA 
to determine the PA binding orientations on the observed footprinting regions for DNase 
I footprinting experiments. The affinity cleavage reactions were performed using 1 nM of 
DNA (40 μL/reaction) in Tris-HCl buffer (10 mM Tris-HCl, pH 7.5) and 10 mM 
CHAPS. The cleavage agent, PA-EDTA conjugate, was complexed with 0.8 equivalent 
of Fe(II) in the form of ammounium iron(II) sulfate hexahydrate (Aldrich, Catalog # 
203505-25G). A titration was then performed by increasing the concentration from 0 to 
200 nM PA-EDTA per 1.5 mL microcentrifuge tube, keeping the total DMSO 
concentration per reaction at 2 % v/v. Polyamide binding to the DNA fragment was 
carried out at 37 °C for 4 h to overnight. After the polyamide-DNA incubation, the 
radical reaction was initiated by the addition of 5 μL 100 mM DTT to each reaction. 
DNA cleavage was performed at room temperature for 30 min. Each reaction was 
quenched by performing DNA purification with a QIAquick PCR Purification Kit. The 
samples were submitted to MU DNA Core for fragmentation analysis and the results 
were processed with GeneMarker Version 2.4.0.   
 
2.3.6 X-ray Crystallography Screening Matrix of Oligonucleotide with PA25 
 
DNA oligomers were purchased from Midland Certified Reagent Company (top 
strand: 5’-GGGATATTTTAGTTTGCGGCG-3’ and bottom strand: 5’-
CCGCAAACTAAAATATCCCCG-3’) and annealed by heating equimolar 
concentrations of these oligos at 95 °C for 5 min, followed by slow cooling to room 
temperature. DNA duplex used for X-ray crystallization screening is given in Figure 
2.10.  
Figure 2.9. Model for the Asymmetric Pattern Observed in Affinity Cleavage. Ferrous iron (Fe2+) is chelated by
the covalently attached EDTA group on the C-terminal Ta tail of the polyamide. The cleavage pattern of the
deoxyribose complement of the nucleotide closest to the ferrous iron on the top strand (5’ – 3’ from left to right) is
shifted by 2 bp in the 3’ direction. Figures adapted from Uil, et al. 2003 (permission # 4087221444733) and Dervan,
1986 (permission # 4087230173714).  
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The Natrix HT crystallization matrix (Hampton Research, Catalog # HR2-131) and a 
matrix generated from reagent conditions published in polyamide literature were used to 
screen crystallization conditions. The Natrix HT kit comes in a user-friendly 96-well 
format that provides a systematic variation in pH, buffer composition, salt and 
precipitant. On the other hand, the generated matrix was based on the crystallization of an 
8-ring cyclic polyamide to its cognate DNA binding site.45 The crystallization conditions 
reported were 21 % of 2-methyl-2,4-pentanediol (MPD), 35 mM calcium acetate and 10 
mM Tris pH 7.5.45 The generated matrix optimizes the MPD concentration from 50 to 10 
%, the calcium acetate concentration from 100 to 30 mM and two pH values (7.5 and 8.0) 
(see Table SI2.1).   
To perform the screening matrixes, four solution stocks were prepared. These stocks 
contained either a 1:1.3 DNA:PA25(formate) (KJK6076 ~98 % purity), 1:2 
DNA:PA25(formate), 1:1.3 DNA:PA25(TFA) (KTK6006 ~95 % purity) or 1:2 
DNA:PA25(TFA). The formate salt of PA25 was included in these experiments as it 
exhibits a higher solubility than its TFA analog. PA25 was added slowly in 1 µL 
intervals every 10 min at 40 °C to minimize polyamide aggregation. Once the correct 
amount of PA25 was added into the DNA sample in a microcentrifuge tube, the solution 
was incubated overnight at 37 °C. The final DNA and PA25 concentrations were 0.39 
mM and 0.51 mM for 1:1.3 DNA:PA25 solutions; and 0.39 mM and 0.78 mM for 1:2 
DNA:PA25 solutions, respectively. The next day, 40 µL of each crystallization reagent 
from either the Natrix HT matrix or the generated matrix were transferred into the 
appropriate reservoir of the crystallization plate. Using a new pipet tip, 1 μL of the 
crystallization reagent from the reservoir and 1 μL of either 1:1.3 or 1:2 DNA:PA 
solutions were added into each sitting drop well. The plates were sealed and carefully 
placed in a Thermo Scientific HERAtherm at 19 °C. After seven weeks, the plates were 
examined for crystal growth under a stereo microscope.  
 
2.3.7 Circular Dichroism (CD) Spectroscopy 
 
Circular dichroism is a spectroscopic technique that measures the absorption 
difference between left-handed and right-handed circularly polarized light by chiral 
Figure 2.10. DNA Fragment Used for X-ray Crystallography. PA25 is shown in between complementary DNA
strands of an oligomer used in X-ray crystallography screening experiments. The match binding site for PA25 is 5’-
W2G7W4-3’. The DNA mismatched nucleotides for PA25 are colored in red fonts; orange font illustrates nucleotides
that by themselves are not mismatched. The polyamide building blocks are represented by open circles for N-
methylpyrroles, filled circle for N-methylimidazole, diamonds for β-alanines, + for the Ta tail and a loop for γ-
aminobutyric acid. Thermodynamic values obtained for hairpin, self-dimer and DNA melting temperature from
http://mfold.rna.albany.edu/?q=mfold/DNA-Folding-Form, http://www.idtdna.com/analyzer/Applications/OligoAnalyzer/ and
http://www.basic.northwestern.edu/biotools/OligoCalc.html, respectively (DNA = 0.5 mM, NaCl = 50 mM, Mg++ = 1 mM). 
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molecules.76 Because this technique allows for the determination of interactions and 
conformations of biological macromolecules with their respective ligands, CD was used 
to measure the interactions of PA1 and PA2 to different DNA duplexes. 
DNA oligomers were purchased from IDT (CHC2050-1 top strand: 5’-
CCCAACCTATTTCGGT-3’ and bottom strand: 5’-ACCGAAATAGGTTGGG-3’; 
CHC2050-2 top strand: 5’-GCGAAGTTAATAGGCG-3’ and bottom strand: 5’-
CGCCTATTAACTTCGC-3’; CHC2050-3 top strand: 5’-GCGAACTTAATAGGCG-3’ 
and bottom strand: 5’-CGCCTATTAAGTTCGC-3’; CHC2050-GH6084C top strand: 5’-
GCGAAGTTAATATGCG-3’ and bottom strand: 5’-CGCATATTAACTTCGC; 
CHC2050-GH6084D top strand: 5’-GCGAACTTAATATGCG-3’ and bottom strand: 5’-
CGCATATTAAGTTCGC-3’) and separately dissolved in MilliQ H2O to make a solution 
of approximately 500 μM using the manufacturer’s determined nanomoles. The actual 
concentrations were determined by UV-Vis using the provided molar extinction 
coefficients. The complementary oligos were then annealed by heating equimolar 
concentrations (100 μM) at 95 °C for 30 s and allowed to slowly cool to room 
temperature.  
CHC2050-1 duplex corresponds to a PA1 binding site (Site #14 in Figure 2.22) 
found in the HPV18 368 bp fragment. A titration with PA1 was performed into a solution 
of the CHC2050-1 duplex. Site #14 can be explained by PA1 binding to a forward triple-
base-pair mismatch site or a reverse double-base-pair mismatch site (Figure 2.11).  
 
  
DNA sequences used for these experiments were flanked by GC nucleotides to 
decrease the possibility of multiple polyamide binding sites. Two titrations with PA1 
were conducted to determine whether binding of PA1 to a forward single-base-pair 
mismatch site exhibited qualitatively different spectra than binding to a reverse single-
base-pair mismatch site on a 16-mer DNA duplex (Figure 2.12). The sequences were 
designed with a single-base-pair mismatch at the nucleotides that interact with the γ-turn 
of PA1. The rationale was that PA1 would prefer the least number of PA-DNA 
mismatches and would have a slight preference for the forward orientation. 
Consequently, the forward binding orientation of PA1 on the CHC2050-2 duplex would 
lead to a single-base-pair mismatch at the γ-turn, where the reverse binding orientation 
(180o rotation of PA1 along its horizontal axis in Figure 2.12) results in a double-base-
pair-mismatch. On the other hand, binding of PA1 in the reverse orientation to the 
CHC2050-3 duplex might be more favorable because this conformation results in a 
Figure 2.11. DNA Sequence for CHC2050-1 Duplex Used in CD Experiments to Evaluate PA1 Binding to Site
#14. CHC2050-1 duplex presents a forward triple-base-pair-mismatch binding site and a reverse double-pair-mismatch
binding site to PA1. Forward and reverse binding orientations are boxed in red and blue, respectively. Mismatches for
the forward binding orientation are shown on the top strand in green, while mismatches for the reverse binding
orientation are highlighted on the bottom strand in orange. PA1 match binding site is 5’-W2G7-3’, where the letter W
(weak) stands for A or T. The polyamide building blocks are represented by open circles for N-methylpyrroles, filled
circle for N-methylimidazole, diamonds for β-alanines, + for the Ta tail and a loop for γ-aminobutyric acid.    
Forward orientation refers to alignment of the 
polyamide N-terminus to C-terminus vector with 
the 5’3’ direction of the DNA.  
Reverse orientation describes the polyamide N-
terminus to C-terminus vector alignment with 
the 3’5’ direction of the DNA. 
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single-base-pair mismatch at the γ-turn, in contrast to a double-base-pair mismatch in the 
forward binding orientation.  
 
 
  
The same experiment was performed using PA2 and two different match binding 
sequences. PA2 shares the same sequence as PA1, except that it has a chiral (R)-NH2 in 
the γ-turn. As a result, it recognizes the same DNA sequence (5’-W2G7-3’) as PA1; 
however, the chiral (R)-substitution on the γ-turn is expected to increase the binding 
preference for the forward orientation.77 The purpose of this experiment was to determine 
whether binding of PA2 to a forward match site exhibited qualitatively different spectra 
than binding to an oligomer with both a forward single-base-pair mismatch site and a 
reverse match site (Figure 2.13). 
 
  
CD measurements were performed in a 10 mm Quartz cuvette using a Jasco J-1500 
CD Spectrometer. Spectra were recorded from 450-200 nm. The baseline consisted of 
192 μL of Buffer EB. To this solution, 8 μL of 100 μM DNA duplex was added to the 
cuvette and mixed using a pipettor. The CD spectrum for this sample was acquired. A 
100 μM PA in DMSO was prepared. Titration of the polyamide was then performed by 
adding 1.6 μL aliquots of 100 μM PA into the solution of 4.0 μM DNA. After each 
aliquot addition, the solution was mixed using a pipettor and allowed to equilibrate for 5 
min before data collection. The resulting ratios ranged from 0.2 to 3.0 PA to DNA. All 
experiments were conducted at 20 °C and two scans were collected per sample using the 
CD parameter file Para1 in Spectra Manager Version 2.10.01. 
 
Figure 2.12. DNA Sequences for CHC2050-2 and -3 Duplexes Used in CD Experiments to Evaluate PA1 Binding
Orientation. CHC2050-2 duplex presents a forward single-base-pair-mismatch binding site to PA1, whereas the
CHC2050-3 duplex contains a reverse PA1 single-base-pair-mismatch binding site. Mismatches are located on the
nucleotides that make contact with the γ-turn from PA1. Red font highlights the nucleotides that are swapped in the
sequences. PA1 match binding site is 5’-W2G7-3’, where the letter W (weak) stands for A or T. The polyamide building
blocks are represented by open circles for N-methylpyrroles, filled circle for N-methylimidazole, diamonds for β-
alanines, + for the Ta tail and a loop for γ-aminobutyric acid.    
Figure 2.13. DNA Sequences for CHC2050-GH6084C and -D Duplexes Used in CD Experiments to Evaluate
PA2 Binding Orientation. CHC2050-GH6084C Duplex presents a forward match binding site to PA2, whereas the
CHC2050-GH6084D duplex contains a reverse match binding site and a forward single-base-pair-mismatch binding
site. Red font highlights the nucleotides that are swapped in the sequences. PA2 match binding site is 5’-W2G7-3’,
where the letter W (weak) stands for A or T. The polyamide building blocks are represented by open circles for N-
methylpyrroles, filled circle for N-methylimidazole, diamonds for β-alanines, + for the Ta tail and a loop for γ-
aminobutyric acid.    
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2.4 RESULTS 
 
We relied on DNase I footprinting and affinity cleavage experiments to map the 
binding sites of PA1 and PA25 on DNA fragments corresponding to the HPV18 LCR 
genomic region under cell-free conditions. We report that anti-HPV hairpin polyamides 
PA1 and PA25 bind avidly to the minor groove of A/T-rich sequences in the HPV18 
LCR with dissociation constants ranging from 0.4 to 2.6 nM. 
 
2.4.1 Restriction Digests of HPV18/pBR322 Clones 
 
In order to confirm that the correct plasmid DNA was transformed and amplified in 
JM109 E. coli cells, restriction digests using BamHI and EcoRI restriction enzymes were 
performed on the purified DNA. The BamHI restriction digest of HPV18/pBR322 is 
expected to generate three DNA fragments with sizes of 1.1 kb, 4.8 kb and 6.6 kb, 
respectively. On the other hand, the restriction digest of HPV18/pBR322 with EcoRI 
should produce two DNA fragments with sizes of 4.5 kb and 8.0 kb, respectively. The 
restriction enzyme profile of the fragmented plasmid DNA separated by agarose gel 
electrophoresis is presented in Figure 2.14. The observed restriction products are in 
agreement with the expected DNA bands for HPV18/pBR322 digestion with BamHI and 
EcoRI restriction enzymes. 
  
  
HPV18‐1  HPV18‐2 
1          2         3          4          5          6           7 
5.0 - 
Kilobases 
10.0 - 8.0 - 6.0 - 
4.0 - 
3.0 - 
2.0 - 
1.5 - 
1.0 - 
0.5 - 
Figure 2.14. Agarose Gel Electrophoresis of Restriction Digest for HPV18/pBR322. BamHI and EcoRI restriction
digests performed on two separate HPV18/pBR322 clones purified from E. coli JM109 cells. Lane 1 corresponds to a 1
kb DNA molecular weight ladder with the expected size in kilobases given on the left of the picture. Lanes 2-4 and
Lanes 5-7 illustrate the results for HPV18-1 and HPV18-2, respectively. Lanes 2 and 5 correspond to the uncut DNA
(12.219 kb). Lanes 3 and 6 correspond to restriction digest products of HPV18-1 and HPV18-2 samples treated with
BamHI restriction enzyme, respectively. Lanes 4 and 7 correspond to restriction digest products of HPV18-1 and
HPV18-2 samples treated with EcoRI restriction enzyme, respectively. 
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2.4.2 Sanger DNA Sequencing of the PCR-amplified DNA Fragments 
Corresponding to 7479-7783 bp and 7647-157 bp Regions within the HPV18 
LCR 
 
The approximate sizes of the PCR-amplified DNA fragments were first evaluated by 
agarose gel electrophoresis. For the DNA fragment corresponding to HPV18 7479-7783 
bp, the expected size is 305 bp; while the DNA fragment corresponding to HPV18 7647-
157 bp, the expected size is 368 bp. The observed apparent fragment sizes of the PCR-
amplified products separated by agarose gel electrophoresis are in agreement with the 
expected 305 and 368 bp fragment sizes (Figure 2.15). 
   
  
  
To ensure that the PCR-amplified fragments corresponded to the HPV 18 LCR 
regions from 7479 to 7783 bp and from 7647 to 157 bp, Sanger DNA sequencing was 
performed. The Sanger sequencing data matched the DNA sequences for both regions of 
the HPV18 LCR ((GenBank Accession No. X05015) (Figure 2.16). 
 
368 bp DNA fragment400 bp ‐ 500 bp ‐ 
1000 bp ‐ 
 1    2   3    4   5 
400 bp ‐ 300 bp ‐ 
 1   2    3   4    5    6    7    8   9   10 
305 bp DNA fragment 
A  B
Figure 2.15. Agarose Gel Electrophoresis of PCR Amplification of HPV18 LCR 7479-7783 (305 bp) and 7647-
157 (368 bp) Fragments. (A) HPV18 LCR 7479-7783; Lane 1 was loaded with a 100 bp DNA ladder size standard.
Lanes 3-10 contain the 305 bp fragment with 5’ fluorescent dyes. (B) HPV18 LCR 7647-157; Lane 1 was loaded with
the 100 bp DNA ladder size standard. Lanes 2 and 3 correspond to the PCR products of a reaction using primers
without 5’ fluorescent dyes for Sanger sequencing. Lanes 4 and 5 contain the 368 bp fragment with 5’ fluorescent dyes.
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2.4.3 DNase I Footprinting – CE Size Indexing for the 305 bp (7479-7783) and 368 
bp (7647-157) Using Sanger Sequencing Chemistry 
 
In order to accurately map the PA1 and PA25 binding sites on the HPV18 fragments 
(7479-7783 and 7647-157), the correct nucleotide position on the HPV18 genome must 
be accurately correlated to the relative CE mobility of the fragment terminating with the 
B 
D 
A 
C 
Figure 2.16. Sanger Sequencing Electropherograms and Regions Amplified from HPV18 LCR Sequence. Sanger
sequencing results for (A) 305 bp fragment 7479-7783 and (C) 368 bp fragment 7647-157 from HPV18. (B) HPV18
LCR sequence (7479-7783) with the expected sequence for the 305 bp fragment (highlighted). (D) HPV18 LCR
sequence (7137-104) is annotated with bold letters and the expected sequence for the 368 bp fragment has been
highlighted. Sanger sequencing results matched the DNA sequences of HPV18 (GenBank Accession No. X05015).
Data were processed using FinchTV v1.4.0.                
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nucleotide in question. Both the sequencing chemistry and the nature of 5’ dye influence 
the CE mobility of the DNA, and as a result the appropriate indexing method must be 
chosen. Particularly for quantitative DNase I footprinting, the cleavage products have a 
neutral hydroxyl group on the 3’ end and display a similar CE mobility to the neutral 
fragments generated by Sanger chemistry. Figure 2.17 provides the indexing of a short 
region and respective electropherogram plot for the USB Sanger sequencing results. In 
this technique, fragments terminating at each nucleotide along the DNA molecule are 
generated upon addition of a particular 2’, 3’-dideoxynucleotide by DNA polymerase. 
The generated fragments were in agreement with the viral genomic sequence of HPV18 
(GenBank Accession No. X05015). Nucleotide position on the HPV18 genome was then 
matched to the relative CE mobility of the fragment terminating with the nucleotide in 
question.  
 
 
  
Fragment indexing data used in DNase I footprinting experiments to correlate the CE 
size calling to sequencing results for both the top (5’-FAM) and bottom (5’-HEX) strands 
of the 305 bp (7479-7783) and 368 bp (7647-157) HPV18 fragments are provided in 
Figures SI2.2A, -B, -C and –D. The USB sequencing reactions performed with 20 ng/µL 
of template DNA yielded better output signal than those with 2 ng/µL of template DNA. 
 
2.4.4 Affinity Cleavage – CE Size Indexing for the 305 bp (7479-7783) and 368 bp 
(7647-157) Using Maxam-Gilbert Sequencing Chemistry 
 
As previously discussed, it is imperative to accurately index the CE fragment size to 
the actual nucleotide on the sequence of interest in order to correctly map the binding site 
of DNA-ligands. To accurately determine the cleavage site in hydroxyl radical 
footprinting and affinity cleavage experiments, the DNA fragment must be indexed by 
Figure 2.17. Representative USB Sequencing Electropherogram Results Indexed to a Short HPV18 Region
(7813-7778). Sample electropherogram (HEX channel) from USB sequencing of a region within the 368 bp fragment
(position in HPV18 from 7813 to 7778 bp). USB sequencing PCR reactions (20 ng/µL template DNA) with (A) ddATP
termination mix, (B) ddCTP termination mix, (C) ddGTP termination mix and (D) ddTTP termination mix. The table
on the right shows the apparent CE position versus the real position of the nucleotide in the fragment of the plotted
region. Data analyzed using GeneMarker Version 2.4.0 and Microsoft Excel 2010. 
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Maxam-Gilbert sequencing chemistry. In this technique, the DNA is cleaved by specific 
base modifications, followed by eviction of the modified bases and strand cleavage at 
these positions.73 The cleavage products from the Maxam-Gilbert sequencing reactions 
have a 3’-phosphate group. Similarly, the cleavage products for affinity cleavage 
experiments and hydroxyl radical footprinting have either a negatively charged phosphate 
group or a phosphoglycolate group on their 3’ end and display a similar CE mobility to 
the fragments generated by Maxam-Gilbert chemistry.72 Figure 2.18 presents a sample 
electropherogram region for the results from Maxam-Gilbert sequencing. The 
electropherogram clearly demonstrates the base modification preference of piperidine 
formate (pH 2.0) for purines and the preference of hydrazine for pyrimidines. In addition, 
the generated fragmentation peaks are in agreement with the viral genomic sequence of 
HPV18 (GenBank Accession No. X05015). Nucleotide position on the HPV18 genome 
was matches to the relative CE mobility of the fragment terminating with the nucleotide 
in question. 
 
Fragment indexing data used in affinity cleavage experiments to correlate the CE size 
calling to sequencing results for both the top (5’-FAM) and bottom (5’-HEX) strands of 
the 305 bp (7479-7783) and 368 bp (7647-157) HPV18 fragments are given in Figures 
SI2.3A, -B, -C and –D). The Maxam-Gilbert sequencing reactions performed for 15 and 
30 min yielded peaks with high signal-to-noise ratios. 
The difference between Sanger and Maxam-Gilbert fragment mobility were plotted 
(Figure 2.19). The results for the DNA fragments are in agreement with the results 
published by Gaofei et al.72 Particularly, the difference is significant (up to 8 nucleotides) 
for fragments of about 100 nucleotides and smaller. On the other hand, for fragments of 
200 nucleotides and larger, this difference reduces to about 2 to 0 nucleotides. Thus, the 
aforementioned observations provide evidence to the importance of indexing the DNA 
sequence prior to the determination of binding sites by either DNase I footprinting, 
affinity cleavage experiments or hydroxyl radical footprinting. 
 
Figure 2.18. Representative Maxam-Gilbert Sequencing Electropherogram Results Indexed to a Short HPV18
Region (7822-7847). Sample electropherogram (FAM channel) from Maxam-Gilbert sequencing of a region within the
368 bp fragment (position in HPV18 from 7822 to 7847 bp). Upper electropherogram illustrates the cleavage pattern
from DNA subjected to piperidine in formic acid (purine base modification); whereas the lower electropherogram
pattern was obtained from hydrazine cleavage (pyrimidine base modification). The table on the right tabulates the
apparent CE position vs the real position of the nucleotide in the fragment of the plotted region. Data analyzed using
GeneMarker Version 2.4.0 and Microsoft Excel 2010. 
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2.4.5 Quantitative DNase I Footprinting: Control DNase I Fragmentation 
 
Quantitative DNase I footprinting reactions must be conducted under conditions of 
single-hit kinetics.51 If the cleavage reaction is not performed under these conditions, the 
cleavage pattern will be biased toward small DNA fragments making it difficult to 
determine ligand footprints.  
Figure 2.20 shows sample electropherograms for the control fragmentation results of 
the 305 bp and 368 bp fragments. Analysis of the intact fluorescently labelled DNA 
fragments in the absence of DNase I did not display any fragmented products, suggesting 
that the DNA was not degraded prior to the cleavage reaction (Figure 2.20 top panels of 
A and B). On the other hand, high DNase I concentrations of 0.03 and 0.05 AU led to 
overdigestion of the 368 bp DNA fragment. The optimal cleavage under single-kit 
kinectic conditions were achieved at DNase I concentrations of 0.06 AU for the 305 bp 
fragment and 0.01 AU for the 368 bp fragment. The difference in the AU between the 
two experiments is most likely due to the age of the DNase I enzyme, as the control 
fragmentation experiment for the 305 bp DNA fragment was conducted months after the 
experiment for the 368 bp DNA fragment. At these DNase I concentrations, the cleavage 
peaks displayed relative fluorescence intensities many folds (~100X) lower than the 
relative fluorescence intensities for the uncut peaks, suggesting appropriate experimental 
conditions for single-hit kinetics. Consequently, these DNase I concentrations were used 
in subsequent quantitative DNase I footprinting experiments at 200 pM DNA. 
 
A 
B 
C 
D 
Figure 2.19. Difference between Sanger and Maxam-Gilbert Sequencing Fragment Mobility for HPV18
Sequences. Mobility difference between Sanger and Maxam-Gilbert (Sanger – Maxam-Gilbert) for (A) the top strand
(5’-FAM labeled) and (B) the bottom strand (5’-HEX labeled) of HPV18 7647-157, (C) the top strand (5’-FAM
labeled) and (D) the bottom strand (5’-HEX labeled) of HPV18 7479-7783. 
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2.4.6 DNase I Footprinting and Affinity Cleavage 
 
We relied on quantitative DNase I footprinting to determine the equilibrium 
dissociation constants of PA-DNA interactions and affinity cleavage experiments to 
assign the PA-binding orientations.   
 
2.4.6.1 PA1 Binding Sites on HPV18 7647-157 bp Determined by DNase I Footprinting 
and Affinity Cleavage Experiments 
 
The putative PA1 binding sites on HPV18 7647-157 were determined by following 
the published PA-DNA recognition rules.20,25,26 Figure SI2.4 maps the expected PA1 
binding sites on the 368 bp fragment covering match binding sites (5’-W2GW7-3’) to 
double-base-pair mismatch binding sites in both reverse and forward orientations. 
Forward orientation refers to alignment of the polyamide N-terminus to C-terminus 
vector with the 5’3’ direction of the DNA, whereas a reverse orientation describes the 
polyamide NC vector alignment with the 3’5’ direction of the DNA (Figure 2.21A).77  
The 368 bp fragment used in this analysis harbors three putative forward match 
binding sites and four reverse match binding sites for PA1. Additionally, there are 37 
predicted single-base-pair mismatch binding sites, while many more putative double-
base-pair mismatch binding sites. Many of these predicted binding sites cluster around 
A  B
Figure 2.20. Representative Electropherograms of Control DNase I Fragmentation. Electropherograms for (A)
305 bp (HPV18 7479-7783) and (B) 368 bp (HPV18 7647-157). Respective DNase I Activity Units (AU) are given in
the upper left corner of each electropherogram. No cleavage pattern with 0 AU was observed for both fragments, which
serves as a control to check for fragment contaminants or DNA degradation. At 0.03 and 0.05 AU DNase I, the 368 bp
fragment is over-digested. Optimal cleavage observed at DNase I concentration of 0.06 AU and 0.01 AU for 305 bp
and 368 bp fragments, respectively. Full length fragments are indicated with vertical orange arrows. 
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the E1 binding region between the E2 binding sites E2BS-1 (7822-7833) and E2BS-2 
(42-53) (see Figure SI2.4). 
Representative results from quantitative DNase I footprinting and affinity cleavage 
experiments corresponding to an HPV18 region bound by PA1 and PA1-EDTA are 
presented in Figure 2.21. The process of determining PA1 binding sites are shown in this 
representative region. To correctly assign the PA-binding orientations within these 
fragments, affinity cleavage experiments were conducted as described previously in the 
literature. Panel A shows both the forward and reverse binding orientations for PA1. 
Panel C provides the raw electropherograms for quantitative DNase I footprinting and 
affinity cleavage experiments. Panel B maps the predicted and observed binding sites for 
PA1 in the HPV18 region corresponding to 7770-7805 bp. Interestingly, PA1 binding to 
the single-base-pair mismatch sequence 5’-ATGAACTATA-3’ (mismatch underlined), as 
predicted following the reported DNA recognition rules, was not observed. On the other 
hand, PA1 binding to another single-base-pair mismatch site, 5’-TAGTCATATT-3’, was 
observed (furthest to the right). Furthermore, a second polyamide binding event was 
observed to the sequence 5’-AACTATAATA-3’, but the polyamide binding orientation 
cannot be determined unequivocally. As a result, both of the possible binding modes are 
illustrated (labelled as Reverse match site or Single-base-pair mismatch). PA1 binding in 
the forward orientation leads to a single-base-pair mismatch at N-methylimidazole, while 
the reverse orientation presents the match site for PA1. 
 
 
 
0 nM PA1 
5 nM PA1 
25 nM PA1‐EDTA 
Affinity Cleavage 
A  C
B 
Figure 2.21. Caption on next page. 
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The PA1 binding events determined from quantitative DNase I footprinting and 
affinity cleavage experiments in the HPV18 LCR corresponding to 7647-157 bp are 
mapped in Figure 2.22. The sequence map summarizes the PA1 binding sites with their 
respective equilibrium dissociation values calculated using the Hill equation followed by 
the standard deviations in parentheses. Table 2.5 summarizes only the higher affinity 
sites (PA1 DNase I footprinting at 5 nM PA / affinity cleavage patterns at 50 nM PA 
conducted at 200 pM DNA and at 1 nM DNA, respectively). 
The binding events are assigned assuming that PA1 has a preference for the lowest 
number of PA-DNA mismatches and prefers the forward orientation binding mode. 
Because the binding orientation (forward vs. reverse) cannot be determined 
unequivocally by our experiments, both the forward orientations and their respective 
reverse, lower mismatch partners are shown in Figure 2.22. This map also includes 
yellow highlighted sequences for observed PA1 footprinting regions at 5 nM and grey 
highlighted sequences for footprinting regions that appeared at 10 nM PA1. The 3’ shift 
of the footprinting patterns observed in our experiments is consistent with DNA cleavage 
by DNase I originating on the minor groove of the B-form DNA.63 
Using the indexing obtained from Maxam-Gilbert sequencing experiments, the actual 
nucleotide positions of the hydroxyl radical attack sites were determined. The obtained 
affinity cleavage patterns revealed an asymmetrical 3’ shift between opposite DNA 
strands, which agrees with PA1-binding to the minor groove of B-form DNA. A total of 
24 distinct affinity cleavage sites were observed by PA1-EDTA affinity cleavage 
experiments and these were labeled 1 through 24 based on their position within the 
fragment. Out of these sites, 16 were observed at 25 and 50 nM PA1 in affinity cleavage 
experiments. The affinity cleavage patterns were obtained for both strands of the binding 
sites except for Site #1 because it is positioned near the beginning of the fragment in the 
FAM channel. Similarly, DNase I footprints were not shown for the first and last 50 
nucleotides of the map. Binding events were determined by the presence of DNase I 
footprints with affinity cleavage flanking at least one end of these protected regions. 
While all of the predicted PA1 match binding sites were in agreement with the affinity 
cleavage and DNase I footprints, various predicted single-base-pair mismatch PA1 
Figure 2.21. Schematic Representation of the Predicted and Observed Binding Sites in HPV18 LCR DNA from
7770-7805 bp for PA1. (A) Binding orientations for PA1 are depicted in between complementary DNA strands. The
DNA match site for PA1 is 5’-W2G7-3’, where the letter W (weak) stands for A or T. The polyamide building blocks
are represented by open circles for N-methylpyrroles, filled circle for N-methylimidazole, diamonds for β-alanines, +
for the Ta tail and a loop for γ-aminobutyric acid. (B) Map of the predicted and observed binding sites along with their
corresponding binding orientations with respect to the Ta tail for PA1 as determined by quantitative DNase I
footprinting and affinity cleavage experiments. Bold sequences depict the observed binding sites as determined from
the plots in Panel C (compare 0 nM and 5 nM polyamide). The respective cleavage patterns are shown as arrows above
or below the DNA sequences. Affinity cleavage patterns were determined from the lower plot from Panel C for the top
strand (affinity cleavage electropherogram for the bottom strand is not shown). Interestingly, PA1 binding to the single-
base-pair mismatch sequence 5’-ATGAACTATA-3’ (mismatch underlined), as predicted following the reported DNA
recognition rules, was not observed. On the other hand, polyamide binding was observed for 5’-TAGTCATATT-3’
(furthest to the right). Furthermore, a second polyamide binding event was observed to the sequence 5’-
AACTATAATA-3’, but the polyamide binding orientation cannot be determined unequivocally. As a result, both of the
possible binding modes are illustrated (labelled as Reverse match site or Single-base-pair mismatch). PA1 binding in
the forward orientation leads to a single-base-pair mismatch at N-methylimidazole, while the reverse orientation
presents the match site for PA1. (C) Raw electropherograms of the HPV18 LCR 7770-7805 sequence using DNase I
footprinting and affinity cleavage. The top panel shows the control DNase I fragmentation (0 nM polyamide) and the
middle panel illustrates the protected region (solid line above pattern) upon addition of 5 nM of PA1. Affinity cleavage
was performed with EDTA-modified PA1 at its Ta tail.  
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binding sites did not produce DNase I footprints and/or did not agree with the observed 
affinity cleavage patterns (Figure SI2.5 & Table SI2.2).   
Each observed site will be briefly discussed in this section. Site #1 is best described 
by PA1 binding in the forward orientation to the match site at genomic position 7669-
7678, while Site #2 corresponds to a single-base-pair mismatch site (7673-7682). 
Although the map shows these two PA1 hairpin polyamides overlapping in their 
recognition sequences, it is unlikely that two hairpin polyamides would fit concurrently 
side-by-side in the minor groove of the DNA duplex. Instead, this apparent overlapping is 
due to the experimental conditions, which require an ensemble of DNA and polyamide 
molecules, leading to an averaged-out determination of DNA-PA interactions. In this 
manner, a population of DNA molecules would be cleaved by PA1-EDTA at Site #1 
while others would be cleaved at Site #2. This rationale applies to other sites on this map 
and PA25 maps. 
Site #3 can be explained by three different forward double-base-pair mismatch 
binding events to the genomic sequence spanning 7694 to 7705. However, the affinity 
cleavage patterns suggest that only one polyamide may bind at this site with the 
polyamide in the middle (7695-7704) displaying the best fit with the top and bottom 
affinity cleavage patterns. In the case of Site #4, the affinity cleavage pattern and DNase I 
footprinting results agree with PA1 binding to either a reverse match site or a forward 
single-base-pair mismatch on 7695-7704, as well as PA1 binding to a forward single-
base-pair mismatch site (7704-7713). It is not clear at this point which of these binding 
sites and conformations (forward vs. reverse) are occupied by the polyamide. The 
dissociation constant shared by PA1 in Site #3 and Site #4 was determined as 1.5(7) nM 
with a Hill coefficient (n) of 1.76 (see Figure SI2.6 for sample binding isotherms). 
Site #5 is best described by PA1 binding in a forward orientation to a single-base-pair 
mismatch site with a Kd of 1.2(4) (n = 1.76) from the FAM channel and 1.4(1) nM (n = 
1.51) from the HEX channel. Similar to Site #4, Site #9 has two possible PA1 binding 
conformations: a reverse match site and a forward single-base-pair mismatch site on the 
same DNA sequence (7782-7791), which cannot be differentiated by our experiments. 
The determined Kd values at Site #9 are 1.9(4) nM (n = 1.63) and 1.2(2) nM (n = 1.45) 
for FAM and HEX channels, respectively. 
Site #10 is in agreement with two predicted single-base-pair mismatch sites (reverse 
7786-7795 and forward 7788-7797) and one forward double-base-pair mismatch site 
(7786-7795). However, the latter fits the highest intensity affinity cleavage pattern better 
than the former. Furthermore, the diffuse nature of the low intensity affinity cleavage 
pattern suggests that PA1 can populate multiple, adjacent double-base-pair mismatch 
sites. The Kd vlues for Site #10 were determined as 1.5(2) nM (n = 2.14) and 1.2(2) nM 
(n = 1.45) for FAM and HEX channels, respectively.   
Unlike all of the other high affinity cleavage sites, Site #12 and #13 are best 
explained by PA1 binding in the forward orientation to two double-base-pair mismatch 
sites (7811-7820 and 7813-7822). However, the generated patterns were low in intensity 
and the Kd values were slightly higher with values of 2.9(3) nM (n = 3.20) and 2.5(3) nM 
(n = 1.72) for FAM and HEX channels, respectively. These two sites bind in close 
proximity (Site #12) or overlap by one nucleotide (Site #13) with E2BS-1 (7822-7833). 
Sites #15, #16, #17, #18 and #19 bind to the E1-binding region of HPV18.78 Site #15 
can be explained by PA1 binding to a forward single-base-pair mismatch site on 7845-
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7854, a reverse match site (7855-7) or a forward single-base-pair mismatch site (7855-7). 
The forward single-base-pair mismatch site at 7845-7854 is bound by PA1 because these 
nucleotides displayed DNase I footprinting at 5 nM PA with a calculated Kd values of 
3.1(5) nM (n = 2.25), 2.6(3) nM (n = 2.70), 2.3(5) nM (n = 2.52) and 2.1(5) nM (2.25) 
from both CE channels. On the other hand, the binding orientation for PA1 on the 
HPV18 sequence from 7855 to 7 cannot be determined based on the data; therefore, both 
the forward single-base-pair mismatch and the reverse match binding modes are 
represented. Furthermore, it is not completely clear if PA1 even binds this sequence 
because Site #15 can be generated by PA1 binding to 7845-7854. Sites #16 and #17 are 
best described by PA1 binding to a forward single-base-pair mismatch site and a forward 
match binding site, respectively. The dissociation constant values shared by PA1 in Sites 
#15, #16 and #17 are 1.2(1) nM (n = 1.71), 1.1(1) nM (n = 1.58) and 1.8(6) nM (n=1.60). 
Site #18 can be explained by PA1 binding in the forward orientation to the match site at 
genomic position 21-30, while Site #19 corresponds to two adjacent single-base-pair 
mismatch sites (24-33 and 25-34). The latter two binding events are within a DNA turn 
from the E2 Binding Site 2 (E2BS-2 42-53). The shared Kd values for Sites #18 and #19 
were determined as 1.4(2) nM (n = 1.93) and 1.9(1) nM (n = 2.41) for FAM and HEX 
channels, respectively. 
Sites #22 and #23 are in close proximity to E2 binding site 3 (E2BS-3 7822-7833). 
Site #22 is best described by PA1 binding in the forward orientation to a single-base-pair 
mismatch at genomic position 68-77 with a Kd value of 1.6(4) nM (n = 1.85), while Site 
#23 corresponds to PA1 recognizing either a forward single-base-pair mismatch site 
and/or a reverse match binding site (73-82) with Kd values of 1.6(4) nM (n = 1.85) and 
1.5(4) nM (n = 1.49).   
On the other hand, the affinity cleavage patterns for Sites #6-8, #11, #14, #20, #21 
and #24 were only observed at high PA1 concentrations (>100 nM) and their calculated 
Kd values were the highest for this fragment. Furthermore, these sites also exhibited large 
Hill coefficient values with Site #11, #14 and #24 displaying the high binding 
cooperativity (n = 2.81, n = 3.76, n = 4.34, respectively).  
In summary, all of the predicted PA1 match binding sites are in agreement with 
DNase I footprints and affinity cleavage pattern(s) flanking these protected regions. In 
contrast, various predicted single-base-pair mismatch PA1 binding sites did not produce 
DNase I footprints and/or did not agree with the observed affinity cleavage patterns, 
indicating that these sites were not bound by the hairpin polyamide (see Figure SI2.5 & 
Table SI2.2). Perhaps these observations are due to the fact that the published PA-DNA 
recognition rules, while they provide an overall prediction of polyamide binding, do not 
account for subtle DNA structural differences between seemingly equivalent DNA 
sequences. Furthermore, these rules fail to include the flanking sequences around the 
predicted binding site and other binding sites nearby that may induce a conformational 
change in the local DNA structure. Thus, recognition of the minor groove by PA1 is not 
simply based on the established PA-DNA recognition rules. 
The high affinity DNase I footprinting (5 nM PA) sites and affinity cleavage patterns 
(25 and 50 nM PA) can be explained with binding sites corresponding to match, single- 
and double-base-pair mismatches. On the other hand, low affinity sites—DNase I 
footprints at 10 nM PA and affinity cleavage patterns at 100 nM PA—required 
polyamide binding to sites with double-, triple- and even quadruple-base-pair 
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mismatches. The equilibrium dissociation constants determined by the Hill-calculated 
binding isotherms ranged from 1.1 to 1.9 nM for match binding sites and from 1.2 to 3.1 
nM for single-base-pair mismatch binding sites. These results indicated that a single-
base-pair mismatch in the binding sequence was tolerated and conferred little to no effect 
on the equilibrium dissociation constant.   
Binding of PA1 to the HPV18 origin of replication may be of importance to the 
antiviral activity of PA1 against HPV18. The 368 bp fragment harbors the viral origin of 
replication, the E2 binding sites (E2BS-1 7822-7833; E2BS-2 42-53; E2BS-3 58-69) and 
the E1 binding site (E1BS 3-18). Because PA1 binds to the E1 binding region and in 
close proximity to the E2 binding sites, this DNA minor groove binder may preclude 
binding of the essential viral proteins E1 and E2 in infected cells to the origin of 
replication by steric hindrance or by modifying the local viral DNA structure.   
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Figure 2.22. PA1 Binding Sites and Hill-Calculated Equilibrium Dissociation Constants on the HPV18 Region
Corresponding to 7647-157 bp. The DNA duplex for the 368 bp HPV18 DNA fragment is shown along with PA1
represented as arrows at its respective binding sites. PA1 is depicted with either a solid arrow (forward orientation) or a
dashed arrow (reverse orientation). HPV E2 binding sites are depicted in green boxes. HPV E1 binds in the region
(HPV18 3-19 bp) flanked by the first and second E2 binding sites. The origin of replication is marked with 1. Numbers
on the left correspond to the nucleotide position in HPV18 genome. Equilibrium dissociation constants calculated using
the Hill equation from the FAM and HEX channels of CE at the particular nucleotide (bold) are given. The sample
standard deviations are in parentheses. Affinity cleavage patterns at 25-50 nM (black arrows) and 100 nM (red arrows)
PA1-EDTA are illustrated. At high polyamide concentrations of 100 nM PA1-EDTA and above, new binding sites in
the 368 bp fragment are populated by the polyamide. Yellow highlighted sequences represent footprinting regions
observed at 5 nM PA1, whereas gray highlighted sequences represent footprinting regions observed at 10 nM PA1.   
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Table 2.5. PA1 Sites on 368 bp Fragment Corresponding to HPV18 7647-157 bp.  
AC 
site 
# 
Sequence Position Site type 
Binding 
orientation 
Integration 
nt 
Kd (nM) 
DNase I 
Hill 
Coeff. 
1 TCCCT AAGTAATAAA ACTGC  7669-7678 Perfect Forward ND ND ND 
2 AAAAG CAGTTTTATT ACTTA 7682-7673 Single Forward ND ND ND 
3a GGCAC ATATTTTAGT TTGTT 7694-7703 Double Forward 7704 1.5 + 0.7 1.76 
3a GCACA TATTTTAGTT TGTTT 7695-7704 Double Forward    
3a CACAT ATTTTAGTTT GTTTT 7696-7705 Double Forward    
4 AAACA AACTAAAATA TGTGC 7704-7695 Single Forward    
   Perfect Reverse    
4 TTAGT TTGTTTTTAC TTAAG 7704-7713 Single Forward 7711 1.4 + 0.1 1.51 
5 AGCTT AAGTAAAAAC AAACT 7715-7706 Single Forward    
9 ACATG AACTATAATA TGACT 7782-7791 Single Forward 7787 1.2 + 0.2 1.45 
   Perfect Reverse    
10 GCTTA GTCATATTAT AGTTC 7795-7786 Single Reverse 7794 1.5 + 0.2 2.14 
10 CAGCT TAGTCATATT ATAGT 7797-7788 Single Forward    
12 ATACA TAGTTTATGC AACCG 7811-7820 Double Forward 7818 2.9 + 0.3 3.20 
13 TCGGT TGCATAAACT ATGTA 7822-7813 Double Forward    
15 ATGAA AAGTATAGTA TGTGC 7854-7845 Single Forward 7850 2.6 + 0.3 2.70 
15 TACTT TTCATTAATA CTTTT 7855-7 Single Forward 2 1.2 + 0.1 1.71 
   Perfect  Reverse    
16 TATTA ATGAAAAGTA TAGTA 2-7850 Single Forward    
17 GTTAA AAGTATTAAT GAAAA 10-1 Perfect Forward    
18 AATTG TAGTATATAA AAAAG 21-30 Perfect Forward 28 1.9 + 0.1 2.41 
19 TCCCT TTTTTATATA CTACA 33-24 Single Forward    
19 CTCCC TTTTTTATAT ACTAC 34-25 Single Forward    
22 AAACG GTGTATATAA AAGAT 68-77 Single Forward 76 1.6 + 0.4 1.85 
23 CTCAC ATCTTTTATA TACAC 82-73 Single Forward    
The affinity cleavage (AC) site # corresponds to the AC patterns in the map provided in the previous page. The PA1 
binding sequences are given in a 5’ to 3’ direction and include 5 nucleotide (nt) flanking regions. The bold nt highlights 
the position where the polyamide imidazole/pyrrole pair binds. Position corresponds to the HPV18 genomic 
nucleotides. The forward binding orientation refers to alignment of the polyamide N-terminus to C-terminus vector 
with the 5’3’ direction of the DNA, whereas a reverse orientation describes the polyamide NC vector alignment 
with the 3’5’ direction of the DNA.                
ND, Not determined. Sites 1 and 2 are found in the beginning of the fragment. All of the predicted PA1 match (perfect) 
sequences where supported by both affinity cleavage patterns and DNase I footprinting results.                                
a A single binding event cannot be assigned due to significant overlap of the predicted PA1 recognition sequences. 
2.4.6.2 PA1 WebLogo 3.3 Motif Analysis  
 
In order to create a graphical representation of the consensus DNA binding sequence 
for PA1, the observed binding sites were inputted into WebLogo 3.3 
(http://weblogo.threeplusone.com/create.cgi). WebLogo 3.3 is a sequence logo 
generator that displays the nucleotide conservation at a particular position for multiple 
user-generated aligned sequences.79 Sequences with DNase I footprinting and flanked 
with the appropriate affinity cleavage pattern (observed in 25 nM and 50 nM PA1-
EDTA) were used to generate the WebLogo plot shown in Figure 2.23 (sample size of n 
= 30). The sequence input consisted of DNA sequences from the strand recognized by the 
N-terminal, top strand of PA1 with polyamide orientations (forward or reverse) leading 
to the lowest DNA-PA mismatches. 
WebLogo analysis (Figure 2.23) confirms that PA1 binds to A/T-rich sequences with 
a strong preference of the imidazole unit of PA1 recognizing the guanine base in the 
duplex DNA. Furthermore, base-pair mismatches are allowed in all of the positions in the 
binding region except the position occupied by a β-alanine on the top strand of PA1 in 
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this data set; however, data from other HPV18 LCR fragments suggest that this position 
can also accommodate mismatches. Because the DNA sequences presented to the PA1 
are limited, these observations can be verified using high-throughput method coupled 
with massively parallel sequencing (see Chapter 5). Thus, random oligonucleotides with 
all the possible DNA sequence permutations in a redundant manner can be interrogated.  
 
2.4.6.3 PA25 Binding Sites Determined by DNase I Footprinting and Affinity Cleavage 
Experiments 
 
The putative PA25 binding sites on HPV18 7479-7783 bp and HPV18 7647-157 bp 
were determined by following the published PA-DNA recognition rules.20,25,26 Figures 
SI2.7 and SI2.8 map the expected PA25 binding sites on the 305 bp and 368 bp 
fragments covering match binding sites (5’-W2GW5GW4-3’) to triple-base-pair mismatch 
binding sites in both reverse and forward orientations. For the two HPV18 LCR 
fragments studied, there are zero PA25 predicted match binding sites. 
Figures 2.24-2.27 (tabulated data in Tables 2.6-2.9) summarize the binding sites, 
affinity cleavage patterns and Kd values for PA25 determined on the 305 bp (7479-7783 
bp) and 368 bp (7647-157 bp) fragments. 
The equilibrium dissociation constants were determined using both the FAM and HEX 
channels from the CE results. The data were fitted to both Langmuir and Hill equations 
using Kaleidagraph 4.1.1. Some equilibrium dissociation constants could not be 
calculated due to been positioned at the beginning of the DNA fragments or because of 
low signal-to-noise ratios. Thus, the two fragments were designed to overlap in order to 
obtain the binding sites at the beginning of the 368 bp fragment. In line with PA1, the 
Figure 2.23. WebLogo Plot for PA1 Binding Sites Observed on the HPV18 Region Corresponding to 7647-157
bp. The relative probability of a given nucleotide to be found in a particular position is represented by the height of the
letter (A = Adenine, T = Thymine, G = Guanine and C = Cytosine). Red box encloses the PA1 binding site. The input
sequences including the flanking DNA sequences (5 bp) are given below the plot. No obvious trend is observed for the
presence or relative position of polyA tracts in or immediately adjacent to the PA1 binding site. 
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assumption is that PA25 has a preference for the lowest number of mismatches, thus 
PA25 may bind in both reverse and forward orientations. However, the binding 
orientation (forward vs. reverse) cannot be determined unequivocally by our experiments, 
thereby, both the forward orientations and their respective reverse, lower mismatch 
partners are shown in Figures 2.24-2.27. These figures include cases where forward 
orientations can also bind in the reverse orientation with one lower mismatch. These 
maps also include yellow highlighted sequences for observed PA25 footprinting regions 
at 2 nM PA25 and grey highlighted sequences for footprinting regions that appeared at 5 
nM PA25 for titrations performed with 200 pM DNA (Figures 2.24 and 2.26). For 
titrations performed with 50 pM DNA, the yellow highlighted sequences correspond to 
footprints observes at 0.5 nM PA25 and the grey highlighted sequences show footprints 
that appeared at 1 nM PA25 (Figures 2.25 and 2.27). Analogous to the previously 
discussed PA1 analysis, the 3’ shift of the footprinting patterns is consistent with the 
DNase I-mediated cleavage of DNA occurring in the minor groove. DNase I footprints 
were not shown for the first and last 50 nucleotides of the map. Binding events were 
determined by the presence of DNase I footprints with affinity cleavage flanking at least 
one end of these protected regions.  
  
2.4.6.4 PA25 Binding Sites Mapped on HPV18 7479-7783 bp 
 
A total of 20 distinct affinity cleavage sites were observed by PA25-EDTA affinity 
cleavage experiments and these were labeled 1 through 20 based on their position in the 
fragment. Out of these sites, 16 were observed in affinity cleavage experiments with 25 
and 50 nM PA25. The affinity cleavage patterns were obtained for both strands of the 
binding sites except for Site #20 because it is positioned near the end of the fragment in 
the FAM channel. There are zero predicted match binding sites for PA25 on this 
fragment. And similar to PA1 results, a predicted single-base-pair mismatch PA25 
binding site (7721-7709) did not generate an affinity cleavage pattern (Figure SI2.9 and 
Table SI2.3).   
Refer to Figures 2.24 and 2.25, as each observed site will be briefly discussed in this 
section. Site #1 is best described by PA25 binding to two forward triple-base-pair 
mismatch sites (7531-7519 and 7528-7540) and a reverse double-base-pair mismatch 
(7528-7540), while Site #2 corresponds to a forward double-base-pair mismatch site 
(7538-7526). It is not clear at this point which of these sites and conformations are bound 
by PA25. Although the affinity cleavage pattern for Sites #1 and #2 do not fit perfectly 
with the described PA25 binding, moving PA25 to 7518-7530 and 7528-7540 leads to a 
quintuple-base-pair mismatch site and a quadruple-base-pair mismatch site, respectively. 
Instead, the disagreement between the affinity cleavage and the described PA25 binding 
may be due to a difference between the fragment indexing and the size calling in the 
experiment as this site is positioned at the beginning/end of the fragment. The shared Kd 
values for Sites #1 and #2 were determined as 0.4(1) nM (n = 1.91) and 0.5(2) nM (n = 
2.21) at 200 pM DNA, and 0.3(2) nM (n = 1.99) and 0.11(1) nM (n = 1.48) at 50 pM 
DNA. Representative binding isotherms are provided in Figure SI2.10. 
Site #3 can be explained by three forward triple-base-pair mismatch sites (7553-7565, 
7555-7567 and 7558-7570) and two reverse double-base-pair mismatch sites 
corresponding to 7553-7565 and 7558-7570. Of the sites mentioned, the forward triple-
56 
 
base-pair mismatch site at 7555-7567 fits best the observed affinity cleavage pattern. In 
the case of Site #5, the affinity cleavage pattern and DNase I footprinting results agree 
with PA25 binding to a forward double-base-pair mismatch site at 7568-7556 and a 
reverse triple-base-pair mismatch site at 7571-7559. The former fits the affinity cleavage 
pattern and DNase I footprint better than the site at 7571-7559. The PA25 dissociation 
constants for Sites #3 and #5 were determined to be 0.7(3) nM (n = 2.13) and 0.6(1) nM 
(n = 1.88) at 200 pM DNA, and 0.43(9) nM (n = 3.09) and 0.24(9) nM (n = 1.35) at 50 
pM DNA. 
Site #8 is best described by PA25 binding in a reverse orientation to a triple-base-pair 
mismatch site (7605-7617), but it may also bind in a forward orientation to a double-
base-pair mismatch site nearby on the sequence corresponding to 7603-7615. Similarly, 
Site #9 is better described by PA25 binding to a reverse triple-base-pair mismatch site on 
7617-7605 than PA25 binding to a forward double-base-pair mismatch site on 7621-
7609. The determined Kd values at Sites #8 and #9 are 0.9(1) nM (n = 2.40) at 200 pM 
DNA and 0.35(5) nM (n = 1.91) at 50 pM DNA.   
Site #10 is in agreement with a reverse triple-base-pair mismatch site (7637-7649), 
while Site #11 can be explained as PA25 binding to a forward triple-base-pair mismatch 
site (7651-7639). Although a reverse double-base-pair mismatch site is found at 7652-
7664, the DNase I footprint does not suggest PA25 binding to this region. The Kd values 
shared by Sites #10 and #11 were determined to be 1.0(4) nM (n = 2.87) and 0.9(3) nM 
(n = 2.24) at 200 pM DNA, and 0.24(1) nM (n = 1.51) and 0.3(1) nM (n = 1.69) at 50 pM 
DNA. 
Site #12 is best described by PA25 binding in a forward orientation to a single-base-
pair mismatch site on 7662-7650 with dissociation constants of 0.9(3) nM (n = 2.23) at 
200 pM DNA and 0.32(4) nM (n = 1.78) at 50 pM DNA. 
Because the end of the 305 bp fragment (7479-7783) overlaps with the beginning of 
the 368 bp fragment (7647-157), the remaining Sites will be discussed in the context of 
the 368 bp fragment (see below). The affinity cleavage patterns and DNase I footprints in 
the overlapping region of the two fragments are in agreement, except for Site #17 which 
is observed for the 305 bp fragment, but not the 368 bp fragment. Because Sites #13-16 
were too close to the beginning of the 368 bp (7647-157) fragment, the Kd values were 
determined using the 305 bp fragment (7479-7783). Site #13 can be explained by PA25 
binding in the forward orientation to the double-base-pair mismatch site at genomic 
position 7669-7681, while Site #15 can be explained by two different triple-base-pair 
mismatch binding events in the forward conformations to positions 7685-7673 and 7688-
7676. The PA25 Kd value for the region shared by Site #13 and #15 was determined as 
0.9(5) nM (n = 1.30) and 0.8(5) nM (n = 3.78) at 200 pM DNA, while at 50 pM DNA 
these values decreased to 0.5(3) nM (n = 1.89) and 0.2(1) nM (n = 1.39).  
For Site #16, the affinity cleavage pattern and DNase I footprinting results agree with 
PA25 binding to a forward double-base-pair mismatch site on 7694-7706. Site #17 was 
only observed in the 305 bp fragment and can be explained by PA25 binding to two 
different forward triple-base-pair mismatch sites and two reverse double-base-pair 
mismatch sites. The Kd values shared by Sites #16 and #17 were determined as 0.4(3) nM 
(n = 1.84) at 200 pM DNA and 0.11(3) nM (n = 1.28) at 50 pM DNA. Site #18 is best 
described by PA25 binding in a reverse orientation to a single-base-pair mismatch site, 
while Site #19 can be explained by a forward double-base-pair mismatch site on 7715-
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7703. Site #20 fits the predicted forward triple-base-pair mismatch site on 7727-7715. 
The determined Kd values at the region shared by these sites were 0.43(8) nM (n = 1.72) 
at 200 pM DNA and 0.14(9) nM (n = 1.40) at 50 pM DNA. 
On the other hand, affinity cleavage patterns for Sites #4, #6-7 and #14 were only 
observed at high PA25 concentrations (>100 nM). Furthermore, Sites #6 and #7 
exhibited large Hill coefficients values (n = 3.54) and high Kd values (2.7 + 0.6 nM).  
A predicted single-base-pair mismatch PA25 binding site did not produce an affinity 
cleavage pattern, indicating that this site was not bound by the hairpin polyamide. Thus, 
recognition of the minor groove by PA25, similar to PA1, is not simply based on the 
established recognition rules. 
In summary, the equilibrium dissociation constants determined by the Hill equation at 
a DNA concentration of 200 pM ranged from 0.4 nM to 1.2 nM for binding events that 
generated affinity cleavage patterns at 25 and 50 nM of PA25-EDTA. When the DNA 
concentration was lowered to 50 pM, these equilibrium dissociation constants decreased 
to 0.1-0.5 nM.   
The high affinity DNase I footprinting sites (2 nM PA25) and affinity cleavage 
patterns (25 and 50 nM PA25-EDTA) can be explained with binding sites corresponding 
to single-, double-, and triple-base-pair mismatches. On the other hand, low affinity sites, 
DNase I footprints at 5 nM PA25 and affinity cleavage patterns at 100 nM PA25-EDTA, 
required polyamide binding to sites with double-, triple-, quadruple- and quintuple-base-
pair mismatches. In contrast to PA1, PA25 has the ability to tolerate a higher number of 
base-pair mismatches, probably due to its expected larger DNA binding site. Analogous 
to the results obtained for PA1, a predicted PA25 single-base-pair mismatch site did not 
agree with the observed affinity cleavage patterns or produced low affinity cleavage 
patterns close to the noise level, indicating that these sites were not bound or were weakly 
bound by the hairpin polyamide.  
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Figure 2.24. PA25 Binding Sites and Hill-calculated Equilibrium Dissociation Constants (200 pM DNA) on the
HPV18 Region Corresponding to 7479-7783 bp. The DNA duplex for the 305 bp HPV18 DNA fragment is shown
along with PA25 represented as arrows at its respective binding sites. PA25 is depicted with either a solid arrow
(forward orientation) or a dashed arrow (reverse orientation). This fragment does not harbor any HPV E2 binding sites.
Numbers on the left correspond to the nucleotide position in HPV18 genome. Equilibrium dissociation constants
calculated using the Hill equation from the FAM and HEX channels of CE at the particular nucleotide (bold) are given.
The sample standard deviations are in parentheses. Affinity cleavage patterns at 25-50 nM (black arrows) and 100 nM
(red arrows) PA25-EDTA are illustrated. At high polyamide concentrations of 100 nM PA25-EDTA and above, new
binding sites in the 305 bp fragment are populated by the polyamide. Yellow highlighted sequences represent
footprinting regions observed at 2 nM PA25, whereas gray highlighted sequences represent footprinting regions
observed at 5 nM PA25.   
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Table 2.6. PA25 Sites on 305 bp Fragment (200 pM DNA) Corresponding to HPV18 7479-7783 bp.  
AC 
site 
# 
Sequence Position Site type 
Binding 
orientation 
Integration 
nt 
Kd (nM) 
DNase I 
Hill 
Coeff. 
1 GATTA AAGTTTGCAATAG TGCCA 7531-7519 Triple Forward 7531 0.4 + 0.1 1.91 
 TGCAA ACTTTAATCTTTT GGGCA 7528-7540 Triple Forward    
   Double Reverse    
2 CCCAA AAGATTAAAGTTT GCAAT 7538-7526 Double Forward    
3a GCTCC TACATATTTTGAA CAATT 7553-7565 Triple Forward 7562 0.7 + 0.3 2.13 
   Double Reverse    
3a TCCTA CATATTTTGAACA ATTGG 7555-7567 Triple Forward    
3a TACAT ATTTTGAACAATT GGCGC 7558-7570 Triple Forward    
   Double Reverse    
5 GCCAA TTGTTCAAAATAT GTAGG 7568-7556 Double Forward    
5 CGCGC CAATTGTTCAAAA TATGT 7571-7559 Triple Reverse    
8 GCACC TGGTATTAGTCAT TTTCC 7603-7615 Double Forward 7613 0.9 + 0.1 2.40 
8 ACCTG GTATTAGTCATTT TCCTG 7605-7617 Triple Reverse    
9 GACAG GAAAATGACTAAT ACCAG 7617-7605 Triple Reverse    
9 TGGAC AGGAAAATGACTA ATACC 7621-7609 Double Forward    
10 GCTAC AACAATTGCTTGC ATAAC 7637-7649 Triple Reverse 7647 0.9 + 0.3 2.24 
11 TAGTT ATGCAAGCAATTG TTGTA 7651-7639 Triple Forward    
12 GGGAG TGGATATAGTTAT GCAAG 7662-7650 Single Forward 7659 0.9 + 0.3 2.23 
13 TCCCT AAGTAATAAAACT GCTTT 7669-7681 Double Forward 7672 0.9 + 0.5 1.30 
15 CCTAA AAGCAGTTTTATT ACTTA 7685-7673 Triple Forward 7682 0.5 + 0.1 2.43 
15 GTGCC TAAAAGCAGTTTT ATTAC 7688-7676 Triple Forward    
16 GGCAC ATATTTTAGTTTG TTTTT 7694-7706 Double Forward 7696 0.4 + 0.3 1.84 
17 AAACA AACTAAAATATGT GCCTA 7704-7692 Triple Forward    
   Double Reverse    
17 TAGTT TGTTTTTACTTAA GCTAA 7705-7717 Triple Forward 7715 0.43 + 
0.08 
1.72 
   Double Reverse    
18 GTTTT TACTTAAGCTAAT TGCAT 7711-7723 Single Reverse    
19 AGCTT AAGTAAAAACAAA CTAAA 7715-7703 Double Forward    
20 AAGTA TGCAATTAGCTTA AGTAA 7727-7715 Triple Forward    
The affinity cleavage (AC) site # corresponds to the AC patterns in the map provided in Figure 2.24. The PA25 
binding sequences are given in a 5’ to 3’ direction and include 5 nucleotide (nt) flanking regions. The bold nt highlights 
the position where the polyamide imidazole/pyrrole pair binds. Position corresponds to the HPV18 genomic 
nucleotides. The forward binding orientation refers to alignment of the polyamide N-terminus to C-terminus vector 
with the 5’3’ direction of the DNA, whereas a reverse orientation describes the polyamide NC vector alignment 
with the 3’5’ direction of the DNA.                
a A single binding event cannot be assigned due to significant overlap of the predicted PA25 recognition sequences. 
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Figure 2.25. PA25 Binding Sites and Hill-calculated Equilibrium Dissociation Constants (50 pM DNA) on the
HPV18 Region Corresponding to 7479-7783 bp. The DNA duplex for the 305 bp HPV18 DNA fragment is shown
along with PA25 represented as arrows at its respective binding sites. PA25 is depicted with either a solid arrow
(forward orientation) or a dashed arrow (reverse orientation). This fragment does not harbor any HPV E2 binding sites.
Numbers on the left correspond to the nucleotide position in HPV18 genome. Equilibrium dissociation constants
calculated using the Hill equation from the FAM and HEX channels of CE at the particular nucleotide (bold) are given.
The sample standard deviations are in parentheses. Affinity cleavage patterns at 25-50 nM (black arrows) and 100 nM
(red arrows) PA25-EDTA are illustrated. At high polyamide concentrations of 100 nM PA25-EDTA and above, new
binding sites in the 305 bp fragment are populated by the polyamide. Yellow highlighted sequences represent
footprinting regions observed at 0.5 nM PA25, whereas gray highlighted sequences represent footprinting regions
observed at 1 nM PA25.   
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Table 2.7. PA25 Sites on 305 bp Fragment (50 pM DNA) Corresponding to HPV18 7479-7783 bp.  
AC 
site 
# 
Sequence Position Site type 
Binding 
orientation 
Integration 
nt 
Kd (nM) 
DNase I 
Hill 
Coeff. 
1 GATTA AAGTTTGCAATAG TGCCA 7531-7519 Triple Forward 7531 0.3 + 0.2 1.99 
 TGCAA ACTTTAATCTTTT GGGCA 7528-7540 Triple Forward    
   Double Reverse    
2 CCCAA AAGATTAAAGTTT GCAAT 7538-7526 Double Forward    
3a GCTCC TACATATTTTGAA CAATT 7553-7565 Triple Forward 7562 0.43 + 
0.09 
3.09 
   Double Reverse    
3a TCCTA CATATTTTGAACA ATTGG 7555-7567 Triple Forward    
3a TACAT ATTTTGAACAATT GGCGC 7558-7570 Triple Forward    
   Double Reverse    
5 GCCAA TTGTTCAAAATAT GTAGG 7568-7556 Double Forward    
5 CGCGC CAATTGTTCAAAA TATGT 7571-7559 Triple Reverse    
8 GCACC TGGTATTAGTCAT TTTCC 7603-7615 Double Forward 7613 0.3 + 0.1 1.65 
8 ACCTG GTATTAGTCATTT TCCTG 7605-7617 Triple Reverse    
9 GACAG GAAAATGACTAAT ACCAG 7617-7605 Triple Reverse    
9 TGGAC AGGAAAATGACTA ATACC 7621-7609 Double Forward    
10 GCTAC AACAATTGCTTGC ATAAC 7637-7649 Triple Reverse 7647 0.3 + 0.1 1.69 
11 TAGTT ATGCAAGCAATTG TTGTA 7651-7639 Triple Forward    
12 GGGAG TGGATATAGTTAT GCAAG 7662-7650 Single Forward 7659 0.32 + 
0.04 
1.78 
13 TCCCT AAGTAATAAAACT GCTTT 7669-7681 Double Forward 7672 0.5 + 0.3 1.89 
15 CCTAA AAGCAGTTTTATT ACTTA 7685-7673 Triple Forward 7680 0.2 + 0.1 1.39 
15 GTGCC TAAAAGCAGTTTT ATTAC 7688-7676 Triple Forward    
16 GGCAC ATATTTTAGTTTG TTTTT 7694-7706 Double Forward 7696 0.11 + 
0.03 
1.28 
17 AAACA AACTAAAATATGT GCCTA 7704-7692 Triple Forward    
   Double Reverse    
17 TAGTT TGTTTTTACTTAA GCTAA 7705-7717 Triple Forward 7711 0.14 + 
0.09 
1.40 
   Double Reverse    
18 GTTTT TACTTAAGCTAAT TGCAT 7711-7723 Single Reverse    
19 AGCTT AAGTAAAAACAAA CTAAA 7715-7703 Double Forward    
20 AAGTA TGCAATTAGCTTA AGTAA 7727-7715 Triple Forward    
The affinity cleavage (AC) site # corresponds to the AC patterns in the map provided in Figure 2.25. The PA25 
binding sequences are given in a 5’ to 3’ direction and include 5 nucleotide (nt) flanking regions. The bold nt highlights 
the position where the polyamide imidazole/pyrrole pair binds. Position corresponds to the HPV18 genomic 
nucleotides. The forward binding orientation refers to alignment of the polyamide N-terminus to C-terminus vector 
with the 5’3’ direction of the DNA, whereas a reverse orientation describes the polyamide NC vector alignment 
with the 3’5’ direction of the DNA.                
a A single binding event cannot be assigned due to significant overlap of the predicted PA25 recognition sequences. 
 
2.4.6.5 PA25 Binding Sites Mapped on HPV18 7647-157 bp 
 
A total of 25 distinct affinity cleavage sites were observed in PA25-EDTA affinity 
cleavage experiments, and these were labeled 1 through 25 based on their position within 
this fragment. Out of these sites, 16 were observed in the affinity cleavage experiments 
with 25 and 50 nM PA25. The affinity cleavage patterns were obtained for both strands 
of the binding sites except for Sites #1 and #25 because these are positioned near the 
beginning/end of the fragment. Unlike PA1, there were zero match binding sites for 
PA25 on this fragment. But similarly to the results in the 305 fragment, the predicted 
PA25 single-base-pair mismatch site at genomic position 7721-7709 did not produce an 
affinity cleavage pattern (Figure SI2.11 and Table SI2.4).     
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Refer to Figures 2.26 and 2.27, as each observed site will be briefly discussed in this 
section. Site #1 is best described by PA25 binding in the forward orientation to the 
double-base-pair mismatch site at genomic position 7669-7681, while Site #3 can be 
explained by two different triple-base-pair mismatch binding events in the forward 
conformations to positions 7685-7673 and 7688-7676. It is not clear at this point which 
of these sites and conformations are bound by the polyamide; however the former fits the 
observed affinity cleavage pattern best. 
In the case of Site #4, the affinity cleavage pattern and DNase I footprinting results 
agree with PA25 binding to a forward double-base-pair mismatch site at 7694-7704. The 
PA25 dissociation constants for Site #4 were determined to be 0.4(2) nM with a Hill 
coefficient (n) of 2.57 at 200 pM DNA and 0.13(2) nM (n = 1.70) at 50 pM DNA. 
Representative binding isotherms are provided in Figure SI2.12. 
Site #5 is best described by PA25 binding in a reverse orientation to a single-base-
pair mismatch site (or forward triple-base-pair mismatch) with a Kd value of 1.1(6) nM (n 
= 2.17) at 200 pM DNA and 0.5(1) nM (n = 2.69) at 50 pM DNA. Whereas Site #6 
agrees with PA25 binding to a forward double-base-pair mismatch site on 7703-7715. 
The determined Kd values at Site #6 are 0.47(5) nM (n= 2.02) at 200 pM DNA and 
0.21(8) nM (n = 1.45) at 50 pM DNA. While Site #7 is in agreement with a forward 
triple-base-pair mismatch site (7727-7715) with Kd values of 1.1(6) nM (n = 2.17) and 
1.2(4) nM (n = 2.32) at 200 pM DNA, and 0.5(1) nM (n = 2.69) at 50 pM DNA. These 
values overlap with PA25 binding to Site #5.  
Unlike all of the other high affinity cleavage sites, Site #12 generated a diffused low-
intensity affinity cleavage pattern that is best explained by PA25 binding in various 
conformations to the HPV18 genome. These conformations include reverse and forward 
single-base-pair mismatch sites, reverse and forward double-base-pair mismatch sites, 
and a forward triple-base-pair mismatch site. The Kd values determined at 200 pM DNA 
for Site #12 are: 0.8(3) nM (n = 1.66), 0.7(3) nM (n = 2.69), 0.7(3) nM (n = 2.62), 0.7(3) 
nM (n = 2.91) and 0.6(3) nM (n = 2.62). On the other hand, the equivalent Kd values 
determined at 50 pM DNA for Site #12 are: 0.24(9) nM (n = 1.58), 0.27(6) nM (n = 
2.09), 0.20(4) nM (n = 1.81), 0.23(5) nM (n = 2.08) and 0.18(4) nM (n = 1.84). Most of 
these Kd values are shared with Site #13 which is best explained by a forward double-
base-pair mismatch and generates an affinity cleavage pattern with higher intensity than 
the pattern observed for Site #12. 
Site #14 is located just upstream of the E2BS-1 (7822-7833). This site is best 
explained by PA25 binding in a forward conformation to a triple-base-pair mismatch site 
at 7817-7805. The Kd values determined at 200 pM DNA for Site #14 are: 0.9(2) nM (n = 
2.10), 0.8(4) nM (n = 2.96) and 0.9(4) nM (n = 2.78). While the equivalent Kd values 
determined at 50 pM DNA are: 0.33(6) nM (n = 2.83), 0.30(5) nM (n = 2.02) and 0.28(9) 
nM (n = 2.17).   
Sites #16, #17, #18, #19 and #20 bind to the E1-binding region of HPV18.78  Site #16 
can be explained by PA25 binding either in the forward conformation to two adjacent 
triple-base-pair mismatch sites (7849-4 and 7850-5), or in the reverse conformations to 
the same sequences to generate double-base-pair mismatch sites. Site #17 is best 
described by PA25 binding to a forward double-base-pair mismatch site (7853-8), but 
two forward triple-base-pair mismatch sites and their equivalent reverse double-base-pair 
mismatch sites cannot be ruled out (7849-4 and 7850-5). The Kd values shared by Sites 
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#16 and #17 at 200 pM DNA are 0.7(4) nM (n = 2.44), 0.6(3) nM (n = 2.45) and 0.7(3) 
nM (n = 2.39). While these Kd values are 0.20(4) nM (n = 2.09), 0.18(4) nM (n = 2.38) 
and 0.25(3) nM (n = 2.20) at 50 pM DNA. Site #18 can be explained by a forward 
double-base-pair mismatch site (7855-10) or two forward triple-base-pair mismatch sites 
(1-13 and 12-24). Site #19 can be described by PA25 binding to a forward single-base-
pair mismatch site (21-33), two forward triple-base-pair mismatch sites (10-22 and 11-
23) and a reverse double-base-pair mismatch site (10-22). Site #20 has four possibilities: 
a reverse double-base-pair mismatch (19-31) and three different forward triple-base-pair 
mismatch sites (19-31, 21-33 and 22-34). The Kd values shared by Sites #18 and #19 at 
200 pM DNA are 0.6(2) nM (n = 2.15) and 0.6(2) nM (n = 2.24); while at 50 pM these Kd 
values are 0.21(5) nM (n = 2.34) and 0.19(7) nM (n = 2.05). The Kd values shared by 
Sites #19 and #20 at 200 pM DNA are 0.7(3) nM (n = 2.43), 0.5(2) nM (n = 2.19) and 
0.6(2) nM (n = 2.40), while at 50 pM these Kd values are 0.24(6) nM (n = 1.47), 0.13(3) 
nM (n = 1.84) and 0.17(4) nM (n = 1.54). Site #20 is within a DNA helical turn from E2 
Binding Site 2 (E2BS-2 42-53).   
Another two binding events, Sites #23 and #24, were observed in close proximity to 
E2 Binding Site 3 (E2BS-3 7822-7833). Site #23 is best described by PA25 binding in 
the forward orientation to a double-base-pair mismatch at genomic position 72-84, while 
Site #23 corresponds to PA25 recognizing either a forward triple-base-pair mismatch site 
and/or a reverse double-base-pair mismatch site (70-82). The Kd values shared by Sites 
#23 and #24 at 200 pM DNA are 0.7(3) nM (n = 1.86) and 0.5(3) nM (n = 2.26), while at 
50 pM these Kd values are 0.22(7) nM (n = 1.84) and 0.13(4) nM (n = 1.49).  
On the other hand, the affinity cleavage patterns for Sites #2, #8-11, #15, #21, #22 
and #25 were only observed at high PA25 concentrations (>100 nM). 
Some single-base-pair mismatch sites bound by PA25 generated affinity cleavage 
with low-intensities, relative to adjacent sites with higher base-pair mismatches (Sites 
#12 and #19). In agreement with the results observed for the 305 bp fragment, the 
predicted PA25 single-base-pair mismatch at genomic position 7721-7709 did not 
generate an affinity cleavage pattern. Thus, recognition of the minor groove by PA25, 
similar to PA1, is not simply based on the established recognition rules. 
Binding of PA25 to the HPV18 origin of replication may be of importance to the 
robust antiviral action of PA25 against HPV18 in monolayer keratinocytes. The 368 bp 
fragment harbors the viral origin of replication, the E2 binding sites (E2BS-1 7822-7833; 
E2BS-2 42-53; E2BS-3 58-69) and the E1 binding site (E1BS 3-18). Because PA25 and 
PA1 bind avidly to the E1 binding region and in close proximity to the E2 binding sites, 
these DNA minor groove binder may preclude binding of the essential viral proteins E1 
and E2 to the origin of replication by steric hindrance or by modifying the local DNA 
structure. Indeed, the equilibrium dissociation constant for HPV18 E2dbd DNA binding 
domain is 4.5 nM.43 Because our hairpin polyamides exhibit affinities to this region of the 
viral genome comparable to the vital HPV18 E2 protein, it is plausible that they can 
function has inhibitors of viral replication, gene expression and/or proper episomal 
segregation during cell division of infected cells. The higher antiviral activity of PA25 
against HPV18 as compared to PA1 may be due to its lower dissociation constant, as well 
as a more extensive coverage of this genomic region important for viral replication, 
particularly in the E1 binding region.    
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Figure 2.26. PA25 Binding Sites and Hill-calculated Equilibrium Dissociation Constants (200 pM DNA) on the
HPV18 Region Corresponding to 7647-157 bp. The DNA duplex for the 368 bp HPV18 DNA fragment is shown
along with PA25 represented as arrows at its respective binding sites. PA25 is depicted with either a solid arrow
(forward orientation) or a dashed arrow (reverse orientation). HPV E2 binding sites are depicted in green boxes. HPV
E1 binds in the region (HPV18 3-19 bp) flanked by the first and second E2 binding sites. The origin of replication is
marked with 1. Numbers on the left correspond to the nucleotide position in HPV18 genome. Equilibrium dissociation
constants calculated using the Hill equation from the FAM and HEX channels of CE at the particular nucleotide (bold)
are given. The sample standard deviations are in parentheses. Affinity cleavage patterns at 25-50 nM (black arrows)
and 100 nM (red arrows) PA25-EDTA are illustrated. At high polyamide concentrations of 100 nM PA25-EDTA and
above, new binding sites in the 368 bp fragment are populated by the polyamide. Yellow highlighted sequences
represent footprinting regions observed at 2 nM PA25; whereas, gray highlighted sequences represent footprinting
regions observed at 5 nM PA25.   
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Table 2.8. PA25 Sites on 368 bp Fragment (200 pM DNA) Corresponding to HPV18 7647-157 bp.  
AC 
site 
# 
Sequence Position Site type 
Binding 
orientation 
Integration 
nt 
Kd (nM) 
DNase I 
Hill 
Coeff. 
1 TCCCT AAGTAATAAAACT GCTTT 7669-7681 Double Forward ND ND ND 
3 CCTAA AAGCAGTTTTATT ACTTA 7685-7673 Triple Forward    
3 GTGCC TAAAAGCAGTTTT ATTAC 7688-7676 Triple Forward    
4 GGCAC ATATTTTAGTTTG TTTTT 7694-7706 Double Forward 7703 0.4 + 0.2 2.57 
6 AGCTT AAGTAAAAACAAA CTAAA 7715-7703 Double Forward    
5 GTTTT TACTTAAGCTAAT TGCAT 7711-7723 Triple Forward 7720 1.1 + 0.6 2.17 
   Single Reverse    
7 AAGTA TGCAATTAGCTTA AGTAA 7727-7715 Triple Forward    
12 a TATTA TAGTTCATGTTAA GGGTA 7786-7774 Single Forward 7790 0.7 + 0.3 2.91 
12 a CCCTT AACATGAACTATA ATATG 7776-7788 Single Reverse    
12 a ACATG AACTATAATATGA CTAAG 7782-7794 Triple Forward    
   Double Reverse    
12 a TGAAC TATAATATGACTA AGCTG 7785-7797 Double Forward    
13 TAGTC ATATTATAGTTCA TGTTA 7792-7780 Double Forward    
14 TTGCA TAAACTATGTATG CACAG 7817-7805 Triple Forward 7807 0.9  + 0.2 2.10 
16 ATACT ATACTTTTCATTA ATACT 7849-4 Triple Forward 4 0.7  + 0.3  2.39 
   Double Reverse    
16 TACTA TACTTTTCATTAA TACTT 7850-5 Triple Forward    
   Double Reverse    
17 TAAAA GTATTAATGAAAA GTATA 8-7853 Double Forward    
18 GTTAA AAGTATTAATGAA AAGTA 10-7855 Double Forward    
18 ATTGT TAAAAGTATTAAT GAAAA 13-1 Triple Forward    
17 ATTAA TACTTTTAACAAT TGTAG 6-18 Triple Forward 15 0.6 + 0.2  2.24 
   Double Reverse    
17 TTAAT ACTTTTAACAATT GTAGT 7-19 Triple Forward    
   Double Reverse    
18 ACTTT TAACAATTGTAGT ATATA 12-24 Triple Forward    
19 TATAC TACAATTGTTAAA AGTAT 22-10 Triple Forward    
   Double Reverse    
19 ATATA CTACAATTGTTAA AAGTA 23-11 Triple Forward    
19 AATTG TAGTATATAAAAA AGGGA 21-33 Single Forward 28 0.6 + 0.2 2.40 
20 a CCTTT TTTATATACTACA ATTGT 31-19 Triple Forward    
   Double Reverse    
20 a TCCCT TTTTTATATACTA CAATT 33-21 Triple Forward    
20 a CTCCC TTTTTTATATACT ACAAT 34-22 Triple Forward    
23 GGTGT ATATAAAAGATGT GAGAA 72-84 Double Forward 80 0.5 + 0.3 2.26 
24 CTCAC ATCTTTTATATAC ACCGT 82-70 Triple Forward    
   Double Reverse    
The affinity cleavage (AC) site # corresponds to the AC patterns in the map provided in Figure 2.26. The PA25 
binding sequences are given in a 5’ to 3’ direction and include 5 nucleotide (nt) flanking regions. The bold nt highlights 
the position where the polyamide imidazole/pyrrole pair binds. Position corresponds to the HPV18 genomic 
nucleotides. The forward binding orientation refers to alignment of the polyamide N-terminus to C-terminus vector 
with the 5’3’ direction of the DNA, whereas a reverse orientation describes the polyamide NC vector alignment 
with the 3’5’ direction of the DNA.             
ND, Not determined. Sites 1 and 3 are found in the beginning of the fragment. 
a A single binding event cannot be assigned due to significant overlap of the predicted PA25 recognition sequences. 
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Figure 2.27. PA25 Binding Sites and Hill-calculated Equilibrium Dissociation Constants (50 pM DNA) on the
HPV18 Region Corresponding to 7647-157 bp. The DNA duplex for the 368 bp HPV18 DNA fragment is shown
along with PA25 represented as arrows at its respective binding sites. PA25 is depicted with either a solid arrow
(forward orientation) or a dashed arrow (reverse orientation). HPV E2 binding sites are depicted in green boxes. HPV
E1 binds in the region (HPV18 3-19 bp) flanked by the first and second E2 binding sites. The origin of replication is
marked with 1. Numbers on the left correspond to the nucleotide position in HPV18 genome. Equilibrium dissociation
constants calculated using the Hill equation from the FAM and HEX channels of CE at the particular nucleotide (bold)
are given. The sample standard deviations are in parentheses. Affinity cleavage patterns at 25-50 nM (black arrows)
and 100 nM (red arrows) PA25-EDTA are illustrated. At high polyamide concentrations of 100 nM PA25-EDTA and
above, new binding sites in the 368 bp fragment are populated by the polyamide. Yellow highlighted sequences
represent footprinting regions observed at 0.5 nM PA25; whereas, gray highlighted sequences represent footprinting
regions observed at 1 nM PA25.   
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Table 2.9. PA25 Sites on 368 bp Fragment (50 pM DNA) Corresponding to HPV18 7647-157 bp.  
AC 
site 
# 
Sequence Position Site type 
Binding 
orientation 
Integration 
nt 
Kd (nM) 
DNase I 
Hill 
Coeff. 
1 TCCCT AAGTAATAAAACT GCTTT 7669-7681 Double Forward ND ND ND 
3 CCTAA AAGCAGTTTTATT ACTTA 7685-7673 Triple Forward    
3 GTGCC TAAAAGCAGTTTT ATTAC 7688-7676 Triple Forward    
4 GGCAC ATATTTTAGTTTG TTTTT 7694-7706 Double Forward 7703 0.13 + 
0.02 
1.70 
6 AGCTT AAGTAAAAACAAA CTAAA 7715-7703 Double Forward    
5 GTTTT TACTTAAGCTAAT TGCAT 7711-7723 Triple Forward 7724 0.5 + 0.1 2.69 
   Single Reverse    
7 AAGTA TGCAATTAGCTTA AGTAA 7727-7715 Triple Forward    
12 a TATTA TAGTTCATGTTAA GGGTA 7786-7774 Single Forward 7790 0.23 + 
0.05 
2.08 
12 a CCCTT AACATGAACTATA ATATG 7776-7788 Single Reverse    
12 a ACATG AACTATAATATGA CTAAG 7782-7794 Triple Forward    
   Double Reverse    
12 a TGAAC TATAATATGACTA AGCTG 7785-7797 Double Forward    
13 TAGTC ATATTATAGTTCA TGTTA 7792-7780 Double Forward    
14 TTGCA TAAACTATGTATG CACAG 7817-7805 Triple Forward 7807 0.33  + 
0.06 
2.83 
16 ATACT ATACTTTTCATTA ATACT 7849-4 Triple Forward 4 0.25  + 
0.03   
2.20 
   Double Reverse    
16 TACTA TACTTTTCATTAA TACTT 7850-5 Triple Forward    
   Double Reverse    
17 TAAAA GTATTAATGAAAA GTATA 8-7853 Double Forward    
18 GTTAA AAGTATTAATGAA AAGTA 10-7855 Double Forward    
18 ATTGT TAAAAGTATTAAT GAAAA 13-1 Triple Forward    
17 ATTAA TACTTTTAACAAT TGTAG 6-18 Triple Forward 15 0.19 + 
0.07  
2.05 
   Double Reverse    
17 TTAAT ACTTTTAACAATT GTAGT 7-19 Triple Forward    
   Double Reverse    
18 ACTTT TAACAATTGTAGT ATATA 12-24 Triple Forward    
19 TATAC TACAATTGTTAAA AGTAT 22-10 Triple Forward    
   Double Reverse    
19 ATATA CTACAATTGTTAA AAGTA 23-11 Triple Forward    
19 AATTG TAGTATATAAAAA AGGGA 21-33 Single Forward 28 0.17 + 
0.04 
1.54 
20 a CCTTT TTTATATACTACA ATTGT 31-19 Triple Forward    
   Double Reverse    
20 a TCCCT TTTTTATATACTA CAATT 33-21 Triple Forward    
20 a CTCCC TTTTTTATATACT ACAAT 34-22 Triple Forward    
23 GGTGT ATATAAAAGATGT GAGAA 72-84 Double Forward 80 0.13 + 
0.04 
1.49 
24 CTCAC ATCTTTTATATAC ACCGT 82-70 Triple Forward    
   Double Reverse    
The affinity cleavage (AC) site # corresponds to the AC patterns in the map provided in Figure 2.27. The PA25 
binding sequences are given in a 5’ to 3’ direction and include 5 nucleotide (nt) flanking regions. The bold nt highlights 
the position where the polyamide imidazole/pyrrole pair binds. Position corresponds to the HPV18 genomic 
nucleotides. The forward binding orientation refers to alignment of the polyamide N-terminus to C-terminus vector 
with the 5’3’ direction of the DNA, whereas a reverse orientation describes the polyamide NC vector alignment 
with the 3’5’ direction of the DNA.                
ND, Not determined. Sites 1 and 3 are found in the beginning of the fragment. 
a A single binding event cannot be assigned due to significant overlap of the predicted PA25 recognition sequences. 
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2.4.6.6 PA25 WebLogo 3.3 Motif Analysis  
 
WebLogo 3.3 was also used to create a graphical representation of the consensus 
DNA binding sequence for the observed binding sequences of PA25 in the studied 
HPV18-derived fragments. The WebLogo analysis (Figure 2.28) shows that PA25, like 
PA1, binds to A/T-rich sequences (sample size of n = 61) with a slight preference of the 
imidazole units of the hairpin polyamide recognizing the guanine base in duplex DNA.  
Furthermore, base-pair mismatches are allowed in all the positions in the polyamide 
binding region.   
 
 
  
2.4.7 X-ray Crystallography Screening Matrix of Oligonucleotide with PA25 
 
The Natrix HT matrix plate using the formate salt of PA25 resulted in many wells with 
crystal growth, whereas the same conditions using the TFA salt of PA25 was limited to 3 
wells. Conversely, the matrix generated from literature conditions yielded mostly 
aggregates with no observable crystals. The loading scheme and screening results are 
shown in Figure 2.29.  
Figure 2.28. WebLogo Plot for PA25 Binding Sites Observed on the HPV18 Regions Corresponding to 7479-
7783 bp and 7647-157 bp. The relative probability of a given nucleotide to be found in a particular position is
represented by the height of the letter (A = Adenine, T = Thymine, G = Guanine and C = Cytosine). Red box encloses
the PA25 binding site. Input sequences including the flanking DNA sequences (5 bp) are given below the plot. No
obvious trend is observed for the presence or relative position of polyA tracts in or immediately adjacent to the PA1
binding site. 
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2.4.8 Circular Dichroism (CD) Titration Experiments 
 
Figure 2.30 shows the CD spectra for the titration of CHC2050-1 DNA duplex (4.0 
µM) with increasing concentrations of PA1 (0-9.6 µM). The CHC2050-1 duplex 
corresponds to a PA1 binding site (Site #14 in Figure 2.22) found in the HPV18 368 bp 
fragment. The CD spectra of the DNA peaks were characteristic of B-form DNA with a 
negative peak at around 250 nm and a positive peak at around 260-280 nm. Binding of 
PA1 to the DNA duplex led to a strong induced CD signal at ~332 nm and ~302 nm, 
while PA1 alone does not generate a CD signal as it is not optically active (achiral) 
(Figure 2.30A and B). Because the induced CD signal (~332 nm) is outside the CD 
spectrum of DNA, ligand binding to DNA can be monitored by this technique. The 
generation of an induced CD signal above 300 nm is consistent with PA1 binding to the 
minor groove of DNA. Furthermore, the presence of multiple isodichroic points at 
approximately 250, 270 and 315 nm suggests a single binding mechanism.80,81 A titration 
curve was generated by plotting the induced CD (mdeg) at the λMAX (~332 nm) versus the 
PA1:DNA duplex ratio (Figure 2.30C). PA1 saturation of the 16-mer oligonucleotides 
was not reached until about 2:1 PA1:DNA ratio, suggesting that two molecules of the 
hairpin polyamide bind per DNA molecule.  
 
 
Figure 2.29. Preliminary X-ray Crystallization Results and Reagent Formulations. A crystallization block consists
of three sitting drop wells and a reservoir. The inset in the top right describes the loading scheme for the crystallization
experiments; sitting drop well a was loaded with 1:1.3 DNA:PA, b with 1:2 DNA:PA and c with DNA alone. A red X
indicates crystal growth in the particular sitting drop well for (A) PA25-formate and (B) PA25-TFA Natrix HT matrix
screens. The screening conditions for those that produced crystals are given in the bottom table. 
A  B
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Two titrations with PA1 were also performed to determine whether binding of PA1 to 
a forward single-base-pair mismatch site exhibited qualitatively different spectra than 
binding to a reverse single-base-pair mismatch site on a 16-mer DNA duplex. The 
sequences were designed with a single-base-pair mismatch at the nucleotides that interact 
with the γ-turn of PA1. The rationale was that PA1 would prefer the least number of 
mismatches and would have a slight preference for the forward orientation. 
Consequently, the forward binding orientation of PA1 on the CHC2050-2 duplex would 
lead to a single-base-pair mismatch at the γ-turn, where the reverse binding orientation 
results in a double-base-pair-mismatch. On the other hand, binding of PA1 in the reverse 
orientation to the CHC2050-3 duplex might be more favorable because this conformation 
results in a single-base-pair mismatch at the γ-turn, in contrast to a double-base-pair 
mismatch in the forward binding orientation. Figure 2.31 shows the CD spectra for the 
titrations of CHC2050-2 and CHC2050-3 DNA duplexes with increasing concentrations 
of PA1. Similar to the results observed with CHC2050-1, the CD spectra of the DNA 
peaks were characteristic of B-form DNA with a negative peak at around 250 nm and a 
positive peak at around 260-280 nm. Binding of PA1 to the DNA duplex led to a strong 
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Figure 2.30. Circular Dichroism Spectra for the Titration of CHC2050-1 with PA1. (A) CD spectra corresponding
to the titration of CHC2050-1 DNA duplex with PA1. Free DNA corresponds to the CD spectra with no induced CD
signal at 332 nm (navy blue line). PA:DNA ratios ranged from 0.2 to 2.4. Black arrows indicate the induced CD band
used to generate the titrations plots. (B) PA1 is an achiral molecule and thus in the absence of DNA, it is CD inactive.
(C) Titration curve is shown below their CD spectra and was generated by plotting the induced CD (mdeg) at the λMAX
(332.4 nm) versus the ligand:DNA ratio. PA1 saturation of the 16-mer oligonucleotides was not reached until about 2:1
PA1:DNA ratios. (D) CHC2050-1 duplex presents a forward triple-base-pair-mismatch binding site and a reverse
double-pair-mismatch binding site to PA1. Forward and reverse binding orientations are boxed in red and blue,
respectively. Mismatches for the forward binding orientation are shown on the top strand in green, while mismatches
for the reverse binding orientation are highlighted on the bottom strand in orange. 
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induced CD signals at ~332 nm and ~302 nm (Figure 2.31). The generation of induced 
CD signals above 300 nm is consistent with PA1 binding to the minor groove of DNA. 
Furthermore, the presence of multiple isodichroic points at approximately 250, 270 and 
315 nm suggests a single binding mechanism.80,81 Titration curves were generated by 
plotting the induced CD (mdeg) at the λMAX (~332 nm) versus the PA1:DNA duplex ratio 
(Figure 2.31C and D). PA1 saturation of the 16-mer oligonucleotides was not reached 
until approximately 2:1 PA1:DNA ratio, suggesting that two molecules of the hairpin 
polyamide bind per DNA molecule. Comparison of the obtained CD spectra for the 
expected forward and reverse PA1 binding orientations displayed nearly identical bands, 
suggesting that either the CD technique cannot differentiate between the two polyamide 
binding modes or that PA1 binds in the same manner—in a forward conformation—to 
the studied DNA sequences. If the latter is correct, PA1 would bind in a forward 
orientation with a single-base-pair mismatch to CHC2050-2 and a forward orientation 
with a double-base-pair mismatch to CHC2050-3.   
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The same experiment was performed using PA2 and two different match binding 
sequences. PA2 shares the same sequence as PA1, except that it has a chiral (R)-NH2 in 
the γ-turn. As a result, it recognizes the same DNA sequence (5’-W2G7-3’) as PA1; 
however, the chiral (R)-substitution on the γ-turn is expected to increase the binding 
preference for the forward orientation.77 The purpose of this experiment was to determine 
whether binding of PA2 to a forward match site exhibited qualitatively different spectra 
than binding to an oligomer with both a forward single-base-pair mismatch site and a 
reverse match site (Figure 2.32). The CD spectra of the DNA peaks are similar to those 
observed for PA1 experiments. However, a second binding event was observed as judged 
by the presence of two distinct slopes at 1.5:1 PA2:DNA ratio. 
 
 
Figure 2.31. Circular Dichroism Spectra for the Titration of CHC2050-2 and CHC2050-3 with PA1. (A and B)
CD spectra corresponding to the titrations of CHC2050-2 and CHC2050-3 DNA duplexes with PA1. Free DNA
corresponds to the CD spectra with no induced CD signal at 332 nm (navy blue line). PA:DNA ratios ranged from 0.2
to 2.4. Black arrows indicate the induced CD band used to generate the titrations plots. (C and D) Titration curves are
shown below their CD spectra and were generated by plotting the induced CD (mdeg) at the λMAX (332.6 and 333.3
nm) versus the ligand:DNA ratio. PA1 saturation of the 16-mer oligonucleotides was not reached until about 1.5:1 and
2:1 PA1:DNA ratios. (E) CHC2050-2 and CHC2050-3 duplexes present a forward single-base-pair-mismatch binding
site and a reverse single-pair-mismatch binding site to PA1. Mismatches are located on the nucleotides that make
contact with the γ-turn from PA1. Red font highlights the nucleotides that are swapped in the sequences. 
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2.5 CONCLUSIONS 
 
We have relied on quantitative DNase I footprinting and affinity cleavage 
experiments to determine the binding sites and equilibrium dissociation constants of PA1 
and PA25 to PCR-amplified DNA sequences corresponding to the HPV18 LCR genomic 
region. 
Results obtained from circular dichroism and affinity cleavage studies support PA1 
and PA25 binding to the minor groove of DNA. The characteristic induced CD signals 
produced above 300 nm and the observed asymmetrical 3’ shift between DNA strands in 
affinity cleavage experiments are consistent with PA1 and PA25 binding to the minor 
groove of DNA. 
We report that PA1 and PA25 hairpin polyamides bind avidly to the minor groove of 
A/T-rich sequences in the LCR of HPV18 with dissociation constants ranging from 1.1 
nM to 2.6 nM for PA1 and 0.4 nM to 1.2 nM for PA25. Compared to the reported short 
hairpin polyamides, these PAs exhibit greater binding promiscuity.82 Specifically, these 
large anti-HPV PAs bind in both forward and reverse orientations and tolerate PA-DNA 
mismatches without a significant decrease in binding affinity. The large nature of these 
antiviral agents may lead to extensive favorable interactions with the minor groove of 
DNA, and as a result a relatively small number of unfavorable interactions are ineffective 
at reducing the binding affinity. While the binding preference for A·T and T·A at Py/Py 
pairs and G·C at Im/Py pairs is retained in these PAs, PA-DNA base-pair mismatches are 
allowed in all of the positions in the PA binding motif. In contrast to PA1, PA25 has the 
ability to tolerate a higher number of base-pair mismatches probably due to its expected 
larger DNA binding site. Most of the binding events observed for PA1 can be explained 
with binding sites corresponding to match, single- and double-base-pair mismatch 
sequences; while most binding sites for PA25 are characterized with single-, double-, and 
triple-base-pair mismatch sequences.  
In some instances, these compounds bind well to double-base-pair mismatch binding 
sites, yet eschew some predicted single-base-pair mismatch DNA sequences. These 
observations may be due to the fact that the published PA-DNA recognition rules, while 
they provide a general prediction of polyamide binding, do not account for subtle DNA 
structural differences between seemingly equivalent DNA sequences. Furthermore, these 
rules fail to include the flanking sequences around the predicted binding site and other 
nearby binding sites that may induce a conformational change in the local DNA structure. 
Thus, recognition of the minor groove by large anti-HPV PAs is not solely based on the 
established recognition rules. 
Quantitative DNase I footprinting and affinity cleavage results suggest no clear 
correlation of antiviral activity with binding affinity. Certainly, the dissociation constants 
Figure 2.32. Circular Dichroism Spectra for the Titration of CHC2050-GH6084C and CHC2050-GH6084D with
PA2. (A and B) CD spectra corresponding to the titrations of CHC2050-GH6084C and CHC2050-GH6084D DNA
duplexes with PA2. Free DNA corresponds to the CD spectra with no induced CD signal at 332 nm (navy blue line).
PA:DNA ratios ranged from 0.2 to 3.0. Black arrows indicate the induced CD band used to generate the titrations plots.
(C and D) Titration curves are shown below their CD spectra and were generated by plotting the induced CD (mdeg) at
the λMAX (332.6 and 332.7 nm) versus the ligand:DNA ratio. PA2 saturation of the 16-mer oligonucleotides was not
reached until about 2.5:1 PA:DNA ratios. (E) CHC2050-GH6084C and CHC2050-GH6084D DNA duplexes present a
forward and a reverse match binding site to PA2, respectively. Red font highlights the nucleotides that are swapped in
the sequences. 
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for PA25 are on average 2-fold lower than those obtained for PA1, but this fold change is 
not sufficient to explain the antiviral differences. However, PA25 exhibits an extensive 
DNase I protection, expected from its larger binding site, than PA1. Because PA25 
exhibits a more extended coverage of the HPV genome proximal to the origin of 
replication, its improved antiviral activity against HPV18 as compared to PA1 may be 
afforded by a more effective inhibition of DNA-protein interactions.  
Hairpin polyamides PA1 and PA25 were rationally designed to inhibit the access of 
viral proteins E1 and E2 to their cognate binding sites within the HPV genome. Yet, our 
results suggest that these bioactive compounds exhibit significant binding promiscuity. 
Thus, it is expected that binding to the host genome also occurs. However, we 
hypothesize that significant selectivity toward the HPV genome may occur because: 1) 
infected keratinocytes maintain 500-1000 episomes per cell in comparison to only 2 
copies of host genome. 2) The human genome is highly compacted into chromosomes 
that may preclude binding of polyamides to potential binding sites, while the viral 
genome is condensed into chromatin-like structures that may be more accessible to 
polyamides.83-88 For example, Dervan et al. suggested that sensitivity of cancer versus 
normal cells to hairpin polyamide-chlorambucil conjugates was a result of an open 
chromatin conformation of the target region in cancer cells, leading to a greater binding 
accessibility of these compounds to their cognate sites.89 Recent findings by our 
collaborators at NanoVir revealed that effective episomal elimination by anti-HPV PAs is 
accompanied by a significant change in the expression of members from the DNA 
Damage Response (DDR) pathways.44 Most notably, the authors demonstrated that this 
altered expression of the DDR pathways was dependent on the presence of HPV in the 
episomal form, as SiHa cells harboring integrated copies of HPV16 and HPV-negative 
cells did not elicit such a response. Likewise, the inactive eight-ring hairpin polyamide 
PA11 had no effect on the DDR transcripts studied.44 Thus, the mode of action by which 
antiviral PAs eliminate HPV episomes is more complex than a simple allosteric inhibition 
of DNA-binding proteins and it may comprise the concerted interplay of multiple cellular 
pathways. Furthermore, one can envisage that more PA-binding events would cause 
substantial topological perturbations in the DNA helix of closed-circular, negatively 
supercoiled episomes. These effects would in turn significantly distort the viral genome, 
leading to its detection as foreign or damaged DNA by the DDR response.44,90 
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2.7 SUPPLEMENTAL INFORMATION 
2.7.1 Maxam-Gilbert Sequencing Protocol 
                   Note: Hydrazine will destroy HEX dye.  
Reagents Preparation 
Piperidine 
Formate Add 4 % formic acid solution to 10 mL of 1 M Piperidine until pH 2.0 is obtained 
30 % Mono 
Hydrazine As is 
3 M NaOAc pH = 
5.0 
Add 1.23 g of NaOAc to 3 mL of MQ H2O, pH to 5.0 with glacial acetic acid. 
Add MQ H2O to a 5 mL total volume 
Stop Solution 
0.3 M NaOAc pH = 7.0, 0.1 mM EDTA: 
1000 µL of 3 M NaOAc pH = 5.0 + 2 µL of 0.5 M EDTA pH = 8.0 + 8998 µL MQ 
H2O 
1 M Piperidine Add 1 mL of 10 M Piperidine to 9 mL of MQ H2O 
  
A+G:         
1.      16 nM DNA (24 µL) + 4 µL of piperidine formate; overall volume = 28 µL.  
2.      Incubate for 15 min or 30 min at 37 °C to optimize fragmentation.     
    
C+T:       
1.      6 nM DNA (24 µL) + 40 µL of mono hydrazine or 11.5 nM DNA (24 µL) + 20 µL of mono      hydrazine.  
2.      Incubate for 15 min or 30 min at 37 °C to optimize fragmentation. 
   
3.      Add 200 µL of stop solution at 0 °C: 
0.3 M NaOAc pH =7.0 (If you have it available, dilute from 3 M NaOAc pH = 5.0) 
0.1 mM EDTA pH = 8.0 
4.      Add 750 µL of EtOH (-20 °C) incubate in freezer (-20 °C) for 20 min. 
5.      Centrifuge for 20 min 13000x g at 4 °C. 
6.      Remove supernatant carefully and dispose of supernatant to appropriate waste bottle. 
7.      Add 300 µL of 0.3 M NaOAc (pH = 5.2) at 0 °C.  
8.      Add 900 µL of EtOH (-20 °C). 
9.      Store 20 min in -20 °C. 
10.    Centrifuge for 20 min 13000x g at 4 °C. 
11.    Remove supernatant carefully. 
12.    Add 1 mL of EtOH (-20 °C). 
13.    Centrifuge for 10 min 13000x g at 4 °C. 
14.    Remove supernatant carefully. 
15.    Speed vac DNA pellet for at least 4 h.  
16.    Add 100 µL of 1 M piperidine, mix (pure piperidine is 10 M, just dilute in water to get 1 M). 
17.    Incubate 30 min at 90 °C. 
18.    Speed vac for 2 h (good stopping point for the day, speed vac piperidine overnight). 
19.    Add 20 µL of H2O, vortex for 30 sec. 
20.    Centrifuge for 10 sec. 
21.    Speed vac for 2 h. 
22.    Add 50 µL of H2O. 
23.    Send different amounts of DNA for fragmentation analysis keeping the total volume equal to 2 µL.  
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2.7.2 Molar Extinction Coefficient Determination for PA1 in 5 % Dextrose / 95 % 
Water (D5W) 
 
Because the molar extinction coefficient of polyamides can differ substantially in 
different solvents,91 the molar extinction coefficient for PA1 in 5 % dextrose / 95 % 
water (D5W) was determined as the provisional value of 88,020 M-1cm-1. This value 
assumes that polyamide did not aggregate in the stock and diluted solutions. Briefly, a 
2.24 mM PA1 in D5W (FT1124) was used as the stock and different concentrations of 
PA1 were prepared by further dilution with D5W (9.90-2.45 μM). The absorbance at λmax 
was determined (around 305 nm) using a Thermo Scientific Evolution 260 Bio UV-
visible spectrophotometer for different PA1 concentrations. Since Beer-Lambert Law 
states that A = εbc (where A is the absorbance at a particular wavelength, ε is the molar 
extinction coefficient, b is the cell path length and c is the concentration of the sample), a 
graph was constructed plotting the measured absorbance versus the polyamide 
concentration (M). The slope of this line corresponds to the molar extinction coefficient 
(Figure SI2.1).     
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
λmax (nm) Absorbance at λmax  Concentration (μM) Concentration (M)
0 0 0
313.80 0.847 9.9 9.86E‐06
316.55 0.675 7.9 7.88E‐06
314.83 0.547 6.6 6.57E‐06
315.62 0.463 5.6 5.63E‐06
313.92 0.394 4.9 4.93E‐06
315.25 0.354 4.4 4.38E‐06
314.82 0.312 3.9 3.94E‐06
312.08 0.251 3.3 3.29E‐06
312.18 0.205 2.8 2.82E‐06
315.79 0.176 2.5 2.46E‐06
y = 88020x ‐ 0.0302
R² = 0.9972
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Figure SI2.1. Absorbance Data and Plot for Different Concentrations of PA1 in 5 % Dextrose / 95 % Water
(D5W). Experimental data used for the determination of the molar extinction coefficient for PA1 in D5W. Plot of
absorbances at 314 + 4.5 nm versus polyamide concentrations (M). Equation of the line is y = 88020x-0.0302, R2 =
81 
 
2.7.3 X-ray Crystallography Matrix 
Table SI2.1. X-ray Crystallization Screening Matrix Generated from Conditions Published in PA Literature. 
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2.7.4 CE Sanger USB and Maxam-Gilbert Indexing 
 
 
HPV18 (7479‐7783) 305 bp (FAM ECF160 Lanes E1, F1, G2, H9 (plate JS4313)
Correction between CE size calling to USB sequencing results
CE postion Sequence Real Position Genome Position CE postion Sequence Real Position Genome Position CE postion Sequence Real Position Genome Position
C 1 7479 116.1 C 121 7599 ‐4.9 236.9 C 241 7719 ‐4.1
T 2 7480 117.1 A 122 7600 ‐4.9 237.8 T 242 7720 ‐4.2
T 3 7481 117.8 C 123 7601 ‐5.2 238.7 A 243 7721 ‐4.3
A 4 7482 118.7 C 124 7602 ‐5.3 240 A 244 7722 ‐4
T 5 7483 119.7 T 125 7603 ‐5.3 240.9 T 245 7723 ‐4.1
G 6 7484 120.8 G 126 7604 ‐5.2 241.9 T 246 7724 ‐4.1
T 7 7485 122 G 127 7605 ‐5 243.1 G 247 7725 ‐3.9
C 8 7486 123.3 T 128 7606 ‐4.7 244 C 248 7726 ‐4
T 9 7487 124.2 A 129 7607 ‐4.8 245 A 249 7727 ‐4
G 10 7488 125.2 T 130 7608 ‐4.8 245.9 T 250 7728 ‐4.1
T 11 7489 126.2 T 131 7609 ‐4.8 247 A 251 7729 ‐4
G 12 7490 127.2 A 132 7610 ‐4.8 248 C 252 7730 ‐4
G 13 7491 128.2 G 133 7611 ‐4.8 249 T 253 7731 ‐4
T 14 7492 129.2 T 134 7612 ‐4.8 250.1 T 254 7732 ‐3.9
T 15 7493 130.2 C 135 7613 ‐4.8 251.3 G 255 7733 ‐3.7
T 16 7494 131 A 136 7614 ‐5 252.3 G 256 7734 ‐3.7
T 17 7495 132 T 137 7615 ‐5 253.3 C 257 7735 ‐3.7
C 18 7496 133 T 138 7616 ‐5 254.2 T 258 7736 ‐3.8
T 19 7497 134 T 139 7617 ‐5 255.1 T 259 7737 ‐3.9
G 20 7498 135 T 140 7618 ‐5 256.3 G 260 7738 ‐3.7
C 21 7499 136 C 141 7619 ‐5 257.2 T 261 7739 ‐3.8
A 22 7500 136.9 C 142 7620 ‐5.1 258.3 A 262 7740 ‐3.7
C 23 7501 137 T 143 7621 ‐6 259.3 C 263 7741 ‐3.7
A 24 7502 139.1 G 144 7622 ‐4.9 260.1 A 264 7742 ‐3.9
A 25 7503 140.2 T 145 7623 ‐4.8 261 A 265 7743 ‐4
T 26 7504 141.2 C 146 7624 ‐4.8 262 C 266 7744 ‐4
A 27 7505 142 C 147 7625 ‐5 262.9 T 267 7745 ‐4.1
C 28 7506 143 A 148 7626 ‐5 264 A 268 7746 ‐4
A 29 7507 144.1 G 149 7627 ‐4.9 265.1 C 269 7747 ‐3.9
G 30 7508 145 G 150 7628 ‐5 266 T 270 7748 ‐4
T 31 7509 146.2 T 151 7629 ‐4.8 267 T 271 7749 ‐4
A 32 7510 147.4 G 152 7630 ‐4.6 268.2 T 272 7750 ‐3.8
C 33 7511 148.3 C 153 7631 ‐4.7 269.2 C 273 7751 ‐3.8
G 34 7512 G 154 7632 270.2 A 274 7752 ‐3.8
C 35 7513 150.2 C 155 7633 ‐4.8 271.2 T 275 7753 ‐3.8
T 36 7514 151 T 156 7634 ‐5 272.5 G 276 7754 ‐3.5
G 37 7515 152 A 157 7635 ‐5 T 277 7755
G 38 7516 153.1 C 158 7636 ‐4.9 274.4 C 278 7756 ‐3.6
C 39 7517 154 A 159 7637 ‐5 275.5 C 279 7757 ‐3.5
A 40 7518 155.1 A 160 7638 ‐4.9 276.1 A 280 7758 ‐3.9
C 41 7519 156.1 C 161 7639 ‐4.9 277.1 A 281 7759 ‐3.9
T 42 7520 157.1 A 162 7640 ‐4.9 278.2 C 282 7760 ‐3.8
A 43 7521 158 A 163 7641 ‐5 279.2 A 283 7761 ‐3.8
T 44 7522 159.1 T 164 7642 ‐4.9 280 T 284 7762 ‐4
T 45 7523 160.2 T 165 7643 ‐4.8 281.2 T 285 7763 ‐3.8
G 46 7524 161.4 G 166 7644 ‐4.6 282.3 C 286 7764 ‐3.7
C 47 7525 162.4 C 167 7645 ‐4.6 283.2 T 287 7765 ‐3.8
A 48 7526 163.3 T 168 7646 ‐4.7 284.4 G 288 7766 ‐3.6
A 49 7527 164.3 T 169 7647 ‐4.7 285.3 T 289 7767 ‐3.7
A 50 7528 165.4 G 170 7648 ‐4.6 286.5 C 290 7768 ‐3.5
40.5 C 51 7529 ‐10.5 166.4 C 171 7649 ‐4.6 287.3 T 291 7769 ‐3.7
42 T 52 7530 ‐10 167.3 A 172 7650 ‐4.7 288.4 A 292 7770 ‐3.6
43.2 T 53 7531 ‐9.8 168.3 T 173 7651 ‐4.7 289.3 C 293 7771 ‐3.7
44.5 T 54 7532 ‐9.5 169.3 A 174 7652 ‐4.7 290.2 C 294 7772 ‐3.8
A 55 7533 170.3 A 175 7653 ‐4.7 291.1 C 295 7773 ‐3.9
A 56 7534 171.3 C 176 7654 ‐4.7 292 T 296 7774 ‐4
48 T 57 7535 ‐9 172.3 T 177 7655 ‐4.7 293.7 T 297 7775 ‐3.3
49 C 58 7536 ‐9 173.3 A 178 7656 ‐4.7 294.3 A 298 7776 ‐3.7
T 59 7537 174.4 T 179 7657 ‐4.6 295.3 A 299 7777 ‐3.7
T 60 7538 175.5 A 180 7658 ‐4.5 296.3 C 300 7778 ‐3.7
54.1 T 61 7539 ‐6.9 176.4 T 181 7659 ‐4.6 297.3 A 301 7779 ‐3.7
55.2 T 62 7540 ‐6.8 177.4 C 182 7660 ‐4.6 298.2 T 302 7780 ‐3.8
G 63 7541 178.3 C 183 7661 ‐4.7 G 303 7781
G 64 7542 179.3 A 184 7662 ‐4.7 A 304 7782
G 65 7543 180.2 C 185 7663 ‐4.8 A 305 7783
59.3 C 66 7544 ‐6.7 181.2 T 186 7664 ‐4.8
60.2 A 67 7545 ‐6.8 182.3 C 187 7665 ‐4.7
60.5 C 68 7546 ‐7.5 183.2 C 188 7666 ‐4.8
61.7 T 69 7547 ‐7.3 184.1 C 189 7667 ‐4.9
62.9 G 70 7548 ‐7.1 185.1 T 190 7668 ‐4.9
63.9 C 71 7549 ‐7.1 186.4 A 191 7669 ‐4.6
65 T 72 7550 ‐7 187.4 A 192 7670 ‐4.6
65.9 C 73 7551 ‐7.1 188.5 G 193 7671 ‐4.5
66.8 C 74 7552 ‐7.2 189.5 T 194 7672 ‐4.5
68 T 75 7553 ‐7 190.6 A 195 7673 ‐4.4
69.3 A 76 7554 ‐6.7 191.4 A 196 7674 ‐4.6
70.2 C 77 7555 ‐6.8 192.5 T 197 7675 ‐4.5
71.5 A 78 7556 ‐6.5 193.5 A 198 7676 ‐4.5
72.5 T 79 7557 ‐6.5 194.5 A 199 7677 ‐4.5
73.7 A 80 7558 ‐6.3 195.4 A 200 7678 ‐4.6
74.7 T 81 7559 ‐6.3 196.4 A 201 7679 ‐4.6
75.9 T 82 7560 ‐6.1 197.4 C 202 7680 ‐4.6
77 T 83 7561 ‐6 198.4 T 203 7681 ‐4.6
78.2 T 84 7562 ‐5.8 199.5 G 204 7682 ‐4.5
79.3 G 85 7563 ‐5.7 200.5 C 205 7683 ‐4.5
A 86 7564 201.5 T 206 7684 ‐4.5
A 87 7565 202.5 T 207 7685 ‐4.5
82.2 C 88 7566 ‐5.8 203.5 T 208 7686 ‐4.5
83.2 A 89 7567 ‐5.8 204.6 T 209 7687 ‐4.4
A 90 7568 205.6 A 210 7688 ‐4.4
T 91 7569 206.8 G 211 7689 ‐4.2
T 92 7570 207.9 G 212 7690 ‐4.1
G 93 7571 208.8 C 213 7691 ‐4.2
G 94 7572 209.6 A 214 7692 ‐4.4
C 95 7573 210.4 C 215 7693 ‐4.6
G 96 7574 211.5 A 216 7694 ‐4.5
C 97 7575 212.3 T 217 7695 ‐4.7
G 98 7576 213.5 A 218 7696 ‐4.5
C 99 7577 214.5 T 219 7697 ‐4.5
C 100 7578 215.6 T 220 7698 ‐4.4
T 101 7579 216.7 T 221 7699 ‐4.3
96.1 C 102 7580 ‐5.9 217.7 T 222 7700 ‐4.3
97.3 T 103 7581 ‐5.7 218.7 A 223 7701 ‐4.3
98.5 T 104 7582 ‐5.5 219.8 G 224 7702 ‐4.2
99.8 T 105 7583 ‐5.2 220.9 T 225 7703 ‐4.1
101.1 G 106 7584 ‐4.9 221.9 T 226 7704 ‐4.1
102.2 G 107 7585 ‐4.8 222.9 T 227 7705 ‐4.1
103.3 C 108 7586 ‐4.7 223.9 G 228 7706 ‐4.1
104.1 G 109 7587 ‐4.9 225 T 229 7707 ‐4
104.6 C 110 7588 ‐5.4 226 T 230 7708 ‐4
105.6 A 111 7589 ‐5.4 226.8 T 231 7709 ‐4.2
106.7 T 112 7590 ‐5.3 228 T 232 7710 ‐4
107.9 A 113 7591 ‐5.1 228.9 T 233 7711 ‐4.1
109 T 114 7592 ‐5 229.9 A 234 7712 ‐4.1
110.2 A 115 7593 ‐4.8 230.8 C 235 7713 ‐4.2
111.2 A 116 7594 ‐4.8 231.9 T 236 7714 ‐4.1
112.5 G 117 7595 ‐4.5 232.8 T 237 7715 ‐4.2
113.1 G 118 7596 ‐4.9 233.8 A 238 7716 ‐4.2
114.4 C 119 7597 ‐4.6 234.8 A 239 7717 ‐4.2
115.3 G 120 7598 ‐4.7 235.9 G 240 7718 ‐4.1
Figure SI2.2A. CE Sanger USB Indexing of the 305 bp HPV18 (7479-7783): Top Strand. CE position versus the
real position of nucleotides from the top strand (5’-FAM) of the 305 bp HPV18 (7479-7783) fragment. 
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HPV18 (7479‐7783) 305 bp (HEX Lanes ECF160 A1,B2,C2,D2)
Correction between CE size calling to USB sequencing results
CE postion Sequence Real Position Genome Position CE postion Sequence Real PositionGenome Position CE postion Sequence Real Position Genome Position
T 1 7783 114.9 G 121 7663 ‐6.1 234.7 C 241 7543 ‐6.3
T 2 7782 115.8 T 122 7662 ‐6.2 235.6 C 242 7542 ‐6.4
C 3 7781 116.9 G 123 7661 ‐6.1 236.5 C 243 7541 ‐6.5
A 4 7780 117.9 G 124 7660 ‐6.1 237.5 A 244 7540 ‐6.5
T 5 7779 118.7 A 125 7659 ‐6.3 238.5 A 245 7539 ‐6.5
G 6 7778 119.8 T 126 7658 ‐6.2 239.5 A 246 7538 ‐6.5
T 7 7777 120.5 A 127 7657 ‐6.5 240.5 A 247 7537 ‐6.5
T 8 7776 121.6 T 128 7656 ‐6.4 241.8 G 248 7536 ‐6.2
A 9 7775 122.4 A 129 7655 ‐6.6 242.6 A 249 7535 ‐6.4
A 10 7774 123.7 G 130 7654 ‐6.3 244 T 250 7534 ‐6
G 11 7773 124.6 T 131 7653 ‐6.4 244.8 T 251 7533 ‐6.2
G 12 7772 125.6 T 132 7652 ‐6.4 245.7 A 252 7532 ‐6.3
G 13 7771 126.4 A 133 7651 ‐6.6 246.7 A 253 7531 ‐6.3
T 14 7770 127.5 T 134 7650 ‐6.5 247.7 A 254 7530 ‐6.3
A 15 7769 128.8 G 135 7649 ‐6.2 248.9 G 255 7529 ‐6.1
G 16 7768 129.5 C 136 7648 ‐6.5 249.9 T 256 7528 ‐6.1
A 17 7767 130.3 A 137 7647 ‐6.7 250.9 T 257 7527 ‐6.1
C 18 7766 131.1 A 138 7646 ‐6.9 251.8 T 258 7526 ‐6.2
A 19 7765 132.5 G 139 7645 ‐6.5 252.9 G 259 7525 ‐6.1
G 20 7764 133 C 140 7644 ‐7 253.8 C 260 7524 ‐6.2
A 21 7763 134.1 A 141 7643 ‐6.9 254.7 A 261 7523 ‐6.3
A 22 7762 135 A 142 7642 ‐7 255.6 A 262 7522 ‐6.4
T 23 7761 136.1 T 143 7641 ‐6.9 256.7 T 263 7521 ‐6.3
G 24 7760 137.2 T 144 7640 ‐6.8 257.6 A 264 7520 ‐6.4
T 25 7759 G 145 7639 258.8 G 265 7519 ‐6.2
T 26 7758 T 146 7638 259.7 T 266 7518 ‐6.3
G 27 7757 140.4 T 147 7637 ‐6.6 260.9 G 267 7517 ‐6.1
G 28 7756 141.8 G 148 7636 ‐6.2 261.6 C 268 7516 ‐6.4
A 29 7755 142.6 T 149 7635 ‐6.4 262 C 269 7515 ‐7
C 30 7754 143.5 A 150 7634 ‐6.5 263.4 A 270 7514 ‐6.6
A 31 7753 144.8 G 151 7633 ‐6.2 264.6 G 271 7513 ‐6.4
T 32 7752 145.5 C 152 7632 ‐6.5 265.4 C 272 7512 ‐6.6
G 33 7751 146.8 G 153 7631 ‐6.2 266.6 G 273 7511 ‐6.4
A 34 7750 147.4 C 154 7630 ‐6.6 267.4 T 274 7510 ‐6.6
A 35 7749 148.3 A 155 7629 ‐6.7 268.4 A 275 7509 ‐6.6
A 36 7748 149.2 C 156 7628 ‐6.8 269.4 C 276 7508 ‐6.6
G 37 7747 150 C 157 7627 ‐7 270.5 T 277 7507 ‐6.5
T 38 7746 151.2 T 158 7626 ‐6.8 271.6 G 278 7506 ‐6.4
A 39 7745 152.5 G 159 7625 ‐6.5 272.7 T 279 7505 ‐6.3
G 40 7744 153.7 G 160 7624 ‐6.3 273.6 A 280 7504 ‐6.4
T 41 7743 154.7 A 161 7623 ‐6.3 274.7 T 281 7503 ‐6.3
T 42 7742 155.7 C 162 7622 ‐6.3 275.8 T 282 7502 ‐6.2
G 43 7741 156.6 A 163 7621 ‐6.4 276.9 G 283 7501 ‐6.1
T 44 7740 157.8 G 164 7620 ‐6.2 277.9 T 284 7500 ‐6.1
A 45 7739 159 G 165 7619 ‐6 279 G 285 7499 ‐6
C 46 7738 160 A 166 7618 ‐6 279.8 C 286 7498 ‐6.2
A 47 7737 160.8 A 167 7617 ‐6.2 280.7 A 287 7497 ‐6.3
A 48 7736 162 A 168 7616 ‐6 281.8 G 288 7496 ‐6.2
G 49 7735 162.6 A 169 7615 ‐6.4 283 A 289 7495 ‐6
C 50 7734 163.8 T 170 7614 ‐6.2 283.6 A 290 7494 ‐6.4
C 51 7733 164.9 G 171 7613 ‐6.1 285 A 291 7493 ‐6
A 52 7732 165.7 A 172 7612 ‐6.3 285.5 A 292 7492 ‐6.5
A 53 7731 166.7 C 173 7611 ‐6.3 287 C 293 7491 ‐6
G 54 7730 167.8 T 174 7610 ‐6.2 288 C 294 7490 ‐6
T 55 7729 168.6 A 175 7609 ‐6.4 288.3 A 295 7489 ‐6.7
46.4 A 56 7728 ‐9.6 170 A 176 7608 ‐6 289.4 C 296 7488 ‐6.6
47.9 T 57 7727 ‐9.1 170.8 T 177 7607 ‐6.2 290.2 A 297 7487 ‐6.8
48.8 G 58 7726 ‐9.2 171.7 A 178 7606 ‐6.3 291 G 298 7486 ‐7
49.6 C 59 7725 ‐9.4 172.7 C 179 7605 ‐6.3 292.3 A 299 7485 ‐6.7
50.5 A 60 7724 ‐9.5 173.5 C 180 7604 ‐6.5 293.4 C 300 7484 ‐6.6
51.2 A 61 7723 ‐9.8 174.4 A 181 7603 ‐6.6 294.3 A 301 7483 ‐6.7
52.7 T 62 7722 ‐9.3 175.7 G 182 7602 ‐6.3 295.3 T 302 7482 ‐6.7
53.9 T 63 7721 ‐9.1 177 G 183 7601 ‐6 296.3 A 303 7481 ‐6.7
54.7 A 64 7720 ‐9.3 178 T 184 7600 ‐6 A 304 7480
56.4 G 65 7719 ‐8.6 179.1 G 185 7599 ‐5.9 G 305 7479
57.1 C 66 7718 ‐8.9 179.7 C 186 7598 ‐6.3
58.4 T 67 7717 ‐8.6 181 G 187 7597 ‐6
59.5 T 68 7716 ‐8.5 181.7 C 188 7596 ‐6.3
60.3 A 69 7715 ‐8.7 182.6 C 189 7595 ‐6.4
61.4 A 70 7714 ‐8.6 183.6 T 190 7594 ‐6.4
63.1 G 71 7713 ‐7.9 185 T 191 7593 ‐6
64 T 72 7712 ‐8 185.7 A 192 7592 ‐6.3
64.9 A 73 7711 ‐8.1 187 T 193 7591 ‐6
65.7 A 74 7710 ‐8.3 187.8 A 194 7590 ‐6.2
66.7 A 75 7709 ‐8.3 189 T 195 7589 ‐6
67.6 A 76 7708 ‐8.4 190.3 G 196 7588 ‐5.7
68.6 A 77 7707 ‐8.4 191.1 C 197 7587 ‐5.9
69.5 C 78 7706 ‐8.5 192.3 G 198 7586 ‐5.7
70.6 A 79 7705 ‐8.4 193 C 199 7585 ‐6
71.5 A 80 7704 ‐8.5 193.9 C 200 7584 ‐6.1
72.6 A 81 7703 ‐8.4 194.8 A 201 7583 ‐6.2
73.5 C 82 7702 ‐8.5 196 A 202 7582 ‐6
74.1 T 83 7701 ‐8.9 196.9 A 203 7581 ‐6.1
74.9 A 84 7700 ‐9.1 198.1 G 204 7580 ‐5.9
75.8 A 85 7699 ‐9.2 198.9 A 205 7579 ‐6.1
76.9 A 86 7698 ‐9.1 200.2 G 206 7578 ‐5.8
A 87 7697 201.2 G 207 7577 ‐5.8
T 88 7696 202 C 208 7576 ‐6
A 89 7695 203.1 G 209 7575 ‐5.9
T 90 7694 203.6 C 210 7574 ‐6.4
G 91 7693 204.7 G 211 7573 ‐6.3
T 92 7692 205.6 C 212 7572 ‐6.4
85.9 G 93 7691 ‐7.1 206.5 C 213 7571 ‐6.5
86.5 C 94 7690 ‐7.5 207.5 A 214 7570 ‐6.5
87.4 C 95 7689 ‐7.6 208.5 A 215 7569 ‐6.5
87.8 T 96 7688 ‐8.2 210 T 216 7568 ‐6
89.5 A 97 7687 ‐7.5 210.8 T 217 7567 ‐6.2
90.5 A 98 7686 ‐7.5 212 G 218 7566 ‐6
91.6 A 99 7685 ‐7.4 213 T 219 7565 ‐6
92.5 A 100 7684 ‐7.5 214 T 220 7564 ‐6
93.9 G 101 7683 ‐7.1 215 C 221 7563 ‐6
94 C 102 7682 ‐8 215.8 A 222 7562 ‐6.2
95.3 A 103 7681 ‐7.7 216.8 A 223 7561 ‐6.2
96.6 G 104 7680 ‐7.4 217.8 A 224 7560 ‐6.2
97.5 T 105 7679 ‐7.5 218.8 A 225 7559 ‐6.2
98.6 T 106 7678 ‐7.4 220 T 226 7558 ‐6
99.7 T 107 7677 ‐7.3 220.8 A 227 7557 ‐6.2
100.8 T 108 7676 ‐7.2 222 T 228 7556 ‐6
101.7 A 109 7675 ‐7.3 223 G 229 7555 ‐6
103.1 T 110 7674 ‐6.9 224.1 T 230 7554 ‐5.9
104.2 T 111 7673 ‐6.8 224.9 A 231 7553 ‐6.1
105.1 A 112 7672 ‐6.9 226 G 232 7552 ‐6
106 C 113 7671 ‐7 227.2 G 233 7551 ‐5.8
107.2 T 114 7670 ‐6.8 228 A 234 7550 ‐6
108 T 115 7669 ‐7 229.2 G 235 7549 ‐5.8
109.2 A 116 7668 ‐6.8 229.9 C 236 7548 ‐6.1
110.5 G 117 7667 ‐6.5 230.8 A 237 7547 ‐6.2
111.8 G 118 7666 ‐6.2 232 G 238 7546 ‐6
112.9 G 119 7665 ‐6.1 232.9 T 239 7545 ‐6.1
113.7 A 120 7664 ‐6.3 234 G 240 7544 ‐6
Figure SI2.2B. CE Sanger USB Indexing of the 305 bp HPV18 (7479-7783): Bottom Strand. CE position versus
the real position of nucleotides from the bottom strand (5’-HEX) of the 305 bp HPV18 (7479-7783) fragment. 
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HPV18 (7647‐157) 368 bp Samples A1, B1, C1 and D3
Top Strand (5'‐FAM)
Correction between CE size calling to sequencing results
CE postion Sequence Real Position Genome Position CE postion Sequence Real Position Genome Position CE postion Sequence Real Position Genome Position
T 1 7647 115.9 T 121 7767 ‐5.1 236.7 A 241 30 ‐4.3
G 2 7648 116.8 C 122 7768 ‐5.2 237.8 A 242 31 ‐4.2
C 3 7649 118 T 123 7769 ‐5 238.8 A 243 32 ‐4.2
A 4 7650 118.8 A 124 7770 ‐5.2 240 A 244 33 ‐4
T 5 7651 119.5 C 125 7771 ‐5.5 240.7 A 245 34 ‐4.3
A 6 7652 120 C 126 7772 ‐6 241.7 G 246 35 ‐4.3
A 7 7653 121.2 C 127 7773 ‐5.8 242.9 G 247 36 ‐4.1
C 8 7654 122.3 T 128 7774 ‐5.7 243.9 G 248 37 ‐4.1
T 9 7655 123.5 T 129 7775 ‐5.5 244.7 A 249 38 ‐4.3
A 10 7656 124.7 A 130 7776 ‐5.3 245.9 G 250 39 ‐4.1
T 11 7657 125.7 A 131 7777 ‐5.3 246.8 T 251 40 ‐4.2
A 12 7658 126.5 C 132 7778 ‐5.5 247.5 A 252 41 ‐4.5
T 13 7659 127.6 A 133 7779 ‐5.4 248.3 A 253 42 ‐4.7
C 14 7660 128.5 T 134 7780 ‐5.5 249.6 C 254 43 ‐4.4
C 15 7661 129.8 G 135 7781 ‐5.2 250.5 C 255 44 ‐4.5
A 16 7662 130.8 A 136 7782 ‐5.2 251.7 G 256 45 ‐4.3
C 17 7663 131.7 A 137 7783 ‐5.3 253.2 A 257 46 ‐3.8
T 18 7664 132.5 C 138 7784 ‐5.5 254 A 258 47 ‐4
C 19 7665 133.6 T 139 7785 ‐5.4 254.9 A 259 48 ‐4.1
C 20 7666 134.6 A 140 7786 ‐5.4 255.6 A 260 49 ‐4.4
C 21 7667 135.8 T 141 7787 ‐5.2 256.5 C 261 50 ‐4.5
T 22 7668 136.7 A 142 7788 ‐5.3 257.6 G 262 51 ‐4.4
A 23 7669 138 A 143 7789 ‐5 259 G 263 52 ‐4
A 24 7670 138.7 T 144 7790 ‐5.3 259.9 T 264 53 ‐4.1
G 25 7671 139.7 A 145 7791 ‐5.3 260.5 C 265 54 ‐4.5
T 26 7672 141 T 146 7792 ‐5 261.6 G 266 55 ‐4.4
A 27 7673 141.9 G 147 7793 ‐5.1 262.6 G 267 56 ‐4.4
A 28 7674 142.9 A 148 7794 ‐5.1 263.8 G 268 57 ‐4.2
T 29 7675 143.7 C 149 7795 ‐5.3 264 A 269 58 ‐5
A 30 7676 144.8 T 150 7796 ‐5.2 265.6 C 270 59 ‐4.4
A 31 7677 145.8 A 151 7797 ‐5.2 266.5 C 271 60 ‐4.5
A 32 7678 146.8 A 152 7798 ‐5.2 267.5 G 272 61 ‐4.5
A 33 7679 148 G 153 7799 ‐5 268.8 A 273 62 ‐4.2
C 34 7680 148.7 C 154 7800 ‐5.3 269.6 A 274 63 ‐4.4
T 35 7681 149.7 T 155 7801 ‐5.3 270.7 A 275 64 ‐4.3
G 36 7682 151 G 156 7802 ‐5 271.5 A 276 65 ‐4.5
C 37 7683 152.1 T 157 7803 ‐4.9 272.4 C 277 66 ‐4.6
T 38 7684 153.2 G 158 7804 ‐4.8 273.6 G 278 67 ‐4.4
T 39 7685 153.8 C 159 7805 ‐5.2 274.6 G 279 68 ‐4.4
T 40 7686 154.8 A 160 7806 ‐5.2 275.5 T 280 69 ‐4.5
T 41 7687 156 T 161 7807 ‐5 276.7 G 281 70 ‐4.3
A 42 7688 156.9 A 162 7808 ‐5.1 277.4 T 282 71 ‐4.6
G 43 7689 157.7 C 163 7809 ‐5.3 278.6 A 283 72 ‐4.4
G 44 7690 158.7 A 164 7810 ‐5.3 279.8 T 284 73 ‐4.2
C 45 7691 160 T 165 7811 ‐5 280.7 A 285 74 ‐4.3
A 46 7692 160.9 A 166 7812 ‐5.1 281.5 T 286 75 ‐4.5
C 47 7693 162.1 G 167 7813 ‐4.9 282.8 A 287 76 ‐4.2
A 48 7694 163.2 T 168 7814 ‐4.8 283.6 A 288 77 ‐4.4
T 49 7695 164.2 T 169 7815 ‐4.8 284.7 A 289 78 ‐4.3
A 50 7696 165.2 T 170 7816 ‐4.8 285.7 A 290 79 ‐4.3
T 51 7697 166.1 A 171 7817 ‐4.9 286.6 G 291 80 ‐4.4
T 52 7698 167.2 T 172 7818 ‐4.8 287.6 A 292 81 ‐4.4
T 53 7699 168.4 G 173 7819 ‐4.6 288.4 T 293 82 ‐4.6
T 54 7700 169.2 C 174 7820 ‐4.8 289.6 G 294 83 ‐4.4
A 55 7701 170.1 A 175 7821 ‐4.9 290.8 T 295 84 ‐4.2
47.5 G 56 7702 ‐8.5 171 A 176 7822 ‐5 291.6 G 296 85 ‐4.4
48.6 T 57 7703 ‐8.4 171.9 C 177 7823 ‐5.1 292.8 A 297 86 ‐4.2
49.5 T 58 7704 ‐8.5 173 C 178 7824 ‐5 293.7 G 298 87 ‐4.3
50.2 T 59 7705 ‐8.8 174.1 G 179 7825 ‐4.9 294.7 A 299 88 ‐4.3
51.4 G 60 7706 ‐8.6 175 A 180 7826 ‐5 295.6 A 300 89 ‐4.4
52.2 T 61 7707 ‐8.8 176 A 181 7827 ‐5 296.3 A 301 90 ‐4.7
54 T 62 7708 ‐8 177 A 182 7828 ‐5 297.2 C 302 91 ‐4.8
55.1 T 63 7709 ‐7.9 178.1 T 183 7829 ‐4.9 298.1 A 303 92 ‐4.9
56.2 T 64 7710 ‐7.8 179.1 A 184 7830 ‐4.9 299 C 304 93 ‐5
56.9 T 65 7711 ‐8.1 180.3 G 185 7831 ‐4.7 300 A 305 94 ‐5
57.6 A 66 7712 ‐8.4 181.4 G 186 7832 ‐4.6 300.9 C 306 95 ‐5.1
58.3 C 67 7713 ‐8.7 182.4 T 187 7833 ‐4.6 301.8 C 307 96 ‐5.2
59.2 T 68 7714 ‐8.8 183.4 T 188 7834 ‐4.6 302.8 A 308 97 ‐5.2
60.5 T 69 7715 ‐8.5 184.4 G 189 7835 ‐4.6 303.8 C 309 98 ‐5.2
61.8 A 70 7716 ‐8.2 185.5 G 190 7836 ‐4.5 304.8 A 310 99 ‐5.2
62.8 A 71 7717 ‐8.2 186.6 G 191 7837 ‐4.4 305.6 A 311 100 ‐5.4
64.3 G 72 7718 ‐7.7 188 C 192 7838 ‐4 306.8 T 312 101 ‐5.2
65 C 73 7719 ‐8 188.3 A 193 7839 ‐4.7 307.9 A 313 102 ‐5.1
66.1 T 74 7720 ‐7.9 189.5 G 194 7840 ‐4.5 308.8 C 314 103 ‐5.2
66.9 A 75 7721 ‐8.1 190.3 C 195 7841 ‐4.7 309.6 T 315 104 ‐5.4
68.1 A 76 7722 ‐7.9 191.2 A 196 7842 ‐4.8 310.8 A 316 105 ‐5.2
69.3 T 77 7723 ‐7.7 192.1 C 197 7843 ‐4.9 311.6 T 317 106 ‐5.4
70.5 T 78 7724 ‐7.5 193 A 198 7844 ‐5 313.1 G 318 107 ‐4.9
71.9 G 79 7725 ‐7.1 194.2 T 199 7845 ‐4.8 314.2 G 319 108 ‐4.8
72.6 C 80 7726 ‐7.4 195.2 A 200 7846 ‐4.8 315.1 C 320 109 ‐4.9
73.6 A 81 7727 ‐7.4 196.1 C 201 7847 ‐4.9 316.3 G 321 110 ‐4.7
74.3 T 82 7728 ‐7.7 197.6 T 202 7848 ‐4.4 317 C 322 111 ‐5
75.7 A 83 7729 ‐7.3 198.2 A 203 7849 ‐4.8 318.2 G 323 112 ‐4.8
76.5 C 84 7730 ‐7.5 199.6 T 204 7850 ‐4.4 319 C 324 113 ‐5
77.8 T 85 7731 ‐7.2 200.4 A 205 7851 ‐4.6 319.9 T 325 114 ‐5.1
79 T 86 7732 ‐7 201.3 C 206 7852 ‐4.7 320.7 T 326 115 ‐5.3
80 G 87 7733 ‐7 202.4 T 207 7853 ‐4.6 321.6 T 327 116 ‐5.4
81.6 G 88 7734 ‐6.4 203.5 T 208 7854 ‐4.5 323.3 G 328 117 ‐4.7
82.4 C 89 7735 ‐6.6 204.3 T 209 7855 ‐4.7 324.2 A 329 118 ‐4.8
83.5 T 90 7736 ‐6.5 205.6 T 210 7856 ‐4.4 325.4 G 330 119 ‐4.6
84.7 T 91 7737 ‐6.3 206.5 C 211 7857 ‐4.5 326.4 G 331 120 ‐4.6
85.7 G 92 7738 ‐6.3 207.4 A 212 1 ‐4.6 327.4 A 332 121 ‐4.6
86.4 T 93 7739 ‐6.6 208.4 T 213 2 ‐4.6 328.8 T 333 122 ‐4.2
87.8 A 94 7740 ‐6.2 209.6 T 214 3 ‐4.4 329.3 C 334 123 ‐4.7
88.6 C 95 7741 ‐6.4 210.6 A 215 4 ‐4.4 330.1 C 335 124 ‐4.9
89.6 A 96 7742 ‐6.4 211.5 A 216 5 ‐4.5 331 A 336 125 ‐5
90.5 A 97 7743 ‐6.5 212.8 T 217 6 ‐4.2 332.1 A 337 126 ‐4.9
91.4 C 98 7744 ‐6.6 213.6 A 218 7 ‐4.4 333 C 338 127 ‐5
92.5 T 99 7745 ‐6.5 214.5 C 219 8 ‐4.5 333.8 A 339 128 ‐5.2
93.6 A 100 7746 ‐6.4 215.5 T 220 9 ‐4.5 334.9 C 340 129 ‐5.1
94.5 C 101 7747 ‐6.5 217 T 221 10 ‐4 336 G 341 130 ‐5
96 T 102 7748 ‐6 217.7 T 222 11 ‐4.3 337.1 G 342 131 ‐4.9
96.8 T 103 7749 ‐6.2 218.7 T 223 12 ‐4.3 338.1 C 343 132 ‐4.9
98 T 104 7750 ‐6 219.8 A 224 13 ‐4.2 339.1 G 344 133 ‐4.9
99 C 105 7751 ‐6 221 A 225 14 ‐4 340 A 345 134 ‐5
100 A 106 7752 ‐6 221.6 C 226 15 ‐4.4 340.9 C 346 135 ‐5.1
101 T 107 7753 ‐6 222.6 A 227 16 ‐4.4 341.8 C 347 136 ‐5.2
102.4 G 108 7754 ‐5.6 223.4 A 228 17 ‐4.6 342.7 C 348 137 ‐5.3
103.6 T 109 7755 ‐5.4 224.2 T 229 18 ‐4.8 343.8 T 349 138 ‐5.2
104.4 C 110 7756 ‐5.6 225.7 T 230 19 ‐4.3 344.8 A 350 139 ‐5.2
105.2 C 111 7757 ‐5.8 226.8 G 231 20 ‐4.2 346 C 351 140 ‐5
106.2 A 112 7758 ‐5.8 227.7 T 232 21 ‐4.3 347.3 A 352 141 ‐4.7
107.2 A 113 7759 ‐5.8 228.6 A 233 22 ‐4.4 348.1 A 353 142 ‐4.9
108.1 C 114 7760 ‐5.9 229.9 G 234 23 ‐4.1 349 G 354 143 ‐5
109.2 A 115 7761 ‐5.8 230.5 T 235 24 ‐4.5 349.8 C 355 144 ‐5.2
110.3 T 116 7762 ‐5.7 231.7 A 236 25 ‐4.3 350.8 T 356 145 ‐5.2
111.5 T 117 7763 ‐5.5 232.9 T 237 26 ‐4.1 351.8 A 357 146 ‐5.2
112.4 C 118 7764 ‐5.6 233.5 A 238 27 ‐4.5 352.8 C 358 147 ‐5.2
113.6 T 119 7765 ‐5.4 234.7 T 239 28 ‐4.3 353.7 C 359 148 ‐5.3
114.8 G 120 7766 ‐5.2 235.8 A 240 29 ‐4.2 354.8 T 360 149 ‐5.2
355.9 G 361 150 ‐5.1
357 A 362 151 ‐5
357.8 T 363 152 ‐5.2
358.9 C 364 153 ‐5.1
360.1 T 365 154 ‐4.9
361.1 G 366 155 ‐4.9
T 367 156
G 368 157
Figure SI2.2C. CE Sanger USB Indexing of the 368 bp HPV18 (7647-157): Top Strand. CE position versus the
real position of nucleotides from the top strand (5’-FAM) of the 368 bp HPV18 (7647-157) fragment. 
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HPV18 (7647‐157) 368 bp Samples E1, F1, G1 and H1
Bottom Strand (5'‐HEX)
Correction between CE size calling to sequencing results
CE postion Sequence Real Position Genome Position CE postion Sequence Real Position Genome Position CE postion Sequence Real Position Genome Position
C 1 157 116.2 C 121 37 ‐4.8 237 A 241 7774 ‐4
A 2 156 117 C 122 36 ‐5 238.3 G 242 7773 ‐3.7
C 3 155 117.9 C 123 35 ‐5.1 239.3 G 243 7772 ‐3.7
A 4 154 119 T 124 34 ‐5 240 G 244 7771 ‐4
G 5 153 120.3 T 125 33 ‐4.7 241.4 T 245 7770 ‐3.6
A 6 152 121.5 T 126 32 ‐4.5 242.4 A 246 7769 ‐3.6
T 7 151 122.6 T 127 31 ‐4.4 243.4 G 247 7768 ‐3.6
C 8 150 123.7 T 128 30 ‐4.3 244.4 A 248 7767 ‐3.6
A 9 149 124.8 T 129 29 ‐4.2 245.2 C 249 7766 ‐3.8
G 10 148 125.7 A 130 28 ‐4.3 246.3 A 250 7765 ‐3.7
G 11 147 126.7 T 131 27 ‐4.3 247.3 G 251 7764 ‐3.7
T 12 146 127.7 A 132 26 ‐4.3 248.4 A 252 7763 ‐3.6
A 13 145 128.7 T 133 25 ‐4.3 249 A 253 7762 ‐4
G 14 144 129.6 A 134 24 ‐4.4 250.3 T 254 7761 ‐3.7
C 15 143 130.3 C 135 23 ‐4.7 251.3 G 255 7760 ‐3.7
T 16 142 131.5 T 136 22 ‐4.5 252 T 256 7759 ‐4
T 17 141 132.5 A 137 21 ‐4.5 253.3 T 257 7758 ‐3.7
G 18 140 133.3 C 138 20 ‐4.7 254.4 G 258 7757 ‐3.6
T 19 139 134.4 A 139 19 ‐4.6 255 G 259 7756 ‐4
A 20 138 135.3 A 140 18 ‐4.7 256.5 A 260 7755 ‐3.5
G 21 137 136.4 T 141 17 ‐4.6 257.3 C 261 7754 ‐3.7
G 22 136 137.4 T 142 16 ‐4.6 258.4 A 262 7753 ‐3.6
G 23 135 138.5 G 143 15 ‐4.5 259.3 T 263 7752 ‐3.7
T 24 134 139.7 T 144 14 ‐4.3 260.3 G 264 7751 ‐3.7
C 25 133 140.7 T 145 13 ‐4.3 261 A 265 7750 ‐4
G 26 132 141.7 A 146 12 ‐4.3 262.3 A 266 7749 ‐3.7
C 27 131 142.6 A 147 11 ‐4.4 263 A 267 7748 ‐4
C 28 130 143.4 A 148 10 ‐4.6 264.3 G 268 7747 ‐3.7
G 29 129 144.4 A 149 9 ‐4.6 265.3 T 269 7746 ‐3.7
T 30 128 145.6 G 150 8 ‐4.4 266.3 A 270 7745 ‐3.7
G 31 127 146.6 T 151 7 ‐4.4 267.3 G 271 7744 ‐3.7
T 32 126 147.5 A 152 6 ‐4.5 268 T 272 7743 ‐4
T 33 125 148.5 T 153 5 ‐4.5 269.3 T 273 7742 ‐3.7
G 34 124 149.5 T 154 4 ‐4.5 270.3 G 274 7741 ‐3.7
G 35 123 150.5 A 155 3 ‐4.5 271.4 T 275 7740 ‐3.6
A 36 122 151.4 A 156 2 ‐4.6 272.3 A 276 7739 ‐3.7
T 37 121 152.6 T 157 1 ‐4.4 273.2 C 277 7738 ‐3.8
C 38 120 153.8 G 158 7857 ‐4.2 274 A 278 7737 ‐4
C 39 119 154.8 A 159 7856 ‐4.2 275.1 A 279 7736 ‐3.9
T 40 118 155.8 A 160 7855 ‐4.2 276.2 G 280 7735 ‐3.8
C 41 117 156.5 A 161 7854 ‐4.5 277 C 281 7734 ‐4
A 42 116 157.5 A 162 7853 ‐4.5 278 C 282 7733 ‐4
A 43 115 158.7 G 163 7852 ‐4.3 279 A 283 7732 ‐4
A 44 114 159.6 T 164 7851 ‐4.4 280 A 284 7731 ‐4
G 45 113 160.6 A 165 7850 ‐4.4 281.1 G 285 7730 ‐3.9
C 46 112 161.5 T 166 7849 ‐4.5 282.1 T 286 7729 ‐3.9
G 47 111 162.5 A 167 7848 ‐4.5 283.1 A 287 7728 ‐3.9
C 48 110 163.7 G 168 7847 ‐4.3 284 T 288 7727 ‐4
G 49 109 164.7 T 169 7846 ‐4.3 285.1 G 289 7726 ‐3.9
C 50 108 165.6 A 170 7845 ‐4.4 286 C 290 7725 ‐4
C 51 107 166.6 T 171 7844 ‐4.4 287 A 291 7724 ‐4
A 52 106 167.7 G 172 7843 ‐4.3 288 A 292 7723 ‐4
T 53 105 168.7 T 173 7842 ‐4.3 289 T 293 7722 ‐4
A 54 104 169.9 G 174 7841 ‐4.1 289.9 T 294 7721 ‐4.1
47.4 G 55 103 ‐7.6 170.7 C 175 7840 ‐4.3 290.9 A 295 7720 ‐4.1
48.5 T 56 102 ‐7.5 171.7 T 176 7839 ‐4.3 292 G 296 7719 ‐4
49.2 A 57 101 ‐7.8 172.8 G 177 7838 ‐4.2 293 C 297 7718 ‐4
50.1 T 58 100 ‐7.9 173.6 C 178 7837 ‐4.4 294 T 298 7717 ‐4
51.1 T 59 99 ‐7.9 174.5 C 179 7836 ‐4.5 295 T 299 7716 ‐4
52.4 G 60 98 ‐7.6 175.4 C 180 7835 ‐4.6 296 A 300 7715 ‐4
53.3 T 61 97 ‐7.7 176.4 A 181 7834 ‐4.6 297 A 301 7714 ‐4
54.8 G 62 96 ‐7.2 177.4 A 182 7833 ‐4.6 298 G 302 7713 ‐4
56 G 63 95 ‐7 178.3 C 183 7832 ‐4.7 299 T 303 7712 ‐4
57 T 64 94 ‐7 179.2 C 184 7831 ‐4.8 300.1 A 304 7711 ‐3.9
58.3 G 65 93 ‐6.7 180.4 T 185 7830 ‐4.6 300.9 A 305 7710 ‐4.1
59.2 T 66 92 ‐6.8 181.5 A 186 7829 ‐4.5 301.9 A 306 7709 ‐4.1
60.4 G 67 91 ‐6.6 182.6 T 187 7828 ‐4.4 302.9 A 307 7708 ‐4.1
61.3 T 68 90 ‐6.7 183.7 T 188 7827 ‐4.3 303.8 A 308 7707 ‐4.2
62.3 T 69 89 ‐6.7 184.8 T 189 7826 ‐4.2 304.6 C 309 7706 ‐4.4
63.4 T 70 88 ‐6.6 185.7 C 190 7825 ‐4.3 305.7 A 310 7705 ‐4.3
64 C 71 87 ‐7 187 G 191 7824 ‐4 306.6 A 311 7704 ‐4.4
65.2 T 72 86 ‐6.8 188 G 192 7823 ‐4 307.6 A 312 7703 ‐4.4
65.9 C 73 85 ‐7.1 189.1 T 193 7822 ‐3.9 308.4 C 313 7702 ‐4.6
67 A 74 84 ‐7 190.1 T 194 7821 ‐3.9 309.6 T 314 7701 ‐4.4
67.8 C 75 83 ‐7.2 191.1 G 195 7820 ‐3.9 310.5 A 315 7700 ‐4.5
69 A 76 82 ‐7 192 C 196 7819 ‐4 311.6 A 316 7699 ‐4.4
70.3 T 77 81 ‐6.7 193 A 197 7818 ‐4 312.6 A 317 7698 ‐4.4
71.1 C 78 80 ‐6.9 194 T 198 7817 ‐4 313.6 A 318 7697 ‐4.4
72.4 T 79 79 ‐6.6 195 A 199 7816 ‐4 314.5 T 319 7696 ‐4.5
73.6 T 80 78 ‐6.4 196 A 200 7815 ‐4 315.7 A 320 7695 ‐4.3
74.9 T 81 77 ‐6.1 196.9 A 201 7814 ‐4.1 316.7 T 321 7694 ‐4.3
76 T 82 76 ‐6 197.8 C 202 7813 ‐4.2 317.8 G 322 7693 ‐4.2
77 A 83 75 ‐6 198.9 T 203 7812 ‐4.1 318.8 T 323 7692 ‐4.2
78.2 T 84 74 ‐5.8 199.9 A 204 7811 ‐4.1 319.9 G 324 7691 ‐4.1
79.2 A 85 73 ‐5.8 201 T 205 7810 ‐4 321 C 325 7690 ‐4
80.3 T 86 72 ‐5.7 202 G 206 7809 ‐4 321.8 C 326 7689 ‐4.2
81.2 A 87 71 ‐5.8 203.1 T 207 7808 ‐3.9 322.7 T 327 7688 ‐4.3
82.1 C 88 70 ‐5.9 204 A 208 7807 ‐4 323.9 A 328 7687 ‐4.1
83.1 A 89 69 ‐5.9 205.1 T 209 7806 ‐3.9 324.8 A 329 7686 ‐4.2
83.8 C 90 68 ‐6.2 206.2 G 210 7805 ‐3.8 325.9 A 330 7685 ‐4.1
84.7 C 91 67 ‐6.3 207.1 C 211 7804 ‐3.9 326.9 A 331 7684 ‐4.1
86.2 G 92 66 ‐5.8 208 A 212 7803 ‐4 327.8 G 332 7683 ‐4.2
87.3 T 93 65 ‐5.7 208.8 C 213 7802 ‐4.2 328.7 C 333 7682 ‐4.3
88 T 94 64 ‐6 209.8 A 214 7801 ‐4.2 330 A 334 7681 ‐4
89.5 T 95 63 ‐5.5 210.8 G 215 7800 ‐4.2 330.7 G 335 7680 ‐4.3
91 T 96 62 ‐5 211.7 C 216 7799 ‐4.3 332 T 336 7679 ‐4
91.5 C 97 61 ‐5.5 212.8 T 217 7798 ‐4.2 333 T 337 7678 ‐4
92.8 G 98 60 ‐5.2 213.8 T 218 7797 ‐4.2 333.7 T 338 7677 ‐4.3
93.8 G 99 59 ‐5.2 214.9 A 219 7796 ‐4.1 335 T 339 7676 ‐4
94.9 T 100 58 ‐5.1 216 G 220 7795 ‐4 335.8 A 340 7675 ‐4.2
95.8 C 101 57 ‐5.2 217.2 T 221 7794 ‐3.8 337 T 341 7674 ‐4
97 C 102 56 ‐5 218 C 222 7793 ‐4 337.7 T 342 7673 ‐4.3
97.4 C 103 55 ‐5.6 219 A 223 7792 ‐4 338.8 A 343 7672 ‐4.2
98.7 G 104 54 ‐5.3 220.1 T 224 7791 ‐3.9 339.7 C 344 7671 ‐4.3
99.7 A 105 53 ‐5.3 221.1 A 225 7790 ‐3.9 341 T 345 7670 ‐4
100.5 C 106 52 ‐5.5 222.1 T 226 7789 ‐3.9 342 T 346 7669 ‐4
101.5 C 107 51 ‐5.5 223.1 T 227 7788 ‐3.9 343 A 347 7668 ‐4
102.7 G 108 50 ‐5.3 224.1 A 228 7787 ‐3.9 343.8 G 348 7667 ‐4.2
103.9 T 109 49 ‐5.1 225.2 T 229 7786 ‐3.8 345 G 349 7666 ‐4
105 T 110 48 ‐5 226.1 A 230 7785 ‐3.9 346 G 350 7665 ‐4
106.2 T 111 47 ‐4.8 227.3 G 231 7784 ‐3.7 347 A 351 7664 ‐4
107.3 T 112 46 ‐4.7 228 T 232 7783 ‐4 347.9 G 352 7663 ‐4.1
108.2 C 113 45 ‐4.8 229.3 T 233 7782 ‐3.7 348.9 T 353 7662 ‐4.1
109 G 114 44 ‐5 230.1 C 234 7781 ‐3.9 350 G 354 7661 ‐4
110.4 G 115 43 ‐4.6 231 A 235 7780 ‐4 351.1 G 355 7660 ‐3.9
111 T 116 42 ‐5 232.1 T 236 7779 ‐3.9 352 A 356 7659 ‐4
112.6 T 117 41 ‐4.4 233.2 G 237 7778 ‐3.8 353 T 357 7658 ‐4
113.5 A 118 40 ‐4.5 234.3 T 238 7777 ‐3.7 354 A 358 7657 ‐4
114.4 C 119 39 ‐4.6 235.3 T 239 7776 ‐3.7 355 T 359 7656 ‐4
115.4 T 120 38 ‐4.6 236.2 A 240 7775 ‐3.8 356 A 360 7655 ‐4
357 G 361 7654 ‐4
358 T 362 7653 ‐4
359 T 363 7652 ‐4
360 A 364 7651 ‐4
361 T 365 7650 ‐4
362 G 366 7649 ‐4
C 367 7648
A 368 7647
Figure SI2.2D. CE Sanger USB Indexing of the 368 bp HPV18 (7647-157): Bottom Strand. CE position versus the
real position of nucleotides from the bottom strand (5’-HEX) of the 368 bp HPV18 (7647-157) fragment. 
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HPV18 (7479‐7783) 305 bp (FAM Lanes A10, C10 and G12)
Correction between CE size calling to Maxam‐Gilbert sequencing results
CE postion Sequence Real Position Genome Position CE postion Sequence Real Position Genome Position CE postion Sequence Real Position Genome Position
C 1 7479 113.7 C 121 7599 ‐7.3 235 C 241 7719 ‐6
T 2 7480 114.4 A 122 7600 ‐7.6 235.8 T 242 7720 ‐6.2
T 3 7481 115.3 C 123 7601 ‐7.7 237 A 243 7721 ‐6
A 4 7482 116.2 C 124 7602 ‐7.8 238 A 244 7722 ‐6
T 5 7483 117.1 T 125 7603 ‐7.9 238.8 T 245 7723 ‐6.2
G 6 7484 118.3 G 126 7604 ‐7.7 239.9 T 246 7724 ‐6.1
T 7 7485 119.6 G 127 7605 ‐7.4 241.1 G 247 7725 ‐5.9
C 8 7486 120.8 T 128 7606 ‐7.2 242.2 C 248 7726 ‐5.8
T 9 7487 121.8 A 129 7607 ‐7.2 243.1 A 249 7727 ‐5.9
G 10 7488 122.7 T 130 7608 ‐7.3 244 T 250 7728 ‐6
T 11 7489 123.7 T 131 7609 ‐7.3 245.2 A 251 7729 ‐5.8
G 12 7490 124.7 A 132 7610 ‐7.3 246.1 C 252 7730 ‐5.9
G 13 7491 125.6 G 133 7611 ‐7.4 246.9 T 253 7731 ‐6.1
T 14 7492 127 T 134 7612 ‐7 248.2 T 254 7732 ‐5.8
T 15 7493 127.9 C 135 7613 ‐7.1 249.4 G 255 7733 ‐5.6
T 16 7494 128.6 A 136 7614 ‐7.4 250.5 G 256 7734 ‐5.5
T 17 7495 129.6 T 137 7615 ‐7.4 251.7 C 257 7735 ‐5.3
C 18 7496 130.7 T 138 7616 ‐7.3 252.6 T 258 7736 ‐5.4
T 19 7497 131.7 T 139 7617 ‐7.3 253.6 T 259 7737 ‐5.4
G 20 7498 132.8 T 140 7618 ‐7.2 254.6 G 260 7738 ‐5.4
C 21 7499 133.8 C 141 7619 ‐7.2 255.7 T 261 7739 ‐5.3
A 22 7500 134.6 C 142 7620 ‐7.4 256.6 A 262 7740 ‐5.4
C 23 7501 135.3 T 143 7621 ‐7.7 257.5 C 263 7741 ‐5.5
A 24 7502 136.4 G 144 7622 ‐7.6 258.5 A 264 7742 ‐5.5
A 25 7503 137.9 T 145 7623 ‐7.1 259.4 A 265 7743 ‐5.6
T 26 7504 138.8 C 146 7624 ‐7.2 260.2 C 266 7744 ‐5.8
A 27 7505 139.6 C 147 7625 ‐7.4 261.2 T 267 7745 ‐5.8
C 28 7506 140.5 A 148 7626 ‐7.5 262.4 A 268 7746 ‐5.6
A 29 7507 141.5 G 149 7627 ‐7.5 263.3 C 269 7747 ‐5.7
G 30 7508 142.8 G 150 7628 ‐7.2 264.1 T 270 7748 ‐5.9
T 31 7509 143.9 T 151 7629 ‐7.1 265.4 T 271 7749 ‐5.6
A 32 7510 145 G 152 7630 ‐7 266.4 T 272 7750 ‐5.6
C 33 7511 146.2 C 153 7631 ‐6.8 267.5 C 273 7751 ‐5.5
G 34 7512 147 G 154 7632 ‐7 268.5 A 274 7752 ‐5.5
C 35 7513 C 155 7633 269.2 T 275 7753 ‐5.8
20.5 T 36 7514 ‐15.5 T 156 7634 270.5 G 276 7754 ‐5.5
21.8 G 37 7515 ‐15.2 149.9 A 157 7635 ‐7.1 271.7 T 277 7755 ‐5.3
23.3 G 38 7516 ‐14.7 150.8 C 158 7636 ‐7.2 272.7 C 278 7756 ‐5.3
24.2 C 39 7517 151.8 A 159 7637 ‐7.2 273.6 C 279 7757 ‐5.4
25.1 A 40 7518 ‐14.9 152.9 A 160 7638 ‐7.1 274.5 A 280 7758 ‐5.5
26.3 C 41 7519 ‐14.7 153.7 C 161 7639 ‐7.3 275.5 A 281 7759 ‐5.5
26.6 T 42 7520 ‐15.4 154.7 A 162 7640 ‐7.3 276.4 C 282 7760 ‐5.6
27.9 A 43 7521 ‐15.1 155.8 A 163 7641 ‐7.2 277.4 A 283 7761 ‐5.6
29 T 44 7522 ‐15 156.7 T 164 7642 ‐7.3 278.3 T 284 7762 ‐5.7
30.2 T 45 7523 ‐14.8 157.8 T 165 7643 ‐7.2 279.6 T 285 7763 ‐5.4
31.5 G 46 7524 ‐14.5 159.1 G 166 7644 ‐6.9 280.5 C 286 7764 ‐5.5
C 47 7525 160.3 C 167 7645 ‐6.7 281.4 T 287 7765 ‐5.6
34.1 A 48 7526 ‐13.9 161.1 T 168 7646 ‐6.9 282.6 G 288 7766 ‐5.4
34.7 A 49 7527 ‐14.3 162.2 T 169 7647 ‐6.8 283.7 T 289 7767 ‐5.3
35.3 A 50 7528 ‐14.7 163.3 G 170 7648 ‐6.7 284.8 C 290 7768 ‐5.2
36.2 C 51 7529 ‐14.8 164.4 C 171 7649 ‐6.6 285.6 T 291 7769 ‐5.4
36.9 T 52 7530 ‐15.1 165.3 A 172 7650 ‐6.7 286.8 A 292 7770 ‐5.2
38 T 53 7531 ‐15 166 T 173 7651 ‐7 287.7 C 293 7771 ‐5.3
39.1 T 54 7532 ‐14.9 167.2 A 174 7652 ‐6.8 288.4 C 294 7772 ‐5.6
40.2 A 55 7533 ‐14.8 168.2 A 175 7653 ‐6.8 C 295 7773
41.2 A 56 7534 ‐14.8 169 C 176 7654 ‐7 T 296 7774
42.2 T 57 7535 ‐14.8 169.9 T 177 7655 ‐7.1 T 297 7775
43.6 C 58 7536 ‐14.4 171.2 A 178 7656 ‐6.8 A 298 7776
44.5 T 59 7537 ‐14.5 172 T 179 7657 ‐7 A 299 7777
46 T 60 7538 ‐14 173.2 A 180 7658 ‐6.8 C 300 7778
47.4 T 61 7539 ‐13.6 174.1 T 181 7659 ‐6.9 A 301 7779
48.7 T 62 7540 ‐13.3 175.2 C 182 7660 ‐6.8 T 302 7780
49.9 G 63 7541 ‐13.1 176.1 C 183 7661 ‐6.9 G 303 7781
51.9 G 64 7542 ‐12.1 177 A 184 7662 ‐7 A 304 7782
53.7 G 65 7543 ‐11.3 177.9 C 185 7663 ‐7.1 A 305 7783
54.9 C 66 7544 ‐11.1 178.8 T 186 7664 ‐7.2
55.7 A 67 7545 ‐11.3 180 C 187 7665 ‐7
56.4 C 68 7546 ‐11.6 180.9 C 188 7666 ‐7.1
57.2 T 69 7547 ‐11.8 181.9 C 189 7667 ‐7.1
58.5 G 70 7548 ‐11.5 182.7 T 190 7668 ‐7.3
60 C 71 7549 ‐11 184.1 A 191 7669 ‐6.9
60.7 T 72 7550 ‐11.3 185.1 A 192 7670 ‐6.9
62 C 73 7551 ‐11 186 G 193 7671 ‐7
62.8 C 74 7552 ‐11.2 187.2 T 194 7672 ‐6.8
63.8 T 75 7553 ‐11.2 188.4 A 195 7673 ‐6.6
65 A 76 7554 ‐11 189.3 A 196 7674 ‐6.7
66.2 C 77 7555 ‐10.8 190.1 T 197 7675 ‐6.9
67 A 78 7556 ‐11 191.2 A 198 7676 ‐6.8
68.3 T 79 7557 ‐10.7 192.3 A 199 7677 ‐6.7
69.4 A 80 7558 ‐10.6 193.2 A 200 7678 ‐6.8
70.6 T 81 7559 ‐10.4 194.1 A 201 7679 ‐6.9
71.9 T 82 7560 ‐10.1 195 C 202 7680 ‐7
73.1 T 83 7561 ‐9.9 195.9 T 203 7681 ‐7.1
74.2 T 84 7562 ‐9.8 197.2 G 204 7682 ‐6.8
75.3 G 85 7563 ‐9.7 198.4 C 205 7683 ‐6.6
76.9 A 86 7564 ‐9.1 199.3 T 206 7684 ‐6.7
77.7 A 87 7565 ‐9.3 200.3 T 207 7685 ‐6.7
78.6 C 88 7566 ‐9.4 201.3 T 208 7686 ‐6.7
79.4 A 89 7567 ‐9.6 202.5 T 209 7687 ‐6.5
80.4 A 90 7568 ‐9.6 203.6 A 210 7688 ‐6.4
81.4 T 91 7569 ‐9.6 204.5 G 211 7689 ‐6.5
82.5 T 92 7570 ‐9.5 205.6 G 212 7690 ‐6.4
83.6 G 93 7571 ‐9.4 206.7 C 213 7691 ‐6.3
85 G 94 7572 ‐9 207.6 A 214 7692 ‐6.4
86.2 C 95 7573 ‐8.8 208.4 C 215 7693 ‐6.6
86.9 G 96 7574 ‐9.1 209.3 A 216 7694 ‐6.7
88 C 97 7575 ‐9 210.3 T 217 7695 ‐6.7
89 G 98 7576 ‐9 211.5 A 218 7696 ‐6.5
90.4 C 99 7577 ‐8.6 212.4 T 219 7697 ‐6.6
90.9 C 100 7578 ‐9.1 213.5 T 220 7698 ‐6.5
91.7 T 101 7579 ‐9.3 214.5 T 221 7699 ‐6.5
93 C 102 7580 ‐9 215.6 T 222 7700 ‐6.4
94 T 103 7581 ‐9 216.7 A 223 7701 ‐6.3
95.7 T 104 7582 ‐8.3 217.6 G 224 7702 ‐6.4
97.3 T 105 7583 ‐7.7 218.9 T 225 7703 ‐6.1
98.3 G 106 7584 ‐7.7 219.9 T 226 7704 ‐6.1
99.4 G 107 7585 ‐7.6 220.9 T 227 7705 ‐6.1
100.5 C 108 7586 ‐7.5 222 G 228 7706 ‐6
101.7 G 109 7587 ‐7.3 223.1 T 229 7707 ‐5.9
102.4 C 110 7588 ‐7.6 224 T 230 7708 ‐6
103.4 A 111 7589 ‐7.6 225.1 T 231 7709 ‐5.9
104.4 T 112 7590 ‐7.6 226 T 232 7710 ‐6
A 113 7591 227 T 233 7711 ‐6
T 114 7592 228.2 A 234 7712 ‐5.8
107.1 A 115 7593 ‐7.9 229 C 235 7713 ‐6
108.1 A 116 7594 ‐7.9 229.7 T 236 7714 ‐6.3
109.1 G 117 7595 ‐7.9 230.9 T 237 7715 ‐6.1
110.4 G 118 7596 ‐7.6 232.1 A 238 7716 ‐5.9
111.6 C 119 7597 ‐7.4 233 A 239 7717 ‐6
112.5 G 120 7598 ‐7.5 233.9 G 240 7718 ‐6.1
Figure SI2.3A. CE Maxam-Gilbert Indexing of the 305 bp HPV18 (7479-7783): Top Strand. CE position versus
the real position of nucleotides from the top strand (5’-FAM) of the 305 bp HPV18 (7479-7783) fragment. 
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HPV18 (7479‐7783) 305 bp (HEX Lanes A10 and G12)
Correction between CE size calling to Maxam‐Gilbert sequencing results
CE postion Sequence Real Position Genome Position CE postion Sequence Real PositionGenome Position CE postion Sequence Real Position Genome Position
T 1 7783 112.6 G 121 7663 ‐8.4 234 C 241 7543 ‐7
T 2 7782 113.8 T 122 7662 ‐8.2 234.9 C 242 7542 ‐7.1
C 3 7781 114.9 G 123 7661 ‐8.1 235.9 C 243 7541 ‐7.1
A 4 7780 116.1 G 124 7660 ‐7.9 236.9 A 244 7540 ‐7.1
T 5 7779 117.2 A 125 7659 ‐7.8 237.8 A 245 7539 ‐7.2
G 6 7778 118 T 126 7658 ‐8 238.8 A 246 7538 ‐7.2
T 7 7777 119 A 127 7657 ‐8 239.8 A 247 7537 ‐7.2
T 8 7776 119.9 T 128 7656 ‐8.1 240.8 G 248 7536 ‐7.2
A 9 7775 120.8 A 129 7655 ‐8.2 242 A 249 7535 ‐7
A 10 7774 121.7 G 130 7654 ‐8.3 242.8 T 250 7534 ‐7.2
G 11 7773 123.1 T 131 7653 ‐7.9 243.9 T 251 7533 ‐7.1
G 12 7772 124 T 132 7652 ‐8 245.1 A 252 7532 ‐6.9
G 13 7771 125 A 133 7651 ‐8 246 A 253 7531 ‐7
T 14 7770 125.9 T 134 7650 ‐8.1 246.9 A 254 7530 ‐7.1
A 15 7769 126.9 G 135 7649 ‐8.1 247.9 G 255 7529 ‐7.1
G 16 7768 128.2 C 136 7648 ‐7.8 248.9 T 256 7528 ‐7.1
A 17 7767 128.9 A 137 7647 ‐8.1 250 T 257 7527 ‐7
C 18 7766 129.8 A 138 7646 ‐8.2 251.1 T 258 7526 ‐6.9
A 19 7765 130.7 G 139 7645 ‐8.3 252.2 G 259 7525 ‐6.8
G 20 7764 131.9 C 140 7644 ‐8.1 253.2 C 260 7524 ‐6.8
A 21 7763 132.7 A 141 7643 ‐8.3 254.1 A 261 7523 ‐6.9
A 22 7762 133.6 A 142 7642 ‐8.4 255 A 262 7522 ‐7
T 23 7761 134.5 T 143 7641 ‐8.5 256 T 263 7521 ‐7
G 24 7760 135.8 T 144 7640 ‐8.2 257 A 264 7520 ‐7
T 25 7759 136.8 G 145 7639 ‐8.2 257.9 G 265 7519 ‐7.1
T 26 7758 137.9 T 146 7638 ‐8.1 259 T 266 7518 ‐7
G 27 7757 139.1 T 147 7637 ‐7.9 260.2 G 267 7517 ‐6.8
G 28 7756 140.1 G 148 7636 ‐7.9 261.3 C 268 7516 ‐6.7
A 29 7755 141.3 T 149 7635 ‐7.7 261.7 C 269 7515 ‐7.3
C 30 7754 142.3 A 150 7634 ‐7.7 262.9 A 270 7514 ‐7.1
A 31 7753 143.3 G 151 7633 ‐7.7 263.9 G 271 7513 ‐7.1
T 32 7752 144.4 C 152 7632 ‐7.6 264.9 C 272 7512 ‐7.1
G 33 7751 145.2 G 153 7631 ‐7.8 265.9 G 273 7511 ‐7.1
A 34 7750 146.6 C 154 7630 ‐7.4 266.9 T 274 7510 ‐7.1
A 35 7749 147.3 A 155 7629 ‐7.7 268.1 A 275 7509 ‐6.9
A 36 7748 148.2 C 156 7628 ‐7.8 268.9 C 276 7508 ‐7.1
G 37 7747 149.1 C 157 7627 ‐7.9 269.7 T 277 7507 ‐7.3
T 38 7746 150 T 158 7626 ‐8 271 G 278 7506 ‐7
A 39 7745 151.2 G 159 7625 ‐7.8 272 T 279 7505 ‐7
G 40 7744 152.5 G 160 7624 ‐7.5 273.2 A 280 7504 ‐6.8
T 41 7743 153.7 A 161 7623 ‐7.3 274 T 281 7503 ‐7
T 42 7742 154.6 C 162 7622 ‐7.4 275.1 T 282 7502 ‐6.9
G 43 7741 155.6 A 163 7621 ‐7.4 276.2 G 283 7501 ‐6.8
T 44 7740 156.6 G 164 7620 ‐7.4 277.3 T 284 7500 ‐6.7
A 45 7739 157.8 G 165 7619 ‐7.2 278.4 G 285 7499 ‐6.6
C 46 7738 158.9 A 166 7618 ‐7.1 279.3 C 286 7498 ‐6.7
32 A 47 7737 ‐15 159.9 A 167 7617 ‐7.1 280.4 A 287 7497 ‐6.6
33.5 A 48 7736 ‐14.5 160.8 A 168 7616 ‐7.2 281.2 G 288 7496 ‐6.8
34.2 G 49 7735 ‐14.8 161.7 A 169 7615 ‐7.3 282.3 A 289 7495 ‐6.7
35.4 C 50 7734 ‐14.6 162.5 T 170 7614 ‐7.5 283.2 A 290 7494 ‐6.8
36 C 51 7733 ‐15 163.7 G 171 7613 ‐7.3 284.1 A 291 7493 ‐6.9
36.6 A 52 7732 ‐15.4 165 A 172 7612 ‐7 285 A 292 7492 ‐7
37.5 A 53 7731 ‐15.5 165.8 C 173 7611 ‐7.2 286.1 C 293 7491 ‐6.9
38.3 G 54 7730 ‐15.7 166.7 T 174 7610 ‐7.3 C 294 7490 ‐294
39.7 T 55 7729 ‐15.3 167.9 A 175 7609 ‐7.1 287.8 A 295 7489 ‐7.2
40.9 A 56 7728 ‐15.1 168.8 A 176 7608 ‐7.2 C 296 7488 ‐296
42 T 57 7727 ‐15 169.7 T 177 7607 ‐7.3 289.7 A 297 7487 ‐7.3
43.3 G 58 7726 ‐14.7 170.9 A 178 7606 ‐7.1 290.7 G 298 7486 ‐7.3
45.1 C 59 7725 ‐13.9 171.8 C 179 7605 ‐7.2 292 A 299 7485 ‐7
45.7 A 60 7724 ‐14.3 172.6 C 180 7604 ‐7.4 292.8 C 300 7484 ‐7.2
46.7 A 61 7723 ‐14.3 173.6 A 181 7603 ‐7.4 293.1 A 301 7483 ‐7.9
47.7 T 62 7722 ‐14.3 174.6 G 182 7602 ‐7.4 T 302 7482 ‐302
49.1 T 63 7721 ‐13.9 175.9 G 183 7601 ‐7.1 A 303 7481 ‐303
50.4 A 64 7720 ‐13.6 177.1 T 184 7600 ‐6.9 A 304 7480 ‐304
51.7 G 65 7719 ‐13.3 178.1 G 185 7599 ‐6.9 G 305 7479 ‐305
53.3 C 66 7718 ‐12.7 179.2 C 186 7598 ‐6.8
54.3 T 67 7717 ‐12.7 180.1 G 187 7597 ‐6.9
55.5 T 68 7716 ‐12.5 181.3 C 188 7596 ‐6.7
56.8 A 69 7715 ‐12.2 182.5 C 189 7595 ‐6.5
57.9 A 70 7714 ‐12.1 183.8 T 190 7594 ‐6.2
58.7 G 71 7713 ‐12.3 184.1 T 191 7593 ‐6.9
59.9 T 72 7712 ‐12.1 185.1 A 192 7592 ‐6.9
61.3 A 73 7711 ‐11.7 186 T 193 7591 ‐7
62.3 A 74 7710 ‐11.7 187.2 A 194 7590 ‐6.8
63.2 A 75 7709 ‐11.8 188.1 T 195 7589 ‐6.9
64.1 A 76 7708 ‐11.9 189.3 G 196 7588 ‐6.7
65 A 77 7707 ‐12 190.4 C 197 7587 ‐6.6
66.1 C 78 7706 ‐11.9 191.3 G 198 7586 ‐6.7
66.9 A 79 7705 ‐12.1 192.4 C 199 7585 ‐6.6
68 A 80 7704 ‐12 193.1 C 200 7584 ‐6.9
69 A 81 7703 ‐12 194.1 A 201 7583 ‐6.9
70.1 C 82 7702 ‐11.9 195.1 A 202 7582 ‐6.9
71 T 83 7701 ‐12 196.1 A 203 7581 ‐6.9
72.4 A 84 7700 ‐11.6 197.1 G 204 7580 ‐6.9
73.5 A 85 7699 ‐11.5 198.3 A 205 7579 ‐6.7
74.5 A 86 7698 ‐11.5 199.2 G 206 7578 ‐6.8
75.5 A 87 7697 ‐11.5 200.4 G 207 7577 ‐6.6
76.6 T 88 7696 ‐11.4 201.5 C 208 7576 ‐6.5
77.9 A 89 7695 ‐11.1 202.3 G 209 7575 ‐6.7
79 T 90 7694 ‐11 C 210 7574
80.1 G 91 7693 ‐10.9 G 211 7573
81.5 T 92 7692 ‐10.5 204.4 C 212 7572 ‐7.6
82.4 G 93 7691 ‐10.6 205.4 C 213 7571 ‐7.6
83.6 C 94 7690 ‐10.4 206.5 A 214 7570 ‐7.5
84.5 C 95 7689 ‐10.5 207.5 A 215 7569 ‐7.5
85.4 T 96 7688 ‐10.6 208.5 T 216 7568 ‐7.5
86.4 A 97 7687 ‐10.6 209.7 T 217 7567 ‐7.3
87.4 A 98 7686 ‐10.6 210.9 G 218 7566 ‐7.1
88.3 A 99 7685 ‐10.7 212.1 T 219 7565 ‐6.9
89.2 A 100 7684 ‐10.8 213.2 T 220 7564 ‐6.8
90.1 G 101 7683 ‐10.9 214.3 C 221 7563 ‐6.7
91.5 C 102 7682 ‐10.5 215.1 A 222 7562 ‐6.9
92.3 A 103 7681 ‐10.7 216.1 A 223 7561 ‐6.9
93.3 G 104 7680 ‐10.7 217 A 224 7560 ‐7
94.9 T 105 7679 ‐10.1 217.9 A 225 7559 ‐7.1
95.9 T 106 7678 ‐10.1 218.8 T 226 7558 ‐7.2
96.6 T 107 7677 ‐10.4 220 A 227 7557 ‐7
98.3 T 108 7676 ‐9.7 220.9 T 228 7556 ‐7.1
99.5 A 109 7675 ‐9.5 222 G 229 7555 ‐7
100.4 T 110 7674 ‐9.6 223.2 T 230 7554 ‐6.8
101.4 T 111 7673 ‐9.6 224.3 A 231 7553 ‐6.7
102.7 A 112 7672 ‐9.3 225.1 G 232 7552 ‐6.9
103.6 C 113 7671 ‐9.4 226.3 G 233 7551 ‐6.7
104.5 T 114 7670 ‐9.5 227.4 A 234 7550 ‐6.6
105.7 T 115 7669 ‐9.3 228.3 G 235 7549 ‐6.7
106.9 A 116 7668 ‐9.1 229.3 C 236 7548 ‐6.7
107.9 G 117 7667 ‐9.1 230.2 A 237 7547 ‐6.8
109.2 G 118 7666 ‐8.8 231.1 G 238 7546 ‐6.9
110.5 G 119 7665 ‐8.5 232.2 T 239 7545 ‐6.8
111.7 A 120 7664 ‐8.3 233.3 G 240 7544 ‐6.7
Figure SI2.3B. CE Maxam-Gilbert Indexing of the 305 bp HPV18 (7479-7783): Bottom Strand. CE position
versus the real position of nucleotides from the bottom strand (5’-HEX) of the 305 bp HPV18 (7479-7783) fragment. 
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HPV18 (7647‐157) 368 bp
Correction between CE size calling to Maxam‐Gilbert sequencing results
CE postion Sequence Real Position Genome Position CE postion Sequence Real Position Genome Position CE postion Sequence Real Position Genome Position
T 1 7647 113.4 T 121 7767 ‐7.6 236.3 A 241 30 ‐4.7
G 2 7648 114.4 C 122 7768 ‐7.6 237.3 A 242 31 ‐4.7
C 3 7649 115.2 T 123 7769 ‐7.8 238 A 243 32 ‐5
A 4 7650 116.2 A 124 7770 ‐7.8 239.2 A 244 33 ‐4.8
T 5 7651 117.2 C 125 7771 ‐7.8 240.2 A 245 34 ‐4.8
A 6 7652 118 C 126 7772 ‐8 241.4 G 246 35 ‐4.6
A 7 7653 118.9 C 127 7773 ‐8.1 242.6 G 247 36 ‐4.4
C 8 7654 119.8 T 128 7774 ‐8.2 243.7 G 248 37 ‐4.3
T 9 7655 121.1 T 129 7775 ‐7.9 244.7 A 249 38 ‐4.3
A 10 7656 122.1 A 130 7776 ‐7.9 244.7 G 250 39 ‐5.3
T 11 7657 123.1 A 131 7777 ‐7.9 245.8 T 251 40 ‐5.2
A 12 7658 124.1 C 132 7778 ‐7.9 246.8 A 252 41 ‐5.2
T 13 7659 124.9 A 133 7779 ‐8.1 247.7 A 253 42 ‐5.3
C 14 7660 126 T 134 7780 ‐8 248.7 C 254 43 ‐5.3
C 15 7661 127.1 G 135 7781 ‐7.9 249.6 C 255 44 ‐5.4
A 16 7662 128.4 A 136 7782 ‐7.6 250.4 G 256 45 ‐5.6
C 17 7663 129.3 A 137 7783 ‐7.7 251.7 A 257 46 ‐5.3
T 18 7664 130.2 C 138 7784 ‐7.8 252.6 A 258 47 ‐5.4
C 19 7665 131.1 T 139 7785 ‐7.9 254 A 259 48 ‐5
C 20 7666 132.2 A 140 7786 ‐7.8 254.5 A 260 49 ‐5.5
C 21 7667 133.2 T 141 7787 ‐7.8 255.6 C 261 50 ‐5.4
T 22 7668 134.3 A 142 7788 ‐7.7 256.4 G 262 51 ‐5.6
A 23 7669 135.3 A 143 7789 ‐7.7 257.6 G 263 52 ‐5.4
A 24 7670 136.2 T 144 7790 ‐7.8 258.8 T 264 53 ‐5.2
G 25 7671 137.3 A 145 7791 ‐7.7 259.8 C 265 54 ‐5.2
T 26 7672 138.3 T 146 7792 ‐7.7 260.6 G 266 55 ‐5.4
8.4 A 27 7673 ‐18.6 139.4 G 147 7793 ‐7.6 261.8 G 267 56 ‐5.2
9.2 A 28 7674 ‐18.8 140.6 A 148 7794 ‐7.4 262.9 G 268 57 ‐5.1
10.3 T 29 7675 ‐18.7 141.5 C 149 7795 ‐7.5 264 A 269 58 ‐5
11.3 A 30 7676 ‐18.7 142.4 T 150 7796 ‐7.6 265 C 270 59 ‐5
12.2 A 31 7677 ‐18.8 143.5 A 151 7797 ‐7.5 265.9 C 271 60 ‐5.1
13.1 A 32 7678 ‐18.9 144.5 A 152 7798 ‐7.5 266.6 G 272 61 ‐5.4
13.9 A 33 7679 ‐19.1 145.5 G 153 7799 ‐7.5 267.6 A 273 62 ‐5.4
15.2 C 34 7680 ‐18.8 146.7 C 154 7800 ‐7.3 268.6 A 274 63 ‐5.4
16.4 T 35 7681 ‐18.6 147.6 T 155 7801 ‐7.4 269.6 A 275 64 ‐5.4
18.3 G 36 7682 ‐17.7 148.7 G 156 7802 ‐7.3 270.6 A 276 65 ‐5.4
C 37 7683 150.1 T 157 7803 ‐6.9 271.7 C 277 66 ‐5.3
20.5 T 38 7684 ‐17.5 151.1 G 158 7804 ‐6.9 272.5 G 278 67 ‐5.5
21.9 T 39 7685 ‐17.1 152.3 C 159 7805 ‐6.7 273.7 G 279 68 ‐5.3
22.9 T 40 7686 ‐17.1 152.8 A 160 7806 ‐7.2 275 T 280 69 ‐5
24 T 41 7687 ‐17 153.9 T 161 7807 ‐7.1 275.9 G 281 70 ‐5.1
25 A 42 7688 ‐17 155 A 162 7808 ‐7 277.1 T 282 71 ‐4.9
25.8 G 43 7689 ‐17.2 156.1 C 163 7809 ‐6.9 278.1 A 283 72 ‐4.9
27.2 G 44 7690 ‐16.8 156.8 A 164 7810 ‐7.2 279 T 284 73 ‐5
C 45 7691 157.9 T 165 7811 ‐7.1 280 A 285 74 ‐5
29.1 A 46 7692 ‐16.9 159 A 166 7812 ‐7 281 T 286 75 ‐5
C 47 7693 160 G 167 7813 ‐7 281.9 A 287 76 ‐5.1
30.5 A 48 7694 ‐17.5 161.4 T 168 7814 ‐6.6 282.9 A 288 77 ‐5.1
31.7 T 49 7695 ‐17.3 162.4 T 169 7815 ‐6.6 283.8 A 289 78 ‐5.2
32.7 A 50 7696 ‐17.3 163.5 T 170 7816 ‐6.5 284.7 A 290 79 ‐5.3
33.8 T 51 7697 ‐17.2 164.4 A 171 7817 ‐6.6 285.7 G 291 80 ‐5.3
34.9 T 52 7698 ‐17.1 165.4 T 172 7818 ‐6.6 286.8 A 292 81 ‐5.2
36.1 T 53 7699 ‐16.9 166.4 G 173 7819 ‐6.6 287.8 T 293 82 ‐5.2
37.4 T 54 7700 ‐16.6 167.7 C 174 7820 ‐6.3 288.8 G 294 83 ‐5.2
38.8 A 55 7701 ‐16.2 168.4 A 175 7821 ‐6.6 290 T 295 84 ‐5
39.7 G 56 7702 ‐16.3 169.3 A 176 7822 ‐6.7 291 G 296 85 ‐5
41.2 T 57 7703 ‐15.8 170.3 C 177 7823 ‐6.7 292.1 A 297 86 ‐4.9
42.3 T 58 7704 ‐15.7 171.2 C 178 7824 ‐6.8 292.9 G 298 87 ‐5.1
43.5 T 59 7705 ‐15.5 172 G 179 7825 ‐7 294.1 A 299 88 ‐4.9
44.5 G 60 7706 ‐15.5 173.4 A 180 7826 ‐6.6 294.9 A 300 89 ‐5.1
46.3 T 61 7707 ‐14.7 174.3 A 181 7827 ‐6.7 295.8 A 301 90 ‐5.2
47.5 T 62 7708 ‐14.5 175.2 A 182 7828 ‐6.8 296.8 C 302 91 ‐5.2
48.7 T 63 7709 ‐14.3 176.3 T 183 7829 ‐6.7 297.6 A 303 92 ‐5.4
49.9 T 64 7710 ‐14.1 177.3 A 184 7830 ‐6.7 298.6 C 304 93 ‐5.4
51.1 T 65 7711 ‐13.9 178.3 G 185 7831 ‐6.7 299.5 A 305 94 ‐5.5
52 A 66 7712 ‐14 179.5 G 186 7832 ‐6.5 300.5 C 306 95 ‐5.5
53.2 C 67 7713 ‐13.8 180.8 T 187 7833 ‐6.2 301.4 C 307 96 ‐5.6
54.1 T 68 7714 ‐13.9 181.8 T 188 7834 ‐6.2 302.3 A 308 97 ‐5.7
55.6 T 69 7715 ‐13.4 182.8 G 189 7835 ‐6.2 303.3 C 309 98 ‐5.7
56.7 A 70 7716 ‐13.3 183.9 G 190 7836 ‐6.1 304.3 A 310 99 ‐5.7
58 A 71 7717 ‐13 185.1 G 191 7837 ‐5.9 305.2 A 311 100 ‐5.8
59.3 G 72 7718 ‐12.7 186.3 C 192 7838 ‐5.7 306.2 T 312 101 ‐5.8
60.9 C 73 7719 ‐12.1 187 A 193 7839 ‐6 307.3 A 313 102 ‐5.7
61.7 T 74 7720 ‐12.3 187.9 G 194 7840 ‐6.1 308.4 C 314 103 ‐5.6
62.7 A 75 7721 ‐12.3 189.2 C 195 7841 ‐5.8 309.2 T 315 104 ‐5.8
63.7 A 76 7722 ‐12.3 189.9 A 196 7842 ‐6.1 310.3 A 316 105 ‐5.7
64.9 T 77 7723 ‐12.1 190.9 C 197 7843 ‐6.1 311.4 T 317 106 ‐5.6
66.2 T 78 7724 ‐11.8 191.7 A 198 7844 ‐6.3 312.4 G 318 107 ‐5.6
67.3 G 79 7725 ‐11.7 192.8 T 199 7845 ‐6.2 313.6 G 319 108 ‐5.4
69 C 80 7726 ‐11 193.8 A 200 7846 ‐6.2 314.8 C 320 109 ‐5.2
69.5 A 81 7727 ‐11.5 194.9 C 201 7847 ‐6.1 315.6 G 321 110 ‐5.4
70.8 T 82 7728 ‐11.2 195.8 T 202 7848 ‐6.2 316.9 C 322 111 ‐5.1
71.7 A 83 7729 ‐11.3 196.9 A 203 7849 ‐6.1 317.7 G 323 112 ‐5.3
73 C 84 7730 ‐11 197.9 T 204 7850 ‐6.1 319 C 324 113 ‐5
73.9 T 85 7731 ‐11.1 199 A 205 7851 ‐6 319.7 T 325 114 ‐5.3
75.3 T 86 7732 ‐10.7 200 C 206 7852 ‐6 320.9 T 326 115 ‐5.1
76.3 G 87 7733 ‐10.7 200.9 T 207 7853 ‐6.1 321.8 T 327 116 ‐5.2
77.7 G 88 7734 ‐10.3 202 T 208 7854 ‐6 322.9 G 328 117 ‐5.1
79.3 C 89 7735 ‐9.7 203.1 T 209 7855 ‐5.9 324 A 329 118 ‐5
80.2 T 90 7736 ‐9.8 204.2 T 210 7856 ‐5.8 324.9 G 330 119 ‐5.1
81.4 T 91 7737 ‐9.6 205.2 C 211 7857 ‐5.8 326.1 G 331 120 ‐4.9
82.5 G 92 7738 ‐9.5 206 A 212 1 ‐6 327.2 A 332 121 ‐4.8
84.1 T 93 7739 ‐8.9 207 T 213 2 ‐6 328.1 T 333 122 ‐4.9
85.1 A 94 7740 ‐8.9 208.1 T 214 3 ‐5.9 329.1 C 334 123 ‐4.9
85.9 C 95 7741 ‐9.1 209.2 A 215 4 ‐5.8 329.9 C 335 124 ‐5.1
86.6 A 96 7742 ‐9.4 210.2 A 216 5 ‐5.8 331 A 336 125 ‐5
87.6 A 97 7743 ‐9.4 211 T 217 6 ‐6 331.7 A 337 126 ‐5.3
88.5 C 98 7744 ‐9.5 212.1 A 218 7 ‐5.9 332.7 C 338 127 ‐5.3
89.4 T 99 7745 ‐9.6 213.1 C 219 8 ‐5.9 333.6 A 339 128 ‐5.4
90.6 A 100 7746 ‐9.4 214 T 220 9 ‐6 334.7 C 340 129 ‐5.3
91.6 C 101 7747 ‐9.4 215.2 T 221 10 ‐5.8 335.6 G 341 130 ‐5.4
92.4 T 102 7748 ‐9.6 216.3 T 222 11 ‐5.7 336.8 G 342 131 ‐5.2
93.7 T 103 7749 ‐9.3 217.3 T 223 12 ‐5.7 338 C 343 132 ‐5
94.9 T 104 7750 ‐9.1 218.4 A 224 13 ‐5.6 338.8 G 344 133 ‐5.2
96 C 105 7751 ‐9 219.3 A 225 14 ‐5.7 340 A 345 134 ‐5
96.8 A 106 7752 ‐9.2 220.3 C 226 15 ‐5.7 341 C 346 135 ‐5
97.8 T 107 7753 ‐9.2 221.1 A 227 16 ‐5.9 341.8 C 347 136 ‐5.2
99.1 G 108 7754 ‐8.9 222.1 A 228 17 ‐5.9 342.6 C 348 137 ‐5.4
101.2 T 109 7755 ‐7.8 223.2 T 229 18 ‐5.8 343.5 T 349 138 ‐5.5
102.6 C 110 7756 ‐7.4 224.3 T 230 19 ‐5.7 344.7 A 350 139 ‐5.3
103.7 C 111 7757 ‐7.3 225.2 G 231 20 ‐5.8 345.8 C 351 140 ‐5.2
104.6 A 112 7758 ‐7.4 226.6 T 232 21 ‐5.4 346.7 A 352 141 ‐5.3
105.8 A 113 7759 ‐7.2 227.5 A 233 22 ‐5.5 347.7 A 353 142 ‐5.3
106.6 C 114 7760 ‐7.4 228.4 G 234 23 ‐5.6 348.7 G 354 143 ‐5.3
107.1 A 115 7761 ‐7.9 229.6 T 235 24 ‐5.4 350 C 355 144 ‐5
108.2 T 116 7762 ‐7.8 230.6 A 236 25 ‐5.4 350.6 T 356 145 ‐5.4
109.2 T 117 7763 ‐7.8 231.6 T 237 26 ‐5.4 351.9 A 357 146 ‐5.1
110.2 C 118 7764 ‐7.8 232.5 A 238 27 ‐5.5 353.1 C 358 147 ‐4.9
111 T 119 7765 ‐8 233.5 T 239 28 ‐5.5 353.8 C 359 148 ‐5.2
111.9 G 120 7766 ‐8.1 234.5 A 240 29 ‐5.5 354.6 T 360 149 ‐5.4
G 361 150
A 362 151
T 363 152
C 364 153
T 365 154
G 366 155
T 367 156
G 368 157
Figure SI2.3C. CE Maxam-Gilbert Indexing of the 368 bp HPV18 (7647-157): Top Strand. CE position versus the
real position of nucleotides from the top strand (5’-FAM) of the 368 bp HPV18 (7647-157) fragment. 
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HPV18 (7647‐157) 368 bp
Correction between CE size calling to Maxam‐Gilbert sequencing results
CE postion Sequence Real Position Genome Position CE postion Sequence Real PositionGenome Position CE postion Sequence Real Position Genome Position
C 1 157 114.7 C 121 37 ‐6.3 236.7 A 241 7774 ‐4.3
A 2 156 116 C 122 36 ‐6 237.5 G 242 7773 ‐4.5
C 3 155 116.4 C 123 35 ‐6.6 238.7 G 243 7772 ‐4.3
A 4 154 117.3 T 124 34 ‐6.7 239.8 G 244 7771 ‐4.2
G 5 153 118.5 T 125 33 ‐6.5 241.1 T 245 7770 ‐3.9
A 6 152 119.7 T 126 32 ‐6.3 242 A 246 7769 ‐4
T 7 151 120.8 T 127 31 ‐6.2 242.9 G 247 7768 ‐4.1
C 8 150 121.9 T 128 30 ‐6.1 244 A 248 7767 ‐4
A 9 149 123 T 129 29 ‐6 245 C 249 7766 ‐4
G 10 148 123.9 A 130 28 ‐6.1 245.8 A 250 7765 ‐4.2
G 11 147 124.8 T 131 27 ‐6.2 246.8 G 251 7764 ‐4.2
T 12 146 125.8 A 132 26 ‐6.2 248 A 252 7763 ‐4
A 13 145 126.8 T 133 25 ‐6.2 248.9 A 253 7762 ‐4.1
G 14 144 127.8 A 134 24 ‐6.2 249.9 T 254 7761 ‐4.1
C 15 143 128.8 C 135 23 ‐6.2 250.9 G 255 7760 ‐4.1
T 16 142 129.6 T 136 22 ‐6.4 252.2 T 256 7759 ‐3.8
T 17 141 130.7 A 137 21 ‐6.3 253.1 T 257 7758 ‐3.9
G 18 140 131.7 C 138 20 ‐6.3 254.1 G 258 7757 ‐3.9
T 19 139 132.5 A 139 19 ‐6.5 255.2 G 259 7756 ‐3.8
A 20 138 133.5 A 140 18 ‐6.5 256.3 A 260 7755 ‐3.7
G 21 137 134.5 T 141 17 ‐6.5 257.2 C 261 7754 ‐3.8
G 22 136 135.6 T 142 16 ‐6.4 258 A 262 7753 ‐4
G 23 135 136.7 G 143 15 ‐6.3 259.1 T 263 7752 ‐3.9
T 24 134 138 T 144 14 ‐6 260 G 264 7751 ‐4
C 25 133 139 T 145 13 ‐6 261.2 A 265 7750 ‐3.8
G 26 132 140 A 146 12 ‐6 262 A 266 7749 ‐4
C 27 131 140.9 A 147 11 ‐6.1 263 A 267 7748 ‐4
C 28 130 141.8 A 148 10 ‐6.2 263.9 G 268 7747 ‐4.1
G 29 129 142.7 A 149 9 ‐6.3 265.2 T 269 7746 ‐3.8
T 30 128 143.6 G 150 8 ‐6.4 266.1 A 270 7745 ‐3.9
16.1 G 31 127 ‐14.9 145 T 151 7 ‐6 267 G 271 7744 ‐4
T 32 126 146 A 152 6 ‐6 268.2 T 272 7743 ‐3.8
T 33 125 147 T 153 5 ‐6 269.3 T 273 7742 ‐3.7
20.6 G 34 124 ‐13.4 148 T 154 4 ‐6 270.2 G 274 7741 ‐3.8
21.8 G 35 123 ‐13.2 149 A 155 3 ‐6 271.4 T 275 7740 ‐3.6
22.9 A 36 122 ‐13.1 150 A 156 2 ‐6 272.3 A 276 7739 ‐3.7
T 37 121 150.9 T 157 1 ‐6.1 273.2 C 277 7738 ‐3.8
C 38 120 152 G 158 7857 ‐6 274.1 A 278 7737 ‐3.9
C 39 119 153.3 A 159 7856 ‐5.7 275 A 279 7736 ‐4
T 40 118 154.2 A 160 7855 ‐5.8 276 G 280 7735 ‐4
26.7 C 41 117 ‐14.3 155.1 A 161 7854 ‐5.9 277.2 C 281 7734 ‐3.8
27.2 A 42 116 ‐14.8 156 A 162 7853 ‐6 278 C 282 7733 ‐4
28.2 A 43 115 ‐14.8 157 G 163 7852 ‐6 278.9 A 283 7732 ‐4.1
29 A 44 114 ‐15 158.3 T 164 7851 ‐5.7 279.9 A 284 7731 ‐4.1
29.8 G 45 113 ‐15.2 159.3 A 165 7850 ‐5.7 280.8 G 285 7730 ‐4.2
31.3 C 46 112 ‐14.7 160.3 T 166 7849 ‐5.7 282.1 T 286 7729 ‐3.9
31.8 G 47 111 ‐15.2 161.2 A 167 7848 ‐5.8 283.1 A 287 7728 ‐3.9
33.5 C 48 110 ‐14.5 162.2 G 168 7847 ‐5.8 284.1 T 288 7727 ‐3.9
34 G 49 109 ‐15 163.5 T 169 7846 ‐5.5 285.1 G 289 7726 ‐3.9
35.7 C 50 108 ‐14.3 164.4 A 170 7845 ‐5.6 286.3 C 290 7725 ‐3.7
36.2 C 51 107 ‐14.8 165.5 T 171 7844 ‐5.5 287.1 A 291 7724 ‐3.9
36.8 A 52 106 ‐15.2 166.4 G 172 7843 ‐5.6 288 A 292 7723 ‐4
38.3 T 53 105 ‐14.7 167.7 T 173 7842 ‐5.3 289 T 293 7722 ‐4
39.7 A 54 104 ‐14.3 168.6 G 174 7841 ‐5.4 290 T 294 7721 ‐4
40.6 G 55 103 ‐14.4 169.9 C 175 7840 ‐5.1 291.1 A 295 7720 ‐3.9
42.1 T 56 102 ‐13.9 170.7 T 176 7839 ‐5.3 292 G 296 7719 ‐4
43.2 A 57 101 ‐13.8 171.7 G 177 7838 ‐5.3 293.3 C 297 7718 ‐3.7
44.3 T 58 100 ‐13.7 173 C 178 7837 ‐5 294.1 T 298 7717 ‐3.9
45.6 T 59 99 ‐13.4 173.8 C 179 7836 ‐5.2 295 T 299 7716 ‐4
46.6 G 60 98 ‐13.4 174.6 C 180 7835 ‐5.4 296.2 A 300 7715 ‐3.8
48.5 T 61 97 ‐12.5 175.4 A 181 7834 ‐5.6 297.1 A 301 7714 ‐3.9
49.4 G 62 96 ‐12.6 176.3 A 182 7833 ‐5.7 298 G 302 7713 ‐4
50.9 G 63 95 ‐12.1 177.4 C 183 7832 ‐5.6 299.2 T 303 7712 ‐3.8
52.6 T 64 94 ‐11.4 178.3 C 184 7831 ‐5.7 300.2 A 304 7711 ‐3.8
53.5 G 65 93 ‐11.5 179.2 T 185 7830 ‐5.8 301.1 A 305 7710 ‐3.9
55.3 T 66 92 ‐10.7 180.3 A 186 7829 ‐5.7 302 A 306 7709 ‐4
56.1 G 67 91 ‐10.9 181.5 T 187 7828 ‐5.5 302.9 A 307 7708 ‐4.1
58.2 T 68 90 ‐9.8 182.8 T 188 7827 ‐5.2 303.8 A 308 7707 ‐4.2
59.4 T 69 89 ‐9.6 183.8 T 189 7826 ‐5.2 304.7 C 309 7706 ‐4.3
60.4 T 70 88 ‐9.6 184.8 C 190 7825 ‐5.2 305.7 A 310 7705 ‐4.3
61.5 C 71 87 ‐9.5 185.6 G 191 7824 ‐5.4 306.7 A 311 7704 ‐4.3
62 T 72 86 ‐10 186.9 G 192 7823 ‐5.1 307.6 A 312 7703 ‐4.4
63.3 C 73 85 ‐9.7 188.2 T 193 7822 ‐4.8 308.6 C 313 7702 ‐4.4
63.8 A 74 84 ‐10.2 189.2 T 194 7821 ‐4.8 309.5 T 314 7701 ‐4.5
65.1 C 75 83 ‐9.9 190.1 G 195 7820 ‐4.9 310.7 A 315 7700 ‐4.3
65.6 A 76 82 ‐10.4 191.4 C 196 7819 ‐4.6 311.6 A 316 7699 ‐4.4
67.1 T 77 81 ‐9.9 192.1 A 197 7818 ‐4.9 312.6 A 317 7698 ‐4.4
68.3 C 78 80 ‐9.7 193.1 T 198 7817 ‐4.9 313.6 A 318 7697 ‐4.4
69.2 T 79 79 ‐9.8 194.1 A 199 7816 ‐4.9 314.5 T 319 7696 ‐4.5
70.5 T 80 78 ‐9.5 195 A 200 7815 ‐5 315.7 A 320 7695 ‐4.3
71.8 T 81 77 ‐9.2 196 A 201 7814 ‐5 316.8 T 321 7694 ‐4.2
73 T 82 76 ‐9 196.9 C 202 7813 ‐5.1 317.8 G 322 7693 ‐4.2
73.9 A 83 75 ‐9.1 197.8 T 203 7812 ‐5.2 319.1 T 323 7692 ‐3.9
75.2 T 84 74 ‐8.8 199 A 204 7811 ‐5 320 G 324 7691 ‐4
76.1 A 85 73 ‐8.9 200 T 205 7810 ‐5 321.3 C 325 7690 ‐3.7
77.3 T 86 72 ‐8.7 201.1 G 206 7809 ‐4.9 322 C 326 7689 ‐4
78.3 A 87 71 ‐8.7 202.3 T 207 7808 ‐4.7 322.8 T 327 7688 ‐4.2
79.5 C 88 70 ‐8.5 203.3 A 208 7807 ‐4.7 324 A 328 7687 ‐4
80.1 A 89 69 ‐8.9 204.2 T 209 7806 ‐4.8 325 A 329 7686 ‐4
81.4 C 90 68 ‐8.6 205.3 G 210 7805 ‐4.7 325.9 A 330 7685 ‐4.1
82.3 C 91 67 ‐8.7 206.5 C 211 7804 ‐4.5 326.9 A 331 7684 ‐4.1
83.2 G 92 66 ‐8.8 207.3 A 212 7803 ‐4.7 327.8 G 332 7683 ‐4.2
84.9 T 93 65 ‐8.1 208.2 C 213 7802 ‐4.8 329.1 C 333 7682 ‐3.9
86 T 94 64 ‐8 209 A 214 7801 ‐5 329.9 A 334 7681 ‐4.1
87.1 T 95 63 ‐7.9 210 G 215 7800 ‐5 330.8 G 335 7680 ‐4.2
88.2 T 96 62 ‐7.8 211.3 C 216 7799 ‐4.7 332.2 T 336 7679 ‐3.8
89.2 C 97 61 ‐7.8 212 T 217 7798 ‐5 333.1 T 337 7678 ‐3.9
89.9 G 98 60 ‐8.1 213.1 T 218 7797 ‐4.9 334.1 T 338 7677 ‐3.9
91.3 G 99 59 ‐7.7 214.2 A 219 7796 ‐4.8 335 T 339 7676 ‐4
92.5 T 100 58 ‐7.5 215.2 G 220 7795 ‐4.8 336.1 A 340 7675 ‐3.9
93.5 C 101 57 ‐7.5 216.5 T 221 7794 ‐4.5 337 T 341 7674 ‐4
94.3 C 102 56 ‐7.7 217.5 C 222 7793 ‐4.5 338.1 T 342 7673 ‐3.9
95.2 C 103 55 ‐7.8 218.3 A 223 7792 ‐4.7 339.1 A 343 7672 ‐3.9
96 G 104 54 ‐8 219.3 T 224 7791 ‐4.7 340.2 C 344 7671 ‐3.8
97.4 A 105 53 ‐7.6 220.4 A 225 7790 ‐4.6 340.9 T 345 7670 ‐4.1
98.4 C 106 52 ‐7.6 221.4 T 226 7789 ‐4.6 342 T 346 7669 ‐4
99.3 C 107 51 ‐7.7 222.5 T 227 7788 ‐4.5 343.1 A 347 7668 ‐3.9
100.3 G 108 50 ‐7.7 223.5 A 228 7787 ‐4.5 344 G 348 7667 ‐4
102.1 T 109 49 ‐6.9 224.5 T 229 7786 ‐4.5 345.2 G 349 7666 ‐3.8
104.8 T 110 48 ‐5.2 225.5 A 230 7785 ‐4.5 346.4 G 350 7665 ‐3.6
105.7 T 111 47 ‐5.3 226.4 G 231 7784 ‐4.6 347.5 A 351 7664 ‐3.5
106.5 T 112 46 ‐5.5 227.7 T 232 7783 ‐4.3 348.3 G 352 7663 ‐3.7
107.4 C 113 45 ‐5.6 228.8 T 233 7782 ‐4.2 349.6 T 353 7662 ‐3.4
107.8 G 114 44 ‐6.2 229.8 C 234 7781 ‐4.2 350.4 G 354 7661 ‐3.6
108.9 G 115 43 ‐6.1 230.5 A 235 7780 ‐4.5 351.5 G 355 7660 ‐3.5
110.1 T 116 42 ‐5.9 231.5 T 236 7779 ‐4.5 352.6 A 356 7659 ‐3.4
111.1 T 117 41 ‐5.9 232.5 G 237 7778 ‐4.5 353.5 T 357 7658 ‐3.5
112 A 118 40 ‐6 233.8 T 238 7777 ‐4.2 354.6 A 358 7657 ‐3.4
112.9 C 119 39 ‐6.1 234.8 T 239 7776 ‐4.2 355.4 T 359 7656 ‐3.6
113.7 T 120 38 ‐6.3 235.7 A 240 7775 ‐4.3 A 360 7655
G 361 7654
T 362 7653
T 363 7652
A 364 7651
T 365 7650
G 366 7649
C 367 7648
A 368 7647
Figure SI2.3D. CE Maxam-Gilbert Indexing of the 368 bp HPV18 (7647-157): Bottom Strand. CE position versus
the real position of nucleotides from the bottom strand (5’-HEX) of the 368 bp HPV18 (7647-157) fragment. 
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2.7.5 Putative PA1 Binding Sites on HPV18 7647-157 bp 
 
 
 
Figure SI2.4. Putative PA1 Binding Sites on the HPV18 Region from 7647-157 bp. According to the literature, PA1
recognizes the DNA sequence 5’-W2GW7-3’. PA1 binding sites are depicted with either a solid arrow (forward
orientation) or a dashed arrow (reverse orientation). The head of the arrow indicates the polyamide end where the Ta is
located (see inset). HPV E2 binding sites are depicted in green boxes. HPV E1 binds in the region (HPV18 3-19 bp)
flanked by the first and second E2 binding sites. The rationale for the project was that the polyamide would interfere
with viral protein binding leading to repression of DNA replication and/or transcription. The origin of replication is
marked with 1. Numbers on the left correspond to the nucleotide position in HPV18 genome. 
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2.7.6 PA1 Single-Base-Pair Mismatch Sites Predicted, But Not Observed on 
HPV18 7647-157 bp 
 
 
Figure SI2.5. PA1 Single-base-pair Mismatch Sites Predicted by PA-DNA Recognition Rules, Yet Not Observed
on the 368 bp (7647-157) HPV18 DNA Fragment. Predicted single-base-pair mismatch binding sites for PA1 are
depicted with a horizontal solid arrow (forward orientation) or a horizontal dashed arrow (reverse orientation) between
DNA duplex. PA1 sites shown in this figure either do not agree with affinity cleavage patterns or lack DNase I
footprints. The head of the arrow indicates the polyamide end where the Ta is located (see inset). HPV E2 binding sites
are depicted with green lines above the sequence duplex. HPV E1 binds in the region (HPV18 3-19 bp) flanked by the
first and second E2 binding sites (blue line above sequence duplex). The origin of replication is marked with 1.
Numbers on the left correspond to the nucleotide position in HPV18 genome.
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Table SI2.2. PA1 Predicted Single-Base-Pair Mismatch Sites Which Were Not Observed on 7647-157 Fragment of 
HPV18. 
Sequence Position Binding orientation Comment 
TTAGG CACATATTTT AGTTT 7691-7700 Reverse No AC 
TATTT TAGTTTGTTT TTACT 7699-7708 Forward No AC 
GTAAA AACAAACTAA AATAT 7708-7699 Reverse No AC 
TATAG TTCATGTTAA GGGTA 7783-7774 Reverse No AC or FP 
TTAAC ATGAACTATA ATATG 7779-7788 Forward No AC 
GCATA AACTATGTAT GCACA 7815-7806 Reverse No AC or FP 
GTGCA TACATAGTTT ATGCA 7807-7816 Reverse No AC or FP 
GCACA TACTATACTT TTCAT 7845-7854 Reverse No AC 
TACTA TACTTTTCAT TAATA 7850-2 Reverse No AC 
ATTAA TACTTTTAAC AATTG 6-15 Reverse No AC or FP 
TACAA TTGTTAAAAG TATTA 17-8 Forward No AC or FP 
CTTTT AACAATTGTA GTATA 13-22 Reverse No FP 
TATAC TACAATTGTT AAAAG 22-13 Reverse No AC or FP 
AACAA TTGTAGTATA TAAAA 18-27 Forward No AC or FP 
TTATA TACTACAATT GTTAA 25-16 Reverse No AC or FP 
TGTAG TATATAAAAA AGGGA 24-33 Forward No AC 
GTAGT ATATAAAAAA GGGAG 25-34 Forward No AC or FP 
PA1 was predicted to bind these sequences with single-base-pair mismatches; however, these sequences did not 
generate affinity cleavage (AC) patterns and/or footprints (FP).   
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2.7.7 Representative PA1 Binding Isotherms Obtained from Quantitative DNase I 
Footprinting Sites Along the DNA Fragment Corresponding to 7647-157 bp 
of the HPV18 LCR 
 
SITE #9 (Integration nt: 7787; Reference nt: 7837 in HEX Channel) 
 
                       Trial #1                                                           Trial #2 
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0.8
1
0 5 10 15 20 40
CHC1095 PA1 HPV18 LCR (7647-157 bp) (0.2 nM DNA)
7787 / 7837
Fra
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d
PA1 [nM]
y = (m1*m0)^m2/(1+(m1*m0)^m2...
ErrorValue
0.0304810.75885m1 
0.12411.7805m2 
NA0.0038761Chisq
NA0.99833R
y = m1*m2*m0/(1+m1*m0)
ErrorValue
0.128730.63065m1 
0.0535481.1067m2 
NA0.030691Chisq
NA0.98672R
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1
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CHC1096-1 PA1 HPV18 LCR (7647-157 bp) (0.2 nM DNA)
7787 / 7837
Fra
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d
PA1 [nM]
y = (m1*m0)^m2/(1+(m1*m0)^m2...
ErrorValue
0.0424151.0272m1 
0.0729721.2905m2 
NA0.0009995Chisq
NA0.99938R
y = m1*m2*m0/(1+m1*m0)
ErrorValue
0.0531211.0219m1 
0.0100061.0454m2 
NA0.0010469Chisq
NA0.99935R
  
 
 
 
                       Trial #3                                                           Trial #4 
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1
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CHC1097 PA1 HPV18 LCR (7647-157 bp) (0.2 nM DNA)
7787 / 7837
Fra
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on
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PA1 [nM]
y = (m1*m0)^m2/(1+(m1*m0)^m2...
ErrorValue
0.0441090.79863m1 
0.0912391.2657m2 
NA0.0048164Chisq
NA0.99758R
y = m1*m2*m0/(1+m1*m0)
ErrorValue
0.068250.70351m1 
0.0238041.0603m2 
NA0.0064569Chisq
NA0.99675R
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1
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CHC1098 PA1 HPV18 LCR (7647-157 bp) (0.2 nM DNA)
7787 / 7837
Fra
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on
 Bo
un
d
PA1 [nM]
y = (m1*m0)^m2/(1+(m1*m0)^m2...
ErrorValue
0.0659260.88496m1 
0.165711.4637m2 
NA0.010473Chisq
NA0.99496R
y = m1*m2*m0/(1+m1*m0)
ErrorValue
0.138590.79275m1 
0.0421671.0707m2 
NA0.021595Chisq
NA0.98958R
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       SITE #9 HEX: All Trials (Hill fit) 
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SITE #10 (Integration nt: 7794; Reference nt: 7840 in FAM Channel) 
 
                       Trial #1                                                         Trial #2 
0
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0.8
1
0 5 10 15 20 40
CHC1095 PA1 HPV18 LCR (7647-157 bp) (0.2 nM DNA)
7794 / 7840
Fra
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d
PA1 [nM]
y = (m1*m0)^m2/(1+(m1*m0)^m2...
ErrorValue
0.0179050.57584m1 
0.156842.3296m2 
NA0.0029876Chisq
NA0.9989R
y = m1*m2*m0/(1+m1*m0)
ErrorValue
0.144710.44119m1 
0.0956541.1397m2 
NA0.077363Chisq
NA0.97099R
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CHC1096-1 PA1 HPV18 LCR (7647-157 bp) (0.2 nM DNA)
7794 / 7840
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un
d
PA1 [nM]
y = (m1*m0)^m2/(1+(m1*m0)^m2...
ErrorValue
0.039950.76437m1 
0.189021.936m2 
NA0.0072215Chisq
NA0.99699R
y = m1*m2*m0/(1+m1*m0)
ErrorValue
0.170480.64714m1 
0.0686261.1052m2 
NA0.051179Chisq
NA0.97847R
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                       Trial #3                                     SITE #10 FAM: All Trials (Hill fit)                              
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0.8
1
0 5 10 15 20 40
CHC1098 PA1 HPV18 LCR (7647-157 bp) (0.2 nM DNA)
7794 / 7840
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PA1 [nM]
y = (m1*m0)^m2/(1+(m1*m0)^m2...
ErrorValue
0.0407110.65323m1 
0.267452.1398m2 
NA0.0093499Chisq
NA0.99601R
y = m1*m2*m0/(1+m1*m0)
ErrorValue
0.168870.47323m1 
0.117361.1508m2 
NA0.071779Chisq
NA0.96898R
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SITE #12 & 13 (Integration nt: 7818; Reference nt: 7840 in FAM Channel) 
 
                       Trial #1                                                        Trial #2
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1
0 5 10 15 20 40
CHC1095 PA1 HPV18 LCR (7647-157 bp) (0.2 nM DNA)
7818 / 7840
Fra
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on
 Bo
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PA1 [nM]
y = (m1*m0)^m2/(1+(m1*m0)^m2...
ErrorValue
0.0119960.3704m1 
0.178482.6927m2 
NA0.0030257Chisq
NA0.999R
y = m1*m2*m0/(1+m1*m0)
ErrorValue
0.09940.24942m1 
0.140391.2059m2 
NA0.1024Chisq
NA0.96547R
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CHC1097 PA1 HPV18 LCR (7647-157 bp) (0.2 nM DNA)
7818 / 7840
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PA1 [nM]
y = (m1*m0)^m2/(1+(m1*m0)^m2...
ErrorValue
0.0027110.30485m1 
0.0649313.4554m2 
NA0.0001919Chisq
NA0.99993R
y = m1*m2*m0/(1+m1*m0)
ErrorValue
0.112060.20051m1 
0.212371.246m2 
NA0.15179Chisq
NA0.94422R
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                       Trial #3                            SITE #12 & 13 FAM: All Trials (Hill fit)           
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y = (m1*m0)^m2/(1+(m1*m0)^m2...
ErrorValue
0.0155710.3858m1 
0.275662.9582m2 
NA0.0049877Chisq
NA0.99837R
y = m1*m2*m0/(1+m1*m0)
ErrorValue
0.116150.26175m1 
0.152741.1926m2 
NA0.12703Chisq
NA0.95767R
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SITE #15 & #16 (Integration nt: 3; Reference nt: 7837 in HEX Channel) 
 
                       Trial #1                                                           Trial #2 
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CHC1095 PA1 HPV18 LCR (7647-157 bp) (0.2 nM DNA)
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PA1 [nM]
y = (m1*m0)^m2/(1+(m1*m0)^m2...
ErrorValue
0.0937321.0714m1 
0.20081.4559m2 
NA0.013699Chisq
NA0.99322R
y = m1*m2*m0/(1+m1*m0)
ErrorValue
0.164260.98221m1 
0.0384171.0735m2 
NA0.019874Chisq
NA0.99014R
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y = m1*m2*m0/(1+m1*m0)
ErrorValue
0.233880.79651m1 
0.0707481.0707m2 
NA0.06094Chisq
NA0.97288R
y = (m1*m0)^m2/(1+(m1*m0)^m2...
ErrorValue
0.0326910.88628m1 
0.163292.1365m2 
NA0.0040613Chisq
NA0.99822R
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                       Trial #3                                                           Trial #4 
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CHC1097 PA1 HPV18 LCR (7647-157 bp) (0.2 nM DNA)
3 / 7837
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PA1 [nM]
y = (m1*m0)^m2/(1+(m1*m0)^m2...
ErrorValue
0.0404140.86516m1 
0.0993031.4327m2 
NA0.0040158Chisq
NA0.99805R
y = m1*m2*m0/(1+m1*m0)
ErrorValue
0.106250.76703m1 
0.0335221.0661m2 
NA0.013417Chisq
NA0.99346R
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CHC1098 PA1 HPV18 LCR (7647-157 bp) (0.2 nM DNA)
3 / 7837
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cti
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d
PA1 [nM]
y = (m1*m0)^m2/(1+(m1*m0)^m2...
ErrorValue
0.0953351.0325m1 
0.172051.3097m2 
NA0.013228Chisq
NA0.99317R
y = m1*m2*m0/(1+m1*m0)
ErrorValue
0.153170.96014m1 
0.0360941.0514m2 
NA0.017363Chisq
NA0.99102R
  
 
 
 
 
SITE #15 & 16 HEX: All Trials (Hill fit) 
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Figure SI2.6. Representative PA1 Binding Isotherms Obtained from Quantitative DNase I Footprinting Sites 
Along the DNA Fragment Corresponding to 7647-157 bp of the HPV18 LCR. Binding isotherms for each trial of 
PA1 are plotted. Calculated parameters for the Langmuir (top inset table) and the Hill (bottom inset table) equations 
(KaleidaGraph 4.1 software). Summary plots are fitted using the Hill equation. 
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2.7.8 Putative PA25 Binding Sites on HPV18 Fragments corresponding to 7479-
7783 bp and 7647-157 bp 
 
 
Figure SI2.7. Putative PA25 Binding Sites on the HPV18 Region from 7479-7783 bp. According to the literature,
PA25 recognizes the DNA sequence 5’-W2GW5GW4-3’. PA25 binding sites are depicted with either a solid arrow
(forward orientation) or a dashed arrow (reverse orientation). The head of the arrow indicates the polyamide end where
the Ta is located (see inset). This fragment does not harbor any HPV E2 binding sites. Numbers on the left correspond
to the nucleotide position in HPV18 genome. 
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Figure SI2.8. Putative PA25 Binding Sites on the HPV18 Region from 7647-157 bp. According to the literature,
PA25 recognizes the DNA sequence 5’-W2GW5GW4-3’. PA25 binding sites are depicted with either a solid arrow
(forward orientation) or a dashed arrow (reverse orientation). The head of the arrow indicates the polyamide end where
the Ta is located (see inset). HPV E2 binding sites are depicted in green boxes. HPV E1 binds in the region (HPV18 3-
19 bp) flanked by the first and second E2 binding sites. The rationale for the project was that the polyamide would
interfere with viral protein binding leading to repression of DNA replication and/or transcription. The origin of
replication is marked with 1. Numbers on the left correspond to the nucleotide position in HPV18 genome. 
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2.7.9 PA25 Single-base-pair Mismatch Sites Predicted, But Not Observed on 
HPV18 7479-7783 bp 
 
 
Figure SI2.9. PA25 Single-base-pair Mismatch Sites Predicted by PA-DNA Recognition Rules, But Not
Observed on the 305 bp (7479-7783) HPV18 DNA Fragment. Predicted single-base-pair mismatch binding site for
PA25 at 7709-7721 bp is depicted with a horizontal solid arrow (forward orientation) between DNA duplex. The head
of the arrow indicates the polyamide end where the Ta is located (see inset). This fragment does not harbor any HPV
E2 binding sites. Numbers on the left correspond to the nucleotide position in HPV18 genome. 
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Table SI2.3. PA25 Predicted Single-Base-Pair Mismatch Sites Which Were Not Observed on 7479-7783 Fragment of 
HPV18 LCR. 
Sequence Position Binding orientation Comment 
GCAAT TAGCTTAAGTAAA AACAA 7709-7721 Forward No AC 
PA25 was predicted to bind this sequence with a single-base-pair mismatch; however, this sequence did not generate an 
affinity cleavage (AC) pattern.   
 
 
 
 
 
 
2.7.10 Representative PA25 Binding Isotherms Obtained from Quantitative DNase 
I Footprinting Sites Along the DNA Fragment Corresponding to 7479-7783 
bp of the HPV18 LCR 
 
SITE #8 and #9 (Integration nt: 7613; Reference nt: 7625 in HEX Channel) 
 
                       Trial #1                                                           Trial #2 
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y = (m1*m0)^m2/(1+(m1*m0)^m2...
ErrorValue
0.0798221.0611m1 
0.501462.7074m2 
NA0.026671Chisq
NA0.98763R
y = m1*m2*m0/(1+m1*m0)
ErrorValue
0.435711.101m1 
0.11141.1095m2 
NA0.11483Chisq
NA0.94557R
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y = (m1*m0)^m2/(1+(m1*m0)^m2...
ErrorValue
0.0728181.0066m1 
0.567412.8993m2 
NA0.023079Chisq
NA0.98839R
y = m1*m2*m0/(1+m1*m0)
ErrorValue
0.449961.0272m1 
0.134551.1049m2 
NA0.11609Chisq
NA0.94014R
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                             Trial #3                                  SITE #8 & 9 HEX: All Trials (Hill fit)
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ErrorValue
0.0359341.073m1 
0.140512.0336m2 
NA0.0038567Chisq
NA0.99807R
y = m1*m2*m0/(1+m1*m0)
ErrorValue
0.244040.99999m1 
0.0712231.1134m2 
NA0.044569Chisq
NA0.97744R
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SITE #11 and #12 (Integration nt: 7659; Reference nt: 7629 in FAM Channel) 
 
                           Trial #1                                                      Trial #2 
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0.118821.4653m1 
0.346532.1098m2 
NA0.017677Chisq
NA0.98992R
y = m1*m2*m0/(1+m1*m0)
ErrorValue
0.450631.3727m1 
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NA0.054273Chisq
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0.342342.471m2 
NA0.015682Chisq
NA0.99234R
y = m1*m2*m0/(1+m1*m0)
ErrorValue
0.477271.3543m1 
0.0913581.1024m2 
NA0.085584Chisq
NA0.95745R
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                       Trial #3                           SITE #11 & 12 FAM: All Trials (Hill fit) 
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SITE #10 and #11 (Integration nt: 7642; Reference nt: 7625 in HEX Channel) 
 
                           Trial #1                                                      Trial #2 
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ErrorValue
0.383884.0353m1 
0.247321.6583m2 
NA0.055822Chisq
NA0.98105R
y = m1*m2*m0/(1+m1*m0)
ErrorValue
0.732953.293m1 
0.0751571.1507m2 
NA0.081807Chisq
NA0.9721R
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y = (m1*m0)^m2/(1+(m1*m0)^m2...
ErrorValue
0.432824.2917m1 
0.180691.3576m2 
NA0.043531Chisq
NA0.98257R
y = m1*m2*m0/(1+m1*m0)
ErrorValue
0.529012.8843m1 
0.075561.2031m2 
NA0.035898Chisq
NA0.98565R
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                       Trial #3                           SITE #10 & 11 HEX: All Trials (Hill fit) 
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y = (m1*m0)^m2/(1+(m1*m0)^m2...
ErrorValue
0.170963.945m1 
0.111321.5476m2 
NA0.0075632Chisq
NA0.99609R
y = m1*m2*m0/(1+m1*m0)
ErrorValue
0.435772.6593m1 
0.0814781.2312m2 
NA0.018339Chisq
NA0.9905R
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Figure SI2.10. Representative PA25 Binding Isotherms Obtained from Quantitative DNase I Footprinting Sites
Along the DNA Fragment Corresponding to 7479-7783 bp of the HPV18 LCR. Binding isotherms for each trial of
PA25 are plotted. Calculated parameters for the Langmuir (top inset table) and the Hill (bottom inset table) equations
(KaleidaGraph 4.1 software). Summary plots are fitted using the Hill equation. 
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2.7.11 PA25 Single-base-pair Mismatch Sites Predicted, But Not Observed on 
HPV18 7647-157 bp 
 
 
Figure SI2.11. PA25 Single-base-pair Mismatch Sites Predicted by PA-DNA Recognition Rules, But Not
Observed on the 368 bp (7647-157) HPV18 DNA Fragment. A predicted single-base-pair mismatch binding site for
PA25 at 7709-7721 bp is depicted with a horizontal solid arrow (forward orientation) between DNA duplex. The head
of the arrow indicates the polyamide end where the Ta is located (see inset). HPV E2 binding sites are depicted in green
boxes. HPV E1 binds in the region (HPV18 3-19 bp) flanked by the first and second E2 binding sites. The rationale for
the project was that the polyamide would interfere with viral protein binding leading to repression of DNA replication
and/or transcription. The origin of replication is marked with 1. Numbers on the left correspond to the nucleotide
position in HPV18 genome. 
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Table SI2.4. PA25 predicted single-base-pair mismatch sites which were not observed on 7647-157 fragment of 
HPV18 LCR. 
Sequence Position Binding orientation Comment 
GCAAT TAGCTTAAGTAAA AACAA 7709-7721 Forward No AC 
PA25 was predicted to bind this sequence with a single-base-pair mismatch; however, this sequence did not generate an 
affinity cleavage (AC) pattern.   
2.7.12 Representative PA25 Binding Isotherms Obtained from Quantitative DNase 
I Footprinting Sites Along the DNA Fragment Corresponding to 7647-157 bp 
of the HPV18 LCR 
 
SITE #12 and #13 (Integration nt: 7786; Reference nt: 7840 in FAM Channel) 
                      
                    Trial #1                                                           Trial #2 
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0 0.5 1 1.5 2
CHC1169 PA25 HPV18 LCR (7647-157 bp) (0.05 nM DNA)
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y = (m1*m0)^m2/(1+(m1*m0)^m2...
ErrorValue
0.397644.802m1 
0.24131.6751m2 
NA0.024091Chisq
NA0.98815R
y = m1*m2*m0/(1+m1*m0)
ErrorValue
0.983244.2915m1 
0.0710561.1094m2 
NA0.049701Chisq
NA0.9754R
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CHC1170 PA25 HPV18 LCR (7647-157 bp) (0.05 nM DNA)
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Fra
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y = (m1*m0)^m2/(1+(m1*m0)^m2...
ErrorValue
0.230014.6227m1 
0.166271.8449m2 
NA0.011036Chisq
NA0.99621R
y = m1*m2*m0/(1+m1*m0)
ErrorValue
0.983644.1611m1 
0.0630691.0772m2 
NA0.072052Chisq
NA0.97499R
   
                       Trial #3                             SITE #10 & 11 FAM: All Trials (Hill fit) 
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y = (m1*m0)^m2/(1+(m1*m0)^m2...
ErrorValue
0.268854.5711m1 
0.271682.1932m2 
NA0.020081Chisq
NA0.9916R
y = m1*m2*m0/(1+m1*m0)
ErrorValue
1.2884.8021m1 
0.0701941.084m2 
NA0.092443Chisq
NA0.96073R
 
0
0.2
0.4
0.6
0.8
1
0 0.5 1 1.5 2
HPV18 (7647-157) CHC1169, 70, 71 (0.05 nM DNA)
7786 / 7840
7786 / 7840
7786 / 7840
Fra
cti
on
 Bo
un
d
PA25 [nM]   
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SITE #16 (Integration nt: 7850; Reference nt: 7840 in FAM Channel) 
 
                       Trial #1                                                           Trial #2 
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CHC1170 PA25 HPV18 LCR (7647-157 bp) (0.05 nM DNA)
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y = (m1*m0)^m2/(1+(m1*m0)^m2...
ErrorValue
0.162893.0516m1 
0.182521.849m2 
NA0.011556Chisq
NA0.99549R
y = m1*m2*m0/(1+m1*m0)
ErrorValue
0.521342.2112m1 
0.0887291.1587m2 
NA0.049426Chisq
NA0.98055R
 
0
0.2
0.4
0.6
0.8
1
0 1 2 3 4 5
CHC1171 PA25 HPV18 LCR (7647-157 bp) (0.05 nM DNA)
7850 / 7840
Fra
cti
on
 Bo
un
d
PA25 [nM]
y = (m1*m0)^m2/(1+(m1*m0)^m2...
ErrorValue
0.211933.9266m1 
0.160251.6785m2 
NA0.016271Chisq
NA0.99416R
y = m1*m2*m0/(1+m1*m0)
ErrorValue
0.658723.5834m1 
0.0535231.0759m2 
NA0.054478Chisq
NA0.98031R
  
 
 
 
 
 
                             Trial #3                             SITE #16 FAM: All Trials (Hill fit) 
0
0.2
0.4
0.6
0.8
1
0 1 2 3 4 5
CHC1179 PA25 HPV18 LCR (7647-157 bp) (0.05 nM DNA)
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y = m1*m2*m0/(1+m1*m0)
ErrorValue
0.554312.5871m1 
0.0807951.1345m2 
NA0.053929Chisq
NA0.97871R
y = (m1*m0)^m2/(1+(m1*m0)^m2...
ErrorValue
0.166783.2896m1 
0.176051.7651m2 
NA0.0147Chisq
NA0.99424R
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SITE #20 and #21 (Integration nt: 40; Reference nt: 7837 in HEX Channel) 
 
                       Trial #1                                                           Trial #2 
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ErrorValue
0.3232.3302m1 
0.376191.5634m2 
NA0.092514Chisq
NA0.9612R
y = m1*m2*m0/(1+m1*m0)
ErrorValue
0.488351.6316m1 
0.132371.1935m2 
NA0.098626Chisq
NA0.95858R
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y = (m1*m0)^m2/(1+(m1*m0)^m2...
ErrorValue
0.1822.4401m1 
0.264581.9282m2 
NA0.022546Chisq
NA0.99149R
y = m1*m2*m0/(1+m1*m0)
ErrorValue
0.399591.6075m1 
0.106881.2333m2 
NA0.053484Chisq
NA0.9797R
  
 
 
 
 
 
                          Trial #3                             SITE #20 and #21 HEX: All Trials (Hill fit) 
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NA0.0081315Chisq
NA0.99721R
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ErrorValue
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NA0.11685Chisq
NA0.95918R
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Figure SI2.12. Representative PA25 Binding Isotherms Obtained from Quantitative DNase I Footprinting Sites
Along the DNA Fragment Corresponding to 7647-157 bp of the HPV18 LCR. Binding isotherms for each trial of
PA25 are plotted. Calculated parameters for the Langmuir (top inset table) and the Hill (bottom inset table) equations
(KaleidaGraph 4.1 software). Summary plots are fitted using the Hill equation. 
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Chapter 3 
 
Improved Antiviral Activity of a Polyamide Against High-Risk Human Papillomavirus 
via N-terminal Guanidinium Substitution 
 
 
 
 
 
 
The text of this chapter was taken in part from a publication co-author with Maria J. 
Scuderi, Terri G. Edwards, George D. Harris, Cynthia M. Dupureur, Kevin J. Koeller, 
Chris Fisher and James K. Bashkin (Department of Chemistry & Biochemistry, 
University of Missouri-St. Louis, St. Louis, MO 63121, USA; NanoVir, LLC, Kalamazoo, 
MI 49008, USA) 
Castaneda, C. H.; Scuderi, M. J.; Edwards, T. G.; Harris, G. D.; Dupureur, C. M.; 
Koeller, K. J.; Fisher, C.; Bashkin, J. K. (2016) Improved antiviral activity of a 
polyamide against high-risk human papillomavirus via N-terminal guanidinium 
substitution. MedChemComm, doi:10.1039/c6md00371k. 
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3.1 ABSTRACT 
 
We report the synthesis of two novel pyrrole–imidazole polyamides with N-terminal 
guanidinium or tetramethylguanidinium groups and evaluate their antiviral activity 
against three cancer-causing human papillomavirus strains. Introduction of guanidinium 
improves antiviral activity when compared to an unsubstituted analog, especially in IC90 
values. These substitutions change DNA-binding preferences, while binding affinity 
remains unchanged. 
3.2 INTRODUCTION 
 
N-methylpyrrole (Py) and N-methylimidazole (Im) hairpin polyamides (PAs) are 
synthetic homologs of the natural antibiotics distamycin A and netropsin which bind AT-
rich regions of DNA in the minor groove.1-4 The antiparallel nature of hairpin PAs allows 
for the side-by-side pairing of building blocks and recognition of DNA base pairs (bp) 
within a double strand (dsDNA). It has been extensively reported that Py/Py and Py/β-
alanine (β) pairs recognize A/T and T/A base pairs, while an Im/Py pair distinguishes 
G/C from C/G.5,6 Furthermore, introduction of the flexible β linker in place of 
heterocycles resets the heterocycle-base pair register and allows targeting of longer DNA 
sequences.7,8  
In numerous reports hairpin PAs distinguish DNA sequences by binding to patterns of 
hydrogen-bond donors and acceptors in the minor groove of DNA,6,9-11 so synthetic PAs 
are attractive for many biomedical applications. Thus, for polyamides themselves and 
related minor groove binders, reports include the regulation of gene expression,12-14 
biological imaging,15 and use as antimicrobial/antiviral agents.16-22 Antiviral polyamides 
include the long polyamides reported here which, as a class, access a new biological 
mechanism: they lead to the degradation of the genome of dsDNA tumour viruses in cells 
while avoiding acute cytotoxicity. The DNA degradation is accomplished via the DNA 
Damage Response (DDR), for which expression is altered significantly only in infected 
cells carrying small circular, dsDNA genomes of the virus, known as episomes.23,24 As 
discussed below, another characteristic of this new class of antiviral polyamides is their 
failure to follow the reported DNA recognition rules described above. 
The process by which the DDR works in concert with the polyamides is not 
completely established at the molecular level, but many details have emerged as a result 
of a variety of experiments, a portion of which are summarized here. For example, 224 
DDR genes were knocked down individually using siRNA, and we checked to see if the 
knockdowns affected polyamide activity in any way; 21 genes were found to affect PA 
activity, and the results were validated by additional experiments using QPCR (rather 
than relying on the PCR array data alone).23,24 Some gene knockdowns enhanced PA 
activity and others opposed PA activity. Additional experiments used Mirin, a small 
molecule inhibitor of DDR enzyme Mre11. Mre11 has many activities alone and in 
protein complexes. For example, Mre11 is a member of the MRN complex, which 
participates in double-strand DNA break repair and telomere maintenance as a member of 
the ATM branch of the DDR.25 As a standalone enzyme, one activity associated with 
MRE11 is that of an endonuclease. MRE11 inhibition experiments were carried out in the 
presence and absence of polyamides.23 100 μM Mirin had no effect on its own, but it 
sensitized cells to PA25, making the compound 4× more active in terms of lower IC50 
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and IC90 values. Part of the activation of the DDR was also followed by phosphorylation 
of Rad9, a protein that is phosphorylated upon DNA damage as part of the ATR pathway 
of the DDR, one of the two major DDR branches (the other being ATM).23,24,26 Treatment 
of HPV16 episome bearing W12E cells with active polyamide causes Rad9 
phosphorylation within 2–4 hours, but HPV-free cervical cancer cell line C33A shows no 
phosphorylation of Rad9 upon treatment with polyamide.23,24 
We previously reported a library of long hairpin PAs, including PA1 and PA25, 
which exhibits antiviral activity against three high-risk (oncogenic) HPVs.27-29 HPV is an 
AT-rich dsDNA virus30,31 that causes cervical cancer, among other diseases, and subtypes 
HPV16 and 18 are responsible for 70 % of cervical cancer in most of the world.32,33 
Although specific HPV vaccines are available,34,35 they are effective prophylactics, not 
therapies. PA1, our first preclinical lead, exhibits anti-HPV activity with no cytotoxicity 
up to its solubility limit in cell culture media of 200 μM.27-29 A characteristic of these 
active anti-HPV polyamides is that they bind at least ten bp, or one full turn of DNA.   
Here, we report the antiviral activities and DNA-binding properties of two PAs of a 
new structural class, PA30 and PA31, where the des-amino N-terminus of the parent 
compound PA1 has been substituted with either tetramethylguanidinium (TMG) or 
guanidinium (Guan), respectively. PA30 and PA31 are biomimetic in that netropsin has 
an N-terminal guanidinium, though PA30 and 31 are not exact structural analogues of 
netropsin. While others have explored guanidinylated DNA-binding ligands, no 
biophysical studies on guanidinylated hairpin PAs have been undertaken, to our 
knowledge.36-38 We found that these substitutions at the N-terminus, which are small 
relative to the overall molecular size, can significantly improve anti-HPV activity. 
However, improvement in antiviral efficacy cannot be attributed to altered DNA binding 
strength, as will be shown. Nevertheless, PA30 and PA31 display noticeable differences 
in binding distribution on a fragment of native HPV18 DNA in comparison with parent 
PA1.  
 
3.3 MATERIALS AND METHODS 
 
3.3.1 Polyamide Synthesis and Characterization 
Polyamides were synthesized by Boc solid-phase methods39,40 as reported27 (PA1) or 
followed by TMG (PA30) or Guan (PA31) conjugation. After cleavage from the resin, 
polyamides were purified by reverse-phase HPLC and characterized with 1H and 13C 
NMR and HR mass spectrometry.  
PA1 and its EDTA conjugate were synthesized and characterized as previously 
described.27,41,42 PA30 and 31 were synthesized by virtually identical solid-phase methods 
up to the Im group (4-amino-N-methyl imidazole-2-carboxamide) and its 4-N-attached 
guanidinyl substituent. For PA30, HATU43 was utilized as the final building block to 
incorporate the TMG group onto the H2N-Im moiety. For PA31, in parallel to the 
literature,44 treatment with N,N’-Bis (tert-butoxycarbonyl)-1H-pyrazole-1-carboxamidine 
and diisopropylethylamine for 24 h, followed by TFA treatment to remove the BOC 
groups produced the desired, unsubstituted Guan group. The EDTA conjugate of PA30 
was prepared via the same method as previously described for PA1’s conjugate.41,42 
Briefly, to a vigorously-stirred mixture of EDTA dianhydride (15.8 mg, 0.060 mmol, 22 
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eq) in N,N-diisopropylethylamine (DIEA) (0.5 mL), DMF (0.25 mL) and DMSO (0.25 
mL) at 55 °C was added a mixture of PA30 (5.9 mg, 0.0027 mmol, 1 eq) in DIEA (0.5 
mL) and DMF (0.5 mL) dropwise over a period of 30 min. The reaction mixture was 
stirred at 55 °C for 30 min. Following addition of 0.1 N NaOH (1.03 mL), the mixture 
was stirred at 55 °C for an additional 20 min. The bottom layer of the biphasic mixture 
was removed from the reaction vessel and neutralized with formic acid (0.013 mL). The 
mixture was diluted with 0.5 mL DMSO, filtered through a 20 μm polyethylene filter, 
and purified by reversed-phase HPLC using a Phenomenex Luna 250 x 30 mm, 5 μm, 
100 Å, C18 (version 2) column maintained at 25 ˚C. Mobile phases were 0.2 % formic 
acid in water (A) and 100 % methanol (B). The gradient was 35 % B for 5 min followed 
by a ramp to 70 % B over 40 min at 50 mL/min. Concentration of pooled fractions, 
followed by lyophilization, gave the PA30-EDTA conjugate (1.0 mg, 16 % yield) as a 
white, fluffy solid: exact mass [M+H]+= 2282.0657, experimental (ESI) [M+H]+ = 
2282.1257. The EDTA conjugate of PA31 was prepared via a virtually identical 
procedure to the one described for PA30, but with the following changes. PA31 (4.0 mg) 
was substituted for PA30. The preparative HPLC purification parameters were identical 
to those described above except mobile phase A consisted of 0.2 % trifluoroacetic acid in 
water. Concentration of pooled fractions, followed by lyophilization gave the PA31-
EDTA conjugate (2.3 mg, 55 % yield) as an off-white fluffy solid: exact mass 
[M+2H+Na]+ = 2250.0007, experimental (ESI) [M+2H+Na]+ = 2249.9562. Analytical 
HPLC characterization was performed using a Phenomenex Jupiter Proteo (C12), 4.6 x 
50 mm, 4 μm, 90 Å maintained at 40˚C. Mobile phases consisted of 0.1 % formic acid in 
water (A) and 100 % acetonitrile (B). The gradient consisted of 5 % B for 0.75 min 
followed by a ramp to 60 % B over 3.25 min at 2 mL/min. Retention times were 2.641 
min, 2.486 min and 2.437 min for PA1, PA30 and PA31, respectively (Figure 3.1). 
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3.3.1.1 PA1 Im-Py-Py-β-Py-Py-Py-β-Py-Py-β-Py-Py-Py-Py-β-Ta (3 TFA) 
1H NMR (600 MHz, DMSO-d6) δ = 10.46 (s, 1 H), 9.93 (s, 1 H), 9.91 (s, 4 H), 9.90 - 
9.87 (m, 2 H), 9.86 (s, 1 H), 9.83 (s, 1 H), 9.63 (br. s., 2 H), 8.12 - 8.02 (m, 5 H), 7.98 - 
7.92 (m, 1 H), 7.88 (br. s., 3 H), 7.40 (s, 1 H), 7.28 (d, J = 1.8 Hz, 1 H), 7.24 - 7.21 (m, 3 
H), 7.21 - 7.18 (m, 4 H), 7.18 - 7.16 (m, 3 H), 7.15 (d, J = 1.8 Hz, 1 H), 7.08 (d, J = 1.8 
Hz, 1 H), 7.07 (d, J = 1.8 Hz, 1 H), 7.06 (s, 1 H), 7.04 (d, J = 1.8 Hz, 1 H), 6.90 (d, J = 
1.8 Hz, 1 H), 6.89 (d, J = 1.8 Hz, 1 H), 6.89 (s, 2 H), 6.85 (s, 2 H), 6.84 (d, J = 1.2 Hz, 1 
H), 3.99 (s, 3 H), 3.85 (s, 3 H), 3.85 (s, 3 H), 3.84 (s, 9 H), 3.82 (s, 6 H), 3.81 (s, 3 H), 
3.81 (s, 9 H), 3.49 - 3.42 (m, 4 H), 3.41 - 3.35 (m, 4 H), 3.25 - 3.16 (m, 4 H), 3.16 - 3.10 
(m, 2 H), 3.10 - 2.98 (m, 4 H), 2.87 (br. s, 2 H), 2.74 (d, J = 4.7 Hz, 3 H), 2.55 - 2.51 (m, 
2 H), 2.36 (t, J = 7.0 Hz, 2 H), 2.28 (t, J = 7.3 Hz, 2 H), 1.96 - 1.87 (m, 2 H), 1.82 - 1.74 
(m, 2 H) 
A 
B 
C 
Figure 3.1. HPLC Purity of Synthesized Polyamides with λ Monitored. (A) PA1 (98 % purity, retention 
time = 2.64 min), (B) PA30 (99 % purity, retention time = 2.49 min) and (C) PA31 (98 % purity, retention 
time = 2.44 min)  
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13C NMR (151 MHz, DMSO-d6) δ = 171.1, 169.3, 167.9, 167.8, 161.3, 158.6, 158.5, 
158.5, 158.4, 158.4, 158.4, 158.1, 157.9, 155.9, 138.7, 126.8, 126.3, 123.0, 122.9, 122.8, 
122.8, 122.8, 122.7, 122.7, 122.2, 122.2, 122.1, 122.1, 122.1, 122.0, 121.9, 121.4, 118.6, 
118.5, 118.4, 118.2, 118.1, 118.0, 117.8, 104.9, 104.8, 104.8, 104.7, 104.3, 104.3, 104.2, 
104.0, 104.0, 103.9, 53.3, 52.1, 40.0, 39.3, 38.2, 36.2, 36.1, 36.1, 36.0, 35.8, 35.8, 35.6, 
35.6, 35.5, 35.4, 35.1, 33.3, 25.7, 24.0, 21.8 
HRMS (ESI) calculated for C91H111N31O16 [MH]+, 1894.8908, found, 1894.8933. 
HPLC purity: 98 %. (see Figure 3.1). 
3.3.1.2 PA30 TMG-Im-Py-Py-β-Py-Py-Py-β-Py-Py-β-Py-Py-Py-Py-β-Ta (4 TFA) 
1H NMR (600 MHz, DMSO-d6) δ = 10.19 (s, 1 H), 10.08 (s, 1 H), 9.94 (s, 1 H), 9.92 
(s, 3 H), 9.91 (s, 1 H), 9.90 (s, 1 H), 9.87 (s, 1 H), 9.84 (s, 1 H), 9.45 (br. s., 1 H), 8.13 - 
8.03 (m, 5 H), 7.86 (br. s., 1 H), 7.80 (br. s., 3 H), 7.29 (d, J = 1.8 Hz, 1 H), 7.23 (d, J = 
1.2 Hz, 2 H), 7.22 - 7.21 (m, 2 H), 7.21 - 7.18 (m, 4 H), 7.16 (s, 3 H), 7.15 (d, J = 1.8 Hz, 
1 H), 7.08 (d, J = 1.8 Hz, 1 H), 7.07 (d, J = 1.8 Hz, 1 H), 7.05 (d, J = 1.2 Hz, 1 H), 6.91 
(d, J = 1.8 Hz, 1 H), 6.89 (d, J = 1.8 Hz, 2 H), 6.88 (s, 1 H), 6.85 (s, 2 H), 6.84 (d, J = 1.2 
Hz, 1 H), 6.56 (br. s., 2 H), 3.99 (s, 3 H), 3.85 (s, 3 H), 3.85 (s, 3 H), 3.84 (s, 3 H), 3.84 
(s, 3 H), 3.84 (s, 6 H), 3.81 (s, 6 H), 3.81 (s, 3 H), 3.80 (s, 6 H), 3.50 - 3.26 (m, 6 H), 3.24 
- 3.16 (m, 3 H), 3.16 - 3.09 (m, 2 H), 3.09 - 2.98 (m, 3 H), 2.98 - 2.80 (m, 14 H), 2.74 (d, 
J = 5.3 Hz, 3 H), 2.55 - 2.51 (m, 4 H), 2.36 (t, J = 7.3 Hz, 2 H), 2.27 (t, J = 7.3 Hz, 2 H), 
1.94 - 1.85 (m, 2 H), 1.82 - 1.73 (m, 4 H) 
13C NMR (151 MHz, DMSO-d6) δ = 171.0, 169.3, 167.9, 167.8, 161.3, 158.5, 158.5, 
158.4, 158.4, 158.4, 158.2, 157.9, 157.8, 155.4, 135.9, 134.8, 123.1, 122.9, 122.8, 122.8, 
122.8, 122.7, 122.7, 122.2, 122.2, 122.1, 122.1, 122.1, 122.1, 122.0, 121.9, 121.1, 118.9, 
118.5, 118.5, 118.2, 118.1, 118.0, 117.8, 115.8, 105.0, 104.8, 104.8, 104.7, 104.3, 104.3, 
104.0, 104.0, 103.9, 53.3, 52.1, 40.0, 39.3, 38.2, 36.2, 36.1, 36.1, 36.0, 35.8, 35.8, 35.6, 
35.6, 35.5, 35.4, 33.3, 25.7, 24.0, 22.5, 21.8 
HRMS (ESI) calculated for C96H122N34O16 [M]+, 2006.9778, found, 2006.9653. 
HPLC purity: 99 %.(see Figure 3.1). 
3.3.1.3 PA31 Guan-Im-Py-Py-β-Py-Py-Py-β-Py-Py-β-Py-Py-Py-Py-β-Ta (4 TFA) 
1H NMR (600 MHz, DMSO-d6) δ = 10.46 (s, 1 H), 10.42 (s, 1 H), 9.94 (s, 1 H), 9.93 
(s, 1 H), 9.92 (s, 3 H), 9.91 (s, 1 H), 9.90 (s, 1 H), 9.87 (s, 1 H), 9.84 (s, 1 H), 9.46 (br. s., 
1 H), 8.13 - 8.07 (m, 4 H), 8.06 (t, J = 5.6 Hz, 2 H), 7.86 (br. s., 1 H), 7.81 (br. s., 3 H), 
7.28 (d, J = 1.8 Hz, 1 H), 7.23 (d, J = 1.2 Hz, 2 H), 7.22 (d, J = 1.2 Hz, 1 H), 7.21 - 7.18 
(m, 5 H), 7.17 (s, 3 H), 7.14 (d, J = 1.8 Hz, 1 H), 7.08 (d, J = 1.2 Hz, 1 H), 7.07 (d, J = 
1.8 Hz, 1 H), 7.04 (d, J = 1.8 Hz, 1 H), 6.91 (d, J = 1.8 Hz, 1 H), 6.89 (s, 2 H), 6.88 (d, J 
= 1.8 Hz, 1 H), 6.87 - 6.85 (m, 2 H), 6.84 (d, J = 1.8 Hz, 1 H), 6.69 (s, 1 H), 6.56 (br. s., 2 
H), 4.00 (s, 3 H), 3.86 (s, 3 H), 3.85 (s, 3 H), 3.84 (s, 3 H), 3.84 (s, 3 H), 3.84 (s, 6 H), 
3.81 (s, 6 H), 3.81 (s, 3 H), 3.80 (s, 6 H), 3.51 - 3.32 (m, 6 H), 3.24 - 3.16 (m, 3 H), 3.16 - 
3.09 (m, J = 6.2, 12.5, 12.5 Hz, 2 H), 3.09 - 2.98 (m, 3 H), 2.90 - 2.81 (m, 2 H), 2.74 (d, J 
= 4.7 Hz, 3 H), 2.55 - 2.51 (m, 4 H), 2.36 (t, J = 7.3 Hz, 2 H), 2.27 (t, J = 7.3 Hz, 2 H), 
1.94 - 1.85 (m, 2 H), 1.82 - 1.75 (m, 4 H) 
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13C NMR (151 MHz, DMSO-d6) δ = 171.1, 169.3, 167.9, 161.3, 161.3, 158.6, 158.5, 
158.5, 158.4, 158.4, 158.3, 158.2, 158.0, 155.2, 154.6, 134.7, 134.4, 123.1, 122.9, 122.8, 
122.8, 122.7, 122.7, 122.2, 122.2, 122.1, 122.1, 122.1, 122.0, 121.9, 120.9, 118.9, 118.5, 
118.4, 118.2, 118.1, 118.0, 118.0, 117.8, 116.1, 113.7, 105.1, 104.8, 104.8, 104.7, 104.3, 
104.3, 104.2, 104.0, 104.0, 103.9, 53.3, 52.1, 40.0, 39.3, 38.2, 36.2, 36.2, 36.1, 36.0, 36.0, 
35.8, 35.8, 35.6, 35.6, 35.5, 35.4, 35.4, 33.3, 25.7, 24.1, 22.5, 21.8 
HRMS (ESI) calculated for C92H114N34O16 [M]+, 1950.9152, found, 1950.9034. 
HPLC purity: 98 %. (see Figure 3.1). 
3.3.2 Compound Efficacy Testing 
 
The antiviral activities were calculated by measuring the ability of PAs to decrease 
the viral DNA (or episomal) load in monolayer keratinocyte cultures. The episomal load 
was determined by Q-PCR as previously described.27 PA1 was already reported, along 
with extensive discussion of how antiviral parameters are defined for this new 
mechanism of antiviral action in which the viral genome is degraded while the host cells 
are unharmed as measured by standard MTT and LDH assays and observations of 
numbers of floating vs. adherent cells, etc.23,27-30 Typical assays were run for 48 h though 
much longer assays have also been run, and ref. 27 also describes organotypic, 
differentiated keratinocyte tissue culture assays as well as cell monolayer assays. Because 
PA1 has been central to our work for over a decade, it has been used as an internal 
standard to benchmark new compound series, so even though we cite the prior study, 
PA1 was studied side-by-side with PA30 and PA31 for the current work. The new PA1 
results were indistinguishable from the dose-response curves previously reported. Dose-
response curves for PA30 and PA31 are given below in Figure 3.4A and 3.4B. 
3.3.3 Molar Extinction Coefficient Determination 
 
The molar extinction coefficient for PA1 was determined as ε = 88,235 M-1cm-1 
by fluorescence as previously described.45 The molar extinction coefficients for PA30 
and PA31 were determined as ε = 91,164 M-1cm-1, ε = 89,263 M-1cm-1 by measuring the 
absorbance at 305 nm of solutions of known polyamide concentration. Briefly, stock 
solutions of 8.44 x 10-4 M of PA30 and 9.22 x 10-4 M of PA31 were prepared by 
separately diluting 1.04 mg of PA30 (4TFA, MW = 2464.3 g/mol, Lot KJK6169) and 
1.11 mg of PA31 (4TFA, MW = 2408.2 g/mol, Lot KJK6170) in 500 µL of DMSO. 
These stocks were further diluted in DMSO to known polyamide concentrations in the 
range 5 x 10-7 M to 7 x 10-5 M using cuvettes of various path lengths (0.2, 1, 5 cm). Since 
Beer-Lambert Law states that A = εbc (where A is the absorbance at a particular 
wavelength, ε is the molar extinction coefficient, b is the cell path length, and c is the 
concentration of the sample), a graph was constructed plotting the measured absorbance 
versus the polyamide concentration (M).  The slope of this line corresponds to the molar 
extinction coefficient (Figure 3.2). 
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3.3.4 Quantitative DNase I Footprinting 
 
Quantitative DNase I footprinting experiments were performed as described 
previously.41,42 Briefly, a 305 bp DNA fragment corresponding to the nucleotides 7479-
7783 in the Long Control Region (LCR) of the HPV18 genome (Genbank accession 
number X05015) was PCR amplified and fluorescently-labeled at both 5’ ends using the 
following primers: (top strand) 5’-FAM-CT TAT GTC TGT GGT TTT CTG and (bottom 
strand) 5’-HEX-TT CAT GTT AAG GGT AGA CAG. The DNA fragment was diluted to 
200 pM in TKMC buffer with 10 mM CHAPS and incubated with different 
concentrations of each polyamide (0.5-40 nM) for at least 4 h at 37 °C. The polyamide 
solutions were always added to DNA solutions not vice versa. At the end of this 
incubation period, each solution was subjected to ~0.08 U of DNase I for 5 min. The 
reactions were then quenched with EDTA and the DNA fragments were purified using a 
QIAquick PCR purification kit. Each experiment was performed at least three times. 
3.3.5 Affinity Cleavage 
 
Affinity cleavage experiments were performed as previously described.29,46 Briefly, 
PA-EDTA conjugates were complexed with 0.8 eq of Fe2+ in the form of ammonium 
iron(II) sulfate hexahydrate. 1 nM DNA fragment in 10 mM Tris, 10 mM CHAPS, pH 
7.5 was incubated with different concentrations of PA-EDTA-conjugates (5-200 nM) for 
at least 4 h at 37 °C. The reaction was initiated with 5 µL of 100 mM DTT and incubated 
at room temperature for 1-2 h. Each cleavage reaction was then quenched and fragments 
were purified using a QIAquick PCR purification kit. 
The samples from quantitative DNase I footprinting and affinity cleavage 
experiments were analyzed using capillary electrophoresis and indexed using Sanger and 
Maxam-Gilbert sequencing, respectively.46 Dissociation constant (Kd) values were 
calculated by normalizing the area from a peak in the footprint region to the area of a 
peak not sensitive to PA concentration. These values were plotted and fitted to Hill and 
Langmuir binding isotherms (as appropriate) with KaleidaGraph 4.1 software in methods 
reported in detail elsewhere. 29,41,42,46 
A  B
Figure 3.2. Plots of Measured Absorbance at 305 nm for Different Concentrations of PA30 and PA31.
Experimental data used for the determination of the molar extinction coefficients for (A) PA30 and (B) PA31
in DMSO.  
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3.4 RESULTS 
 
Structures of PA1, PA30 and PA31 and their EDTA-conjugates used in affinity 
cleavage maps are shown in Figure 3.3. Anti-HPV activities and MTT cell toxicity 
assays (shown for PA1, Figure SI3.1) were determined as previously described.27 New 
side-by-side, concentration-dependent assays were performed for previously reported 
PA1.27 Table 3.1 provides the resulting pseudo IC50 and IC90 values for PA1, PA30 and 
PA31 corresponding to the PA concentration that causes a 50 % or 90 % decrease in viral 
DNA concentration. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3.1  IC50 and IC90 Values of PA1,a PA30, and PA31 against High-Risk HPV16, HPV18 and HPV31 Types. 
 HPV16 HPV18 HPV31 
 IC50 (µM) IC90 (µM) n IC50 (µM) 
IC90 
(µM) n IC50 (µM) 
IC90 
(µM) n 
PA1 0.1(1) 1.1(8) 4 0.7(4) >10 3 0.1(1) 1.0(5) 4 
PA30 0.3(1) >10 3 0.2(2) >10 3 0.13(4) 0.9(7) 3 
PA31 0.10(1) 0.38(8) 3 0.2(2) 0.9(6) 3 0.14(4) 0.8(2) 3 
The numbers in parentheses are sample standard deviations; n is the number of independent measurements. [a] IC50 
values for PA1 were first reported in reference 27; we re-measured them and found them unchanged. 
Figure 3.4 gives dose-response curves for PA30 and PA31 while data are given for 
PA1 against HPV16 and HPV31 in Figure SI3.1; data for PA1 were the same as 
previously reported.27,47 Although IC50 values for the compounds are comparable against 
HPV16 and HPV31, PA30 and PA31 afforded somewhat improved IC50 values against 
HPV18. In contrast, significant improvement in IC90 for HPV16 and HPV18 was 
observed with PA31. However, PA30 activity plateaus just below a 90 % decrease in 
viral DNA and, in two days, does not quite reach an IC90, an important measure of 
antiviral activity. We will explore longer time intervals, but higher concentrations do not 
Figure 3.3. Chemical Structure of PA1, PA30 and PA31. RF refers to the substituent used for DNase I
footprinting experiments, whereas RAC indicates the EDTA-Fe conjugate for affinity cleavage experiments.
Inset: cartoon representation of the PA with building blocks represented by open circles for N-methylpyrrole,
filled circles for N-methylimidazole, diamonds for β, + for the Ta tail and  for γ-aminobutyric acid. PA1,
PA30, and PA31 share the same predicted DNA binding site (5’-WWGWWWWWWW-3’, where W = A or
T) and a general PA representing all three is depicted between two complementary DNA strands. 
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seem promising based on the dose-response curves, and would make PA30 a poor 
competitor with the more-active PA31. 
 
Because only PA31 showed an improved IC90 against HPV18, we investigated the 
DNA-binding properties of these hairpin PAs on a natural HPV18 sequence and 
compared them to the parent compound, PA1. Based on well-established PA-DNA 
pairing rules,6 PA1, PA30, and PA31 were expected to target the ten base-pair DNA 
sequence WWGWWWWWWW, where W=A or T (Figure 3.3 inset). A PA-DNA 
mismatch refers to any deviation from this recognition motif, i.e. where a PA building 
block pair binds to a noncanonical Watson-Crick base pair: one not predicted by the 
pairing rules.1 We used quantitative DNase I footprinting48,49 to obtain dissociation 
constants (Kd) and affinity cleavage experiments to assign binding orientations of the 
compounds on a 305 bp DNA fragment corresponding to nucleotides (nt) 7479 to 7783 in 
the Long Control Region (LCR) of HPV18, a viral genomic region containing regulatory 
elements for replication.50 We determined Kd values and orientation for all PA binding 
events along the entire 305 bp DNA fragment (see Figure SI3.2 for PA30 binding sites 
in this fragment), and representative dissociation constants at three binding sites are given 
in Table 3.2. Similar results were observed in the rest of the DNA fragment (see Figure 
SI3.2 and Table SI3.1 for PA30 dissociation constants for entire fragment). Kd was 
determined by the Hill or Langmuir equation, based on the magnitude of the derived Hill 
coefficient and overall fit (see Table 3.3 and 3.4).41,42 
Figure 3.4. Dose-response Curves for PA30 and PA31 Against HPV16, 18 and 31. IC50 and IC90 values
were determined for (A) PA30 and for (B) PA31. 
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  Table 3.3.  Kd Values Determined by Hill Equation for Sites 1-3 with Hill Coefficients and Overall Fit. 
 
   Table 3.4.  Kd Values Determined by Langmuir Equation for Sites 1-3 with Overall Fit. 
 
 
There is no significant difference in DNA-binding affinities of PA1, PA30, and PA31, 
indicating that the addition of a potential H-bond donor and a positive charge for PA30 
and PA31 vs. PA1 does not explain enhanced antiviral activity. It is noteworthy that since 
we are sampling an ensemble of different binding conformations in multiple linear, cell-
free DNA molecules, binding affinities are the sum of these binding events at a particular 
binding site. Furthermore, the negative supercoiling of the viral genome, and bound viral 
and host proteins in vivo, probably affect binding (see Conclusions). We are currently 
examining these matters experimentally. All three PAs bind to sites 1 and 2 (single-
mismatch sites) with Kd values ranging from 0.9-1.2 nM, and it is noteworthy that they all 
tolerate a triple base-pair mismatch at Site 3 with Kd values ranging from 2.2-3.2 nM 
(Table 3.2). The high Hill coefficients at this site are explained by previously-reported 
polyamide binding cooperativity,11 in which the binding of one polyamide can 
preorganize the minor groove for the binding of a second (and more) polyamides, for 
example by widening the minor groove. This cooperativity would be most expected in 
areas of high polyamide density on the DNA, which is what we found in the Long 
Control Region. We need to point out that we used a single-site binding model to analyze 
binding thermodynamics. If we had parameterized binding to allow multiple Hill 
coefficients to float simultaneously, we would more accurately have accounted for the 
Table 3.2.  Representative PA1, PA30 and PA31 Binding Sites on nt 7479-7783 of the HPV18 LCR as Determined by Quantitative DNase I Footprinting and Affinity Cleavage.
 Kd (nM) 
Site  Sequence Position Site Type PA1 PA30 PA31 
1  CCTGG TATTAGTCAT TTTCC 7606-7615 Single-mismatch 0.9 ± 0.1 1.2 ± 0.2 1.0 ± 0.1 
2  ACATA TTTTGAACAA TTGGC 7559-7568 Single-mismatch 0.9 ± 0.2 1.1 ± 0.2 1.0 ± 0.1 
3  CTTTG GCGCATATAA GGCGC 7585-7594 Triple-mismatch 2.7 ± 0.5 3.2 ± 0.3 2.2 ± 0.2 
DNA sequences are illustrated so that the middle block represents the PA binding site along with 5 flanking nt. In 
each sequence, the underlined base is bound by imidazole/pyrrole (or pyrrole/imidazole) pair of the polyamide. 
The bold bases in column 2 correspond to mismatches according to recognition "rules." Kd values were calculated 
from DNase I experiments performed at least in triplicate (Table 3.3 and 3.4). 
 
 
PA1 PA30 PA31 
Kd 
(Hill) 
Hill 
Coeff. R 
Kd 
(Hill) 
Hill 
Coeff. R 
Kd 
(Hill) 
Hill 
Coeff. R 
Site 1 0.9 ± 0.1 1.6 ± 0.4 >0.99 1.2 + 0.2 1.8 + 0.2 >0.99 1.0 ± 0.1 2.0 ± 0.3 >0.99 
Site 2 0.9 ± 0.2 1.8 ± 0.6 1 1.1 + 0.2 2.0 + 0.3 >0.98 1.0 ± 0.1 1.6 ± 0.2 >0.99 
Site 3 2.7 ± 0.5 3.8 ± 0.8 >0.99 3.2 + 0.3 3.4 + 0.5 >0.98 2.2 ± 0.2 3.8 ± 0.8 1 
 
PA1 PA30 PA31 
Kd 
(Langmuir) R Kd (Langmuir) R Kd (Langmuir) R 
Site 1 1.0 ± 0.1 >0.98 1.4 + 0.3 >0.98 1.3 + 0.4 >0.97 
Site 2 1.0 ± 0.2 >0.97 1.3 + 0.3 >0.96 1.3 + 0.3 >0.99 
Site 3 3.5 ± 0.5 >0.92 6 + 1 >0.95 2.9 + 1.5 >0.95 
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statistics of multi-site binding. The results would likely have been that some Hill Kd 
values and coefficients would have decreased, and others would have increased. 
However, we were not convinced that our data would hold up to the introduction of so 
many additional parameters (a Hill coefficient per binding site and orientation), and did 
not believe that the outcome would change significantly in a scientific sense with a more 
precise handling of the statistical question. We will revisit this with more complete data 
sets for multiple compounds to test whether our approximation, which is normal in 
polyamide literature,1-11 is suitable or not.  
Thus, large antiviral hairpin PAs tolerate reportedly unfavourable DNA interactions 
without a significant decrease in binding affinity, which agrees with our prior work on 
HPV16.41,42 In fact, in that prior work we found for 14-ring PA1 that numerous 
“mismatch” sites were bound with higher affinity than so-called canonical sites. Also, up 
to four mismatches were tolerated with 2 nM dissociation constants identical to numerous 
“perfect-match” sites. For a larger, 20-ring antiviral polyamide (PA25), four mismatches 
were even more common than with PA1, leading to a complete blanketing of the HPV16 
Long Control Region when only sparse binding, at best, was predicted.42 
Data for HPV18-polyamide binding to a large portion of the LCR are reported here 
(also see Figure SI3.2) allow us to expand our understanding (polyamide-HPV18 
binding was previously reported for the E2-protein binding sites).16 We hypothesize that 
a deviation from established binding rules occurs for our unusually large hairpin PAs 
because they form many H-bonds with DNA and significant internal π-stacking 
compared to the smaller PAs typically found in the literature.51 Thus, a few unfavourable 
enthalpic interactions are likely insignificant. The entropy of binding is likely very 
favourable for long PAs from the loss of many water molecules previously resident in the 
minor groove and from loss of exposed nonpolar surface area upon π-stacking. Entropy 
and enthalpy are being determined by the CM Dupureur group. Since we measured 
polyamide-DNA binding properties in the context of a large, natural DNA sequences 
instead of a small artificial, DNA sequences designed to examine sequence preferences at 
a single location, our results are much more complex than those found in the literature. 
Published binding rules are not obeyed in our system with significant fidelity, and 
“mismatches” are very well tolerated (see also He et al.41 and Qiao et al.52). 
Binding sites for PA1, PA30, and PA31 in a region of HPV18 DNA spanning nt 
7601-7620 are shown in Figure 3.4A. In this part of the viral genome, there are two 
predicted single-mismatch binding sites, sequence (i) 5’-TATTAGTCAT-3’ (7606-7615) 
and sequence (ii) 5’-TAGTCATTTT-3’ (7609-7618). Our data indicate that PA1 and 
PA31 bind both of these sites, while PA30 only binds to (i). 
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Raw DNase I footprinting data of dsDNA (top strand) is shown in Figures 3.4B 
(control) and 3.4C (5 nM PA). Inspection of the footprints generated by the three PAs 
reveals subtle differences in the protected regions. For instance, the peaks at the left-hand 
edge of the protected region corresponding to nt 7606-09 (Figure 3.4* shows 7606) 
display increased nuclease accessibility in the case of PA1 vs. PA30 and PA31. At the 
right-hand edge of the protected region, the peak corresponding to nt 7619 (Figure 
3.4C†) is less protected from DNase I by PA30 (Figure 3.4C middle panel) than by 
PA1 (Figure 3.4C left panel) at equivalent PA concentrations. In contrast, PA31 affords 
more-extended nuclease protection than either PA1 or PA30, with a footprint including 
extra nt 7619-7626; this extra nuclease protection corresponds to the double-mismatch 
Figure 3.4. PA1, PA30 and PA31 Binding Sites on HPV18 (7600-7620 bp). (A) Binding sites for PA1,
PA30, and PA31 from a section of HPV18 LCR corresponding to 7600-7620 as determined by capillary
electrophoresis, DNase I footprinting and AC. The relative heights above the DNA sequence correspond to
observed AC intensities. The remaining panels show the top strand of ten more base pairs than panel A, 7600–
7630. Representative electropherograms showing the top strand for (B) DNase I footprinting controls (0 nM
PA), (C) DNase I-protected regions upon the addition of 5 nM of PA and (D) AC patterns at 50 nM PA. The
red line below each plot corresponds to the DNA sequence shown in panel (A). The * and † symbols mark nt
7606 and 7619. Arrows inside the plots show the PA binding direction, with the arrowhead in the position of
the PA tail. PA building blocks as defined in Figure 3.1; TMG and Guan groups are open and filled triangles.
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site (iii) at 7612-7621. For steric reasons, the TMG group of PA30 may not be bound to 
DNA, making it less sequence-specific than PA1 and PA31.  
Footprinting differences are supported by affinity cleavage (AC) results.53 Patterns 
generated by PA1-, PA30- and PA31-EDTA conjugates are given in Figure 3.4D. For 
PA1 and PA31 there are two binding events, each corresponding to a distinct AC pattern, 
agreeing with DNase I data that both PAs bind at both available single-mismatch sites, (i) 
and (ii). However, an extra AC pattern was observed for PA31 corresponding to the 
double mismatch site (iii). Conversely, only one of the predicted single-mismatch sites is 
occupied by PA30: a single AC pattern corresponding to site (i) was observed. The AC 
pattern for site (ii) did not appear even upon increasing the concentration of PA30 from 
50 nM to 200 nM (data not shown). Our results with these 14-ring PAs agree with 
previous 8-ring PAs studies reporting that substitution at the N-terminal imidazole can 
modulate orientation and DNA-binding preferences of hairpin polyamides.54,55 
3.5 CONCLUSIONS 
 
In summary, we show that N-terminal substitution of anti-HPV polyamide PA1 
improves antiviral activity against the two high-risk HPV types that are most prevalent 
(HPV16 and HPV18). N-terminal substitution with TMG gives PA30 and leads to 
improvement in anti-HPV activity (IC50) against HPV18. N-terminal substitution with 
guanidinium itself gives PA31 with enhanced anti-HPV activity even further relative to 
PA1 by decreasing IC50 against HPV18 and IC90 for both HPV16 and HPV18. For 
antiviral agents in general, a dosage above IC90 decreases viral load, magnitude, and 
frequency of viral rebound,56 and the probability of viral mutation, so improvements in 
IC90 are significant for therapy, as they are for EC90.57  
Although the dissociation constants for the reported PAs are similar and cannot 
account for the differences in antiviral activity, differences in PA-DNA binding 
distribution were observed: PA31 binds more sites on the LCR of HPV18 than PA1 or 
PA30. Binding kinetics may be more important for activity58,59 and remain under 
investigation. Polyamide uptake is also under investigation. We note that PA1 and its 
analogues PA30 and PA31 are among the smallest molecules in a library of 75+ active 
compounds that reach nearly twice the molecular weight of PA1. We have also prepared 
a series of compounds based on the highly-active PA25 and other active series, and they 
will be described subsequently. PA25 was our second preclinical lead because of its 
IC50/IC90 data (μM) as follows: HPV16, 0.036/0.35; HPV18, 0.056/1.5; HPV31, 
0.030/0.51.27,47 The first biophysical studies of PA25 were reported recently.42 However, 
PA25 is a more difficult synthetic and purification challenge than PA1 and its 
derivatives, though we have scaled up both PA1 and PA25 to 10 g, and the cost-of-goods 
is much higher for the 20-ring PA25 than the 14-ring PA1, so we were interested to see if 
modifications to PA1 could increase its activity significantly. That goal was successful 
with PA31. 
Long hairpin polyamides of this general class function by a novel polyamide 
mechanism that invokes the host DNA Damage Response to destroy the viral 
genome.23,24,30 Their activity is not limited to HPV but is also found for other small, 
double-stranded DNA tumour viruses, including polyomaviruses.47 This mechanism is 
unrelated to any prior polyamide literature that we can determine, even though our work 
was initially inspired by early PA research. PA30/31 represent an improved class of long 
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polyamide that invokes this new mechanism to combat cancer-causing HPV. More 
recently, Dervan has reported a similar, non-sequence-specific, polyamide-induced DNA 
Damage Response.60 
Why might this nonspecific binding, or poorly-specific binding, be so relevant? We have 
come to hypothesize and are performing experiments to test the idea, that the interaction 
of large polyamides with small, circular, double-stranded DNA genomes is biologically 
important more from physical than chemical reasons. Hydrogen bonding does go on in 
the minor groove, albeit at moderate selectivity, but of great importance is the binding of 
many hundreds or more of rigid, crescent-shaped molecules to supercoiled DNA targets. 
This must result in considerable strain on the supercoiled viral genomes, and could in the 
most extreme case result in single-stranded DNA regions appearing, which would be 
rapidly noticed and acted upon by the DNA Damage Response machinery. However, the 
process may be simpler: the dsDNA viruses evolved to use parts of the DDR for their life 
cycles but otherwise to hide, to avoid having their genomes recognized as foreign or 
damaged in any way. When the supercoiled genomes are distorted by the effect of many 
bound polyamides, and 50 % of HPV DNA is bound by active polyamides, at least for the 
linearized pieces we have reported on to date,29,41,42 the viral genome may no longer 
remain hidden. The strain imposed by all of the bound polyamides may change the shape 
enough so that the DDR naturally notices unwanted additions to the chromatin and is 
automatically activated. Support for this hypothesis is found in our recently published 
patent application, where, as mentioned above, we showed that the same polyamides 
active against HPV are also active against three polyomaviruses having little in common 
with HPV except a small, dsDNA genome that is supercoiled.47 The DNA Damage 
Response is also altered for these disparate viruses.  
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3.8  SUPPLEMENTAL INFORMATION 
3.8.1 Dose-Response Curves for PA1 against HPV16 and HPV31 
 
 
  
 
 
 
 
 
 
 
 
A 
B 
Figure SI3.1. Dose‐Response Curves for PA1 against HPV16 and 31 from which IC50 and IC90 Values
were Determined. (A) Results for HPV16 and 31 with cell toxicity data. (B) Expanded detail of results for
HPV16, plotted as the inverse of the other results (as the percent decrease of viral DNA vs. control, reaching
100 % decrease at maximum efficacy, instead of the simple decrease in DNA vs. control). 
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3.8.2 Sequence Map of PA30 Affinity Cleavage and DNase I Footprinting in the 
7479-7783 bp LCR Region of HPV18 
 
 
Figure SI3.2. PA30 Binding Sites and Hill-Calculated Equilibrium Dissociation Constants at 200 pM of
the 305 bp (7479-7783) HPV18 DNA Fragment. The DNA duplex for the 305 bp HPV18 DNA fragment is
shown along with PA30 hairpin polyamide represented as arrows at its respective binding sites (see inset).
PA30 is depicted with either a solid arrow (forward orientation) or a dashed arrow (reverse orientation). HPV
E2 binding sites are depicted in green boxes. HPV E1 binds in the region flanked by the first and second E2
binding sites. The origin of replication is marked with 1. Numbers on the left correspond to the nucleotide
position in HPV18 genome. Equilibrium dissociation constants calculated using the Hill equation from the
FAM (blue) and HEX (green) channel of CE at the particular nucleotide are given. The sample standard
deviations are in parentheses. PA30 binding orientations were determined by affinity cleavage. Affinity
cleavage patterns observed at 50 nM and 100 nM PA (not observed at 50 nM) are shown as black and red
vertical arrows (n = 3). Yellow highlighted sequences represent footprinting regions observed at 5 nM PA30;
whereas, gray highlighted sequences represent footprinting regions observed at 10 nM PA30 (n = 5).   
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3.8.3 PA30 Equilibrium Dissociation Constants on HPV18 LCR 7479-7783 bp  
  
Table SI3.1 summarizes only the higher affinity sites (PA30 DNase I footprinting at 
5 nM PA / Affinity cleavage patterns at 50 nM PA) in the HPV18 LCR region 
corresponding to 7479-7783 bp. DNase I footprinting experiments conducted at 200 pM 
DNA and affinity cleavage experiments at 1 nM DNA. 
 
   Table SI3.1. PA30 Binding Sites on HPV18 LCR Fragment Corresponding to 7479-7783 bp.  
AC 
site # Sequence Position 
Site 
type 
Binding 
orientation 
Integration 
nt 
Kd (nM) 
DNase I 
1 TTGCA AACTTTAATC TTTTG 7527-7536 Double Forward 7535 0.9 + 0.2
   Single Forward  
2 CCCAA AAGATTAAAG TTTGC 7538-7529 Single Forward  
3 GCTCC TACATATTTT GAACA 7553-7562 Single Forward 7557 4.2 + 0.6
   Perfect Reverse   
4 ATATT TTGAACAATT GGCGC 7561-7570 Double Forward 7566 1.1 + 0.2 
5 AATTG TTCAAAATAT GTAGG 7565-7556 Single Forward   
   Perfect Reverse   
6 GCCAA TTGTTCAAAA TATGT 7568-7559 Single Forward   
10 GGAAA ATGACTAATA CCAGG 7615-7606 Single Forward 7613 1.1 + 0.1 
12 TGCGC TACAACAATT GCTTG 7634-7643 Double Forward 7642 1.2 + 0.1 
   Perfect Reverse   
13 TATGC AAGCAATTGT TGTAG 7647-7638 Double Forward   
13 ATTGC TTGCATAACT ATATC 7646-7655 Double Forward 7655  1.1 + 0.1 
14 AGTGG ATATAGTTAT GCAAG 7659-7650 Double Forward   
14 GGGAG TGGATATAGT TATGC 7822-7813 Double Forward   
15 TCCCT AAGTAATAAA ACTGC 7669-7678 Perfect Forward 7672 0.5 + 0.2 
16 AAAAG CAGTTTTATT ACTTA 7682-7673 Single Forward   
17a GGCAC ATATTTTAGT TTGTT 7694-7703 Double Forward 7699 0.7 + 0.2 
17a GCACA TATTTTAGTT TGTTT 7695-7704 Double Forward   
17a CACAT ATTTTAGTTT GTTTT 7696-7705 Double Forward   
19 TTAAG TAAAAACAAA CTAAA 7712-7703 Double Forward 7711 0.8 + 0.1 
19 AGCTT AAGTAAAAAC AAACT 7715-7706 Single Forward   
20 GCAAT TAGCTTAAGT AAAAA 7721-7712 Double Forward   
21 TTGGC TTGTACAACT ACTTT 7736-7745 Double Forward ND ND 
The affinity cleavage (AC) site # corresponds to the AC patterns in the map provided in Figure SI3.2. The PA30 
binding sequences are given in a 5’ to 3’ direction and include 5 nucleotide (nt) flanking regions. The bold nt 
highlights the position where the polyamide imidazole/pyrrole pair binds. The position corresponds to the HPV18 
genomic nucleotides. The forward binding orientation refers to alignment of the polyamide N-terminus to C-
terminus vector with the 5’-3’ direction of the DNA, whereas a reverse orientation describes the polyamide NC 
vector alignment with the 3’5’ direction of the DNA.      
 
ND, Not determined. Site 21 is found at the end of the fragment.                                    
a A single binding event cannot be assigned due to significant overlap of the predicted PA30 recognition sequences. 
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3.8.4 PA30 Predicted, But Not Observed Single-base-pair Mismatch Sites on 
HPV18 LCR 7479-7783 bp 
 
Table SI3.2. PA30 Predicted Single-Base-Pair Mismatch Sites Which Were Not Observed on HPV18 LCR 
Fragment Corresponding to 7479-7783 bp. 
 Sequence Position Binding orientation Comment 
 GGTAT TAGTCATTTT CCTGT 7609-7618 Forward No AC
 TTAGG CACATATTTT AGTTT 7691-770 Reverse No AC
 AAACA AACTAAAATA TGTGC 7704-7695 Forward No ACa 
 TATTT TAGTTTGTTT TTACT 7700-7709 Forward No AC 
 TTAGT TTGTTTTTAC TTAAG 7704-7713 Forward No ACa 
PA30 was predicted to bind these sequences with single-base-pair mismatches; however, these sequences did not 
generate affinity cleavage (AC) patterns and/or footprints (FP).   
a The affinity cleavage pattern for Site 18, a predicted PA30 reverse match (perfect) sequence and a single-base-pair 
mismatch, was only observed at 100 nM of PA-EDTA conjugate. 
The differences that we observe between PA1 and PA30 may be due to a steric clash 
between TMG and the Ta tail, leading to a 180o rotation of the last C-terminal pyrrole 
ring (where the β-ala / tail is attached) and exclusion of the tail from the minor groove. 
Consequently, a mixed population of conformers with the normal pyrrole ring 
conformation and the rotated form may be present during the PA30 experiments. In the 
case of rotated C-terminal pyrrole conformers, the favorable contacts between the minor 
groove and the Ta tail are not present, leading to both a decrease in affinity (may explain 
the reduced AC pattern reduction/disappearance at some sites) and an increased 
preference for reversed binding orientations.55 Further analysis of the data is required to 
validate this hypothesis.  
3.8.5 Representative PA30 Isotherms Obtained from Quantitative DNase I 
Footprinting Sites Along the DNA Fragment Corresponding to 7479-7783 bp 
of the HPV18 LCR 
 
SITE #1 & 2 (Integration nt: 7535; Reference nt: 7603 in FAM Channel) 
 
                 Trial #1                                                           Trial #2 
0
0.2
0.4
0.6
0.8
1
0 2 4 6 8 10
CHC2064 PA30 HPV18 LCR (7479-7783 bp) (0.2 nM DNA)
7535 / 7603
Fra
ctio
n B
ou
nd
PA30 [nM]
y = m1*m2*m0/(1+m1*m0)
ErrorValue
0.158840.74161m1 
0.0646241.1184m2 
NA0.02996Chisq
NA0.98487R
y = (m1*m0)^m2/(1+(m1*m0)^m2...
ErrorValue
0.0607780.87671m1 
0.167971.6115m2 
NA0.011226Chisq
NA0.99436R
0
0.2
0.4
0.6
0.8
1
0 2 4 6 8 10
CHC2065 PA30 HPV18 LCR (7479-7783 bp) (0.2 nM DNA)
7535 / 7603
Fra
cti
on
 Bo
un
d
PA30 [nM]
y = (m1*m0)^m2/(1+(m1*m0)^m2...
ErrorValue
0.0599381.2031m1 
0.170381.9091m2 
NA0.0063282Chisq
NA0.99682R
y = m1*m2*m0/(1+m1*m0)
ErrorValue
0.282611.146m1 
0.0630651.1053m2 
NA0.03841Chisq
NA0.98052R
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                            Trial #3                                                           Trial #4 
0
0.2
0.4
0.6
0.8
1
0 2 4 6 8 10
CHC2071 PA30 HPV18 LCR (7479-7783 bp) (0.2 nM DNA)
7535 / 7603
Fra
ctio
n B
ou
nd
PA30 [nM]
y = (m1*m0)^m2/(1+(m1*m0)^m2...
ErrorValue
0.149670.9837m1 
0.211761.1146m2 
NA0.025314Chisq
NA0.98284R
y = m1*m2*m0/(1+m1*m0)
ErrorValue
0.167720.80767m1 
0.065971.0877m2 
NA0.019766Chisq
NA0.98663R
 
0
0.2
0.4
0.6
0.8
1
0 2 4 6 8 10
CHC2072 PA30 HPV18 LCR (7479-7783 bp) (0.2 nM DNA)
7535 / 7603
Fra
ctio
n B
ou
nd
PA30 [nM]
y = (m1*m0)^m2/(1+(m1*m0)^m2...
ErrorValue
0.0707021.1139m1 
0.100861.2585m2 
NA0.005859Chisq
NA0.99653R
y = m1*m2*m0/(1+m1*m0)
ErrorValue
0.12791.0398m1 
0.0311171.0551m2 
NA0.0087947Chisq
NA0.99479R
  
 
 
 
 
 
 
 
                              Trial #5                                SITE #1 & 2 FAM: All Trials (Hill fit)                            
  
0
0.2
0.4
0.6
0.8
1
0 2 4 6 8 10
CHC2073 PA30 HPV18 LCR (7479-7783 bp) (0.2 nM DNA)
7535 / 7603
Fra
ctio
n B
ou
nd
PA30 [nM]
y = (m1*m0)^m2/(1+(m1*m0)^m2...
ErrorValue
0.214181.4205m1 
0.183431.1001m2 
NA0.021031Chisq
NA0.98714R
y = m1*m2*m0/(1+m1*m0)
ErrorValue
0.229581.275m1 
0.0419571.0485m2 
NA0.018124Chisq
NA0.98893R
 
0
0.2
0.4
0.6
0.8
1
0 5 10 15 20
HPV18 (7479-7783) CHC2064, 65, 71, 72, 73
7535 / 7603
7535 / 7603
7535 / 7603
7535 / 7603
7535 / 7603
Fra
ctio
n B
ou
nd
PA30 [nM]    
 
 
 
 
 
132 
 
SITE #1 & 2 (Integration nt: 7530; Reference nt: 7625 in HEX Channel) 
 
                 Trial #1                                                           Trial #2 
0
0.2
0.4
0.6
0.8
1
0 5 10 15 20
CHC2064 PA30 HPV18 LCR (7479-7783 bp) (0.2 nM DNA)
7530 / 7625
Fra
ctio
n B
ou
nd
PA30 [nM]
y = (m1*m0)^m2/(1+(m1*m0)^m2...
ErrorValue
0.0528210.73599m1 
0.299862.208m2 
NA0.014743Chisq
NA0.99241R
y = m1*m2*m0/(1+m1*m0)
ErrorValue
0.280610.6356m1 
0.156681.122m2 
NA0.094021Chisq
NA0.95054R
 
0
0.2
0.4
0.6
0.8
1
0 5 10 15 20
CHC2065 PA30 HPV18 LCR (7479-7783 bp) (0.2 nM DNA)
7530 / 7625
Fra
ctio
n B
ou
nd
PA30 [nM]
y = (m1*m0)^m2/(1+(m1*m0)^m2...
ErrorValue
0.211470.96814m1 
0.326451.1086m2 
NA0.039041Chisq
NA0.97263R
y = m1*m2*m0/(1+m1*m0)
ErrorValue
0.228840.77521m1 
0.0957391.0987m2 
NA0.031712Chisq
NA0.97782R
  
 
 
 
 
 
 
 
 
             
                            Trial #3                                                           Trial #4 
 
0
0.2
0.4
0.6
0.8
1
0 5 10 15 20
CHC2071 PA30 HPV18 LCR (7479-7783 bp) (0.2 nM DNA)
7530 / 7625
Fra
ctio
n B
ou
nd
PA30 [nM]
y = (m1*m0)^m2/(1+(m1*m0)^m2...
ErrorValue
0.128821.194m1 
0.232591.4889m2 
NA0.020915Chisq
NA0.98875R
y = m1*m2*m0/(1+m1*m0)
ErrorValue
0.230471.0914m1 
0.0544541.0946m2 
NA0.027779Chisq
NA0.98503R
0
0.2
0.4
0.6
0.8
1
0 2 4 6 8 10
CHC2072 PA30 HPV18 LCR (7479-7783 bp) (0.2 nM DNA)
7530 / 7625
Fra
ctio
n B
ou
nd
PA30 [nM]
y = (m1*m0)^m2/(1+(m1*m0)^m2...
ErrorValue
0.206271.4718m1 
0.25661.3574m2 
NA0.020943Chisq
NA0.987R
y = m1*m2*m0/(1+m1*m0)
ErrorValue
0.220151.1821m1 
0.0545881.1301m2 
NA0.014144Chisq
NA0.99124R
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       SITE #1 & 2 HEX: All Trials (Hill fit)                                       
0
0.2
0.4
0.6
0.8
1
0 5 10 15 20
HPV18 (7479-7783) CHC2064, 65, 71, 72
7530 / 7625
7530 / 7625
7530 / 7625
7530 / 7625
Fra
ctio
n B
ou
nd
PA30 [nM]   
 
 
 
 
 
 
 
 
 
 
SITE #10 (Integration nt: 7613; Reference nt: 7603 in FAM Channel) 
 
                 Trial #1                                                           Trial #2 
0
0.2
0.4
0.6
0.8
1
0 2 4 6 8 10
CHC2064 PA30 HPV18 LCR (7479-7783 bp) (0.2 nM DNA)
7613 / 7603
Fra
ctio
n B
ou
nd
PA30 [nM]
y = (m1*m0)^m2/(1+(m1*m0)^m2...
ErrorValue
0.0365430.81854m1 
0.219532.2775m2 
NA0.0046154Chisq
NA0.99733R
y = m1*m2*m0/(1+m1*m0)
ErrorValue
0.268750.86501m1 
0.0810561.1175m2 
NA0.038964Chisq
NA0.97721R
 
0
0.2
0.4
0.6
0.8
1
0 2 4 6 8 10
CHC2065 PA30 HPV18 LCR (7479-7783 bp) (0.2 nM DNA)
7613 / 7603
Fra
ctio
n B
ou
nd
PA30 [nM]
y = (m1*m0)^m2/(1+(m1*m0)^m2...
ErrorValue
0.0937890.89688m1 
0.285441.7087m2 
NA0.022631Chisq
NA0.9875R
y = m1*m2*m0/(1+m1*m0)
ErrorValue
0.20260.73605m1 
0.0959771.1568m2 
NA0.039206Chisq
NA0.97825R
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                 Trial #3                                                           Trial #4 
0
0.2
0.4
0.6
0.8
1
0 2 4 6 8 10
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NA0.98197R
y = (m1*m0)^m2/(1+(m1*m0)^m2...
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0.0620950.89073m1 
0.201341.786m2 
NA0.012734Chisq
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y = m1*m2*m0/(1+m1*m0)
ErrorValue
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NA0.97696R
  
 
 
 
 
 
 
 
 
 
                           Trial #5                                     SITE #10 FAM: All Trials (Hill fit)                             
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NA0.99825R
y = m1*m2*m0/(1+m1*m0)
ErrorValue
0.0825050.76887m1 
0.031911.1158m2 
NA0.0075041Chisq
NA0.99603R
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SITE #12 & 13 (Integration nt: 7647; Reference nt: 7625 in HEX Channel) 
 
                   Trial #1                                             Trial #2 
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NA0.011363Chisq
NA0.99465R
y = m1*m2*m0/(1+m1*m0)
ErrorValue
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y = m1*m2*m0/(1+m1*m0)
ErrorValue
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NA0.088471Chisq
NA0.96259R
   
                  Trial #3                                              Trial #4 
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   SITE #12 & 13 HEX: All Trials (Hill fit)      
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Figure SI3.3. Representative PA30 Binding Isotherms Obtained from Quantitative DNase I Footprinting Sites
Along the DNA Fragment Corresponding to 7479-7783 bp of the HPV18 LCR. Binding isotherms for each trial of
PA30 are plotted. Calculated parameters for the Langmuir (top inset table) and the Hill (bottom inset table) equation
(KaleidaGraph 4.1 software).  Summary plots are fitted using the Hill equation. 
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Chapter 4 
 
In vitro Genome-wide Mapping of a Potent Antiviral Hairpin Polyamide (PA1) to 
Human Papillomavirus 16 using Hydroxyl Radical Footprinting Coupled to Massively 
Parallel DNA Sequencing (∙OH-Seq) 
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4.1 ABSTRACT 
 
PA1 is a cell-permeable, minor groove binder that belongs to the hairpin polyamide class 
of compounds. PA1 targets the DNA sequence 5’-W2GW7 (where W = A or T) according 
to the established polyamide-DNA recognition rules. PA1 was rationally designed to 
target A/T-rich DNA sequences near the HPV16 (human papillomavirus 16) origin of 
replication essential for both viral transcription and replication. PA1 exhibits apparent 
IC50/IC90 values of 0.1/1.1 µM against HPV16 in monolayer keratinocyte cultures 
without measurable cytotoxicity. Here, we have employed hydroxyl radical footprinting 
coupled to massively parallel DNA sequencing (·OH-Seq) to map the genome-wide 
binding events of PA1 onto the HPV16 genome in vitro (cell-free) as a preliminary stage 
prior to our cell-based studies. 
 
4.2 INTRODUCTION 
 
4.2.1 Deciphering Specific Interactions in DNA-Ligand Complexes by 
Footprinting Methods 
 
Gene expression and DNA replication are tightly regulated by the specific formation 
of DNA and protein complexes. Thus, deciphering the occupancy of DNA-binding 
proteins to their cognate binding sites is of great importance toward the understanding of 
these fundamental cellular processes. Footprinting methods are widely used for the 
interrogation of specific DNA-protein interactions.1,2 In these techniques, a DNA 
fragment harboring the sequence of interest is end-labelled, either radioactively with 32P 
or fluorescently for visualization purposes. The DNA fragment is then subjected to mild 
digestion by an enzymatic or chemical cleavage agent, both in the presence and absence 
of a DNA-ligand. The fragmented DNA is separated by electrophoresis and the cleavage 
patterns are compared between the naked and ligand-bound DNA samples. Binding of the 
ligand to its recognition site, or cognate sequence, leads to increased protection of DNA 
at that particular location, providing a ‘footprint’.1,2 DNase I footprinting pioneered by 
Galas and Schmitz3 provides a powerful yet simple technique for deciphering the specific 
contacts in DNA-protein complexes. This method has been successfully employed to 
determine the sequence selectivity of numerous DNA-ligands including intercalators,4-7 
transcription factors,8-10 and minor groove DNA binders.4,5,7,11,12 
DNase I footprinting relies on the enzymatic cleavage of DNA by the endonuclease 
DNase I.2,3 Although DNase I is often preferred as a cleavage agent due to its ease of use, 
the nature of its DNA-binding properties presents some disadvantages. For instance, the 
cleavage pattern generated by DNase I often exhibits uneven cleavage of the 
phosphodiester backbone as a result of local sequence-dependent structural motifs. Thus, 
regions of DNA that are poor substrates for DNase I fail to provide information about 
ligand binding. In addition, DNase I is relatively large, with a DNA-binding surface of 
approximately 10 bp, which causes overestimation of ligand binding site sizes and poor 
resolution of multiple ligands bound in close proximity of each other.1,2,13  
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4.2.2 Hydroxyl Radical Footprinting 
 
Due to the disadvantages of DNase I footprinting, various smaller cleavage 
reagents14-17 have been introduced for the determination of DNA structure and DNA-
ligand interactions. The development of hydroxyl radicals as a high-resolution chemical 
probe has allowed the elucidation of nucleic acid structure18-21 and nucleic acid-protein 
complexes at nucleotide-resolution.16,22-26 In particular, hydroxyl radicals are small, 
charge-neutral, and highly reactive species that attack deoxyribose hydrogen atoms in a 
sequence-independent manner.27,28 These qualities cause a more intimate attack of DNA 
providing high-resolution single-nucleotide information of the ligand-nucleic acid 
interactions. Furthermore, the flexibility and relative ease of hydroxyl radical generation 
allows for footprinting of small molecules and proteins in solution via Fenton 
chemistry16,22 or ionizing radiation.23,24  
The highly-reactive hydroxyl radical moiety is produced by the Fenton reaction 
between ferrous iron (Fe2+) and hydrogen peroxide (H2O2) (Equation 4.1). Reduction of 
H2O2 by the [Fe(II)(EDTA)]2- complex leads to the production of a hydroxide ion (OH-), 
[Fe(III)(EDTA)]- and the hydroxyl radical (·OH). Addition of sodium ascorbate reduces 
Fe(III) to regenerate Fe(II), affording a reaction catalytic in iron. Furthermore, the 
negatively charged [Fe(II)(EDTA)]2- complex prevents direct electrostatic interactions 
between the metal ions and the negatively charged DNA backbone.25  
 
ሾFeሺIIሻሺEDTAሻሿଶି ൅ HଶOଶ			 → 			ሾFeሺIIIሻሺEDTAሻሿି ൅ OHି ൅	൉ ۽۶														(4.1)          
 
Once the hydroxyl radical is generated, it quickly reacts with the DNA backbone in a 
sequence-independent fashion by abstracting a solvent accessible hydrogen atom from 
the deoxyribose sugar, leading to cleavage of the DNA backbone at this position.28 The 
extent of cleavage in a given position relates to either steric factors or the conformation 
of the deoxyribose along with the stability of the radical generated upon hydroxyl radical 
attack. Specifically, kinetic isotope effect studies of nucleotides deuterated separately at 
each deoxyribose position revealed that the degree of reactivity of hydroxyl radical 
toward the different hydrogen atoms correlated with their solvent accessibility within the 
DNA backbone (5’ H > 4’ H > 3’ H ~ 2’ H ~ 1’ H)27,28 (Figure 4.1). 
 
 
  
The reaction products of the oxidative damage of DNA by hydroxyl radicals are 
comprised of single-stranded breaks along the DNA duplex. Thus far, three DNA lesions 
generated by a hydroxyl radical attack have been characterized: 1) a single-nucleoside 
Figure 4.1. Chemical Structure of a Single DNA Nucleotide. Theoretically, hydroxyl radical attack can occur at any
of the seven deoxyribose hydrogen atoms. However, their respective reactivity toward the oxidizing agent is correlated
to their relative accessibilities (5’ H > 4’ H > 3’ H ~ 2’H ~ 1’H). 
ascorbate
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gap flanked by two phosphates (Figure 4.2 Top), 2) a single-nucleoside gap flanked by a 
5’ phosphate and a 3’ phosphoglycolate (Figure 4.2 Middle) and 3) a single-stranded 
nick flanked by a 5’ aldehyde and a 3’ phosphate (Figure 4.2 Bottom).20,25,27 
 
  
  
Analysis of the cleavage reaction products has typically been conducted by high-
resolution polyacrylamide gel electrophoresis (PAGE). Alternate approaches relying on 
fragment analysis by automated capillary electrophoresis (CE) have provided several 
advantages over PAGE.29,30 Importantly, the high-throughput nature of CE allows 
multiple samples to be analyzed concurrently. Furthermore, detection of the fragmented 
DNA by CE relies on fluorescent dyes, eliminating the use of radioisotopes. However, 
both of these analyses are severely limited by the length of DNA that can be interrogated 
and require prior sequence indexing in order to accurately map DNA-ligand binding 
regions.31 Here we present the use of massively parallel DNA sequencing as an attractive 
alternative to analyze hydroxyl radical footprinting cleavage products. 
  
4.2.3 Next-Generation Sequencing 
 
With the advent of next-generation sequencing (NGS), it is now possible to sequence 
millions of nucleotides in a high-throughput and cost-effective manner. Consequently, 
NGS has allowed for novel approaches to answer scientific inquiries in the areas of high-
Figure 4.2. Chemical Structures of the Lesions Generated by Hydroxyl Radical DNA Cleavage. Abstraction of a
deoxyribose hydrogen atom produces single-stranded nicks (~50 %) and gaps (~50 %) along the DNA duplex.
Depending on the site of hydroxyl radical attack, the resulting reaction products consist of a single-nucleoside gap
flanked by two phosphates (40 %) (Top), a single-nucleoside gap flanked by a 5’ phosphate and a 3’ phosphoglycolate
(~10 %) (Middle), or a single-stranded nick flanked by a 5’ aldehyde and a 3’ phosphate (Bottom). P = phosphate, PG
= phosphoglycolate, A = aldehyde. 
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throughput genome-wide sequencing,32 transcriptome profiling,33 transcription factor 
discovery9,34 and genome-wide mapping of small molecules.35,36  
The typical next-generation sequencing workflow consists of four steps: 1) library 
preparation from randomly fragmented DNA, 2) cluster generation on a solid surface, 3) 
sequencing by synthesis and 4) alignment and data analysis (Figure 4.3).37  
 
 
 
Figure 4.3. Illumina Next-generation Sequencing Technology Workflow. Illumina’s sequencing by synthesis (SBS)
chemistry affords for the sequencing of millions of DNA fragments in a massively parallel manner. (1) Library
preparation - DNA is randomly fragmented and modified at the 5’ and 3’ ends by covalent attachment of adapters. (2)
Cluster amplification – Constructed libraries hybridize to covalently bound oligos on the surface of the flow cell.
Clonal clusters are generated throughout the flow cell, in which each cluster is derived from a single fragment through
bridge amplification. (3) Sequencing by synthesis – SBS consists of the stepwise incorporation of fluorescently labeled
nucleotides by DNA polymerase, followed by identification of the incorporated nucleotide based on the emission
wavelength. The dye is then removed along with the protecting group on the 3’-OH so that the next round of SBS can
be carried out. (4) Data analysis – Sequence reads are mapped to a reference genome using an alignment program. The
aligned reads can then be subjected to other analyses determined by the basis of the scientific inquiry. 
(Figure adapted from www.illumina.com/technology/next-generation-sequencing.html) 
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Library construction entails the random fragmentation of high-molecular DNA, 
followed by ligation of distinct oligonucleotide adapters to both ends of these fragments. 
Adapters are synthetic oligonucleotides that contain specialized indexing sequences for 
multiplexing samples, as well as sequences complementary to single-stranded 
oligonucleotides covalently attached on the flow cell surface (Figure 4.4).  
 
 
 
  
After ligation, the ligated fragments are enriched by primer-specific PCR 
amplification. These adapter-ligated fragments are then denatured into single-stranded 
DNA molecules, allowing these fragments to hybridize onto the flow cell and undergo 
cluster amplification. After generation of the spatially separated clusters, DNA 
polymerase and all four nucleotides with labile-fluorescently labelled reversible 
terminators are added to initiate the first cycle of sequencing by synthesis. Because these 
nucleotides have a 3’-OH blocking group, only a single, complementary nucleotide is 
incorporated into the nascent strand. After washing of unincorporated nucleotides, the 
instrument optics scans and records the emitted fluorescence at each cluster, allowing for 
the identification of the incorporated nucleotide. At this point, chemical cleavage of the 
3’-OH blocking group in the growing strand permits the incorporation of a single 
nucleotide in the next round. The cycle is then repeated for a specific number of times, 
resulting in a “read” with known length.37,38 
 
4.2.4 Hydroxyl Radical Footprinting Coupled to Massively Parallel DNA 
Sequencing  
 
Tullius et al. introduced hydroxyl radical footprinting in 1986.16 It has evolved into a 
powerful technique to decipher the structural details of DNA-ligand interactions. Recent 
efforts by the Tullius lab have aimed at developing a modified hydroxyl radical 
footprinting method using next-generation sequencing as the readout of the cleavage 
patterns. Xu et al.18 demonstrated the feasibility of this method by studying hydroxyl 
radical cleavage patterns of genomic DNA in vitro. Using pUC18 plasmid as a model 
DNA genome, hydroxyl radicals generated by Fenton chemistry were used to fragment 
the plasmid DNA to low-molecular weight species. Because most of the commercially 
available NGS library preparation kits require intact double-stranded DNA fragments, the 
resulting single-stranded DNA breaks were subsequently processed with T7 
endonuclease I to produce double-stranded DNA breaks at hydroxyl radical attack sites. 
Using NGS as a digital readout, they obtained “genome-wide” cleavage intensities for 
plasmid pUC18 that were in agreement with the cleavage pattern predicted by ORChID 
Figure 4.4. Structural Details of Adapter-Ligated Fragment. The constructed adapter-ligated fragment consists  of
1)  DNA insert (sequence of interest) flanked by adapter constructs that contain primer binding sites, 2) unique index
sequences, and 3) sequences complementary to oligos on the flow cell surface (P5 and P7). 
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(·OH Radical Cleavage Intensity) based on the pUC18 DNA sequence. As a result, the 
use of massively parallel DNA sequencing as a digital readout for hydroxyl radical 
footprinting is highly promising. 
Here, we employ hydroxyl radical footprinting coupled to massively parallel DNA 
sequencing (·OH-Seq) to map the genome-wide binding events of PA1 onto the human 
papillomavirus 16 (HPV16) genome in vitro. PA1 is a cell-permeable, minor groove 
binder belonging to the hairpin polyamide (PA) class of compounds (Figure 4.5A). N-
methylpyrrole/N-methylimidazole (Py/Im) hairpin polyamides are synthetic 
heteroaromatic compounds inspired by the chemical structures of the natural antibiotics 
netropsin and distamycin A.12,39-43 These crescent-shaped molecules, collectively known 
as polyamides, bind with high affinity (nano- to picomolar dissociation constants) to the 
minor groove of dsDNA in a sequence-selective fashion.44-46 According to the established 
polyamide-DNA recognition rules (vide infra), PA1 targets the DNA sequence 5’-
W2GW7 (where W = A or T) by recognizing the sequence-dependent H-bonds presented 
by the Watson-Crick bases in the minor groove of B-DNA (Figure 4.5B). In this manner, 
a Py/Im pair H-bonds to a G·C (but not a C·G), whereas a Py/Py H-bonds to the 
degenerate A·T and T·A base pairs. Notably, substitution of Py heterocycles with the 
flexible β-alanine (β) substituent relieves the inherent overcurvature observed in 
polyamides with four or more contiguous heterocycles and resets the H-bond register 
between the ligand and DNA.47,48 The gamma-aminobutyric turn recognizes the 
degenerate A·T and T·A base pairs preferentially due to steric factors.49 The C-terminal 
positively-charged tail recognizes A·T and T·A base pairs and mimics the cationic 
moieties found in distamycin A and netropsin.39,49 This reported specificity is achieved 
by the optimal positioning of the H-bond acceptors and donors, van der Waals 
interactions with the walls of the minor groove, and appropriate curvature of the 
polyamide with respect to the minor groove of B-DNA.50  
 
  
  
Figure 4.5. Chemical Structure of PA1 and Watson-Crick Base Pairs. (A) Hairpin polyamide 1 (PA1) has the
sequence dIm-Py-Py-β-Py-Py-Py-γ-Py-Py-β-Py-Py-Py-Py-β-Ta (dIm = des-amino-N-methylimidazole, Py = N-
methylpyrrole, β = beta-alanine, γ = gamma-aminobutyric acid, Ta = bis(aminopropyl)N-methylamine. (B) Chemical
structure of the Watson-Crick base pairs showing the available H-bond acceptors (red electron cloud) and H-bond
donor (blue circled H) in the DNA minor groove (Top). Hydrogen boding (dashed lines) scheme for PA1-DNA
binding depicting PA1 in the minor groove of a double-stranded DNA molecule with the sequence 5’-W2GW7, where
W = A or T. Blue and red dashed lines represents PA1 H-bond acceptor and donors, respectively (Bottom).  
A  B
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Our lab and its collaborators have previously demonstrated the efficacy of PA1 as an 
antiviral agent against oncogenic human papillomavirus (HPV) types maintained in 
organotypic raft tissues and monolayer keratinocytes.51,52 HPV is a circular, double-
stranded DNA virus that infects basal keratinocytes of cutaneous and mucosal tissues.53  
To date, over 180 types have been isolated of which approximately 15 oncogenic types 
have been identified.54-56 The development of cervical cancer, the second most prevalent 
cancer affecting women worldwide, is closely associated with persistent infections of 
oncogenic HPV types.57-59 Specifically, oncogenic HPV DNA has been detected in 99.7 
% of cervical cancers, as well as in ~90 % of anal cancers and ~60 % of oropharyngeal 
(mouth and throat) cancers.60 PA1 was rationally designed to target A/T-rich DNA 
sequences near the HPV16 origin of replication essential for both viral transcription and 
replication.51 HPV16 was used as the target because it alone is responsible for 
approximately 50 % of cervical cancers worldwide.61 Treatment of monolayer 
keratinocyte cultures with PA1 for 48 h followed by quantification of viral DNA levels 
using qPCR (quantitative PCR) revealed a dose-dependent response in the decrease of 
viral DNA. Based on these results, PA1 exhibits apparent IC50/IC90 values of 0.1/1.1 µM 
against HPV16 without measurable cytotoxicity via MTT assays.51,52  
Our lab has mapped PA1 binding interactions and their respective binding affinities 
extensively by CE-based quantitative DNase I footprinting and affinity cleavage 
experiments on a number of DNA sequences derived from the natural sequence of 
different oncogenic HPV types.52,62-64 We found that PA1 binds avidly to the minor 
groove of A/T-rich sequences with nanomolar dissociation constants. Furthermore, PA1 
can tolerate PA-DNA mismatches (single- and double-base-pair) without a significant 
decrease in binding affinity. However, the technologies that we initially relied on, while 
powerful, were limited due to their scalability. Specifically, CE-based fragment analysis 
is severely limited by the length (maximum of ~350 bp) of DNA that can be interrogated. 
This fragment length is much smaller than the read-lengths amenable to CE-based DNA 
sequencing because of the stricter requirements for signal-to-noise ratios in CE data that 
integrated for quantitative DNase I footprinting than for data analyzed in a relatively 
digital manner for the Yes/No appearance of the A, C, G, or T-associated fluorescent 
dyes used in sequencing. Because the HPV16 genome consists of 7.904 kilobases, a 
minimum of 23 fragments of 350 base pairs must be amplified using specific 
fluorescently labelled primers in order to cover the entire genome. This estimate does not 
account the requirement for the fragments to overlap, since binding sites occurring at the 
beginning and end of the fragment suffer from low signal-to-noise ratios in the CE 
experiment. Additionally, the raw data obtained from the electropherograms require prior 
base pair indexing in order to accurately map the polyamide binding regions. Therefore, 
our prior approach is both labor-intensive and slow, though it was successful in 
answering fundamental questions about in binding of drug candidates to viral DNA.   
Thus, hydroxyl radical footprinting coupled to massively parallel DNA sequencing is 
an attractive approach to map the genome-wide binding events of PA1 onto the HPV16 
genome in vitro. Figure 4.6 summarizes our experimental workflow. Briefly, 
HPV16/pUC18 DNA was incubated in the presence and absence of PA1, and 
subsequently subjected to hydroxyl radicals generated by Fenton chemistry (Figure 4.6 
Top). As described above, cleavage of the DNA phosphodiester backbone by hydroxyl 
radicals leads to single-stranded breaks with various chemistries on the 5’ and 3’ ends. Of 
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these, only the fraction of fragments containing phosphate groups on both ends can be 
ligated to the NGS adapters in succeeding steps (Figure 4.6 Middle). Furthermore, a 
library preparation kit compatible with nicked samples must be employed for Illumina 
library preparation of the fragmented DNA. Therefore, an Accel-NGS 1S Plus DNA 
Library Kit (Swift Biosciences) was used for library preparation of hydroxyl radical 
footprint samples. This kit is compatible with single-stranded, denatured and nicked input 
DNA making it ideal for hydroxyl radical cleavage products. The technology employed 
by this kit relies on the ligation of a truncated adapter to the 3’ end of single-stranded 
DNA (ssDNA) fragments, followed by an extension step to facilitate the ligation of the 
second truncated adapter during the ligation step. The resulting insert flanked by 
truncated adapters is then subjected to PCR to amplify these fragments and to insert the 
indexed adapters for subsequent sequencing (Figure 4.6 Bottom Left). NGS sequencing 
was performed on these libraries using single-end, 51 base pair read length on an 
Illumina HiSeq 2500. Unique sequencing reads were then aligned to the HPV16/pUC18 
reference genome. A detailed scheme of Illumina’s NGS technology is also provided 
below (Figure 4.6 Bottom Right). Computational analysis of the aligned reads revealed 
the cleavage patterns at single-nucleotide resolution, allowing us to determine the 
genome-wide binding events of PA1 on HPV16 in vitro. 
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 Figure 4.6. Caption on next page. 
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4.3 MATERIALS AND METHODS 
 
4.3.1 Buffers and Reagents used for in vitro ·OH Footprinting Experiments 
 
Starting reagents were used without further purification, unless specifically noted. 
Autoclaved MilliQ H2O (18.2 MΩ·cm at 25 °C, Millipore Integral 10) was used in the 
preparation of all reagents. HPV16/pUC18 plasmid was obtained from Professor Paul 
Lambert’s lab. Lysogenic Broth (LB) Agar was obtained from Sigma, Catalog # L7533-
6X500ML. Glucose was purchased from Aldrich, Catalog # 158968-1KG. Ampicillin 
was purchased from Fisher Scientific, Catalog #BP1760-25. QIAGEN Plasmid Maxi kit 
was purchased from QIAGEN, Catalog # 12162. BamHI restriction enzyme (Catalog # 
R0136S, 20,000 U/mL), 1X NEBuffer 3.1 (Catalog # R7203S, 10X concentration), Gel 
Loading Dye, Blue (6X, Catalog # B7021S), 1 kb DNA ladder (Catalog # N3232S, 500 
µg/mL) were purchased from New England Biolabs. Ethylenediaminetetraacetic acid 
(EDTA) was purchased from Sigma, Catalog # E5134-100G. 1X TAE buffer consisted of 
40 mM Tris-acetate, 1 M EDTA, pH 8.0. Ethidium bromide was obtained from Spectrum 
(Catalog # E1031, 1 % solution). Low EDTA TE buffer (10 mM Tris·Cl, 0.1 mM EDTA, 
pH 8.0) was purchased from Teknova, Catalog # T0227. 1 M Tris HCl, pH 7.5 was 
obtained from Invitrogen, Catalog # 15567-027. Dimethyl sulfoxide was purchased from 
Sigma Life Science, Catalog # D2650. Ammonium iron(II) sulfate hexahydrate was 
obtained from Aldrich, Catalog # 203505-25G. Sodium ascorbate was obtained from 
(Sigma, Catalog # 11140-50G). H2O2 was purchased from Fisher Chemical, Catalog # 
H325-500, 30 % wt/vol. 0.22 µm MILLEX-GP filters were purchased from Merck 
Millipore Ltd. 100 % ethanol was obtained from Decon Laboratories, Inc., Catalog # 
2716. Agilent Bioanalyzer RNA 6000 Nanochip kit was purchased from Agilent 
Technologies, Catalog # 5067-1511. Agarose was obtained from Sigma, Catalog # 
A9539-100G. Qubit dsDNA BR (Broad-Range) Assay kit (Catalog # Q32853) and Qubit 
assay tubes (Catalog # Q32856) were obtained from Life technologies. Accel-NGS 1S 
Plus DNA Library Kit was purchased from Swift Biosciences, Catalog # DL-IL1SP-
12/48. SPRIselect reagent kit was obtained from Beckman Coulter, Catalog # B23317. 
Agilent DNA 1000 kit was obtained from Agilent Technologies, Catalog # 5067-1505. 
 
 
 
 
Figure 4.6. Hydroxyl Radical Footprinting Coupled to Illumina Massively Parallel DNA Sequencing Workflow.
HPV16/pUC18 DNA was incubated in the absence (DMSO) and in the presence of PA1. Plasmid DNA was then
fragmented by hydroxyl radicals generated by Fenton chemistry (Top). The chemical structures of the lesions generated
by hydroxyl radical DNA cleavage are provided and the adaptable fragments are represented in red fragments (Middle).
The cleavage products were then used to construct Illumina next-generation sequencing libraries using an Accel-NGS
1S Plus DNA Library Kit (Bottom Left). Sequencing was performed using an Illumina HiSeq 2500 (Bottom Right).
Sequencing is accomplished by hybridizing single-stranded library molecules to complementary oligos found on the
flow cell. After synthesis of the reverse strand, covalently attached fragments undergo cluster amplification by bridge
amplification, generating millions of the spatially separated clusters throughout the flow cell surface. At this point, the
P5 regions are cleaved, resulting in clusters composed of fragments (forward strand) attached covalently to the flow
cell via their P7 region. To initiate the sequencing cycle, the sequencing primer is added and it anneals to the P5 region.
In each cycle of SBS, nucleotides with labile-fluorescently labelled reversible terminators are added, followed by a
detection step and a deblocking step to license the incorporation of the next nucleotide. Sequencing of the index
barcode ensues by the removal of Read 1, followed by annealing of the Index sequencing primer and extension. 
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4.3.2 Polyamide Synthesis 
 
Hairpin polyamide synthesis was performed by Dr. K. J. Koeller and Dr. G. D. 
Harris, Jr. PA1 was synthesized by Boc solid-phase methods65 as previously reported in 
the literature.51  
 
4.3.3 Preparation of HPV16/pUC18 Plasmid DNA 
 
4.3.3.1 Amplification and Purification of HPV16/pUC18 Plasmid DNA 
 
The HPV16/pUC18 plasmid was obtained from Professor Paul Lambert’s lab.66 The 
plasmid consists of the full HPV16 genome from W12E keratinocyte cells (GenBank 
Accession No. AF125673) that has been cloned into the BamHI restriction site of the 
pUC18 vector (total length = 10589 bp). Because the BamHI restriction site (which 
cleaves the 5’ guanine on each DNA strand of the sequence 5’-GGATCC-3’) occurs 
within the open reading frame of L1, cloning of the HPV16 genome into the pUC18 
vector leads to the disruption of the L1 coding region (Figure 4.7). HPV16/pUC18 
plasmid DNA66 was amplified in transformed JM109 Escherichia coli cells in 1 % 
glucose/LB media (Aldrich, Catalog # 158968-1KG / Sigma, Catalog # L7533-
6X500ML) containing ampicillin (Fisher Scientific, Catalog #BP1760-25). Plasmid DNA 
was then purified from the harvested cells using a QIAGEN Plasmid Maxi kit (QIAGEN, 
Catalog # 12162) and further concentrated by ethanol precipitation. Plasmid DNA 
concentration was determined by measuring the absorbance at 260 nm using a Thermo 
Scientific Evolution 260 Bio UV-visible spectrophotometer. 
 
 
  
4.3.3.2 Restriction Digests of HPV16/pUC18 Clones 
 
To confirm that the correct HPV16/pUC18 DNA plasmid was amplified, a restriction 
digest using BamHI restriction enzyme (NEB, Catalog # R0136S, 20,000 U/mL) was 
Figure 4.7. HPV16/pUC18 Plasmid Map. Plasmid construct used for the in vitro ·OH-Seq experiments. The HPV16 
coding regions are given with their respective positions within the construct. Cloning of the full genome of HPV16 into
pUC18 disrupts the L1 gene coding region.  
10589 bp 
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performed on the purified DNA for an hour at 37 °C in 1X NEBuffer 3.1 (NEB, Catalog 
# R7203S, 10X concentration). The reaction products produced by BamHI treatment 
were mixed with Gel Loading Dye, Blue (6X, NEB, Catalog # B7021S) and 
electrophoresed on 1 % agarose gel in 1X TAE buffer (40 mM Tris-acetate, 1 M EDTA, 
pH 8.0) at 110 V, room temperature for 2 h. After electrophoresis, the agarose gel was 
stained with 0.5 µg/mL ethidium bromide (Spectrum E1031, 1 % solution) for 20 min 
and washed with autoclaved MilliQ H2O for 5 min in a staining box. The fragmented 
DNA and 1 kb DNA ladder (NEB, Catalog # N3232S, 500 µg/mL) were visualized with 
a FOTO/Convertible UV-light box equipped with an ethidium bromide filter 
(FOTODYNE Incorporated). The agarose gel was imaged and analyzed with 
FOTO/Analyst PC Image version 5.00.  
 
4.3.4 Hydroxyl Radical (·OH) Cleavage of HPV16/pUC18 Plasmid DNA 
 
4.3.4.1 Optimization of Hydroxyl Radical (∙OH) Reagent Concentration 
 
For in vitro ·OH-Seq footprinting experiments, hydroxyl radicals were generated by 
the Fenton reaction (Equation 4.1). To determine the appropriate working concentrations 
of the hydroxyl radical reagents required to generate a significant population of DNA 
fragments with lengths <1000 bp, 5 µg of HPV16/pUC18 plasmid DNA (6,541,200 
g/mol; OligoCalc)67 were diluted to a final concentration of 38.2 nM DNA, 5 mM Tris 
HCl, pH 7.5 (Invitrogen, Catalog # 15567-027) and 2 % v/v DMSO (Sigma Life Science, 
Catalog # D2650). This solution was incubated for 10 min at 37 °C. Stock solutions of 10 
mM Fe(II)-EDTA and 0.3 % H2O2 (30 % wt/vol, Fisher Chemical, Catalog # H325-500) 
were prepared immediately before use and wrapped in aluminum foil to protect them 
from light exposure. The 10 mM Fe(II)-EDTA solution was prepared by mixing equal 
volumes of 20 mM aqueous Fe(II) solution in the form of ammonium iron(II) sulfate 
hexahydrate (Aldrich, Catalog # 203505-25G) and 40 mM aqueous EDTA (Sigma, 
Catalog # E5134-100G). The excess EDTA ensures complete chelation of the metal. A 
stock of 200 mM sodium ascorbate (Sigma, Catalog # 11140-50G) in autoclaved MilliQ 
H2O was prepared and wrapped in aluminum foil to protect from light exposure. These 
stocks were then filtered through a 0.22 µm MILLEX-GP filter before use (Merck 
Millipore Ltd). The HPV16/pUC18 plasmid DNA solution (38.2 nM) was then treated 
with various concentrations of the hydroxyl radical reagents at 20 °C for a fixed reaction 
time of 5 min. The final concentrations of the cleavage reagents ranged from 0.43 mM 
Fe(II)-EDTA, 8.7 mM sodium ascorbate and 0.013 mM H2O2 to 2.50 mM Fe(II)-EDTA, 
50 mM sodium ascorbate and 0.075 mM H2O2. The cleavage reaction was quenched by 
the addition of 3X volume of cold (4 °C) 100 % ethanol (Decon Laboratories, Inc., 
Catalog # 2716). Ethanol precipitation of the fragmented DNA was then performed. The 
DNA pellet was resuspended in 20 µL Low EDTA TE buffer (Teknova, Catalog # 
T0227, 10 mM Tris·Cl, 0.1 mM EDTA, pH 8.0) and stored at -20 °C. Fragment size 
distribution of the reaction products were assessed by 1 % agarose gel electrophoresis 
and Agilent Bioanalyzer RNA 6000 Nanochip kit (Agilent Technologies, Catalog # 5067-
1511). 
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4.3.4.2 Hydroxyl Radical (∙OH) Footprinting 
 
HPV16/pUC18 DNA (38.2 nM) was incubated with either 2 µM or 20 µM PA1 for at 
least 4 h at 37 °C before subjecting the samples to the hydroxyl radical cleavage reagents. 
Hydroxyl radical cleavage reactions were performed on the plasmid DNA in the absence 
and in the presence of PA1 for 5 min at 20 °C in triplicate. DNA cleavage by ·OH was 
initiated by the addition of 20 µL each of 10 mM Fe(II)-EDTA, 200 mM sodium 
ascorbate and 0.3 % H2O2 followed by rapid mixing (2.5 mM Fe(II)-EDTA, 50 mM 
sodium ascorbate and 0.075 % H2O2 final concentration). After 5 min, the cleavage 
reaction was quenched by the addition of 3X volume of cold (4 °C) 100 % ethanol and 
vortexing. Ethanol precipitation of the fragmented DNA was then performed. The DNA 
pellet was resuspended in 20 µL Low EDTA TE buffer and stored at -20 °C. Fragment 
size distribution of the reaction products were estimated with a 1 % agarose gel 
electrophoresis and Agilent Bioanalyzer RNA 6000 Nanochip kit. DNA concentration 
was determined using a Qubit dsDNA BR (Broad-Range) Assay kit (Life technologies, 
Catalog # Q32853). 
4.3.4.3 Assessment of Fragment Size Distribution by 1 % Agarose Gel Electrophoresis 
and Agilent Bioanalyzer RNA 6000 Nanochip Kit 
 
The DNA cleavage products generated by hydroxyl radicals were resolved by agarose 
gel electrophoresis. 1.250 µg of fragmented HPV16/pUC18 was mixed with Gel Loading 
Dye, Blue and loaded in a 1 % agarose gel. The gel was run in a 1X TAE buffer at a 
voltage of 147 V for 4-5 h at room temperature. After electrophoresis, the agarose gel 
was stained with 0.5 µg/mL ethidium bromide for 20 min and washed with autoclaved 
MilliQ H2O for 5 min in a staining box. The fragmented DNA and 1 kb DNA ladder were 
visualized with a FOTO/Convertible UV-light box equipped with an ethidium bromide 
filter (FOTODYNE Incorporated). The agarose gel was imaged and analyzed with 
FOTO/Analyst PC Image version 5.00.  
For the assessment of ssDNA fragment size distribution produced by the cleavage 
reaction, an Agilent Bioanalyzer RNA 6000 Nanochip kit was used following the 
manufacturer’s instructions. Briefly, 2 µL of 62.5 ng/µL fragmented DNA was heat 
denatured at 95 °C for 3 min using a Mastercycler Nexus Thermal Cycler (Eppendorf) 
and immediately placed on ice until ready to load on the Nanochip. Then, 1 µL of ssDNA 
was loaded onto a sample well containing 5 µL of Agilent RNA marker solution. The 
RNA 6000 Nanochip was then analyzed in an Agilent 2100 Bioanalyzer using the 
Eukaryote Total RNA Nano Series II assay conditions. The results were analyzed using 
Agilent Technologies 2100 Bioanalyzer 2100 Expert Version B.02.08.SI648 (SR3) 
software. The Agilent 2100 Bioanalyzer is an analytical system that allows for the 
determination of fragment size and concentration of nucleic acid fragments. This chip-
based technology relies on the separation of nucleic acid oligos based on their size by 
electrophoresis that are detected, in real-time, by a specific (but proprietary) fluorescent 
dye that binds with nucleic acids. Using a ladder of known fragment sizes and 
concentrations, the size and concentration of the sample can be estimated based on its 
relative mobility and fluorescence intensity. 
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4.3.4.4 Quantification of dsDNA using Qubit dsDNA BR Assay Kit 
 
DNA concentration of the ethanol-precipitated, cleavage reaction products and 
prepared libraries were quantified using a Qubit dsDNA BR assay kit and a Qubit 2.0 
Fluorometer (Life technologies) following the manufacturer’s instructions. Briefly, Qubit 
dsDNA BR Standards #1 and #2 were prepared by separately diluting 10 µL of either 
Standard #1 (0 ng/ µL) or Standard #2 (100 ng/µL) in 190 µL of Qubit working solution 
(1:200 Qubit dsDNA BR Reagent:Qubit dsDNA BR buffer) in separate Qubit assay tubes 
(Life technologies, Catalog # Q32856). Unknowns were prepared by diluting 2 µL of 
cleavage reaction products or 4 µL of Illumina NGS library sample to a total volume of 
200 µL with Qubit working solution in separate Qubit assay tubes. Standards and 
unknown solutions were vigorously vortexed and allowed to incubate at room 
temperature for at least 2 min. After the incubation period, the fluorescence signal of each 
of these solutions was quantified with a Qubit 2.0 Fluorometer (Life technologies). The 
fluorescence signal emitted by the proprietary Qubit dsDNA BR Reagent fluorescent dye 
upon intercalation into dsDNA is directly proportional to the amount of dsDNA in the 
sample, which allows for the calculation of dsDNA concentration based on a two-point 
standard calibration curve. The Qubit 2.0 Fluorometer provides a dsDNA concentration 
in µg/mL of the diluted sample. Thus, Equation 4.2 is used to calculate dsDNA 
concentration of the sample. 
ܥ݋݊ܿ݁݊ݐݎܽݐ݅݋݊	݋݂	ݑ݊݇݊݋ݓ݊ ൌ ܳݑܾ݅ݐ	2.0	ܨ݈ݑ݋ݎ݋݉݁ݐ݁ݎ	ݒ݈ܽݑ݁	ሺμg/mLሻ	x	 ଶ଴଴୶             (4.2) 
																												ݓ݄݁ݎ݁	ݔ	݅ݏ	ݐ݄݁	ݒ݋݈ݑ݉݁	݋݂	ݏܽ݉݌݈݁	ݑݏ݁݀	݅݊	݉݅ܿݎ݋݈݅ݐ݁ݎݏ 
4.3.5 Illumina Next-Generation Sequencing 
 
4.3.5.1 Preparation of Illumina Next-Generation Sequencing Libraries 
 
Illumina next-generation sequencing libraries were constructed using an Accel-NGS 
1S Plus DNA Library Kit (Swift Biosciences, Catalog # SI-IL1SP-12A) following the 
manufacturer’s protocol (refer to Section 4.8.1 for detailed protocol). Thermal cycling 
steps were performed with a Mastercycler Nexus Thermal Cycler. Briefly, a 15 µL (10 
ng/µL) aliquot of ·OH double-hit fragments in Low EDTA TE buffer was heat denatured 
in a thermal cycler at 95 °C for 2 min and immediately placed on ice for 2 min before 
proceeding to the Adaptase step. The Adaptase step is a proprietary reaction that 
performs fragment end repair, 3’ end tailing and 3’ ligation of a truncated adapter. 25 µL 
of the Adaptase Reaction Mix was added to the 15 µL sample aliquot containing the 
denature ssDNA and cycled with the following thermal profile: 37 °C for 15 min, 95 °C 
for 2 min and 4 °C hold. Following 3’ end repair and truncated adapter ligation, adapter-
ligated DNA molecules were amplified by adding 47 µL of the Extension Reaction Mix 
and cycling with the following thermal profile: 98 °C for 30 s, 63 °C for 15 s, 68 °C for 5 
min and 4 °C hold. The newly synthesized strand allows for the ligation of the second 
truncated adapter to the 5’ end of the DNA fragment. This synthesized strand is not 
sequenced. In order to remove oligonucleotides and small fragments, paramagnetic SPRI-
based (Solid Phase Reversible Immobilization) bead purification of the Extension step 
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was performed with a SPRIselect reagent kit (Beckman Coulter, Catalog # B23317). 
Using a 1.2 ratio of SPRIselect reagent to sample, DNA fragments greater than or equal 
to 200 bp were size-selected and eluted with 20 µL of Low EDTA TE buffer. Although 
the composition of the SPRIselect reagent kit is proprietary, SPRI-based bead size-
selection relies on the use of carboxyl-coated paramagnetic beads to reversibly and 
selectively bind dsDNA of desired lengths as a function of the concentration of a 
crowding agent (polyethylene glycol, PEG) and salt (NaCl or MgCl2).68-70 Specifically, 
increasing the ratio of the SPRIselect reagent to sample volume results in an increasing 
amount of fragments with shorter lengths bound to the beads.71 Addition of the second 
truncated adapter were achieved by adding 20 µL of the Ligation Reaction Mix and 
cycled with the following thermal profile: 25 °C for 15 min and 4 °C hold. Clean-up of 
the Ligation step was then performed with a 1.0 ratio of SPRIselect reagent:sample to 
size-select for dsDNA fragments of sizes > 200 bp using a 12-tube magnetic separation 
rack (NEB, Catalog # S1509S), followed by elution from the beads with 20 µL of Low 
EDTA TE buffer. Addition of the full-length indexed adapters was performed by adding 
5 µL of Reagent R1 (index primer, SI-IL1SP-12A) and 25 µL of the PCR Reaction Mix. 
Table 4.1 provides the specific indexing adapters used for each sample. The reaction 
mixture was then amplified by cycling with the following thermal profile: 98 °C for 30 s, 
8 cycles of 98 °C for 10 s, 60 °C for 30 s and 68 °C for 60 s, followed by a 4 °C hold. 
The amplified NGS libraries were then size-selected with a 0.85 ratio of SPRIselect 
reagent:sample and eluted with 20 µL of Low EDTA TE buffer. Fragment size 
distribution was assessed by Agilent Bioanalyzer 2100 analysis using an Agilent DNA 
1000 kit (Agilent Technologies, Catalog # 5067-1505). DNA concentration was 
determined using a Qubit 2.0 Fluorometer with a Qubit dsDNA BR Assay kit. 
 
Table 4.1. Summary of NGS Library Preparation Parameters  
Sample Input DNA (ng) 
Adapter        
(SI-IL1SP-12A) 
Index 
Sequence 
Number of 
PCR Cycles 
Control-1 150 I6 GCCAAT(A) 8 
PA1-1 (2 µM) 150 I15 ATGTCA(G) 8 
PA1-1 (20 µM) 150 I14 AGTTCC(G) 8 
Control-2 150 I5 ACAGTG(A) 8 
PA1-2 (20 µM) 150 I16 CCGTCC(C) 8 
Control-3 150 I18 GTCCGC(A) 8 
PA1-3 (20 µM) 150 I19 GTGAAA(C) 8 
Accel-NGS 1S Plus DNA Library Kit was used to prepare NGS libraries. Index sequence refers to a unique DNA 
sequence identifier in the adapter that allows for multiple libraries to be sequenced simultaneously in a sample lane. 
 
4.3.5.2 Quality Control of NGS Libraries 
 
Constructed libraries were quantified by Qubit 2.0 Fluorometer using a Qubit dsDNA 
BR assay kit and the fragment size distribution was determined by Agilent Bioanalyzer 
2100 analysis using an Agilent DNA 1000 kit per manufacturer’s directions. Briefly, 1 
µL of the library sample was loaded onto a sample well containing 5 µL of Agilent DNA 
marker solution. The DNA 1000 Nanochip was then analyzed in an Agilent 2100 
Bioanalyzer using the DNA 1000 Series II assay conditions. The results were analyzed 
using Agilent Technologies 2100 Bioanalyzer 2100 Expert Version B.02.08.SI648 (SR3) 
software. Equation 4.3 was used to calculate the molar concentration of each NGS 
library.  
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The molar concentration of the constructed NGS libraries was also verified by the 
DNA Core Facility at the University of Missouri using a Qubit 3.0 Fluorometer (Life 
technologies) prior to high-throughput Illumina HiSeq 2500 sequencing. 
 
4.3.5.3 Illumina Next-generation Sequencing  
 
High-throughput Illumina sequencing of ·OH-treated HPV16/pUC18 plasmid 
samples in the presence or absence of PA1 were performed by the DNA Core Facility at 
the University of Missouri using single-end, 51 base pair read length on an Illumina 
HiSeq 2500. Because the libraries derived from different ·OH-treated samples were 
constructed using different indexing adapters, three or six libraries were multiplexed per 
lane to achieve an appropriate signal-to-noise ratio (and cost) for the determination of 
PA1-protected regions in the HPV16/pUC18 genome.  
 
4.3.6 Bioinformatics Analysis of NGS Results 
 
4.3.6.1 Sequence Alignment and Analysis of ∙OH Cleavage Intensities 
 
Demultiplexing was subsequently performed on the sequencing reads to segregate the 
sequencing results into separate data sets. Unique sequencing reads were aligned to the 
HPV16/pUC18 reference genome using Bowtie 2 (version 2.2.9).72 The reference 
genome consisted of HPV16 (GenBank Accession No. AF125673) cloned into the 
BamHI cloning site of pUC18 (GenBank Accession No. L08752) with minor 
modifications in the pUC18 sequence. The aligned, or mapped reads in the resulting 
SAM file were then processed with CountNicks.pm, a Perl script written by Dr. 
Christopher Bottoms and Dr. Scott Givan of the MU Informatics Core (in consultation 
with our group) to determine the ·OH cleavage intensity at each nucleotide (refer to 
Section 4.8.2 for detailed bioinformatics instructions). Because attack of hydroxyl radical 
results in the chemical destruction of a nucleotide base (refer to Section 4.2.2), the 
CountNicks.pm script assumes that the start of the sequence “read” for a nicked region 
occurs just 3’ of the cleaved nucleotide.  
 
4.4 RESULTS 
 
We relied on hydroxyl radicals as a footprinting/cleavage reagent to generate short 
DNA fragments that were subsequently analyzed using massively parallel sequencing to 
determine the binding sites at single-nucleotide resolution of PA1 to the negatively 
supercoiled HPV16/pUC18 plasmid. Although nicking of the negatively supercoiled 
DNA results in the relaxation of the supercoiled DNA, PA1 binding sites that are 
observed may correspond to events that occurred under the supercoiled topology of the 
HPV16/pUC18 molecule. 
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4.4.1 Restriction Digests of HPV16/pUC18 Clones 
 
In order to confirm that the correct plasmid DNA was amplified in transformed 
JM109 E. coli cells, a restriction digest using BamHI restriction enzyme was performed 
on the purified DNA. BamHI restriction digest of HPV16/pUC18 is expected to generate 
two DNA fragments with sizes of 2.7 kb and 7.9 kb, respectively. The restriction enzyme 
profile of the fragmented plasmid DNA separated by agarose gel electrophoresis is 
presented in Figure 4.8. The observed restriction products of approximately 2.7 kb and 
7.9 kb suggest that the plasmid DNA purified from JM109 E. coli cells is HPV16/pUC18. 
 
 
  
4.4.2 Optimization of Hydroxyl Radical Reagent Concentrations  
 
Conventional library preparation for Illumina next-generation sequencing platform 
requires random fragmentation of genomic DNA into double-stranded fragment lengths 
of < 600 bp by either enzymatic digestion or mechanical methods.73 Here we have used 
hydroxyl radicals to produce short single-stranded fragments derived from two ·OH nicks 
in close proximity within the same DNA strand, allowing us to determine relative ligand-
mediated protection in comparison to a control in addition to the specific location within 
the genome by Illumina next-generation sequencing. Since oxidative damage to DNA by 
hydroxyl radicals leads to single-stranded breaks along the DNA molecule, we employed 
the Accel-NGS 1S Plus DNA Library Kit for library preparation due to its compatibility 
with denatured, single-stranded, and nicked samples.  
We first aimed at defining the appropriate working concentrations of the hydroxyl 
radical reagents required to generate a significant population of DNA fragments with 
lengths between 200-600 bp. To this aim, 5 µg of HPV16/pUC18 plasmid DNA were 
treated with various concentrations of the hydroxyl radical reagents at 20 °C for a fixed 
Figure 4.8. Agarose Gel Electrophoresis of Restriction Digest for HPV16/pUC18. BamHI restriction digest
performed on HPV16/pUC18 plasmid DNA purified from transformed JM109 E. coli cells. Lane 1 corresponds to 1 kb
DNA molecular weight ladder with the expected size in kilobases given on the left of the picture. Lane 2 corresponds
to uncut plasmid DNA (10.591 kb). Lane 3 corresponds to BamHI restriction digest products (2.7 kb and 7.9 kb).
Treatment of HPV16/pUC18 with BamHI leads to the release of HPV16. 
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reaction time of 5 min. The final concentrations of the cleavage reagents are tabulated in 
the inset of Figure 4.9. Agarose gel electrophoresis was used to evaluate the 
concentration dependence on the conversion of supercoiled plasmid DNA to 
nicked/relaxed DNA and linear DNA species. As the concentration of the hydroxyl 
radical cleavage reagents are increased, the supercoiled plasmid population decreases, 
giving rise to higher amounts of relaxed nicked/relaxed DNA which in turn is converted 
to linear DNA derived from double-stranded breaks (Figure 4.9). With higher 
concentrations of the cleavage reagents, the average fragment size of these linear DNA 
molecules decreases due to an increase in the population of fragments with shorter 
lengths. Agarose gel analysis also suggested that at hydroxyl radical reagent 
concentrations of 2.50 mM Fe(II)-EDTA, 50.00 mM sodium ascorbate and 0.075% H2O2, 
the supercoiled and relaxed plasmid species were completely depleted leading to a 
population of linear DNA molecules bearing fragment sizes in the range of approximately 
0.7-5.0 kb.   
 
                   
  
These double-stranded fragments also contain single-stranded breaks produced by 
hydroxyl radical treatment. While agarose gel electrophoresis provides an estimate of 
dsDNA fragment size distribution, it fails to provide the fragment size distribution of 
ssDNA molecules that can be generated upon heat denaturation of the hydroxyl radical 
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Figure 4.9. Concentration Dependence of Hydroxyl Radicals on Cleavage Reaction Products. Agarose gel
electrophoresis analysis of hydroxyl radical concentration dependence on the conversion of plasmid DNA molecules
from the intact, supercoiled form to the nicked/relaxed and linear forms. (A) Lanes 1 and 8 correspond to the 1 kb
DNA ladder. Lane 2 corresponds to untreated HPV16/pUC18 plasmid control. Two bands represent the intact,
supercoiled and relaxed forms of the plasmid DNA. Lanes 3-7 correspond to the ·OH-treated HPV16/pUC18 samples
to different hydroxyl radical reagent concentrations (see Panel C). (B) Conversion scheme of plasmid DNA to linear
DNA molecules; R: relaxed, L: linear and S: supercoiled.
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products. These ssDNA fragments will ultimately serve as the template for Illumina 
library preparation using the Accel-NGS 1S Plus DNA Library Kit. As a result, fragment 
size distribution of ssDNA generated from ·OH-treated HPV16/pUC18 samples were 
estimated using a RNA 6000 Nanochip kit on an Agilent Bioanalyzer 2100. Although this 
kit is designed for sizing RNA fragments, the proprietary dye will also interact with 
nucleic acids from heat denatured DNA samples. We used this assay because it does not 
require radioactively labeled nucleic acids and it allows rapid analysis of small sample 
volumes. To validate the use of the RNA 6000 Nanochip kit for estimating ssDNA 
fragment size distribution, 1 µL (44 ng/µL) of a heat denatured, PCR amplified linear 
DNA fragment (368 nucleotides per strand) was analyzed. The calculated average size of 
the ssDNA fragment was estimated as 387 nucleotides with a range of 339 to 439 
nucleotides. Furthermore, two smaller peaks of 463 and 493 nucleotides were observed, 
respectively (Figure 4.10A). While this assay overestimated the fragment size of heat 
denatured ssDNA, it provided an appropriate estimate of the fragment size length for the 
purposes of library construction. Heat denatured DNA cleavage products derived from 
various concentrations of the hydroxyl radical reagents were then analyzed using the 
RNA 6000 Nanochip assay. Sample electropherograms (Figure 4.10B) demonstrate that 
increasing the hydroxyl radical cleavage reagents led to an increase in the population of 
shorter length ssDNA fragments. Of interest, hydroxyl radical reagent concentrations of 
2.50 mM Fe(II)-EDTA, 50.00 mM sodium ascorbate and 0.075 % H2O2 afforded the 
production of a significant population of ssDNA fragments with lengths between 200-600 
bp, compatible with downstream NGS library preparation. These cleavage reaction 
conditions were used for ·OH footprinting experiments. 
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4.4.3 Hydroxyl Radical (·OH) Footprinting 
 
Samples of 5 µg of HPV16/pUC18 plasmid DNA were incubated in the presence and 
absence of PA1 (2 and 20 µM) for at least 4 h at 37 °C in triplicate. After the incubation 
period, control and PA1-treated samples were subjected to hydroxyl radical cleavage 
reagents (2.5 mM Fe(II)-EDTA, 50 mM sodium ascorbate and 0.075 % H2O2) for 5 min 
at 20 °C. Fragmented DNA products were ethanol precipitated, followed by DNA 
concentration and sizing analysis. 
368 nucleotide ssDNAA 
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Sample 3  Sample 4 
Sample 5  Sample 6 
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Figure 4.10. Single-Stranded DNA Fragment Size Distribution as a Function of Hydroxyl Radical Reagent 
Concentrations. RNA 6000 Nanochip assay analysis of heat denatured ssDNA fragment size distribution from
HPV16/pUC18 DNA treated to various cleavage reagent concentrations. (A) A PCR-amplified dsDNA fragment 
was heat denatured to produce ssDNA fragments of 368 nucleotides. Analysis of the fragment size distribution
revealed an overestimation of the fragment size. The calculated sizes were 387, 463 and 493 nucleotides for peak 1,
2 and 3, respectively. (B) Samples 1-6 correspond to HPV16/pUC18 DNA samples treated to increasing hydroxyl 
radical reagent concentrations. Sample 1: control; Sample 2: 0.43 mM Fe(II)-EDTA, 8.70 mM sodium ascorbate, 
0.013 % H2O2; Sample 3: 0.77 mM Fe(II)-EDTA, 15.38 mM sodium ascorbate, 0.023 % H2O2; Sample 4: 1.43 mM
Fe(II)-EDTA, 28.57 mM sodium ascorbate, 0.043 % H2O2; Sample 5: 2.00 mM Fe(II)-EDTA, 40.00 mM sodium 
ascorbate, 0.060 % H2O2; Sample 6: 2.50 mM Fe(II)-EDTA, 50.00 mM Na ascorbate, 0.075 % H2O2. M: RNA 
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4.4.3.1 Determination of Fragment Size Distribution and DNA Concentration of ∙OH-
treated HPV16/pUC18 DNA  
 
Fragment size distribution for each ·OH footprinting reaction sample was estimated 
using the RNA 6000 Nanochip assay and their respective DNA concentrations were 
quantified by Qubit dsDNA BR assay. The estimated fragment size distribution for the 
nine ·OH footprinting samples is provided in Figure 4.11. The hydroxyl radical cleavage 
conditions used for the ·OH footprinting experiments generated a significant number of 
fragments of length (500 bp) compatible with subsequent NGS library construction. 
Table 4.2 summarizes the DNA concentrations of the ·OH footprinting samples. 
  
Table 4.2. DNA Concentrations of ·OH Footprinting Samples by Qubit dsDNA BR Assay 
Trial 1 Trial 2 Trial 3 
Sample [dsDNA] (ng/µL) Sample 
[dsDNA] 
(ng/µL) Sample 
[dsDNA] 
(ng/µL) 
Control-1 185 Control-2 214 Control-3 190 
PA1-1 (2 µM) 122 PA1-2 (2 µM) 243 PA1-3 (2 µM) 237 
PA1-1 (20 µM) 157 PA1-2 (20 µM) 174 PA1-3 (20 µM) 258 
 
4.4.4 Illumina Next-generation Sequencing 
 
4.4.4.1 Quality Control of NGS Libraries 
 
DNA concentration was measured by the Qubit dsDNA BR assay and fragment size 
distribution was determined by the Agilent DNA 1000 assay for the constructed libraries. 
The molar concentrations of the constructed libraries were calculated according to 
Equation 4.3 using the DNA concentration measured by Qubit and the average fragment 
size of the library determined by Bioanalyzer (Table 4.3). Fragment size distribution 
profiles of the prepared NGS libraries are provided in Figure 4.12.  
Figure 4.11. Single-Stranded DNA Fragment Size Distribution of ·OH Footprinting Samples. RNA 6000
Nanochip assay analysis of heat denatured ssDNA fragment size distribution for ·OH footprinting samples of PA1 on
HPV16/pUC18 DNA. Control and PA1-treated samples were each subjected to 2.5 mM Fe(II)-EDTA, 50 mM sodium
ascorbate and 0.075 % H2O2 for 5 min at 20 °C. M: RNA marker. 
Control‐1 
Control‐2 
Control‐3 
PA1‐1 (2 µM)
PA1‐2 (2 µM)
PA1‐3 (2 µM)
PA1‐2 (20 µM)
PA1‐1 (20 µM)
PA1‐3 (20 µM)
M  M M 
M  M M 
M  M M 
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Table 4.3. ·OH Footprinting of PA1 on HPV16/pUC18 - Summary of NGS Library Information.  
Sample Adapter      (SI-IL1SP-12A) 
Index 
Sequence 
Qubit 2.0 
(ng/µL) 
MU Qubit 
3.0 (ng/µL) 
Bioanalyzer   
Average Size 
(bp) 
Molar 
Concentration 
(nM) 
Control-1 I6 GCCAAT(A) 18.90 ND 458 62.52 
PA1-1 (2 µM) I15 ATGTCA(G) 23.30 ND 449 78.63 
PA1-1 (20 µM) I14 AGTTCC(G) 22.40 ND 467 72.68 
Control-2 I5 ACAGTG(A) 19.50 34.65 456 64.79 
PA1-2 (20 µM) I16 CCGTCC(C) 12.40 20.50 451 41.66 
Control-3 I18 GTCCGC(A) 23.20 39.40 428 82.13 
PA1-3 (20 µM) I19 GTGAAA(C) 5.50 8.615 450 18.52 
Accel-NGS 1S Plus DNA Library Kit was used to prepare NGS libraries. Index sequence refers to a unique DNA 
sequence identifier in the adapter that allows for multiple libraries to be sequenced simultaneously in a single sample 
lane and be identified and grouped together properly via bioinformatics processing of the sequence data. Molar 
concentrations were calculated according to Equation 4.3 using the Qubit 2.0 data. ND – not determined. 
 
 
  
4.4.4.2 Illumina HiSeq2500 NGS   
 
Illumina NGS libraries of ·OH footprinting samples were sequenced using single-end, 
51 base pair read length on an Illumina HiSeq 2500. Samples were multiplexed by 
pooling three or six libraries per single lane for a theoretical 50 or 25 million reads per 
library, respectively. Table 4.4 tabulates the number of reads obtained for each library.   
 
4.4.4.3 DNA Sequence Validation of HPV16/pUC18 Plasmid using Illumina HiSeq 
2500 Sequencing Data 
 
De novo DNA sequencing of the HPV16/pUC18 plasmid further verified the identity 
of the amplified plasmid. The raw .fastq file from the ·OH-treated HPV16/pUC18 
plasmid sample in the absence of PA1 was used to manually aligned the sequence reads 
into contiguous sequences. The plasmid sequence determined matched the HPV16 
sequence (GenBank Accession No. AF125673) cloned into the BamHI cloning site of 
pUC18 (GenBank Accession No. L08752). BLASTN74 alignment of determined HPV16 
and pUC18 sequences are shown in Figure 4.13B & C. However, a deletion of a single 
cytidine at nucleotide position 220 and a mutation from cytosine to thymine at nucleotide 
Control‐1  PA1‐1 (2 µM) 
PA1‐3 (20 µM) 
PA1‐1 (20 µM) 
M 
M 
Control‐2 
M 
M 
Control‐3 
M 
M 
M 
M 
M 
M 
M 
M 
M 
M 
PA1‐2 (20 µM) 
Figure 4.12. Fragment Size Distribution of Illumina NGS Libraries. Agilent DNA1000 assay analysis prepared 
NGS libraries. 
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position 2063 were observed in the pUC18 sequence. The determined sequence for this 
HPV18 variant was used as the reference genome to map the sequencing reads from ·OH-
treated HPV16/pUC18 samples (Figure 4.13A).  
 
 
AGCGTGGGTCTCGCGGTATCATTGCAGCACTGGGGCCAGATGGTAAGCCCTCCCGTATCGTAGTTATCTACACGACGGGGAGTCAGGCAACTATGGATGAACGAAATAGACAGATCGCTGAGATAGGTGCCTCACTGATTAAG
CATTGGTAACTGTCAGACCAAGTTTACTCATATATACTTTAGATTGATTTAAAACTTCATTTTTAATTTAAAAGGATCTAGGTGAAGATCCTTTTTGATAATCTCATGACCAAAATCCCTTAACGTGAGTTTTCGTTCCACTG
AGCGTCAGACCCCGTAGAAAAGATCAAAGGATCTTCTTGAGATCCTTTTTTTCTGCGCGTAATCTGCTGCTTGCAAACAAAAAAACCACCGCTACCAGCGGTGGTTTGTTTGCCGGATCAAGAGCTACCAACTCTTTTTCCGA
AGGTAACTGGCTTCAGCAGAGCGCAGATACCAAATACTGTTCTTCTAGTGTAGCCGTAGTTAGGCCACCACTTCAAGAACTCTGTAGCACCGCCTACATACCTCGCTCTGCTAATCCTGTTACCAGTGGCTGCTGCCAGTGGC
GATAAGTCGTGTCTTACCGGGTTGGACTCAAGACGATAGTTACCGGATAAGGCGCAGCGGTCGGGCTGAACGGGGGGTTCGTGCACACAGCCCAGCTTGGAGCGAACGACCTACACCGAACTGAGATACCTACAGCGTGAGCT
ATGAGAAAGCGCCACGCTTCCCGAAGGGAGAAAGGCGGACAGGTATCCGGTAAGCGGCAGGGTCGGAACAGGAGAGCGCACGAGGGAGCTTCCAGGGGGAAACGCCTGGTATCTTTATAGTCCTGTCGGGTTTCGCCACCTCT
GACTTGAGCGTCGATTTTTGTGATGCTCGTCAGGGGGGCGGAGCCTATGGAAAAACGCCAGCAACGCGGCCTTTTTACGGTTCCTGGCCTTTTGCTGGCCTTTTGCTCACATGTTCTTTCCTGCGTTATCCCCTGATTCTGTG
GATAACCGTATTACCGCCTTTGAGTGAGCTGATACCGCTCGCCGCAGCCGAACGACCGAGCGCAGCGAGTCAGTGAGCGAGGAAGCGGAAGAGCGCCCAATACGCAAACCGCCTCTCCCCGCGCGTTGGCCGATTCATTAATG
CAGCTGGCACGACAGGTTTCCCGACTGGAAAGCGGGCAGTGAGCGCAACGCAATTAATGTGAGTTAGCTCACTCATTAGGCACCCCAGGCTTTACACTTTATGCTTCCGGCTCGTATGTTGTGTGGAATTGTGAGCGGATAAC
AATTTCACACAGGAAACAGCTATGACATGATTACGAATTCGAGCTCGGTACCCGGGGATCCCCATGTACCAATGTTGCAGTAAATCCAGGTGATTGTCCACCATTAGAGTTAATAAACACAGTTATTCAGGATGGTGATATGG
TTGATACTGGCTTTGGTGCTATGGACTTTACTACATTACAGGCTAACAAAAGTGAAGTTCCACTGGATATTTGTACATCTATTTGCAAATATCCAGATTATATTAAAATGGTGTCAGAACCATATGGCGACAGCTTATTTTTT
TATTTACGAAGGGAACAAATGTTTGTTAGACATTTATTTAATAGGGCTGGTGCTGTTGGTGAAAATGTACCAGACGATTTATACATTAAAGGCTCTGGGTCTACTGCAAATTTAGCCAGTTCAAATTATTTTCCTACACCTAG
TGGTTCTATGGTTACCTCTGATGCCCAAATATTCAATAAACCTTATTGGTTACAACGAGCACAGGGCCACAATAATGGCATTTGTTGGGGTAACCAACTATTTGTTACTGTTGTTGATACTACACGCAGTACAAATATGTCAT
TATGTGCTGCCATATCTACTTCAGAAACTACATATAAAAATACTAACTTTAAGGAGTACCTACGACATGGGGAGGAATATGATTTACAGTTTATTTTTCAACTGTGCAAAATAACCTTAACTGCAGACGTTATGACATACATA
CATTCTATGAATTCCACTATTTTGGAGGACTGGAATTTTGGTCTACAACCTCCCCCAGGAGGCACACTAGAAGATACTTATAGGTTTGTAACATCCCAGGCAATTGCTTGTCAAAAACATACACCTCCAGCACCTAAAGAAGA
TCCCCTTAAAAAATACACTTTTTGGGAAGTAAATTTAAAGGAAAAGTTTTCTGCAGACCTAGATCAGTTTCCTTTAGGACGCAAATTTTTACTACAAGCAGGATTGAAGGCCAAACCAAAATTTACATTAGGAAAACGAAAAG
CTACACCCACCACCTCATCTACCTCTACAACTGCTAAACGCAAAAAACGTAAGCTGTAAGTATTGTATGTATGTTGAATTAGTGTTGTTTGTTGTTTATATGTTTGTATGTGCTTGTATGTGCTTGTAAATATTAAGTTGTAT
GTGTGTTTGTATGTATGGTATAATAAACACGTGTGTATGTGTTTTTAAATGCTTGTGTAACTATTGTGTCATGCAACATAAATAAACTTATTGTTTCAACACCTACTAATTGTGTTGTGGTTATTCATTGTATATAAACTATA
TTTGCTACATCCTGTTTTTGTTTTATATATACTAAATTTTGTAGCGCCAGCGGCCATTTTGTAGCTTCAACCGAATTCGGTTGCATGCTTTTTGGCACAAAATGTGTTTTTTTAAATAGTTCTATGTCAGCAACTATAGTTTA
AACTTGTACGTTTCCTGCTTGCCATGCGTGCCAAATCCCTGTTTTCCTGACCTGCACTGCTTGCCAACCATTCCATTGTTTTTTACACTGCACTATGTGCAACTACTGAATCACTATGTACATTGTGTCATATAAAATAAATC
ACTATGCGCCAACGCCTTACATACCGCTGTTAGGCACATATTTTTGGCTTGTTTTAACTAACCTAATTGCATATTTGGCATAAGGTTTAAACTTCTAAGGCCAACTAAATGTCACCCTAGTTCATACATGAACTGTGTAAAGG
TTAGTCATACATTGTTCATTTGTAAAACTGCACATGGGTGTGTGCAAACCGTTTTGGGTTACACATTTACAAGCAACTTATATAATAATACTAAACTACAATAATTCATGTATAAAACTAAGGGCGTAACCGAAATCGGTTGA
ACCGAAACCGGTTAGTATAAAAGCAGACATTTTATGCACCAAAAGAGAACTGCAATGTTTCAGGACCCACAGGAGCGACCCAGAAAGTTACCACAGTTATGCACAGAGCTGCAAACAACTATACATGATATAATATTAGAATG
TGTGTACTGCAAGCAACAGTTACTGCGACGTGAGGTATATGACTTTGCTTTTCGGGATTTATGTATAGTATATAGAGATGGGAATCCATATGCTGTATGTGATAAATGTTTAAAGTTTTATTCTAAAATTAGTGAGTATAGAC
ATTATTGTTATAGTGTGTATGGAACAACATTAGAACAGCAATACAACAAACCGTTGTGTGATTTGTTAATTAGGTGTATTAACTGTCAAAAGCCACTGTGTCCTGAAGAAAAGCAAAGACATCTGGACAAAAAGCAAAGATTC
CATAATATAAGGGGTCGGTGGACCGGTCGATGTATGTCTTGTTGCAGATCATCAAGAACACGTAGAGAAACCCAGCTGTAATCATGCATGGAGATACACCTACATTGCATGAATATATGTTAGATTTGCAACCAGAGACAACT
GATCTCTACTGTTATGAGCAATTAAATGACAGCTCAGAGGAGGAGGATGAAATAGATGGTCCAGCTGGACAAGCAGAACCGGACAGAGCCCATTACAATATTGTAACCTTTTGTTGCAAGTGTGACTCTACGCTTCGGTTGTG
CGTACAAAGCACACACGTAGACATTCGTACTTTGGAAGACCTGTTAATGGGCACACTAGGAATTGTGTGCCCCATCTGTTCTCAGAAACCATAATCTACCATGGCTGATCCTGCAGGTACCAATGGGGAAGAGGGTACGGGAT
GTAATGGATGGTTTTATGTAGAGGCTGTAGTGGAAAAAAAAACAGGGGATGCTATATCAGATGACGAGAACGAAAATGACAGTGATACAGGTGAAGATTTGGTAGATTTTATAGTAAATGATAATGATTATTTAACACAGGCA
GAAACAGAGACAGCACATGCGTTGTTTACTGCACAGGAAGCAAAACAACATAGAGATGCAGTACAGGTTCTAAAACGAAAGTATTTGGGTAGTCCACTTAGTGATATTAGTGGATGTGTAGACAATAATATTAGTCCTAGATT
AAAAGCTATATGTATAGAAAAACAAAGTAGAGCTGCAAAAAGGAGATTATTTGAAAGCGAAGACAGCGGGTATGGCAATACTGAAGTGGAAACTCAGCAGATGTTACAGGTAGAAGGGCGCCATGAGACTGAAACACCATGTA
GTCAGTATAGTGGTGGAAGTGGGGGTGGTTGCAGTCAGTACAGTAGTGGAAGTGGGGGAGAGGGTGTTAGTGAAAGACACACTATATGCCAAACACCACTTACAAATATTTTAAATGTACTAAAAACTAGTAATGCAAAGGCA
GCAATGTTAGCAAAATTTAAAGAGTTATACGGGGTGAGTTTTTCAGAATTAGTAAGACCATTTAAAAGTAATAAATCAACGTGTTGCGATTGGTGTATTGCTGCATTTGGACTTACACCCAGTATAGCTGACAGTATAAAAAC
ACTATTACAACAATATTGTTTATATTTACACATTCAAAGTTTAGCATGTTCATGGGGAATGGTTGTGTTACTATTAGTAAGATATAAATGTGGAAAAAATAGAGAAACAATTGAAAAATTGCTGTCTAAACTATTATGTGTGT
CTCCAATGTGTATGATGATAGAGCCTCCAAAATTGCGTAGTACAGCAGCAGCATTATATTGGTATAAAACAGGTATATCAAATATTAGTGAAGTGTATGGAGACACGCCAGAATGGATACAAAGACAAACAGTATTACAACAT
AGTTTTAATGATTGTACATTTGAATTATCACAGATGGTACAATGGGCCTACGATAATGACATAGTAGACGATAGTGAAATTGCATATAAATATGCACAATTGGCAGACACTAATAGTAATGCAAGTGCCTTTCTAAAAAGTAA
TTCACAGGCAAAAATTGTAAAGGATTGTGCAACAATGTGTAGACATTATAAACGAGCAGAAAAAAAACAAATGAGTATGAGTCAATGGATAAAATATAGATGTGATAGGGTAGATGATGGAGGTGATTGGAAGCAAATTGTTA
TGTTTTTAAGGTATCAAGGTGTAGAGTTTATGTCATTTTTAACTGCATTAAAAAGATTTTTGCAAGGCATACCTAAAAAAAATTGCATATTACTATATGGTGCAGCTAACACAGGTAAATCATTATTTGGTATGAGTTTAATG
AAATTTCTGCAAGGGTCTGTAATATGTTTTGTAAATTCTAAAAGCCATTTTTGGTTACAACCATTAGCAGATGCCAAAATAGGTATGTTAGATGATGCTACAGTGCCCTGTTGGAACTACATAGATGACAATTTAAGAAATGC
ATTGGATGGAAATTTAGTTTCTATGGATGTAAAGCATAGACCATTGGTACAACTAAAATGCCCTCCATTATTAATTACATCTAACATTAATGCTGGTACAGATTCTAGGTGGCCTTATTTACATAATAGATTGGTGGTGTTTA
CATTTCCTAATGAGTTTCCATTTGACGAAAACGGAAATCCAGTGTATGAGCTTAATGATAAGAACTGGAAATCCTTTTTCTCAAGGACGTGGTCCAGATTAAGTTTGCACGAGGACGAGGACAAGGAAAACGATGGAGACTCT
TTGCCAACGTTTAAATGTGTGTCAGGACAAAATACTAACACATTATGAAAATGATAGTACAGACCTACGTGACCATATAGACTATTGGAAACACATGCGCCTAGAATGTGCTATTTATTACAAGGCCAGAGAAATGGGATTTA
AACATATTAACCACCAGGTGGTGCCAACACTGGCTGTATCAAAGAATAAAGCATTACAAGCAATTGAACTGCAACTAACGTTAGAAACAATATATAACTCACAATATAGTAATGAAAAGTGGACATTACAAGACGTTAGCCTT
GAAGTGTATTTAACTGCACCAACAGGATGTATAAAAAAACATGGATATACAGTGGAAGTGCAGTTTGATGGAGACATATGCAATACAATGCATTATACAAACTGGACACATATATATATTTGTGAAGAAGCATCAGTAACTGT
GGTAGAGGGTCAAGTTGACTATTATGGTTTATATTATGTTCATGAAGGAATACGAACATATTTTGTGCAGTTTAAAGATGATGCAGAAAAATATAGTAAAAATAAAGTATGGGAAGTTCATGCGGGTGGTCAGGTAATATTAT
GTCCTACATCTGTGTTTAGCAGCAACGAAGTATCCTCTCCTGAAATTATTAGGCAGCACTTGGCCAACCACTCCGCCGCGACCCATACCAAAGCCGTCGCCTTGGGCACCGAAGAAACACAGACGACTATCCAGCGACCAAGA
TCAGAGCCAGACACCGGAAACCCCTGCCACACCACTAAGTTGTTGCACAGAGACTCAGTGGACAGTGCTCCAATCCTCACTGCATTTAACAGCTCACACAAAGGACGGATTAACTGTAATAGTAACACTACACCCATAGTACA
TTTAAAAGGTGATGCTAATACTTTAAAATGTTTAAGATATAGATTTAAAAAGCATTGTACATTGTATACTGCAGTGTCGTCTACATGGCATTGGACAGGACATAATGTAAAACATAAAAGTGCAATTGTTACACTTACATATG
ATAGTGAATGGCAACGTGACCAATTTTTGTCTCAAGTTAAAATACCAAAAACTATTACAGTGTCTACTGGATTTATGTCTATATGACAAATCTTGATACTGCATCCACAACATTACTGGCGTGCTTTTTGCTTTGCTTTTGTG
TGCTTTTGTGTGTCTGCCTATTAATACGTCCGCTGCTTTTGTCTGTGTCTACATACACATCATTAATACTATTGGTATTACTATTGTGGATAACAGCAGCCTCTGCGTTTAGGTGTTTTATTGTATATATTGTATTTGTTTAT
ATACCATTATTTTTAATACATACACATGCACGCTTTTTAATTACATAATGTATATGTACAAAATGTAATTGTTACATATAATTGTTGTATACCATAACTTACTATTTTTTCTTTTTTATTTTCATATATATTTTTTTTTTGTT
TGTTTGTTTGTTTTTTAATAAACTGTTATCACTTAACAATGCGACACAAACGTTCTGCAAAACGCACAAAACGTGCATCGGCTACCCAACTTTATAAAACATGCAAACAGGCAGGTACATGTCCACCTGACATTATACCTAAG
GTTGAAGGCAAAACTATTGCTGATCAAATATTACAATATGGAAGTATGGGTGTATTTTTTGGTGGGTTAGGAATTGGAACAGGGTCGGGTACAGGCGGACGCACTGGGTATATTCCATTGGGAACAAGGCCTCCCACAGCTAC
AGATACACTTGCTCCTGTAAGACCCCCTTTAACAGTAGATCCTGTGGGCCCTTCCGATCCTTCTATAGTTTCTTTAGTGGAAGAAACTAGTTTTATTGATGCTGGTGCACCAACATCTGTACCTTCCATTCCCCCAGATGTAT
CAGGATTTAGTATTACTACTTCAACTGATACCACACCTGCTATATTAGATATTAATAATACTGTTACTACTGTTACTACACATAATAATCCCACTTTCACTGACCCATCTGTATTGCAGCCTCCAACACCTGCAGAAACTGGA
GGGCATTTTACACTTTCATCATCCACTATTAGTACACATAATTATGAAGAAATTCCTATGGATACATTTATTGTTAGCACAAACCCTAACACAGTAACTAGTAGCACACCCATACCAGGGTCTCGCCCAGTGGCACGCCTAGG
ATTATATAGTCGCACAACACAACAAGTTAAAGTTGTAGACCCTGCTTTTATAACCACTCCCACTAAACTTATTACATATGATAATCCTGCATATGAAGGTATAGATGTGGATAATACATTATATTTTTCTAGTAATGATAATA
GTATTAATATAGCTCCAGATCCTGACTTTTTGGATATAGTTGCTTTACATAGGCCAGCATTAACCTCTAGGCGTACTGGCATTAGGTACAGTAGAATTGGTAATAAACAAACACTACGTACTCGTAGTGGAAAATCTATAGGT
GCTAAGGTACATTATTATTATGATTTTAGTACTATTGATTCTGCAGAAGAAATAGAATTACAAACTATAACACCTTCTACATATACTACCACTTCACATGCAGCCTTACCTACTTCTATTAATAATGGATTATATGATATTTA
TGCAGATGACTTTATTACAGATACTTCTACAACCCCGGTACCATCTGTACCCTCTACATCTTTATCAGGTTATATTCCTGCAAATACAACAATTCCTTTTGGTGGTGCATACAATATTCCTTTAGTATCAGGTCCTGATATAC
CCATTAATATAACTGACCAAGCTCCTTCATTAATTCCTATAGTTCCAGGGTCTCCACAATATACAATTATTGCTGATGCAGGTGACTTTTATTTACATCCTAGTTATTACATGTTACGAAAACGACGTAAACGTTTACCATAT
TTTTTTTCAGATGTCTCTTTGGCTGCCTAGTGAGGCCACTGTCTACTTGCCTCCTGTCCCAGTATCTAAGGTTGTAAGCACGGATGAATATGTTGCACGCACAAACATATATTATCATGCAGGAACATCCAGACTACTTGCAG
TTGGACATCCCTATTTTCCTATTAAAAAACCTAACAATAACAAAATATTAGTTCCTAAAGTATCAGGATTACAATACAGGGTATTTAGAATACATTTACCTGACCCCAATAAGTTTGGTTTTCCTGACACCTCATTTTATAAT
CCAGATACACAGCGGCTGGTTTGGGCCTGTGTAGGTGTTGAGGTAGGCCGTGGTCAGCCATTAGGTGTGGGCATTAGTGGCCATCCTTTATTAAATAAATTGGATGACACAGAAAATGCTAGTGCTTATGCAGCAAATGCAGG
TGTGGATAATAGAGAATGTATATCTATGGATTACAAACAAACACAATTGTGTTTAATTGGTTGCAAACCACCTATAGGGGAACACTGGGGCAAAGGATCCTCTAGAGTCGACCTGCAGGCATGCAAGCTTGGCACTGGCCGTC
GTTTTACAACGTCGTGACTGGGAAAACCCTGGCGTTACCCAACTTAATCGCCTTGCAGCACATCCCCCTTTCGCCAGCTGGCGTAATAGCGAAGAGGCCCGCACCGATCGCCCTTCCCAACAGTTGCGCAGCCTGAATGGCGA
ATGGCGCCTGATGCGGTATTTTCTCCTTACGCATCTGTGCGGTATTTCACACCGCATATGGTGCACTCTCAGTACAATCTGCTCTGATGCCGCATAGTTAAGCCAGCCCCGACACCCGCCAACACCCGCTGACGCGCCCTGAC
GGGCTTGTCTGCTCCCGGCATCCGCTTACAGACAAGCTGTGACCGTCTCCGGGAGCTGCATGTGTCAGAGGTTTTCACCGTCATCACCGAAACGCGCGAGACGAAAGGGCCTCGTGATACGCCTATTTTTATAGGTTAATGTC
ATGATAATAATGGTTTCTTAGACGTCAGGTGGCACTTTTCGGGGAAATGTGCGCGGAACCCCTATTTGTTTATTTTTCTAAATACATTCAAATATGTATCCGCTCATGAGACAATAACCCTGATAAATGCTTCAATAATATTG
AAAAAGGAAGAGTATGAGTATTCAACATTTCCGTGTCGCCCTTATTCCCTTTTTTGCGGCATTTTGCCTTCCTGTTTTTGCTCACCCAGAAACGCTGGTGAAAGTAAAAGATGCTGAAGATCAGTTGGGTGCACGAGTGGGTT
ACATCGAACTGGATCTCAACAGCGGTAAGATCCTTGAGAGTTTTCGCCCCGAAGAACGTTTTCCAATGATGAGCACTTTTAAAGTTCTGCTATGTGGCGCGGTATTATCCCGTATTGACGCCGGGCAAGAGCAACTCGGTCGC
CGCATACACTATTCTCAGAATGACTTGGTTGAGTACTCACCAGTCACAGAAAAGCATCTTACGGATGGCATGACAGTAAGAGAATTATGCAGTGCTGCCATAACCATGAGTGATAACACTGCGGCCAACTTACTTCTGACAAC
GATCGGAGGACCGAAGGAGCTAACCGCTTTTTTGCACAACATGGGGGATCATGTAACTCGCCTTGATCGTTGGGAACCGGAGCTGAATGAAGCCATACCAAACGACGAGCGTGACACCACGATGCCTGTAGCAATGGCAACAA
CGTTGCGCAAACTATTAACTGGCGAACTACTTACTCTAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGCGGATAAAGTTGCAGGACCACTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCTGATAAATCTGGA
GCCGGTG 
BLASTN Results 
Human papillomavirus type 16 isolate 16W12E, complete genome 
Sequence ID: gb|AF125673.1|AF125673       Length: 7904          
Number of Matches: 1                                    Range 1: 1 to 7904 
Score Expect Identities Gaps Strand 
14597 
bits(7904) 0.0 7904/7904(100 %) 0/7904(0 %) Plus/Plus 
Query  1     ACTACAATAATTCATGTATAAAACTAAGGGCGTAACCGAAATCGGTTGAACCGAAACCGGTTAGTATAAAAGCAGACATTTTATGCACCAAAAGAGAACTGCAATGTTTCAGGACCCACA  120 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
SBJCT  1     ACTACAATAATTCATGTATAAAACTAAGGGCGTAACCGAAATCGGTTGAACCGAAACCGGTTAGTATAAAAGCAGACATTTTATGCACCAAAAGAGAACTGCAATGTTTCAGGACCCACA  120 
 
QUERY  121   GGAGCGACCCAGAAAGTTACCACAGTTATGCACAGAGCTGCAAACAACTATACATGATATAATATTAGAATGTGTGTACTGCAAGCAACAGTTACTGCGACGTGAGGTATATGACTTTGC  240 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
SBJCT  121   GGAGCGACCCAGAAAGTTACCACAGTTATGCACAGAGCTGCAAACAACTATACATGATATAATATTAGAATGTGTGTACTGCAAGCAACAGTTACTGCGACGTGAGGTATATGACTTTGC  240 
 
QUERY  241   TTTTCGGGATTTATGTATAGTATATAGAGATGGGAATCCATATGCTGTATGTGATAAATGTTTAAAGTTTTATTCTAAAATTAGTGAGTATAGACATTATTGTTATAGTGTGTATGGAAC  360 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
SBJCT  241   TTTTCGGGATTTATGTATAGTATATAGAGATGGGAATCCATATGCTGTATGTGATAAATGTTTAAAGTTTTATTCTAAAATTAGTGAGTATAGACATTATTGTTATAGTGTGTATGGAAC  360 
 
QUERY  361   AACATTAGAACAGCAATACAACAAACCGTTGTGTGATTTGTTAATTAGGTGTATTAACTGTCAAAAGCCACTGTGTCCTGAAGAAAAGCAAAGACATCTGGACAAAAAGCAAAGATTCCA  480 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
SBJCT  361   AACATTAGAACAGCAATACAACAAACCGTTGTGTGATTTGTTAATTAGGTGTATTAACTGTCAAAAGCCACTGTGTCCTGAAGAAAAGCAAAGACATCTGGACAAAAAGCAAAGATTCCA  480  
 
QUERY  481   TAATATAAGGGGTCGGTGGACCGGTCGATGTATGTCTTGTTGCAGATCATCAAGAACACGTAGAGAAACCCAGCTGTAATCATGCATGGAGATACACCTACATTGCATGAATATATGTTA  600 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
SBJCT  481   TAATATAAGGGGTCGGTGGACCGGTCGATGTATGTCTTGTTGCAGATCATCAAGAACACGTAGAGAAACCCAGCTGTAATCATGCATGGAGATACACCTACATTGCATGAATATATGTTA  600 
A 
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QUERY  601   GATTTGCAACCAGAGACAACTGATCTCTACTGTTATGAGCAATTAAATGACAGCTCAGAGGAGGAGGATGAAATAGATGGTCCAGCTGGACAAGCAGAACCGGACAGAGCCCATTACAAT  720 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
SBJCT  601   GATTTGCAACCAGAGACAACTGATCTCTACTGTTATGAGCAATTAAATGACAGCTCAGAGGAGGAGGATGAAATAGATGGTCCAGCTGGACAAGCAGAACCGGACAGAGCCCATTACAAT  720 
 
QUERY  721   ATTGTAACCTTTTGTTGCAAGTGTGACTCTACGCTTCGGTTGTGCGTACAAAGCACACACGTAGACATTCGTACTTTGGAAGACCTGTTAATGGGCACACTAGGAATTGTGTGCCCCATC  840 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
SBJCT  721   ATTGTAACCTTTTGTTGCAAGTGTGACTCTACGCTTCGGTTGTGCGTACAAAGCACACACGTAGACATTCGTACTTTGGAAGACCTGTTAATGGGCACACTAGGAATTGTGTGCCCCATC  840 
 
QUERY  841   TGTTCTCAGAAACCATAATCTACCATGGCTGATCCTGCAGGTACCAATGGGGAAGAGGGTACGGGATGTAATGGATGGTTTTATGTAGAGGCTGTAGTGGAAAAAAAAACAGGGGATGCT  960 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
SBJCT  841   TGTTCTCAGAAACCATAATCTACCATGGCTGATCCTGCAGGTACCAATGGGGAAGAGGGTACGGGATGTAATGGATGGTTTTATGTAGAGGCTGTAGTGGAAAAAAAAACAGGGGATGCT  960 
 
QUERY  961   ATATCAGATGACGAGAACGAAAATGACAGTGATACAGGTGAAGATTTGGTAGATTTTATAGTAAATGATAATGATTATTTAACACAGGCAGAAACAGAGACAGCACATGCGTTGTTTACT  1080 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
SBJCT  961   ATATCAGATGACGAGAACGAAAATGACAGTGATACAGGTGAAGATTTGGTAGATTTTATAGTAAATGATAATGATTATTTAACACAGGCAGAAACAGAGACAGCACATGCGTTGTTTACT  1080 
 
QUERY  1081  GCACAGGAAGCAAAACAACATAGAGATGCAGTACAGGTTCTAAAACGAAAGTATTTGGGTAGTCCACTTAGTGATATTAGTGGATGTGTAGACAATAATATTAGTCCTAGATTAAAAGCT  1200 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
SBJCT  1081  GCACAGGAAGCAAAACAACATAGAGATGCAGTACAGGTTCTAAAACGAAAGTATTTGGGTAGTCCACTTAGTGATATTAGTGGATGTGTAGACAATAATATTAGTCCTAGATTAAAAGCT  1200 
 
QUERY  1201  ATATGTATAGAAAAACAAAGTAGAGCTGCAAAAAGGAGATTATTTGAAAGCGAAGACAGCGGGTATGGCAATACTGAAGTGGAAACTCAGCAGATGTTACAGGTAGAAGGGCGCCATGAG  1320 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
SBJCT  1201  ATATGTATAGAAAAACAAAGTAGAGCTGCAAAAAGGAGATTATTTGAAAGCGAAGACAGCGGGTATGGCAATACTGAAGTGGAAACTCAGCAGATGTTACAGGTAGAAGGGCGCCATGAG  1320 
 
QUERY  1321  ACTGAAACACCATGTAGTCAGTATAGTGGTGGAAGTGGGGGTGGTTGCAGTCAGTACAGTAGTGGAAGTGGGGGAGAGGGTGTTAGTGAAAGACACACTATATGCCAAACACCACTTACA  1440 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
SBJCT  1321  ACTGAAACACCATGTAGTCAGTATAGTGGTGGAAGTGGGGGTGGTTGCAGTCAGTACAGTAGTGGAAGTGGGGGAGAGGGTGTTAGTGAAAGACACACTATATGCCAAACACCACTTACA  1440 
 
QUERY  1441  AATATTTTAAATGTACTAAAAACTAGTAATGCAAAGGCAGCAATGTTAGCAAAATTTAAAGAGTTATACGGGGTGAGTTTTTCAGAATTAGTAAGACCATTTAAAAGTAATAAATCAACG  1560 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
SBJCT  1441  AATATTTTAAATGTACTAAAAACTAGTAATGCAAAGGCAGCAATGTTAGCAAAATTTAAAGAGTTATACGGGGTGAGTTTTTCAGAATTAGTAAGACCATTTAAAAGTAATAAATCAACG  1560 
 
QUERY  1561  TGTTGCGATTGGTGTATTGCTGCATTTGGACTTACACCCAGTATAGCTGACAGTATAAAAACACTATTACAACAATATTGTTTATATTTACACATTCAAAGTTTAGCATGTTCATGGGGA  1680 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
SBJCT  1561  TGTTGCGATTGGTGTATTGCTGCATTTGGACTTACACCCAGTATAGCTGACAGTATAAAAACACTATTACAACAATATTGTTTATATTTACACATTCAAAGTTTAGCATGTTCATGGGGA  1680 
 
QUERY  1681  ATGGTTGTGTTACTATTAGTAAGATATAAATGTGGAAAAAATAGAGAAACAATTGAAAAATTGCTGTCTAAACTATTATGTGTGTCTCCAATGTGTATGATGATAGAGCCTCCAAAATTG  1800 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
SBJCT  1681  ATGGTTGTGTTACTATTAGTAAGATATAAATGTGGAAAAAATAGAGAAACAATTGAAAAATTGCTGTCTAAACTATTATGTGTGTCTCCAATGTGTATGATGATAGAGCCTCCAAAATTG  1800 
 
QUERY  1801  CGTAGTACAGCAGCAGCATTATATTGGTATAAAACAGGTATATCAAATATTAGTGAAGTGTATGGAGACACGCCAGAATGGATACAAAGACAAACAGTATTACAACATAGTTTTAATGAT  1920 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
SBJCT  1801  CGTAGTACAGCAGCAGCATTATATTGGTATAAAACAGGTATATCAAATATTAGTGAAGTGTATGGAGACACGCCAGAATGGATACAAAGACAAACAGTATTACAACATAGTTTTAATGAT  1920 
 
QUERY  1921  TGTACATTTGAATTATCACAGATGGTACAATGGGCCTACGATAATGACATAGTAGACGATAGTGAAATTGCATATAAATATGCACAATTGGCAGACACTAATAGTAATGCAAGTGCCTTT  2040 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
SBJCT  1921  TGTACATTTGAATTATCACAGATGGTACAATGGGCCTACGATAATGACATAGTAGACGATAGTGAAATTGCATATAAATATGCACAATTGGCAGACACTAATAGTAATGCAAGTGCCTTT  2040 
 
QUERY  2041  CTAAAAAGTAATTCACAGGCAAAAATTGTAAAGGATTGTGCAACAATGTGTAGACATTATAAACGAGCAGAAAAAAAACAAATGAGTATGAGTCAATGGATAAAATATAGATGTGATAGG  2160 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
SBJCT  2041  CTAAAAAGTAATTCACAGGCAAAAATTGTAAAGGATTGTGCAACAATGTGTAGACATTATAAACGAGCAGAAAAAAAACAAATGAGTATGAGTCAATGGATAAAATATAGATGTGATAGG  2160 
 
QUERY  2161  GTAGATGATGGAGGTGATTGGAAGCAAATTGTTATGTTTTTAAGGTATCAAGGTGTAGAGTTTATGTCATTTTTAACTGCATTAAAAAGATTTTTGCAAGGCATACCTAAAAAAAATTGC  2280 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
SBJCT  2161  GTAGATGATGGAGGTGATTGGAAGCAAATTGTTATGTTTTTAAGGTATCAAGGTGTAGAGTTTATGTCATTTTTAACTGCATTAAAAAGATTTTTGCAAGGCATACCTAAAAAAAATTGC  2280 
 
QUERY  2281  ATATTACTATATGGTGCAGCTAACACAGGTAAATCATTATTTGGTATGAGTTTAATGAAATTTCTGCAAGGGTCTGTAATATGTTTTGTAAATTCTAAAAGCCATTTTTGGTTACAACCA  2400 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
SBJCT  2281  ATATTACTATATGGTGCAGCTAACACAGGTAAATCATTATTTGGTATGAGTTTAATGAAATTTCTGCAAGGGTCTGTAATATGTTTTGTAAATTCTAAAAGCCATTTTTGGTTACAACCA  2400 
 
QUERY  2401  TTAGCAGATGCCAAAATAGGTATGTTAGATGATGCTACAGTGCCCTGTTGGAACTACATAGATGACAATTTAAGAAATGCATTGGATGGAAATTTAGTTTCTATGGATGTAAAGCATAGA  2520 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
SBJCT  2401  TTAGCAGATGCCAAAATAGGTATGTTAGATGATGCTACAGTGCCCTGTTGGAACTACATAGATGACAATTTAAGAAATGCATTGGATGGAAATTTAGTTTCTATGGATGTAAAGCATAGA  2520 
 
QUERY  2521  CCATTGGTACAACTAAAATGCCCTCCATTATTAATTACATCTAACATTAATGCTGGTACAGATTCTAGGTGGCCTTATTTACATAATAGATTGGTGGTGTTTACATTTCCTAATGAGTTT  2640 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
SBJCT  2521  CCATTGGTACAACTAAAATGCCCTCCATTATTAATTACATCTAACATTAATGCTGGTACAGATTCTAGGTGGCCTTATTTACATAATAGATTGGTGGTGTTTACATTTCCTAATGAGTTT  2640 
 
QUERY  2641  CCATTTGACGAAAACGGAAATCCAGTGTATGAGCTTAATGATAAGAACTGGAAATCCTTTTTCTCAAGGACGTGGTCCAGATTAAGTTTGCACGAGGACGAGGACAAGGAAAACGATGGA  2760 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
SBJCT  2641  CCATTTGACGAAAACGGAAATCCAGTGTATGAGCTTAATGATAAGAACTGGAAATCCTTTTTCTCAAGGACGTGGTCCAGATTAAGTTTGCACGAGGACGAGGACAAGGAAAACGATGGA  2760 
 
QUERY  2761  GACTCTTTGCCAACGTTTAAATGTGTGTCAGGACAAAATACTAACACATTATGAAAATGATAGTACAGACCTACGTGACCATATAGACTATTGGAAACACATGCGCCTAGAATGTGCTAT  2880 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
SBJCT  2761  GACTCTTTGCCAACGTTTAAATGTGTGTCAGGACAAAATACTAACACATTATGAAAATGATAGTACAGACCTACGTGACCATATAGACTATTGGAAACACATGCGCCTAGAATGTGCTAT  2880 
 
QUERY  2881  TTATTACAAGGCCAGAGAAATGGGATTTAAACATATTAACCACCAGGTGGTGCCAACACTGGCTGTATCAAAGAATAAAGCATTACAAGCAATTGAACTGCAACTAACGTTAGAAACAAT  3000 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
SBJCT  2881  TTATTACAAGGCCAGAGAAATGGGATTTAAACATATTAACCACCAGGTGGTGCCAACACTGGCTGTATCAAAGAATAAAGCATTACAAGCAATTGAACTGCAACTAACGTTAGAAACAAT  3000 
 
QUERY  3001  ATATAACTCACAATATAGTAATGAAAAGTGGACATTACAAGACGTTAGCCTTGAAGTGTATTTAACTGCACCAACAGGATGTATAAAAAAACATGGATATACAGTGGAAGTGCAGTTTGA  3120 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
SBJCT  3001  ATATAACTCACAATATAGTAATGAAAAGTGGACATTACAAGACGTTAGCCTTGAAGTGTATTTAACTGCACCAACAGGATGTATAAAAAAACATGGATATACAGTGGAAGTGCAGTTTGA  3120 
 
QUERY  3121  TGGAGACATATGCAATACAATGCATTATACAAACTGGACACATATATATATTTGTGAAGAAGCATCAGTAACTGTGGTAGAGGGTCAAGTTGACTATTATGGTTTATATTATGTTCATGA  3240 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
SBJCT  3121  TGGAGACATATGCAATACAATGCATTATACAAACTGGACACATATATATATTTGTGAAGAAGCATCAGTAACTGTGGTAGAGGGTCAAGTTGACTATTATGGTTTATATTATGTTCATGA  3240 
 
QUERY  3241  AGGAATACGAACATATTTTGTGCAGTTTAAAGATGATGCAGAAAAATATAGTAAAAATAAAGTATGGGAAGTTCATGCGGGTGGTCAGGTAATATTATGTCCTACATCTGTGTTTAGCAG  3360 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
SBJCT  3241  AGGAATACGAACATATTTTGTGCAGTTTAAAGATGATGCAGAAAAATATAGTAAAAATAAAGTATGGGAAGTTCATGCGGGTGGTCAGGTAATATTATGTCCTACATCTGTGTTTAGCAG  3360 
 
QUERY  3361  CAACGAAGTATCCTCTCCTGAAATTATTAGGCAGCACTTGGCCAACCACTCCGCCGCGACCCATACCAAAGCCGTCGCCTTGGGCACCGAAGAAACACAGACGACTATCCAGCGACCAAG  3480 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
SBJCT  3361  CAACGAAGTATCCTCTCCTGAAATTATTAGGCAGCACTTGGCCAACCACTCCGCCGCGACCCATACCAAAGCCGTCGCCTTGGGCACCGAAGAAACACAGACGACTATCCAGCGACCAAG  3480 
 
QUERY  3481  ATCAGAGCCAGACACCGGAAACCCCTGCCACACCACTAAGTTGTTGCACAGAGACTCAGTGGACAGTGCTCCAATCCTCACTGCATTTAACAGCTCACACAAAGGACGGATTAACTGTAA  3600 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
SBJCT  3481  ATCAGAGCCAGACACCGGAAACCCCTGCCACACCACTAAGTTGTTGCACAGAGACTCAGTGGACAGTGCTCCAATCCTCACTGCATTTAACAGCTCACACAAAGGACGGATTAACTGTAA  3600 
 
QUERY  3601  TAGTAACACTACACCCATAGTACATTTAAAAGGTGATGCTAATACTTTAAAATGTTTAAGATATAGATTTAAAAAGCATTGTACATTGTATACTGCAGTGTCGTCTACATGGCATTGGAC  3720 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
SBJCT  3601  TAGTAACACTACACCCATAGTACATTTAAAAGGTGATGCTAATACTTTAAAATGTTTAAGATATAGATTTAAAAAGCATTGTACATTGTATACTGCAGTGTCGTCTACATGGCATTGGAC  3720 
 
QUERY  3721  AGGACATAATGTAAAACATAAAAGTGCAATTGTTACACTTACATATGATAGTGAATGGCAACGTGACCAATTTTTGTCTCAAGTTAAAATACCAAAAACTATTACAGTGTCTACTGGATT  3840 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
SBJCT  3721  AGGACATAATGTAAAACATAAAAGTGCAATTGTTACACTTACATATGATAGTGAATGGCAACGTGACCAATTTTTGTCTCAAGTTAAAATACCAAAAACTATTACAGTGTCTACTGGATT  3840 
 
QUERY  3841  TATGTCTATATGACAAATCTTGATACTGCATCCACAACATTACTGGCGTGCTTTTTGCTTTGCTTTTGTGTGCTTTTGTGTGTCTGCCTATTAATACGTCCGCTGCTTTTGTCTGTGTCT  3960 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
SBJCT  3841  TATGTCTATATGACAAATCTTGATACTGCATCCACAACATTACTGGCGTGCTTTTTGCTTTGCTTTTGTGTGCTTTTGTGTGTCTGCCTATTAATACGTCCGCTGCTTTTGTCTGTGTCT  3960 
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QUERY  3961  ACATACACATCATTAATACTATTGGTATTACTATTGTGGATAACAGCAGCCTCTGCGTTTAGGTGTTTTATTGTATATATTGTATTTGTTTATATACCATTATTTTTAATACATACACAT  4080 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
SBJCT  3961  ACATACACATCATTAATACTATTGGTATTACTATTGTGGATAACAGCAGCCTCTGCGTTTAGGTGTTTTATTGTATATATTGTATTTGTTTATATACCATTATTTTTAATACATACACAT  4080 
 
QUERY  4081  GCACGCTTTTTAATTACATAATGTATATGTACAAAATGTAATTGTTACATATAATTGTTGTATACCATAACTTACTATTTTTTCTTTTTTATTTTCATATATATTTTTTTTTTGTTTGTT  4200 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
SBJCT  4081  GCACGCTTTTTAATTACATAATGTATATGTACAAAATGTAATTGTTACATATAATTGTTGTATACCATAACTTACTATTTTTTCTTTTTTATTTTCATATATATTTTTTTTTTGTTTGTT  4200 
 
QUERY  4201  TGTTTGTTTTTTAATAAACTGTTATCACTTAACAATGCGACACAAACGTTCTGCAAAACGCACAAAACGTGCATCGGCTACCCAACTTTATAAAACATGCAAACAGGCAGGTACATGTCC  4320 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
SBJCT  4201  TGTTTGTTTTTTAATAAACTGTTATCACTTAACAATGCGACACAAACGTTCTGCAAAACGCACAAAACGTGCATCGGCTACCCAACTTTATAAAACATGCAAACAGGCAGGTACATGTCC  4320 
 
QUERY  4321  ACCTGACATTATACCTAAGGTTGAAGGCAAAACTATTGCTGATCAAATATTACAATATGGAAGTATGGGTGTATTTTTTGGTGGGTTAGGAATTGGAACAGGGTCGGGTACAGGCGGACG  4440 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
SBJCT  4321  ACCTGACATTATACCTAAGGTTGAAGGCAAAACTATTGCTGATCAAATATTACAATATGGAAGTATGGGTGTATTTTTTGGTGGGTTAGGAATTGGAACAGGGTCGGGTACAGGCGGACG  4440 
 
QUERY  4441  CACTGGGTATATTCCATTGGGAACAAGGCCTCCCACAGCTACAGATACACTTGCTCCTGTAAGACCCCCTTTAACAGTAGATCCTGTGGGCCCTTCCGATCCTTCTATAGTTTCTTTAGT  4560 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
SBJCT  4441  CACTGGGTATATTCCATTGGGAACAAGGCCTCCCACAGCTACAGATACACTTGCTCCTGTAAGACCCCCTTTAACAGTAGATCCTGTGGGCCCTTCCGATCCTTCTATAGTTTCTTTAGT  4560 
 
QUERY  4561  GGAAGAAACTAGTTTTATTGATGCTGGTGCACCAACATCTGTACCTTCCATTCCCCCAGATGTATCAGGATTTAGTATTACTACTTCAACTGATACCACACCTGCTATATTAGATATTAA  4680 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
SBJCT  4561  GGAAGAAACTAGTTTTATTGATGCTGGTGCACCAACATCTGTACCTTCCATTCCCCCAGATGTATCAGGATTTAGTATTACTACTTCAACTGATACCACACCTGCTATATTAGATATTAA  4680 
 
QUERY  4681  TAATACTGTTACTACTGTTACTACACATAATAATCCCACTTTCACTGACCCATCTGTATTGCAGCCTCCAACACCTGCAGAAACTGGAGGGCATTTTACACTTTCATCATCCACTATTAG  4800 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
SBJCT  4681  TAATACTGTTACTACTGTTACTACACATAATAATCCCACTTTCACTGACCCATCTGTATTGCAGCCTCCAACACCTGCAGAAACTGGAGGGCATTTTACACTTTCATCATCCACTATTAG  4800 
 
QUERY  4801  TACACATAATTATGAAGAAATTCCTATGGATACATTTATTGTTAGCACAAACCCTAACACAGTAACTAGTAGCACACCCATACCAGGGTCTCGCCCAGTGGCACGCCTAGGATTATATAG  4920 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
SBJCT  4801  TACACATAATTATGAAGAAATTCCTATGGATACATTTATTGTTAGCACAAACCCTAACACAGTAACTAGTAGCACACCCATACCAGGGTCTCGCCCAGTGGCACGCCTAGGATTATATAG  4920 
 
QUERY  4921  TCGCACAACACAACAAGTTAAAGTTGTAGACCCTGCTTTTATAACCACTCCCACTAAACTTATTACATATGATAATCCTGCATATGAAGGTATAGATGTGGATAATACATTATATTTTTC  5040 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
SBJCT  4921  TCGCACAACACAACAAGTTAAAGTTGTAGACCCTGCTTTTATAACCACTCCCACTAAACTTATTACATATGATAATCCTGCATATGAAGGTATAGATGTGGATAATACATTATATTTTTC  5040 
 
QUERY  5041  TAGTAATGATAATAGTATTAATATAGCTCCAGATCCTGACTTTTTGGATATAGTTGCTTTACATAGGCCAGCATTAACCTCTAGGCGTACTGGCATTAGGTACAGTAGAATTGGTAATAA  5160 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
SBJCT  5041  TAGTAATGATAATAGTATTAATATAGCTCCAGATCCTGACTTTTTGGATATAGTTGCTTTACATAGGCCAGCATTAACCTCTAGGCGTACTGGCATTAGGTACAGTAGAATTGGTAATAA  5160 
 
QUERY  5161  ACAAACACTACGTACTCGTAGTGGAAAATCTATAGGTGCTAAGGTACATTATTATTATGATTTTAGTACTATTGATTCTGCAGAAGAAATAGAATTACAAACTATAACACCTTCTACATA  5280 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
SBJCT  5161  ACAAACACTACGTACTCGTAGTGGAAAATCTATAGGTGCTAAGGTACATTATTATTATGATTTTAGTACTATTGATTCTGCAGAAGAAATAGAATTACAAACTATAACACCTTCTACATA  5280 
 
QUERY  5281  TACTACCACTTCACATGCAGCCTTACCTACTTCTATTAATAATGGATTATATGATATTTATGCAGATGACTTTATTACAGATACTTCTACAACCCCGGTACCATCTGTACCCTCTACATC  5400 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
SBJCT  5281  TACTACCACTTCACATGCAGCCTTACCTACTTCTATTAATAATGGATTATATGATATTTATGCAGATGACTTTATTACAGATACTTCTACAACCCCGGTACCATCTGTACCCTCTACATC  5400 
 
QUERY  5401  TTTATCAGGTTATATTCCTGCAAATACAACAATTCCTTTTGGTGGTGCATACAATATTCCTTTAGTATCAGGTCCTGATATACCCATTAATATAACTGACCAAGCTCCTTCATTAATTCC  5520 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
SBJCT  5401  TTTATCAGGTTATATTCCTGCAAATACAACAATTCCTTTTGGTGGTGCATACAATATTCCTTTAGTATCAGGTCCTGATATACCCATTAATATAACTGACCAAGCTCCTTCATTAATTCC  5520 
 
QUERY  5521  TATAGTTCCAGGGTCTCCACAATATACAATTATTGCTGATGCAGGTGACTTTTATTTACATCCTAGTTATTACATGTTACGAAAACGACGTAAACGTTTACCATATTTTTTTTCAGATGT  5640 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
SBJCT  5521  TATAGTTCCAGGGTCTCCACAATATACAATTATTGCTGATGCAGGTGACTTTTATTTACATCCTAGTTATTACATGTTACGAAAACGACGTAAACGTTTACCATATTTTTTTTCAGATGT  5640 
 
QUERY  5641  CTCTTTGGCTGCCTAGTGAGGCCACTGTCTACTTGCCTCCTGTCCCAGTATCTAAGGTTGTAAGCACGGATGAATATGTTGCACGCACAAACATATATTATCATGCAGGAACATCCAGAC  5760 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
SBJCT  5641  CTCTTTGGCTGCCTAGTGAGGCCACTGTCTACTTGCCTCCTGTCCCAGTATCTAAGGTTGTAAGCACGGATGAATATGTTGCACGCACAAACATATATTATCATGCAGGAACATCCAGAC  5760 
 
QUERY  5761  TACTTGCAGTTGGACATCCCTATTTTCCTATTAAAAAACCTAACAATAACAAAATATTAGTTCCTAAAGTATCAGGATTACAATACAGGGTATTTAGAATACATTTACCTGACCCCAATA  5880 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
SBJCT  5761  TACTTGCAGTTGGACATCCCTATTTTCCTATTAAAAAACCTAACAATAACAAAATATTAGTTCCTAAAGTATCAGGATTACAATACAGGGTATTTAGAATACATTTACCTGACCCCAATA  5880 
 
QUERY  5881  AGTTTGGTTTTCCTGACACCTCATTTTATAATCCAGATACACAGCGGCTGGTTTGGGCCTGTGTAGGTGTTGAGGTAGGCCGTGGTCAGCCATTAGGTGTGGGCATTAGTGGCCATCCTT  6000 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
SBJCT  5881  AGTTTGGTTTTCCTGACACCTCATTTTATAATCCAGATACACAGCGGCTGGTTTGGGCCTGTGTAGGTGTTGAGGTAGGCCGTGGTCAGCCATTAGGTGTGGGCATTAGTGGCCATCCTT  6000 
 
QUERY  6001  TATTAAATAAATTGGATGACACAGAAAATGCTAGTGCTTATGCAGCAAATGCAGGTGTGGATAATAGAGAATGTATATCTATGGATTACAAACAAACACAATTGTGTTTAATTGGTTGCA  6120 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
SBJCT  6001  TATTAAATAAATTGGATGACACAGAAAATGCTAGTGCTTATGCAGCAAATGCAGGTGTGGATAATAGAGAATGTATATCTATGGATTACAAACAAACACAATTGTGTTTAATTGGTTGCA  6120 
 
QUERY  6121  AACCACCTATAGGGGAACACTGGGGCAAAGGATCCCCATGTACCAATGTTGCAGTAAATCCAGGTGATTGTCCACCATTAGAGTTAATAAACACAGTTATTCAGGATGGTGATATGGTTG  6240 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
SBJCT  6121  AACCACCTATAGGGGAACACTGGGGCAAAGGATCCCCATGTACCAATGTTGCAGTAAATCCAGGTGATTGTCCACCATTAGAGTTAATAAACACAGTTATTCAGGATGGTGATATGGTTG  6240 
 
QUERY  6241  ATACTGGCTTTGGTGCTATGGACTTTACTACATTACAGGCTAACAAAAGTGAAGTTCCACTGGATATTTGTACATCTATTTGCAAATATCCAGATTATATTAAAATGGTGTCAGAACCAT  6360 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
SBJCT  6241  ATACTGGCTTTGGTGCTATGGACTTTACTACATTACAGGCTAACAAAAGTGAAGTTCCACTGGATATTTGTACATCTATTTGCAAATATCCAGATTATATTAAAATGGTGTCAGAACCAT  6360 
 
QUERY  6361  ATGGCGACAGCTTATTTTTTTATTTACGAAGGGAACAAATGTTTGTTAGACATTTATTTAATAGGGCTGGTGCTGTTGGTGAAAATGTACCAGACGATTTATACATTAAAGGCTCTGGGT  6480 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
SBJCT  6361  ATGGCGACAGCTTATTTTTTTATTTACGAAGGGAACAAATGTTTGTTAGACATTTATTTAATAGGGCTGGTGCTGTTGGTGAAAATGTACCAGACGATTTATACATTAAAGGCTCTGGGT  6480 
 
QUERY  6481  CTACTGCAAATTTAGCCAGTTCAAATTATTTTCCTACACCTAGTGGTTCTATGGTTACCTCTGATGCCCAAATATTCAATAAACCTTATTGGTTACAACGAGCACAGGGCCACAATAATG  6600 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
SBJCT  6481  CTACTGCAAATTTAGCCAGTTCAAATTATTTTCCTACACCTAGTGGTTCTATGGTTACCTCTGATGCCCAAATATTCAATAAACCTTATTGGTTACAACGAGCACAGGGCCACAATAATG  6600 
 
QUERY  6601  GCATTTGTTGGGGTAACCAACTATTTGTTACTGTTGTTGATACTACACGCAGTACAAATATGTCATTATGTGCTGCCATATCTACTTCAGAAACTACATATAAAAATACTAACTTTAAGG  6720 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
SBJCT  6601  GCATTTGTTGGGGTAACCAACTATTTGTTACTGTTGTTGATACTACACGCAGTACAAATATGTCATTATGTGCTGCCATATCTACTTCAGAAACTACATATAAAAATACTAACTTTAAGG  6720 
 
QUERY  6721  AGTACCTACGACATGGGGAGGAATATGATTTACAGTTTATTTTTCAACTGTGCAAAATAACCTTAACTGCAGACGTTATGACATACATACATTCTATGAATTCCACTATTTTGGAGGACT  6840 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
SBJCT  6721  AGTACCTACGACATGGGGAGGAATATGATTTACAGTTTATTTTTCAACTGTGCAAAATAACCTTAACTGCAGACGTTATGACATACATACATTCTATGAATTCCACTATTTTGGAGGACT  6840 
 
QUERY  6841  GGAATTTTGGTCTACAACCTCCCCCAGGAGGCACACTAGAAGATACTTATAGGTTTGTAACATCCCAGGCAATTGCTTGTCAAAAACATACACCTCCAGCACCTAAAGAAGATCCCCTTA  6960 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
SBJCT  6841  GGAATTTTGGTCTACAACCTCCCCCAGGAGGCACACTAGAAGATACTTATAGGTTTGTAACATCCCAGGCAATTGCTTGTCAAAAACATACACCTCCAGCACCTAAAGAAGATCCCCTTA  6960 
 
QUERY  6961  AAAAATACACTTTTTGGGAAGTAAATTTAAAGGAAAAGTTTTCTGCAGACCTAGATCAGTTTCCTTTAGGACGCAAATTTTTACTACAAGCAGGATTGAAGGCCAAACCAAAATTTACAT  7080 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
SBJCT  6961  AAAAATACACTTTTTGGGAAGTAAATTTAAAGGAAAAGTTTTCTGCAGACCTAGATCAGTTTCCTTTAGGACGCAAATTTTTACTACAAGCAGGATTGAAGGCCAAACCAAAATTTACAT  7080 
 
QUERY  7081  TAGGAAAACGAAAAGCTACACCCACCACCTCATCTACCTCTACAACTGCTAAACGCAAAAAACGTAAGCTGTAAGTATTGTATGTATGTTGAATTAGTGTTGTTTGTTGTTTATATGTTT  7200 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
SBJCT  7081  TAGGAAAACGAAAAGCTACACCCACCACCTCATCTACCTCTACAACTGCTAAACGCAAAAAACGTAAGCTGTAAGTATTGTATGTATGTTGAATTAGTGTTGTTTGTTGTTTATATGTTT  7200 
 
QUERY  7201  GTATGTGCTTGTATGTGCTTGTAAATATTAAGTTGTATGTGTGTTTGTATGTATGGTATAATAAACACGTGTGTATGTGTTTTTAAATGCTTGTGTAACTATTGTGTCATGCAACATAAA  7320 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
SBJCT  7201  GTATGTGCTTGTATGTGCTTGTAAATATTAAGTTGTATGTGTGTTTGTATGTATGGTATAATAAACACGTGTGTATGTGTTTTTAAATGCTTGTGTAACTATTGTGTCATGCAACATAAA  7320 
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QUERY  7321  TAAACTTATTGTTTCAACACCTACTAATTGTGTTGTGGTTATTCATTGTATATAAACTATATTTGCTACATCCTGTTTTTGTTTTATATATACTAAATTTTGTAGCGCCAGCGGCCATTT  7440 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
SBJCT  7321  TAAACTTATTGTTTCAACACCTACTAATTGTGTTGTGGTTATTCATTGTATATAAACTATATTTGCTACATCCTGTTTTTGTTTTATATATACTAAATTTTGTAGCGCCAGCGGCCATTT  7440 
 
QUERY  7441  TGTAGCTTCAACCGAATTCGGTTGCATGCTTTTTGGCACAAAATGTGTTTTTTTAAATAGTTCTATGTCAGCAACTATAGTTTAAACTTGTACGTTTCCTGCTTGCCATGCGTGCCAAAT  7560 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
SBJCT  7441  TGTAGCTTCAACCGAATTCGGTTGCATGCTTTTTGGCACAAAATGTGTTTTTTTAAATAGTTCTATGTCAGCAACTATAGTTTAAACTTGTACGTTTCCTGCTTGCCATGCGTGCCAAAT  7560 
 
QUERY  7561  CCCTGTTTTCCTGACCTGCACTGCTTGCCAACCATTCCATTGTTTTTTACACTGCACTATGTGCAACTACTGAATCACTATGTACATTGTGTCATATAAAATAAATCACTATGCGCCAAC  7680 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
SBJCT  7561  CCCTGTTTTCCTGACCTGCACTGCTTGCCAACCATTCCATTGTTTTTTACACTGCACTATGTGCAACTACTGAATCACTATGTACATTGTGTCATATAAAATAAATCACTATGCGCCAAC  7680 
 
QUERY  7681  GCCTTACATACCGCTGTTAGGCACATATTTTTGGCTTGTTTTAACTAACCTAATTGCATATTTGGCATAAGGTTTAAACTTCTAAGGCCAACTAAATGTCACCCTAGTTCATACATGAAC  7800 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
SBJCT  7681  GCCTTACATACCGCTGTTAGGCACATATTTTTGGCTTGTTTTAACTAACCTAATTGCATATTTGGCATAAGGTTTAAACTTCTAAGGCCAACTAAATGTCACCCTAGTTCATACATGAAC  7800 
 
QUERY  7801  TGTGTAAAGGTTAGTCATACATTGTTCATTTGTAAAACTGCACATGGGTGTGTGCAAACCGTTTTGGGTTACACATTTACAAGCAACTTATATAATAATACTAA  7904 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
SBJCT  7801  TGTGTAAAGGTTAGTCATACATTGTTCATTTGTAAAACTGCACATGGGTGTGTGCAAACCGTTTTGGGTTACACATTTACAAGCAACTTATATAATAATACTAA  7904 
 
 
 
 
BLASTN results  
Sequence ID: lcl|Query_54813  Length: 2685  Number of Matches: 1 
Range 1: 1 to 2685 
Score Expect Identities Gaps Strand 
4948 bits(2679) 0.0 2684/2686(99 %) 1/2686(0 %) Plus/Plus 
pUC18  1     GCGCCCAATACGCAAACCGCCTCTCCCCGCGCGTTGGCCGATTCATTAATGCAGCTGGCACGACAGGTTTCCCGACTGGAAAGCGGGCAGTGAGCGCAACGCAATTAATGTGAGTTAGCT  120 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
SAMPL  1     GCGCCCAATACGCAAACCGCCTCTCCCCGCGCGTTGGCCGATTCATTAATGCAGCTGGCACGACAGGTTTCCCGACTGGAAAGCGGGCAGTGAGCGCAACGCAATTAATGTGAGTTAGCT  120 
 
PUC18  121   CACTCATTAGGCACCCCAGGCTTTACACTTTATGCTTCCGGCTCGTATGTTGTGTGGAATTGTGAGCGGATAACAATTTCACACAGGAAACAGCTATGACCATGATTACGAATTCGAGCT  240 
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| |||||||||||||||||||| 
SAMPL  121   CACTCATTAGGCACCCCAGGCTTTACACTTTATGCTTCCGGCTCGTATGTTGTGTGGAATTGTGAGCGGATAACAATTTCACACAGGAAACAGCTATGA-CATGATTACGAATTCGAGCT  239 
 
PUC18  241   CGGTACCCGGGGATCCTCTAGAGTCGACCTGCAGGCATGCAAGCTTGGCACTGGCCGTCGTTTTACAACGTCGTGACTGGGAAAACCCTGGCGTTACCCAACTTAATCGCCTTGCAGCAC  360 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
SAMPL  240   CGGTACCCGGGGATCCTCTAGAGTCGACCTGCAGGCATGCAAGCTTGGCACTGGCCGTCGTTTTACAACGTCGTGACTGGGAAAACCCTGGCGTTACCCAACTTAATCGCCTTGCAGCAC  359 
 
PUC18  361   ATCCCCCTTTCGCCAGCTGGCGTAATAGCGAAGAGGCCCGCACCGATCGCCCTTCCCAACAGTTGCGCAGCCTGAATGGCGAATGGCGCCTGATGCGGTATTTTCTCCTTACGCATCTGT  480 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
SAMPL  360   ATCCCCCTTTCGCCAGCTGGCGTAATAGCGAAGAGGCCCGCACCGATCGCCCTTCCCAACAGTTGCGCAGCCTGAATGGCGAATGGCGCCTGATGCGGTATTTTCTCCTTACGCATCTGT  479 
 
PUC18  481   GCGGTATTTCACACCGCATATGGTGCACTCTCAGTACAATCTGCTCTGATGCCGCATAGTTAAGCCAGCCCCGACACCCGCCAACACCCGCTGACGCGCCCTGACGGGCTTGTCTGCTCC  600 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
SAMPL  480   GCGGTATTTCACACCGCATATGGTGCACTCTCAGTACAATCTGCTCTGATGCCGCATAGTTAAGCCAGCCCCGACACCCGCCAACACCCGCTGACGCGCCCTGACGGGCTTGTCTGCTCC  599 
 
PUC18  601   CGGCATCCGCTTACAGACAAGCTGTGACCGTCTCCGGGAGCTGCATGTGTCAGAGGTTTTCACCGTCATCACCGAAACGCGCGAGACGAAAGGGCCTCGTGATACGCCTATTTTTATAGG  720 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
SAMPL  600   CGGCATCCGCTTACAGACAAGCTGTGACCGTCTCCGGGAGCTGCATGTGTCAGAGGTTTTCACCGTCATCACCGAAACGCGCGAGACGAAAGGGCCTCGTGATACGCCTATTTTTATAGG  719 
 
PUC18  721   TTAATGTCATGATAATAATGGTTTCTTAGACGTCAGGTGGCACTTTTCGGGGAAATGTGCGCGGAACCCCTATTTGTTTATTTTTCTAAATACATTCAAATATGTATCCGCTCATGAGAC  840 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
SAMPL  720   TTAATGTCATGATAATAATGGTTTCTTAGACGTCAGGTGGCACTTTTCGGGGAAATGTGCGCGGAACCCCTATTTGTTTATTTTTCTAAATACATTCAAATATGTATCCGCTCATGAGAC  839 
 
PUC18  841   AATAACCCTGATAAATGCTTCAATAATATTGAAAAAGGAAGAGTATGAGTATTCAACATTTCCGTGTCGCCCTTATTCCCTTTTTTGCGGCATTTTGCCTTCCTGTTTTTGCTCACCCAG  960 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
SAMPL  840   AATAACCCTGATAAATGCTTCAATAATATTGAAAAAGGAAGAGTATGAGTATTCAACATTTCCGTGTCGCCCTTATTCCCTTTTTTGCGGCATTTTGCCTTCCTGTTTTTGCTCACCCAG  959 
 
PUC18  961   AAACGCTGGTGAAAGTAAAAGATGCTGAAGATCAGTTGGGTGCACGAGTGGGTTACATCGAACTGGATCTCAACAGCGGTAAGATCCTTGAGAGTTTTCGCCCCGAAGAACGTTTTCCAA  1080 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
SAMPL  960   AAACGCTGGTGAAAGTAAAAGATGCTGAAGATCAGTTGGGTGCACGAGTGGGTTACATCGAACTGGATCTCAACAGCGGTAAGATCCTTGAGAGTTTTCGCCCCGAAGAACGTTTTCCAA  1079 
 
PUC18  1081  TGATGAGCACTTTTAAAGTTCTGCTATGTGGCGCGGTATTATCCCGTATTGACGCCGGGCAAGAGCAACTCGGTCGCCGCATACACTATTCTCAGAATGACTTGGTTGAGTACTCACCAG  1200 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
SAMPL  1080  TGATGAGCACTTTTAAAGTTCTGCTATGTGGCGCGGTATTATCCCGTATTGACGCCGGGCAAGAGCAACTCGGTCGCCGCATACACTATTCTCAGAATGACTTGGTTGAGTACTCACCAG  1199 
 
PUC18  1201  TCACAGAAAAGCATCTTACGGATGGCATGACAGTAAGAGAATTATGCAGTGCTGCCATAACCATGAGTGATAACACTGCGGCCAACTTACTTCTGACAACGATCGGAGGACCGAAGGAGC  1320 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
SAMPL  1200  TCACAGAAAAGCATCTTACGGATGGCATGACAGTAAGAGAATTATGCAGTGCTGCCATAACCATGAGTGATAACACTGCGGCCAACTTACTTCTGACAACGATCGGAGGACCGAAGGAGC  1319 
 
PUC18  1321  TAACCGCTTTTTTGCACAACATGGGGGATCATGTAACTCGCCTTGATCGTTGGGAACCGGAGCTGAATGAAGCCATACCAAACGACGAGCGTGACACCACGATGCCTGTAGCAATGGCAA  1440 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
SAMPL  1320  TAACCGCTTTTTTGCACAACATGGGGGATCATGTAACTCGCCTTGATCGTTGGGAACCGGAGCTGAATGAAGCCATACCAAACGACGAGCGTGACACCACGATGCCTGTAGCAATGGCAA  1439 
 
PUC18  1441  CAACGTTGCGCAAACTATTAACTGGCGAACTACTTACTCTAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGCGGATAAAGTTGCAGGACCACTTCTGCGCTCGGCCCTTCCGGCTG  1560 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
SAMPL  1440  CAACGTTGCGCAAACTATTAACTGGCGAACTACTTACTCTAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGCGGATAAAGTTGCAGGACCACTTCTGCGCTCGGCCCTTCCGGCTG  1559 
 
PUC18  1561  GCTGGTTTATTGCTGATAAATCTGGAGCCGGTGAGCGTGGGTCTCGCGGTATCATTGCAGCACTGGGGCCAGATGGTAAGCCCTCCCGTATCGTAGTTATCTACACGACGGGGAGTCAGG  1680 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
SAMPL  1560  GCTGGTTTATTGCTGATAAATCTGGAGCCGGTGAGCGTGGGTCTCGCGGTATCATTGCAGCACTGGGGCCAGATGGTAAGCCCTCCCGTATCGTAGTTATCTACACGACGGGGAGTCAGG  1679 
 
PUC18  1681  CAACTATGGATGAACGAAATAGACAGATCGCTGAGATAGGTGCCTCACTGATTAAGCATTGGTAACTGTCAGACCAAGTTTACTCATATATACTTTAGATTGATTTAAAACTTCATTTTT  1800 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
SAMPL  1680  CAACTATGGATGAACGAAATAGACAGATCGCTGAGATAGGTGCCTCACTGATTAAGCATTGGTAACTGTCAGACCAAGTTTACTCATATATACTTTAGATTGATTTAAAACTTCATTTTT  1799 
 
PUC18  1801  AATTTAAAAGGATCTAGGTGAAGATCCTTTTTGATAATCTCATGACCAAAATCCCTTAACGTGAGTTTTCGTTCCACTGAGCGTCAGACCCCGTAGAAAAGATCAAAGGATCTTCTTGAG  1920 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
SAMPL  1800  AATTTAAAAGGATCTAGGTGAAGATCCTTTTTGATAATCTCATGACCAAAATCCCTTAACGTGAGTTTTCGTTCCACTGAGCGTCAGACCCCGTAGAAAAGATCAAAGGATCTTCTTGAG  1919 
 
PUC18  1921  ATCCTTTTTTTCTGCGCGTAATCTGCTGCTTGCAAACAAAAAAACCACCGCTACCAGCGGTGGTTTGTTTGCCGGATCAAGAGCTACCAACTCTTTTTCCGAAGGTAACTGGCTTCAGCA  2040 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
SAMPL  1920  ATCCTTTTTTTCTGCGCGTAATCTGCTGCTTGCAAACAAAAAAACCACCGCTACCAGCGGTGGTTTGTTTGCCGGATCAAGAGCTACCAACTCTTTTTCCGAAGGTAACTGGCTTCAGCA  2039 
 
PUC18  2041  GAGCGCAGATACCAAATACTGTCCTTCTAGTGTAGCCGTAGTTAGGCCACCACTTCAAGAACTCTGTAGCACCGCCTACATACCTCGCTCTGCTAATCCTGTTACCAGTGGCTGCTGCCA  2160 
             |||||||||||||||||||||| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
SAMPL  2040  GAGCGCAGATACCAAATACTGTTCTTCTAGTGTAGCCGTAGTTAGGCCACCACTTCAAGAACTCTGTAGCACCGCCTACATACCTCGCTCTGCTAATCCTGTTACCAGTGGCTGCTGCCA  2159 
 
PUC18  2161  GTGGCGATAAGTCGTGTCTTACCGGGTTGGACTCAAGACGATAGTTACCGGATAAGGCGCAGCGGTCGGGCTGAACGGGGGGTTCGTGCACACAGCCCAGCTTGGAGCGAACGACCTACA  2280 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
SAMPL  2160  GTGGCGATAAGTCGTGTCTTACCGGGTTGGACTCAAGACGATAGTTACCGGATAAGGCGCAGCGGTCGGGCTGAACGGGGGGTTCGTGCACACAGCCCAGCTTGGAGCGAACGACCTACA  2279 
 
PUC18  2281  CCGAACTGAGATACCTACAGCGTGAGCTATGAGAAAGCGCCACGCTTCCCGAAGGGAGAAAGGCGGACAGGTATCCGGTAAGCGGCAGGGTCGGAACAGGAGAGCGCACGAGGGAGCTTC  2400 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
SAMPL  2280  CCGAACTGAGATACCTACAGCGTGAGCTATGAGAAAGCGCCACGCTTCCCGAAGGGAGAAAGGCGGACAGGTATCCGGTAAGCGGCAGGGTCGGAACAGGAGAGCGCACGAGGGAGCTTC  2399 
 
PUC18  2401  CAGGGGGAAACGCCTGGTATCTTTATAGTCCTGTCGGGTTTCGCCACCTCTGACTTGAGCGTCGATTTTTGTGATGCTCGTCAGGGGGGCGGAGCCTATGGAAAAACGCCAGCAACGCGG  2520 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
SAMPL  2400  CAGGGGGAAACGCCTGGTATCTTTATAGTCCTGTCGGGTTTCGCCACCTCTGACTTGAGCGTCGATTTTTGTGATGCTCGTCAGGGGGGCGGAGCCTATGGAAAAACGCCAGCAACGCGG  2519 
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PUC18  2521  CCTTTTTACGGTTCCTGGCCTTTTGCTGGCCTTTTGCTCACATGTTCTTTCCTGCGTTATCCCCTGATTCTGTGGATAACCGTATTACCGCCTTTGAGTGAGCTGATACCGCTCGCCGCA  2640 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
SAMPL  2520  CCTTTTTACGGTTCCTGGCCTTTTGCTGGCCTTTTGCTCACATGTTCTTTCCTGCGTTATCCCCTGATTCTGTGGATAACCGTATTACCGCCTTTGAGTGAGCTGATACCGCTCGCCGCA  2639 
 
PUC18  2641  GCCGAACGACCGAGCGCAGCGAGTCAGTGAGCGAGGAAGCGGAAGA  2686 
             |||||||||||||||||||||||||||||||||||||||||||||| 
SAMPL  2640  GCCGAACGACCGAGCGCAGCGAGTCAGTGAGCGAGGAAGCGGAAGA  2685 
 
 
 
4.4.5 Bioinformatics Analysis: Bowtie 2 Alignment and CountNicks.pm Cleavage 
Intensities 
 
Bowtie 2 alignment statistics are summarized in Table 4.4. Unique sequencing reads 
were aligned to the HPV16/pUC18 reference genome using the --score-min C,0.  
 
Table 4.4. Alignment Information of NGS Library Samples.  
Sample Total Reads Aligned Exactly 1 Time Aligned > 1 Times 
Control-1 41,796,887 33,704,078 0 
PA1-1 (2 µM) 54,016,161 41,737,458 0 
PA1-1 (20 µM) 50,338,723 39,302,839 0 
Control-2 23,221,340 17,147,585 0 
PA1-2 (20 µM) 21,465,957 14,040,109 0 
Control-3 20,910,159 15,826,078 0 
PA1-3 (20 µM) 20,527,338 14,508,498 0 
Reads were mapped using Bowtie 2 (--score-min C,0) 
The mapped reads in the SAM file were then processed with CountNicks.pm. 
Because attack of hydroxyl radical results in the chemical destruction of the nucleotide 
base (refer to Section 4.2.2), the CountNicks.pm script assumes that the start of the 
sequence read occurs just 3’ of the cleaved nucleotide. The output file obtained from the 
CountNicks.pm script consists of normalized cleavage intensities in reads per million 
(RPM) at each nucleotide position of the plasmid sequence. The average of the 
normalized cleavage intensities for the control samples (n = 3) and for the PA1-treated 
samples (n = 2) were calculated and used for subsequent analysis. Figure 4.14 
summarizes the normalized, global cleavage intensities (RPM) for HPV16/pUC18 at 
single-nucleotide resolution. Even at this scale, hotspots of PA1 binding can be observed 
in the HPV16/pUC18 sequence.   
  
 
 
 
Figure 4.13. Reference Genome for HPV16/pUC18 Plasmid and BLASTN Alignment. (A) Reference genome used
to align sequence reads from ·OH-treated plasmid experiments. The reference genome started at nucleotide position
1344 of the pUC18 sequence. Blue font corresponds to pUC18 DNA sequence, red underlined font depicts BamHI
cloning sites and black bold font corresponds to HPV16 DNA sequence. BLASTN analyses of (B) the HPV16 DNA
sequence and (C) the pUC18 DNA sequence. Red bold font highlights minor differences between the determined and
published pUC18 DNA vector sequence.  
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The % change in cleavage protection for each nucleotide was then determined by 
calculating the ratio of the normalized cleavage intensities from the drug-treated sample 
to the control sample, subtracting this ratio from 1 and multiplying this value by 100 
(Equation 4.4). 
 
%	݄ܿܽ݊݃݁	݅݊	݈ܿ݁ܽݒܽ݃݁	݌ݎ݋ݐ݁ܿݐ݅݋݊ ൌ ሺ1 െ	 ௖௟௘௔௩௔௚௘	௜௡௧௘௡௦௜௧௬	ሺௗ௥௨௚ሻ௖௟௘௔௩௔௚௘	௜௡௧௘௡௦௜௧௬	ሺ௖௢௡௧௥௢௟ሻሻ	ݔ	100                (4.4) 
 
Footprints were identified by plotting the % change in cleavage protection against the 
nucleotide plasmid position and represented in a histogram form. Positive values 
correspond to nucleotides that are protected by bound PA1. 
 
4.4.6 ·OH-Seq Provides Single-Nucleotide Resolution of PA1 Binding Sites  
 
Our lab previously reported the PA1 binding sites within the Long Control Region 
(LCR) of HPV16 (nucleotides 7348-122) by DNase I footprinting and affinity cleavage 
methodologies.64 We have focused our attention in this region of the HPV genome 
because it harbors the promoter and enhancer elements important for gene expression and 
replication.75  
PA1 footprints could not be detected at low PA1 (2 µM) concentration. Under these 
conditions, the molar ratio of drug added to DNA molecules is approximately 50-fold. As 
a result, the vast majority of the available sites are not saturated by PA, leading to a low 
Figure 4.14. Global Cleavage Intensities for HPV16/pUC18. Average cleavage intensities for control (no PA1) and
PA1-treated samples were plotted for the entire HPV16/pUC18 duplex at single-nucleotide resolution. Plots summarize
the cleavage intensities observed on the top and bottom strands (left and right panels, respectively). (A) HPV16/pUC18
plasmid subjected to 2 µM PA1. (B) HPV16/pUC18 plasmid subjected to 20 µM PA1. Red bars above cleavage
patterns highlighted representative regions of extensive nucleotide (nt) protection from ·OH cleavage by bound PA1.
Black traces, no PA1 present. Blue traces, PA1 present.  
A
B
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signal-to-noise ratio. Therefore, the data for hydroxyl radical footprinting at 20 µM PA1 
are provided (500:1 PA:DNA ratio). Results from a representative region from 7351-
7450 nt in the HPV16 LCR (Figure 4.15) demonstrate PA1 binding abates cleavage in 
both the forward and reverse strands by hydroxyl radicals relative to the control.  
 
                                      
 
Figure 4.15. Representative Hydroxyl Radical Footprints of 20 µM PA1 in a Region of the HPV16 LCR (7351-
7451). The top graphs in each panel correspond to the normalized cleavage intensities per nucleotide for the control
(black trace) and the PA1-treated samples (blue trace). Below each graph, the % change in cleavage protection per
nucleotide is depicted in histogram form. Positive values correspond to nucleotides protected in different degrees by
bound PA1. Results for (A) forward and (B) reverse strands are provided. 
A 
B 
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Figure 4.16. Hydroxyl Radical Footprinting of 20 µM PA1 in the HPV16 LCR. HPV16 LCR (7158-83 bp)
sequence shown as a DNA duplex with the viral E1- and E2-binding sites indicated in orange. The vertical bars on top
and below the sequences correspond to the calculated % change in cleavage protection for the forward/top and
reverse/bottom strands, respectively. Each protected region is numbered from 1 to 19 in red font. The blue horizontal
lines show the PA1 binding sites previously determined by DNase I and affinity cleavage experiments from 7390-70
bp. The green horizontal lines depict the PA1 binding sites consistent with the ·OH-Seq data. Inset depicts forward and
reverse binding motifs for PA1. Sequences highlighted in red correspond to forward cognate sites, while underlined
sequences depict reverse cognate sites. 
167 
 
Figure 4.16 summarizes the PA1 binding sites at 20 µM toward the DNA sequence 
comprising 7151-96 bp of the HPV16 viral genome. The HPV16 LCR consists of the 
region from 7158 to 83 bp that harbors the binding sites for the viral E1 helicase and the 
E2 DNA-binding protein. The latter binds the major groove of the palindromic sequence 
ACCgN4cGGT (upper case designates required nucleotides, lower case represents 
preferred nucleotides, and N denotes no nucleotide preference) in close proximity to the 
viral origin of replication (oriR).76,77 There, E1 recruits the host replication machinery to 
initiate viral DNA replication.53 In this fragment, there are a total of 21 predicted cognate 
binding sites, with 13 of these sites corresponding to sequences that can accommodate the 
forward binding motif and 8 sites corresponding to the reverse binding motif. The 
forward motif refers to alignment of the PA1 N-terminus to C-terminus vector with the 
5’-3’ direction of the DNA, whereas a reverse motif describes the PA1 NC vector 
alignment with the 3’-5’ direction of the DNA (see Figure 4.16 Inset). According to the 
protected regions, there are at least 19 PA1 binding sites, although most of these regions 
can accommodate multiple binding events within the ensemble of DNA molecules. The 
binding sites were assigned to sequences located in the center of the protected regions. 
These sequences were further identified based on the assumption that PA1 prefers sites 
with the least number of mismatches. This may not always be true,52,62-64 but it is not far 
off and provides the best starting point for analysis. The observed protected regions 
determined by hydroxyl radical are in agreement with those previously reported by 
Vasilieva et al. However, the ·OH-Seq results show that under the present experimental 
conditions where the genome is incorporated into a strained supercoiled plasmid, many of 
the multiple mismatch sites are not populated by PA1: most protected regions containing 
cognate (forward and reverse motifs) and single-base-pair mismatch sequences. Of 
course, even a “single-base-pair” mismatch vastly increases the number of binding sites 
available to PA1 over published, predictive rules; and “single” is somewhat  misleading 
because many different single-base-pair mismatch sites are observed in these new results. 
Protected region 1 can be explained by PA1 binding to two forward, single-base-pair 
mismatch sites (5’-AAGTATTGTA and 5’-TTGTATGTAT; mismatch underlined). 
Protected region 2 can be explained by PA1 binding to a single-base-pair mismatch site 
(5’-TTGTTGTTTA) and two cognate sites; one event in the forward (5’-TTGTTTATAT) 
and the other in the reverse orientation (5’-AACATATAAA). Note that while PA1 can 
bind to the latter in a reverse orientation; it may prefer to bind in the forward orientation 
leading to a PA1-DNA single-base-pair mismatch interaction. Similarly, protected region 
3 can be explained by PA1 occupancy of two cognate sites in the forward (5’-
TTGTAAATAT) and reverse (5’-AACTTAATAT) binding motifs. Protected region 4 
results from PA1 binding to two single-base-pair mismatch sites (5’-GTGTTTATTA and 
5’-TGGTATAATA). Similarly, protected region 5 can be explained by PA1 binding to 
three single-base-pair mismatch sites (5’-ATGTGTTTTT, 5’-GTGTTTTTAA and 5’-
AAGCATTTAA). Protected region 6 can be explained by PA1 binding to a single-base-
pair mismatch site (5’-TTGAAACAAT) and two cognate sites in the reverse (5’-
AACATAAATA) and forward (5’-AAGTTTATTT) orientations.  
Protected regions 7, 8 and 17 exhibit an extended protection pattern as a result of their 
high A·T content. Protected region 7 can be explained by PA1 binding to a double-base-
pair mismatch site (5’-TTCATTGTAT) and two cognate sites in the forward (5’-
TTGTATATAA) and reverse (5’-AACTATATTT) orientations. Protected regions 8 thru 
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18 have been previously described in the literature.64 However, most of the protected 
regions observed in the present study contain cognate (forward and reverse motifs) and a 
range of single-base-pair mismatch sequences. Furthermore, regions of high G·C content 
(region flanked by protected regions 16 and 17, in addition to others not shown) are not 
bound by PA1 in this experiment.   
 Of note, PA1 populates sequences near, as well as sequences shared by the E2 and 
E1 protein binding sites. Specifically, an extended protection is observed within the E1 
binding site (protected region 17) and protection near one of the E2 binding sites is also 
observed (protected region 18). As a result, PA1 could disrupt E1- and E2-DNA 
interactions thus inhibiting their functions within the viral lifecycle. Furthermore, 
polyamide-binding events impart significant structural perturbations to DNA. 
Specifically, eight-ring polyamides have been shown to widen the minor groove by up to 
4 Å, leading to a narrowing of the major groove by 4 Å and bending of the DNA helix.78 
These perturbations provide an elegant molecular mechanism for the allosteric repression 
of gene transcription by polyamides since a narrow major groove would fail to properly 
accommodate the interaction moieties from DNA-binding proteins.78 This mechanism 
seems particularly powerful given the high affinity of hairpin PAs to DNA is similar to 
the affinities observed by many transcription factors to DNA.79 Similarly, these synthetic 
DNA-targeting agents can disrupt viral protein-DNA interactions on the viral genome. 
Yasuda et al. designed Py-Im hairpin polyamides targeting the Epstein-Barr Nuclear 
Antigen 1 binding sites in the origin of plasmid replication (oriP) within the viral 
genome, and demonstrated an efficient inhibition of EBNA1-binding and reduced 
recruitment of host replication machinery to the oriP in chromatin immunoprecipitation 
(ChIP) assays.80 Schaal et al. showed that tandem hairpin polyamides were able to 
displace the HPV18 E2, a major groove binding protein, from its canonical E2BS4 (E2 
Binding Site 4) DNA binding site. Consistent with the allosteric model, the authors 
showed that minor-groove binding tandem hairpin polyamides prevented the bending of 
DNA structure required for E2 binding in the minor groove, and also showed that PAs 
displace E2 from DNA.81     
We have previously shown that PA1 binds to the minor groove of DNA (Chapter 2). 
Because approximately 80 % of hydroxyl radical attacks take place in the minor groove, 
the protection patterns are expected to be asymmetrical with a 3’ shift between opposite 
strands.26,27 The unexpected 5’-shift observed and extended protection toward the 5’-end 
in the PA1 footprints may be a result of our detection methods. Here, we relied on 
hydroxyl radicals to cleavage the plasmid DNA. However, depending the site of attack by 
hydroxyl radicals, different 5’-end groups can be generated. Specifically, abstraction of a 
hydrogen atom at the C4’ site of the deoxyribose ring results in the formation of a 5’-
phosphate, while attack at the C5’ site leads to the generation of an aldehyde. Because 
fragments consisting of 5’-phosphates are the only species that can be ligated to NGS 
adapters in our method, it is possible that binding of PA1 may result in the increased 
formation of products containing a 5’-aldehyde.27,82 Further investigation is required to 
test this hypothesis, including repeating these experiments using DNase I as the cleavage 
agent. Similar to our results, Bialonska et al. studied the structural details of DAPI- and 
Hoechst-DNA complexes by a hydroxyl radical footprinting method coupled to capillary 
electrophoresis. The data also revealed a 5’ shift in the protected regions for these minor 
groove binders that agreed to the predicted solvent accessible surface areas of the 
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deoxyribose hydrogen atoms.26 Indexing or other bioinformatics problems could also 
cause the observed 5’-shift; however, there is no indication of misalignment of our 
footprinting data. 
 
4.4.7 Hydroxyl Radical as a Chemical Probe Reveals Structural Details 
 
4.4.7.1 Comparison of Experimentally Determined Hydroxyl Radical Cleavage 
Patterns and ∙OH Radical Cleavage Intensity Database (ORChID) Prediction 
 
The degree of reactivity of hydroxyl radical toward the different hydrogen atoms 
correlates with their solvent accessibility within the DNA backbone. As a result, the 
relative hydroxyl radical pattern reflects the structure and local shape of DNA. 
Greengaum et al. developed ORChID, a tetramer window algorithm, for predicting the 
hydroxyl radical cleavage patterns of any input sequence based on experimentally 
determined cleavage data with high accuracy.21  
To investigate the relative correlation between the experimentally determined 
hydroxyl radical cleavage patterns and the ORChID predicted cleavage patterns for our 
case, we calculated the Pearson coefficients for all the pairwise cleavage patterns.21 
Although the determined Pearson correlation coefficients were low (rforward strand = 0.27 
and rreverse strand = 0.25), visual comparison of the experimental and predicted cleavage 
patterns show similar cleavage features (Figure 4.18). 
  
  
4.4.7.2 Hydroxyl Radical Cleavage at Adenine Tracts 
 
It is well-established that A/T-rich regions including poly(dA)·poly(dT) exhibit 
narrow minor grooves.83 Indeed, Tullius and colleagues demonstrated that hydroxyl 
radical cleavage at polyA tracts result in a sequential decrease in the cleavage rate per 
adenine in the 5’ to 3’ vector, with the 3’-most adenine displaying the lowest cutting 
Figure 4.18. Comparison between ·OH-Seq Cleavage Patterns and ORChID Predictions. Experimentally
determined hydroxyl radical patterns aligned to ORChID predicted cleavage patterns.
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frequency. Correspondly, the complement strand, harboring the polyT tract, displays a 
similar decrease in the cleavage rate, except that the lowest cutting frequency is offset 
one to two bases in the 3’ direction. These results are in agreement with the expected 
narrow minor groove of these adenine tracts.19,83  
We also observed decreased cleavage intensity in our ·OH-Seq data corresponding to 
adenine tracts. Figure 4.19 provides the ·OH cleavage of the region from 904 to 973 bp 
in the HPV16 genome. The region corresponding to a 9 bp adenine tract (5’-
AAAAAAAAA; 941-949 bp) displays decreased cleavage intensity within the A/T-rich 
sequence. Inspection of the adenine-rich strand reveals an overall decrease of the 
cleavage rate in the 5’ to 3’ direction; however the cutting minimum is not seen for the 
3’-most adenine. Conversely, the cleavage rate for the thymine-rich strand smoothly 
decreases in the 3’ to 5’ direction with lowest cutting near the 5’-most thymine. 
Comparison of the minima from the adenine-rich and thymine-rich strands reveals an 
offset by roughly 5 bases in the 3’ direction. These results require further investigation. 
 
 
 
 
Figure 4.19. Hydroxyl Radical Cleavage of an Adenine Tract within HPV16 (904-973 bp). Hydroxyl radical
patterns for the forward and reverse strands of a region in the HPV16 genome harboring a 9 bp adenine/thymine tract
for control experiments (n = 3). Sequence is provided above the cleavage pattern. (A) Forward strand with adenine
tract, (B) reverse strand with thymine tract. 
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4.5 CONCLUSIONS 
 
We have used a hydroxyl radical footprinting method coupled with massively parallel 
DNA sequencing (·OH-Seq) to map PA1 binding sites at single-nucleotide resolution in 
the viral genome of HPV16; the first example of single-nucleotide resolution mapping of 
PA binding at the genomic level. Because of its high-throughput nature, next-generation 
sequencing allows for the analysis at a genome-wide scale. Furthermore, this method 
allows for the detection of fragmented DNA without the requirement of radioactive end-
labelling.   
Here, we present the PA1 binding sites determined by hydroxyl radical footprinting 
in the viral genome of HPV16. The binding sites observed in the HPV16 LCR are in 
agreement with those previously reported by our group relying on DNase I and affinity 
cleavage experiments coupled to automated capillary electrophoresis. However, using our 
adapted ·OH-Seq methodology, a large number of the previously observed binding sites 
containing multiple mismatches are not populated by PA1. Instead, most of the protected 
regions observed by ·OH-Seq can be described by PA1 binding to cognate and single-
base-pair mismatch sequences.  
Although hydroxyl radical footprinting has been successfully applied to examine the 
structural details of protein-DNA complexes in cells by gamma-radiation, the detection of 
the footprinting regions typically requires the electrophoretic separation of radiolabeled 
DNA. Because radiolabeling of DNA in cells is not generally possible, the fragmented 
DNA must be radioactively end-labelled by primer extension prior to analysis.24 
Therefore, this method is severely limited by the length of DNA that can be interrogated 
and the loci about which interrogation is carried out. Because the in vitro ·OH-Seq 
experiments yielded promising results in a genome-wide manner, the application of ·OH-
Seq methodology to HPV16-infected keratinocyte monolayers may allow for mapping of 
the PA1 and other DNA-ligand binding sites within the context of chromatin structures in 
cells (see Chapter 5). 
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4.7  SUPPLEMENTAL INFORMATION 
4.7.1 Ethanol Precipitation of DNA 
 
MATERIALS 
1. 3 M sodium acetate, pH 5.2 (store at 4 °C) 
Dissolve 2.46 g of sodium acetate (Sigma S7545-250G, MW 82.03 g/mol) in 
approximately 5 mL of MilliQ H2O and adjust the pH to 5.2 with glacial acetic acid (~1.5 
mL). Add MilliQ H2O to a final volume of 10 mL. Filter-sterilize using a 0.22 μm filter. 
2. Cold (4 °C) 100 % EtOH 
3. Cold (4 °C) 70 % EtOH 
4. EB buffer (10 mM Tris·Cl, pH 8.5) 
 
 
PROCEDURE 
1. Add 1/10 volume of 3 M sodium acetate, pH 5.2 to DNA sample 
2. Mix well by inverting the closed vial/tube ~6 times. 
3. Add 3 volumes of cold 100 % EtOH. 
4. Mix well by inverting the closed vial/tube ~6 times. 
5. Place sample in -20 °C freezer overnight. 
6. Spin sample at 17,900x g at 4 °C for 30 min. 
7. Decant the supernatant being careful not to disturb DNA pellet. 
8. Wash DNA pellet with 400 μL of cold 70 % EtOH and centrifuge sample at17,900x g at 4 °C for 
15 min. 
9. Decant the supernatant being careful not to disturb DNA pellet. 
10. Air-dry the DNA pellet for ~ 20 min. 
11. Resuspend DNA in appropriate EB buffer or Low EDTA TE buffer (usually 50 μL). 
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4.7.2 Accel-NGS 1S Plus Protocol 
 
Cleaning and Preparation of Work Area 
To mitigate library and DNA contamination:  
1. Physically separate the laboratory areas where pre-PCR and post-PCR steps are 
executed.  
2. Use 10 % bleach to clean work areas. 
3. Use wide orifice, barrier pipette tips to reduce DNA fragmentation and cross-
contamination. 
Prepare a fresh 80 % ethanol solution (5 mL / sample). 
DNA Fragmentation: Fragment HPV16/pUC18 plasmid DNA by hydroxyl radical 
reagent cleavage.  
Input DNA Quality Control: Determine the fragmented DNA size distribution using 
Agilent RNA 6000 Nano kit (ref. CHC2151).   
DENATURATION 
1. Remove Adaptase reagents from -20°C storage and place on ice for at least 10 
min in order to allow reagents to reach 4°C. 
i. Buffer G1 
ii. Reagent G2 
iii. Reagent G3 
iv. Enzyme G4 
v. Enzyme G5 
vi. Enzyme G6 
2. Once thawed, vortex reagents well (except enzymes). 
3. Pre-assemble an Adaptase Reaction Mix and place on ice. 
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 Reagent Volume per Reaction
Pre-assemble 
Low EDTA TE 11.5 μL 
Buffer G1     4 μL 
Reagent G2     4 μL 
Reagent G3  2.5 μL 
 
4. Load 1 denature DNA program on the Eppendorf Mastercycler under 
carlos/accel 1s ngs. 
Incubation Conditions 
Pre-heat to 95°C, lid heating ON (105°C) and pause 
95°C for 2 min, lid heating ON (105°C) 
Immediately place on ice for 2 min then proceed to Adaptase step 
 
5. Transfer each 15 μL of fragmented DNA to a clean 0.2 mL PCR vial.  
6. Place each vial in thermocycler and unpause the 1 denarute DNA program. 
7. Immediately place samples on ice for 2 min then proceed to Adaptase step to 
maximize the amount of ssDNA substrate 
 
ADAPTASE 
1. Load 2 adaptase program on the Eppendorf Mastercycler under carlos/accel 1s 
ngs. 
Adaptase Thermocycler Program 
Pre-heat to 37°C, lid heating ON (105°C) and pause 
37°C for 15 min, lid heating ON (105°C) 
95°C for 2 min, lid heating ON (105°C) 
4°C hold 
 
2. Complete the Adaptase Reaction Mix by adding Enzymes G4, G5 and G6.  
Assembly Order Reagent Volume per Reaction
Pre-assemble 
Low EDTA TE 11.5 μL 
Buffer G1     4 μL 
Reagent G2     4 μL 
Reagent G3  2.5 μL 
   
Add just before use 
Enzyme G4 1 μL 
Enzyme G5  1 μL 
Enzyme G6 1 μL 
 
3. Gently vortex to mix. 
4. Transfer 25 μL of the Adaptase Reaction Mix to each PCR vial containing a 15 
μL denatured DNA sample.  
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5. Gently vortex the reaction and spin down. 
6. Place each vial in thermocycler and unpause the 2 adaptase program. 
 
EXTENSION 
1. Load 3 extension program on the Eppendorf Mastercycler under carlos/accel 1s 
ngs. 
Extension Thermocycler Program 
Pre-heat to 98°C, lid heating ON (105°C) and pause 
98°C for 30 s, lid heating ON (105°C) 
63°C for 15 s, lid heating ON (105°C) 
68°C for 5 min, lid heating ON (105°C) 
4°C hold 
2. Remove Extension reagents from -20°C storage and place on ice for at least 10 
min in order to allow reagents to reach 4°C. 
i. Reagent Y1 
ii. Reagent W2 
iii. Buffer W3 
iv. Enzyme W4 
3. Once thawed, vortex reagents well (except enzymes). 
4. On ice, prepare an Extension Reaction Mix and place on ice. 
Assembly Order Reagent Volume per Reaction
Pre-assemble 
Low EDTA TE 18.5 μL 
Reagent Y1      2 μL 
Reagent W2      7 μL 
Buffer W3 17.5 μL 
   
Add just before use Enzyme W4      2 μL 
 
5. Gently vortex to mix. 
6. Transfer 47 μL of the Extension Reaction Mix to each PCR vial containing a 40 
μL Adaptase Reaction.  
7. Gently vortex the reaction and spin down. 
8. Place each vial in thermocycler and unpause the 3 extension program. 
 
POST-EXTENSION SPRI 
1. Substitute the correct volume for Sample, SPRI, and Elution in the protocol 
given below to perform fragment size selection by SPRIselect beads. 
 For DNA inputs > 1 ng, perform fragment size selection using the following 
reagent ratios: 
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Input Sample SPRI Elution 
> 1 ng, 200 bp 87 μL 104 μL (ratio: 1.2) 20 μL > 1 ng, 350 bp 70 μL (ratio: 0.8) 
 
 For DNA inputs < 1 ng, perform fragment size selection with two consecutive 
clean-ups using the following reagent ratios: 
Input                 Sample SPRI Elution
< 1 ng, 200 bp 1
st SPRI       87 μL 104 μL (ratio: 1.2) 50 μL 
2nd SPRI      50 μL (1st SPRI eluate) 60 μL (ratio: 1.2) 20 μL 
    
< 1 ng, 350 bp 1
st SPRI       87 μL 70 μL (ratio: 0.8) 50 μL 
2nd SPRI      50 μL (1st SPRI eluate) 40 μL (ratio: 0.8) 20 μL 
 
2. Homogenize the SPRIselect beads by gently vortexing the solution. 
3. Transfer each Sample volume to a clean 1.5 mL Eppendorf microcentrifuge vial 
and add the appropriate SPRI volume to each sample. 
4. Homogenize the sample by vortexing or pipetting 10 times. Briefly spin down the 
samples to collect droplets (no bead-sample droplets on the sides of the tube). 
5. Incubate the sample suspensions for 5 min at room temperature. 
6. Place the sample suspension on a magnetic stand until the beads settle and a clear 
solution is observed (~ 2 min). 
7. Carefully remove and discard the clear supernatant. Do not disturb the bead pellet, 
as the DNA is associated with the beads. 
8. While on the magnet stand, add 500 μL of the freshly prepared 80 % ethanol 
solution to the vial without disturbing the bead pellet. Incubate for 30 s, and 
carefully remove and discard the ethanol solution. Do not disturb the bead pellet, 
as the DNA is associated with the beads. 
9. Repeat step 8. 
10. Briefly spin down the sample. Place back on the magnetic stand and remove any 
residual ethanol from the bottom of the vial. 
11. Air-dry the bead pellet. 
12. Resuspend the pellet by adding Elution volume of Low EDTA TE. Homogenize 
the suspension by pipetting up and down. Briefly spin down the samples to collect 
droplets (no bead-sample droplets on the sides of the tube). 
13. Incubate suspension for 5 min and place the tube on the magnetic stand. 
14. Transfer the entire eluate supernatant to a clean 0.2 mL PCR vial, ensuring not to 
pipette any magnetic beads. If magnetic beads are present in the eluate, transfer 
eluate to a new 0.2 mL PCR vial, place on magnetic stand and collect eluate 
again. 
 
Protocol can be stopped at this point. Store samples at 4°C until ready 
to continue.   
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LIGATION 
1. Load 5 ligation program on the Eppendorf Mastercycler under carlos/accel 1s 
ngs. 
Extension Thermocycler Program 
Pre-heat to 25°C, lid heating ON (105°C) and pause 
25°C for 15 min, lid heating ON (105°C) 
4°C hold 
 
2. Remove Ligation reagents from -20°C storage and place on ice for at least 10 
min in order to allow reagents to reach 4°C. 
i. Buffer B1 
ii. Reagent B2 
iii. Enzyme B3 
 
3. Once thawed, vortex reagents well (except enzymes). 
4. On ice, prepare a Ligation Reaction Mix and place on ice. 
Assembly Order Reagent Volume per Reaction
Pre-assemble 
Low EDTA TE 4 μL 
Buffer B1 4 μL 
Reagent B2               10 μL 
   
Add just before use Enzyme B3 2 μL 
 
5. Gently vortex to mix. 
6. Transfer 20 μL of the Ligation Reaction Mix to each PCR vial containing a 20 
μL SPRI eluate.  
7. Gently vortex the reaction and spin down. 
8. Place each vial in thermocycler and unpause the 5 ligation program. 
 
POST-LIGATION SPRI 
1. Substitute the correct volume for Sample, SPRI, and Elution in the protocol 
given below to perform fragment size selection by SPRIselect beads. 
Input Sample SPRI Elution 
200 bp 40 μL 40 μL (ratio: 1.0) 20 μL 350 bp 32 μL (ratio: 0.8) 
 
2. Homogenize the SPRIselect beads by gently vortexing the solution. 
3. Transfer each Sample volume to a clean 1.5 mL Eppendorf microcentrifuge vial 
and add the appropriate SPRI volume to each sample. 
4. Homogenize the sample by vortexing or pipetting 10 times. Briefly spin down the 
samples to collect droplets (no bead-sample droplets on the sides of the tube). 
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5. Incubate the sample suspensions for 5 min at room temperature. 
6. Place the sample suspension on a magnetic stand until the beads settle and a clear 
solution is observed (~ 2 min). 
7. Carefully remove and discard the clear supernatant. Do not disturb the bead pellet, 
as the DNA is associated with the beads. 
8. While on the magnet stand, add 500 μL of the freshly prepared 80 % ethanol 
solution to the vial without disturbing the bead pellet. Incubate for 30 s, and 
carefully remove and discard the ethanol solution. Do not disturb the bead pellet, 
as the DNA is associated with the beads. 
9. Repeat step 8. 
10. Briefly spin down the sample. Place back on the magnetic stand and remove any 
residual ethanol from the bottom of the vial. 
11. Air-dry the bead pellet. 
12. Resuspend the pellet by adding Elution volume of Low EDTA TE. Homogenize 
the suspension by pipetting up and down. Briefly spin down the samples to collect 
droplets (no bead-sample droplets on the sides of the tube). 
13. Incubate suspension for 5 min and place the tube on the magnetic stand. 
14. Transfer the entire eluate supernatant to a clean 0.2 mL PCR vial, ensuring not to 
pipette any magnetic beads. If magnetic beads are present in the eluate, transfer 
eluate to a new 0.2 mL PCR vial, place on magnetic stand and collect eluate 
again. 
 
Protocol can be stopped at this point. Store samples at 4°C until ready 
to continue.  
 
  
INDEXING PCR 
1. Remove Indexing PCR reagents from -20°C storage and place on ice for at least 
10 min in order to allow reagents to reach 4°C. 
i. Reagent R1 (index primer) 
/ Index D50X and Index 
D7XX 
ii. Reagent W2 
iii. Buffer W3 
iv. Enzyme W4 
 
2. Once thawed, vortex reagents well (except enzymes). 
3. Add indexing reagent(s) directly to 20 μL SPRI eluate. 
Reagent Volume per Sample 
(SI-IL1SP-12A) 
Volume per Sample 
(DI-IL1SP-48) 
Reagent R1 (index primer) 5 μL - 
Index D50X - 2.5 μL  
Index D7XX - 2.5 μL 
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4. On ice, prepare a PCR Reaction Mix and place on ice. 
Assembly Order Reagent Volume per Reaction
Pre-assemble 
Low EDTA TE 10 μL 
Reagent W2   4 μL 
Buffer W3 10 μL 
   
Add just before use Enzyme W4 1 μL 
 
5. Gently vortex to mix. 
6. Transfer 25 μL of the PCR Reaction Mix to each PCR vial containing 20 μL 
SPRI eluate and 5 μL indexing primers.  
7. Mix by pipetting. 
8. Place reactions in thermocycler. 
9. Load 7 indexing pcr program on the Eppendorf Mastercycler under carlos/accel 
1s ngs. 
Indexing PCR Thermocycler Program  Input Quantity Recommended PCR Cycles 
98°C for 30 s, lid heating ON (105°C)  250 ng 3 
PCR Cycles: 
     98°C for 10 s, lid heating ON (105°C) 
     60°C for 30 s, lid heating ON (105°C) 
     68°C for 60 s, lid heating ON (105°C) 
 100 ng 4 
10 ng 7 
1 ng 10 
100 pg 14 
4°C hold  10 pg 17 
 Exact number of PCR cycles must be determined by user 
 
POST-PCR SPRI 
1. Substitute the correct volume for Sample, SPRI, and Elution in the protocol 
given below to perform fragment size selection by SPRIselect beads. 
Input Sample SPRI Elution 
200 bp 50 μL 42.5 μL (ratio: 0.85) 20 μL 350 bp 
 
2. Homogenize the SPRIselect beads by gently vortexing the solution. 
3. Transfer each Sample volume to a clean 1.5 mL Eppendorf microcentrifuge vial 
and add the appropriate SPRI volume to each sample. 
4. Homogenize the sample by vortexing or pipetting 10 times. Briefly spin down the 
samples to collect droplets (no bead-sample droplets on the sides of the tube). 
5. Incubate the sample suspensions for 5 min at room temperature. 
6. Place the sample suspension on a magnetic stand until the beads settle and a clear 
solution is observed (~ 2 min). 
7. Carefully remove and discard the clear supernatant. Do not disturb the bead pellet, 
as the DNA is associated with the beads. 
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8. While on the magnet stand, add 500 μL of the freshly prepared 80 % ethanol 
solution to the vial without disturbing the bead pellet. Incubate for 30 s, and 
carefully remove and discard the ethanol solution. Do not disturb the bead pellet, 
as the DNA is associated with the beads. 
9. Repeat step 8. 
10. Briefly spin down the sample. Place back on the magnetic stand and remove any 
residual ethanol from the bottom of the vial. 
11. Air-dry the bead pellet. 
12. Resuspend the pellet by adding Elution volume of Low EDTA TE. Homogenize 
the suspension by pipetting up and down. Briefly spin down the samples to collect 
droplets (no bead-sample droplets on the sides of the tube). 
13. Incubate suspension for 5 min and place the tube on the magnetic stand. 
14. Transfer the entire eluate supernatant to a clean 0.2 mL PCR vial, ensuring not to 
pipette any magnetic beads. If magnetic beads are present in the eluate, transfer 
eluate to a new 0.2 mL PCR vial, place on magnetic stand and collect eluate 
again. 
 
Store samples at 4°C until ready to quantify and sequence libraries. 
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INDEXED ADAPTER SEQUENCES  
Single Index “Set A” Adapters Sequence* SI-IL1SP-12A 
Reagent R1 (I2) CGATGT(A) 6 μL 
Reagent R1 (I4) TGACCA(A) 6 μL 
Reagent R1 (I5) ACAGTG(A) 6 μL 
Reagent R1 (I6) GCCAAT(A) 6 μL 
Reagent R1 (I7) CAGATC(A) 6 μL 
Reagent R1 (I12) CTTGTA(A) 6 μL 
Reagent R1 (I13) AGTCAA(C) 6 μL 
Reagent R1 (I14) AGTTCC(G) 6 μL 
Reagent R1 (I15) ATGTCA(G) 6 μL 
Reagent R1 (I16) CCGTCC(C) 6 μL 
Reagent R1 (I18) GTCCGC(A) 6 μL 
Reagent R1 (I19) GTGAAA(C) 6 μL 
*Base in parentheses is used for phasing calculations, but is not considered part of the index sequence 
Dual Index Adapters Sequence DI-IL1SP-48 
Index D501 TATAGCCT 22 μL 
Index D502 ATAGAGGC 22 μL 
Index D503 CCTATCCT 22 μL 
Index D504 GGCTCTGA 22 μL 
Index D505 AGGCGAAG 22 μL 
Index D506 TAATCTTA 22 μL 
Index D507 CAGGACGT 22 μL 
Index D508 GTACTGAC 22 μL 
   
Index D701 ATTACTCG 17 μL 
Index D702 TCCGGAGA 17 μL 
Index D703 CGCTCATT 17 μL 
Index D704 GAGATTCC 17 μL 
Index D705 ATTCAGAA 17 μL 
Index D706 GAATTCGT 17 μL 
Index D707 CTGAAGCT 17 μL 
Index D708 TAATGCGC 17 μL 
Index D709 CGGCTATG 17 μL 
Index D710 TCCGCGAA 17 μL 
Index D711 TCTCGCGC 17 μL 
Index D712 AGCGATAG 17 μL 
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4.7.3 Bioinformatics Instructions 
1. Install Bowtie 2. 
a. Install Python27 or newer version. 
b. Create a directory for installation (something like C:\Users\jkblab\Desktop\Bowtie). 
c. Download Bowtie 2 (https://sourceforge.net/projects/bowtie-bio/files/bowtie2/2.2.9/bowtie2-
2.2.9-mingw-win64.zip/download or newer version). 
d. Unzip it and install in newly created folder. 
e. Add environmental variables - Click on Start Menu and right click My Computer. Click on 
Properties. Click on Advanced System Settings. Under the Advanced tab, click on 
Environment Variables (this is where we can add Python to the Path environmental variable). 
Click Edit and add the Variable name: python and Variable value: C:\Python27\ (path to 
Python installation). Save changes.  
2. Create a reference genome using Vector NTI and rename it as a FASTA file (example: HPV16-
pUC18.fa). Place it in the Bowtie folder. 
3. Align FASTQ result file to the reference genome. 
a. Open the command line (cmd) and navigate to the C:\Users\jkblab\Desktop\Bowtie directory:  
cd Users\jkblab\Desktop\Bowtie 
b. Build the reference genome index by entering at the command line: 
bowtie2-build HPV16-pUC18.fa HPV16-pUC18 
c. This command will create 6 files with a .bt2 file extension. These will then be used by 
bowtie2 to map data.  
d. Place the FASTQ file in the C:\Users\jkblab\Desktop\Bowtie directory. 
e. Map the FASTQ file by entering the following command: 
bowtie2 –-score-min C,0 –x HPV16-pUC18 [name of FASTQ 
file].fastq > [name of desired output SAM file].sam 
Alternatively, reads with mismatches can be mapped by entering the following command:    
bowtie2 –x HPV16-pUC18 [name of FASTQ file].fastq > [name of 
desired output SAM file].sam 
 
4. Install Strawberry Perl. 
a. Create a directory for installation (something like C:\Users\jkblab\Strawberry). 
b. Download Strawberry Perl (http://strawberryperl.com/download/5.24.0.1/strawberry-perl-
5.24.0.1-64bit-portable.zip or newer version). 
c. Unzip it and install in newly created folder. 
d. Run “portableshell.bat” to open Strawberry Perl.  
5. Install cpanm. 
a. Download and install cpanm by entering the following command: 
cpan App::cpanminus 
6. Install CountNicks program written by Christopher Bottoms.  
a. Download Count Nicks (https://github.com/MU-IRCF/Bio-IRCF-
CountNicks/blob/master/current_distribution/Bio-IRCF-CountNicks-0.0022.tar.gz or newer 
version) and copy compressed file in a folder named CountNicks 
(C:\Users\jkblab\Desktop\CountNicks). 
b. Open portableshell.bat found in the Strawberry Perl folder (C:\Users\jkblab\Strawberry) and 
navigate to C:\Users\jkblab\Desktop\CountNicks. 
c. Install CountNicks by entering the following command: 
cpanm Bio-IRCF-CountNicks-0.0022.tar.gz 
7. Count nicks with CountNicks script. 
a. Open portableshell.bat found in the Strawberry Perl folder (C:\Users\jkblab\Strawberry) and 
navigate to C:\Users\jkblab\Desktop\Bowtie directory. 
b. Run script by entering the following command: 
Count_nicks [name of sam file].sam 
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Chapter 5 
 
Genome-Wide Mapping of Antiviral Hairpin Polyamides using Hydroxyl Radical 
Footprinting Coupled to Massively Parallel DNA Sequencing (∙OH-Seq) and 
Crosslinking of Small Molecules (COSMIC-Seq) 
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5.1 ABSTRACT 
 
The rational design of small molecules to selectively target predetermined DNA 
sequences is a major goal in the development of novel therapeutics. N-methylpyrrole/N-
methylimidazole (Py/Im) hairpin polyamides (PAs) represent a class of synthetic 
heteroaromatic compounds that can reportedly be rationally designed to target 
predetermined sequences for the control of gene expression and other biological 
functions at the DNA level. Here, we have performed COSMIC (crosslinking of small 
molecules for isolation of chromatin) and hydroxyl radical footprinting coupled with 
massively parallel DNA sequencing (·OH Seq) to map the binding sites of potent anti-
HPV hairpin polyamides in live cells. 
 
5.2 INTRODUCTION 
 
Deciphering both the viral and host genomic sites targeted by our bioactive 
polyamides (PAs) in live cells will provide important insights into the mechanism of 
action by which these DNA minor groove binders elicit their functions. These antiviral 
compounds, belonging to the N-methylpyrrole/N-methylimidazole (Py/Im) PAs of 
synthetic molecules, bind avidly to A/T rich sequences in the HPV Long Control Region 
(LCR) with dissociation constants in the low nanomolar range, leading to an extensive 
coverage of regions important for viral transcription and replication (see Chapter 2 and 
Chapter 3).1-4 They also bind avidly to other A/T-rich regions in the viral genome, as 
described in Chapter 4. To date, we have performed binding studies of our antiviral 
polyamides across short linear DNA fragments and in a plasmid form under cell-free 
experiments; however, these experiments disregard the complexity of host and viral 
genomes found in cells.  
In eukaryotic cells, host genomes are packaged in condensed form into nucleosome 
core particles consisting of 146-bp of dsDNA wound around a histone octamer. These 
nucleosome core particles fold into higher order structures referred to chromatin, which 
in turn fold into chromosomes. Similarly, the viral genome is negatively supercoiled, 
condensed into chromatin-like structures and bound by host and viral proteins in cells.5-10 
Because of the compact nature of genomes in eukaryotic cells, a large number of the 
potential DNA-binding sequences may be inaccessible to PAs. Although nucleosomal 
DNA-binding sites that are partially or fully facing away from the histone octamer are 
accessible to conventional eight-ring polyamides,11 these sites may not be accessible to 
our large hairpin polyamides due to their required larger binding site (>10 bp of DNA). In 
line with these results, Sugiyama et al. reported that alkylating polyamides exhibited 
limited accessibility toward binding sites found in the central core of well-positioned 
nucleosomes in isolated nuclei of human cells.12 Recently, Erwin et al. demonstrated that 
two structurally distinct polyamides (hairpin and linear conformers) were able to populate 
diverse chromatin architectures including active and repressive states in live H1-hECs.13 
Thus, the relative accessibility of large hairpin PAs to chromatinized genomes requires 
further investigation.  
To investigate the relative chromatin accessibility of our large hairpin, we performed 
COSMIC (crosslinking of small molecules for isolation of chromatin) and hydroxyl 
radical footprinting (·OH) coupled with massively parallel DNA sequencing (Seq) to map 
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the binding sites of anti-HPV hairpin polyamides in H1 human embryonic stem cells 
(H1-hESC) and HPV16-harboring W12E keratinocytes. 
 
5.2.1 In-Cell Hydroxyl Radical Footprinting 
 
In 1986, Tullius et al. introduced hydroxyl radical footprinting as a powerful 
technique to study the structural interaction details of ligand-DNA complexes under cell-
free conditions.14 The highly-reactive hydroxyl radical moiety is used as a chemical 
probe to measure the relative accessibility of the cleavage agent toward DNA in the 
presence of a DNA-ligand. Binding of the ligand to its cognate sequence leads to 
increased protection of DNA at that particular location, providing a ‘footprint’.15,16 
Hydroxyl radicals are an attractive cleavage agent due to their small size, neutral charge, 
relatively sequence-neutral activity and ease of use.17,18   
Hydroxyl radicals can be produced in solution by Fenton chemistry14,19 or ionizing 
radiation.20,21 In the former, hydroxyl radicals (·OH) are generated upon the reduction of 
H2O2 by the [Fe(II)(EDTA)]2- complex, while addition of sodium ascorbate reduces 
Fe(III) to regenerate Fe(II), affording a reaction catalytic in iron (Equation 5.1).  
 
ሾFeሺIIሻሺEDTAሻሿଶି ൅ HଶOଶ			 → 			ሾFeሺIIIሻሺEDTAሻሿି ൅ OHି ൅	൉ ۽۶														(5.1)  
Hydroxyl radicals can also be generated by the gamma radiolysis of water. Of 
interest, Tullius et al. demonstrated using gamma-radiation as the source of hydroxyl 
radicals that footprinting experiments of the bacteriophage λ repressor/operator complex 
provided identical cleavage patterns as those generated by Fenton chemistry.20 
Furthermore, the γ-ray technique has also been successfully applied to examine structural 
details of protein-DNA complexes in cells. In γ-ray methodology, cells are irradiated with 
γ-rays to generate hydroxyl radicals and the fragmented DNA is then extracted and 
radioactively end-labelled by primer extension, followed by gel electrophoresis 
analysis.21 Recently, Taylor et al.22 devised a novel procedure that permits in-cell 
hydroxyl radical footprinting using Fenton chemistry (Equation 5.1). In this technique, 
cell membranes are permeabilized by lysolecithin treatment, which allows the Fenton 
reagents to enter the nucleus, leading to genomic DNA cleavage by hydroxyl radicals.22 
To map the genome-wide binding sites of bioactive polyamides in HPV16-maintaining 
W12E cells, we applied hydroxyl radical footprinting by gamma-radiation and Fenton 
chemistry followed by next-generation sequencing. Footprinting experiments using 
gamma-radiation were performed in five vehicle-control replicates and six PA1-treated 
biological replicates. Footprinting experiments using Fenton reagents were performed 
with seven anti-HPV PAs and one inactive PA in five biological replicates. The bioactive 
compounds were chosen based on their broad range of antiviral activities (IC50 = 0.036-
0.304 µM) (Table 5.1). Chemical structures of these PAs are provided in Section 5.7.1.  
In these experiments, HPV16-harboring W12E keratinocytes are treated with E media 
containing 0.1 µM polyamide and a final DMSO concentration of 0.1 %. In other culture 
plates, cells are simultaneously treated with a vehicle control consisting of E media 
(complete) with a final DMSO concentration of 0.1 %. After 24 h incubation, the cells are 
either dissociated with trypsin and subjected to gamma-radiation, or treated with a cell 
membrane permeabilization agent (i.e. lysolecithin) followed by treatment with Fenton 
ascorbate
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chemistry reagents. After oxidative DNA cleavage, low molecular DNA from W12E cell 
samples is extracted using a modified Hirt method.23 The purified DNA is then analyzed 
by next-generation sequencing as previously described in Chapter 4 (Figure 5.1). 
 
Table 5.1. HPV16 IC50 and IC90 Values for Polyamides Studied In-Cell Hydroxyl Radical Footprinting Experiments.    
Polyamide DNA Binding Motif Molecular Weight (g/mol) (TFA salt) HPV16 IC50 [µM] HPV16 IC90 [µM] 
PA11 W2GW2GW 1564.39 NOT ACTIVEa 
PA1 W2GW7 2237.12 0.100a 1.113a 
NV1111 W11GW 2865.68 0.017b 0.121b 
PA30 W2GW7 2464.31 0.304a >10a 
PA31 W2GW7 2408.20 0.103a 0.378a 
NV1078 W8GW4 2850.71 0.046b  0.307b 
NV1087 W11GW 2921.79 0.031b  0.200b 
PA25 W2GW5GW4 2982.19 0.036a 0.351a 
a Antiviral activities against HPV16 were previously reported.3,24,25 
b Antiviral activities against HPV16 were determined in W12E monolayers by T.G. Edwards (unpublished data).  
 
 
 
Figure 5.11. Experimental Scheme for ·OH-Seq Experiments. W12E keratinocyte monolayers are separately
subjected to vehicle-control or PAs. After 24 h incubation, cells are irradiated with gamma-rays at Missouri Research
Reactor or Fenton chemistry reagents. After oxidative DNA cleavage, low molecular DNA is extracted and the
fragmented DNA is sequenced by next-generation sequencing. Subsequent bioinformatics analysis is performed to
determine the cleavage intensity at single-nt resolution throughout the genome in order to map PA-DNA interactions.
191 
 
5.2.2 Cognate Site Identification (CSI) Analysis 
 
Cognate Site Identification analysis, developed by Ansari and colleagues, has been 
successfully applied to examine the DNA-binding preferences of artificial transcription 
factors and PAs.26-28 In the SELEX-based approach of CSI, biotinylated DNA-ligands are 
incubated with a DNA library containing randomized permutations of 20-bp sequences. 
Affinity capture using streptavidin-coated beads allows for the enrichment of the bound 
sequences, and subsequent NGS analysis of the enriched sequences provides the 
specificity profiles of these minor groove DNA-binding ligands. Furthermore, CSI 
analysis allows for the determination of structural contributions afforded by the 
sequences flanking the binding motif.13 Ansari et al. have demonstrated that the binding 
intensities obtained from CSI analysis are directly proportional to the equilibrium 
association constant values of PA-DNA interactions.26 As a result, CSI data have been 
used to predict the probability of binding to specific sequences in a genome-wide 
manner.29  
 
5.2.3 Crosslinking of Small Molecules for Isolation of Chromatin (COSMIC) 
 
In tandem to in-cell hydroxyl radical footprinting experiments, we also performed 
COSMIC experiments using PA1 and PA25 derivatives in H1 human embryonic stem 
cells at the University of Wisconsin-Madison and in W12E keratinocytes at the 
University of Missouri-St. Louis in biological duplicates. This method, recently 
developed by the Ansari group, allows for the mapping of PA interactions with DNA in 
its native chromatinized form.29 Indeed, the Ansari group demonstrated that polyamides 
were able to populate diverse chromatin architectures including actively transcribed and 
repressed states.13 Furthermore, the Ansari group reported that polyamides bind similarly 
to loci presenting multiple clustered binding sites with low- and medium affinities as they 
bind to loci with few high-affinity binding sites.13,29 
In COSMIC, the polyamide is conjugated on its C-terminal tail with a bifunctional 
moiety comprised of psoralen and biotin. The psoralen moiety affords the reversible 
photo-crosslinking of PA-DNA interactions, whereas biotin allows for the sequence 
enrichment of photo-crosslinked DNA with streptavidin-coated magnetic beads. Psoralen 
is a tricyclic furocoumarin which intercalates into DNA base pairs with an affinity of 103-
104 M-1 and forms interstrand crosslinks preferentially to thymine bases (5’-TpA sites)30 
upon irradiation with long wavelength UV light (320-380 nm).29,31 Cells grown as 
monolayers are treated with the PA-PB (psoralen/biotin) conjugate for 24 h. At the end of 
the treatment period, psoralen-DNA crosslinking is performed at 365 nm under the native 
chromatin structure in living cells. The cells are lysed and the DNA is sonicated. After 
sonication, the psoralen-DNA adducts are captured using streptavidin-coated magnetic 
beads via the biotinylated polyamide. After removal of non-specific DNA interactions, 
the psoralen-DNA crosslinks are reversed by hot alkali treatment and the DNA is 
purified. The enriched fragments are sequenced and aligned to the genome of interest by 
next-generation sequencing analysis to uncover genomic regions occupied by PAs 
(Figure 5.2).13,29 
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5.3 MATERIALS AND METHODS 
 
5.3.1 Buffers and Reagents 
 
Starting reagents were used without further purification, unless specifically noted. 
Autoclaved MilliQ H2O (18.2 MΩ·cm at 25 °C, Millipore Integral 10) was used in the 
preparation of all reagents. All reagents were filtered using a 0.22 µm MILLEX-GP filter 
before use. W12E cervical keratinocytes (clonal cell line # 20850) harboring HPV16 
episomes and J2 3T3 fibroblasts were a kind gift of Professor Paul Lambert (University 
of Wisconsin-Madison). Peptide acid psoralen-biotin moiety was synthesized by Dr. 
Graham Erwin (University of Wisconsin-Madison) as previously described.29 Biotin-
PEG4-NHS ester (Catalog # CP-3026-100MG) was purchased from Conju-Probe. 
Anhydrous N-Methyl-2-pyrrolidinone (NMP) (Catalog # 328634-100ML), trifluoroacetic 
A  B W12E keratinocytemonolayers
Treat W12E cells
with PA-PB (24 h)
PA-psoralen-biotin
(PA1-PB)
Crosslink PA-PB to DNA
with UV (365 nm)
PA binding to
host and viral genomes
Host and viral DNA
fragmentation by sonication
PA-DNA fragment capture
Fragment size 100-500 bp
PA
Magnetic
bead
Streptavidin Biotin
PA
DNA purification
NGS library preparation
Alkali treatment
to reverse crosslinks
AGTCAAATGATAATTAATGTA
1
1000 HPV LCR (7137-7857)
Next-Generation Sequencing by Illumina HiSeq 2500
Figure 5.2. Chemical Structures of PA1 and PA25 Functionalized with Psoralen-Biotin (PB) Moiety and
Experimental Scheme for COSMIC-Seq. (A) Chemical structures of polyamide-PB conjugates used for COSMIC
experiments. According to the PA-DNA recognition rules, PA1 and PA25 target the DNA sequences 5’-W2GW7-3’
and 5’-W2GW5GW4-3’, respectively (where W can be A or T). Polyamide building blocks are represented by open
circles for N-methylpyrrole, filled circles for N-methylimidazole, diamonds for β-alanine, + for the Ta tail and  for γ-
aminobutyric acid. (B) W12E keratinocyte monolayers are treated PA-PB conjugates (PA1-PB or PA25-PB). The cells
are then subjected to UV radiation (365 nm) which leads to the crosslinking of the psoralen moiety to viral and
genomic DNA. After the cells are lysed and the DNA is sheared (100-500 bp), streptavidin-coated magnetic beads are
used to capture covalent PA-DNA complexes. The captured DNA is then dissociated from beads by alkali treatment to
reverse the crosslinks and the released DNA is analyzed by NGS (Illumina HiSeq 2500). 
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acid (Catalog # T6508-2L) and formic acid (Catalog # F0507-100ML) were obtained 
from Sigma-Aldrich. N,N-Diisopropylethylamine (DIEA) (Catalog # 400136) was 
purchased from Applied Biosystems. 1-[Bis(dimethylamino)methylene]-1H-1,2,3-
triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate (HATU) (Catalog # AS-60263-
100) was obtained from AnaSpec, Inc. HPLC-grade methanol (MeOH) (Catalog # 
AH230-4) was purchased from Honeywell Burdick & Jackson. LCMS Chromasolv 
acetonitrile (Catalog # 34967-4L) was obtained from Fluka. Ham’s F-12K (Kaighn’s) 
medium (Gibco Catalog # 21127-030), Dulbecco’s Modified Eagle’s Medium with high 
glucose, L-glutamine, phenol red, with pyruvate (Gibco Catalog # 11995-081) and 
without pyruvate (Gibco Catalog # 11965-126), 0.05 % and 0.25 % Trypsin-EDTA with 
phenol red (Gibco Catalog # 25300-054 and 25200-056) and fetal bovine serum (Catalog 
# 16140-071) were obtained from ThermoFisher Scientific. Epidermal growth factor 
(Catalog # PHG0311) was purchased from Invitrogen. Penicillin-streptomycin solution 
(10,000 U penicillin / 10 mg streptomycin per mL; Catalog # P4333-20ML), bovine 
serum albumin (Catalog # A4919-1G), 1 M HEPES buffer (Catalog # 83264-100ML-F), 
hydrocortisone powder (Catalog # H0888-1G), adenine hydrochloride hydrate (Catalog # 
A9795-1G), insulin from bovine pancreas (Catalog # I6634-50MG), human apo-
transferrin (Catalog # T1147-100MG), T3 thyroid hormone, 3,3’,5-triiodo-L-thyronine 
sodium salt (Catalog # T6397-100MG), phenol red (Catalog # P3532-5G), dimethyl 
sulfoxide (Catalog # D2650) and cholera toxin (Catalog # C9903-.5MG) were purchased 
from Sigma-Aldrich. 1X phosphate buffer saline, pH 7.4 (Catalog # 10010-031), 
mytomycin C (Catalog # BP2531-2), sodium chloride (Catalog # BP358-1), potassium 
chloride (Catalog # BP366-500), sodium bicarbonate (Catalog # BP328-1), sodium 
phosphate monobasic monohydrate (Catalog # BP330-500), magnesium sulfate 
heptahydrate (Catalog # M80-500) and ferric nitrate nonahydrate (Catalog # I110-100) 
were obtained from Fisher Scientific. Sodium hydroxide (Catalog # BP359-500) and 
hydrogen peroxide (30 % wt/vol; Catalog # H325-500) were purchased from Fisher 
Scientific. 0.22 µm MILLEX-GP filters were purchased from Merck Millipore Ltd. 
Sucrose (Catalog # 84097) was obtained from Fluka. 100 % ethanol (Catalog # 2716) 
was obtained from Decon Laboratories, Inc. Potassium chloride (Catalog # P9333-500G), 
potassium phosphate dibasic trihydrate (Catalog # P5504-100G), magnesium chloride 
(Catalog # M8266-100G), calcium chloride (Catalog # C1016-100G), 4-(2-
hydroxyethyl)piperazine-1-ethanesulfonic acid (Catalog # H3375-100G), lysolecithin 
Type I (Catalog # L4129-100MG), thiourea (Catalog # 88810-100G), EDTA disodium 
salt dehydrate (Catalog # E5134-100G), ammonium iron(II) sulfate hexahydrate (Catalog 
# 203505-25G), sodium ascorbate (Catalog # 11140-50G) and agarose (Catalog # A9539-
100G) were purchased from Sigma-Aldrich. Buffer P1 (Catalog # 19051) and QIAprep 
2.0 Spin Columns (Catalog # 27115) were obtained from QIAGEN. Glacial acetic acid 
(Catalog # A38-212), 1 M Tris-HCl [pH 7.5] (Catalog # 15567-027) and RNase A 
(Catalog # EN0531; 10 mg/mL) were purchased from ThermoFisher Scientific. Sodium 
dodecyl sulfate (Catalog # L4509-100G), cesium chloride (Catalog # C4036-50G) and 
potassium acetate (Catalog # P1190-100G) were purchased from Sigma-Aldrich. TaqMan 
probes and primers used for real-time quantitative PCR were purchased from Integrated 
DNA Technologies. CalSun facial tanning sun lamp (Catalog # B001BH0A1A) was 
obtained from CalSun. Trizma base (Catalog # T1503-1KG), Triton X-100 (Catalog # 
X100-100ML), deoxycholate acid sodium salt (Catalog # D6750-10G) and urea (Catalog 
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# U5128-100G) were purchased from Sigma-Aldrich. Streptavidin-coated magnetic 
beads (Dynabeads® MyOneTM Streptavidin C1, Catalog # 65001), benzamidine HCl 
(Catalog # BP435-25), concentrated HCl (Catalog # A144C-212), proteinase K (Catalog 
# FEREO0491; 20 mg/mL) and nuclease-free water (Catalog # R0581) were purchased 
from ThermoFisher Scientific. NP40 (IGEPAL CA-630; Catalog # 198596) was 
purchased from MP Biomedicals. QIAquick PCR purification kit (Catalog # 28104) was 
obtained from QIAGEN. Phenylmethylsulfonyl fluoride (PMSF) (Catalog # 786-055) 
was purchased from G-Biosciences. Pepstatin A (Catalog # J60237-LB0) and potassium 
hydroxide (Catalog # A16199-0E) were obtained from Alfa Aesar. 1 M Tris-HCl buffer 
[pH 8.0] (Catalog # 15-568-025) was purchased from Invitrogen. Lithium chloride 
(Catalog # 199880050) was obtained from Acros Organic. Gel Loading Dye, Blue (6X, 
Catalog # B7021S) and 1 kb DNA ladder (Catalog # N3232S, 500 µg/mL) were 
purchased from New England Biolabs. 1X TAE buffer consisted of 40 mM Tris-acetate, 
1 M EDTA, pH 8.0. Ethidium bromide was obtained from Spectrum (Catalog # E1031, 1 
% solution). Agilent Bioanalyzer RNA 6000 Nanochip kit (Catalog # 5067-1511) was 
purchased from Agilent Technologies. Qubit dsDNA BR (Broad-Range) Assay kit 
(Catalog # Q32853), Qubit dsDNA HS (High Sensitivity) Assay kit (Catalog # Q32851) 
and Qubit assay tubes (Catalog # Q32856) were obtained from Life technologies. Accel-
NGS 1S Plus DNA Library Kit (Catalog # DL-IL1SP-12/48) was purchased from Swift 
Biosciences. Low EDTA TE buffer (Catalog # T0227; 10 mM Tris·Cl, 0.1 mM EDTA, 
pH 8.0) was purchased from Teknova. SPRIselect reagent kit (Catalog # B23317) was 
obtained from Beckman Coulter. Agilent DNA 1000 kit (Catalog # 5067-1505) was 
obtained from Agilent Technologies. 
 
5.3.2 Polyamide Conjugates Synthesis 
 
Hairpin polyamide synthesis was performed by Dr. K. J. Koeller, Dr. G. D. Harris, Jr. 
and K. Aston. Hairpin polyamides were synthesized by Boc solid-phase methods32 as 
previously reported in the literature.24 
Biotinylated PA conjugates KA2127-PEG4-Biotin, PA1-PEG4-Biotin and PA25-
PEG4-Biotin (Figure 5.3) were synthesized by reacting a solution of 1 eq. of biotin-
PEG4-NHS ester (Conju-Probe, Catalog # CP-3026-100MG) in anhydrous NMP (Sigma-
Aldrich, Catalog # 328634-100ML) with a solution of 1.5 eq. of PA (either KA2127 
formate salt, PA1 TFA salt or PA25 TFA salt), 50 eq. of DIEA in anhydrous NMP at 
room temperature for 3-4 h.  
 
195 
 
 
  
Covalent conjugation of anti-HPV polyamides PA1 and PA25 to a psoralen-biotin 
moiety (PB)29 afforded PA1-PB and PA25-PB. Briefly, a solution of 1 eq. of the peptide 
acid of PB in anhydrous NMP was treated with a solution of 3 eq. of PA (either PA1 or 
PA25 as TFA salts), 0.95 eq. HATU and 3 eq. of DIEA in anhydrous NMP at room 
temperature for at least 2 h. Biotinylated and PB-conjugated PAs were then purified by 
reverse-phase HPLC with a Dionex Ultimate 3000 prep-LC using a Macherey-Nagel 
Nucleodur C18 column (2 columns in series) (21.0 mm x 50 mm each) and program 
Gilson M-N short. Mobile phases were 0.2 % formic acid in water (A) and 100 % 
methanol (B). The gradient consisted of a flowrate of 30 mL/min with a ramp from 25 % 
to 75 % B over 35 min, followed by a ramp from 75 % to 90 % B over 1 min and held for 
Figure 5.3. Chemical Structures of KA2127, PA1 and PA25 Functionalized with PEG4-Biotin. Chemical
structures of polyamide-PEG4-Biotin conjugates used for Cognate Site Identification (CSI) experiments. Biotin
conjugation to these polyamides was achieved via the primary amine on their TA tails. The PEG spacer minimizes any
steric hindrance that may arise from the attachment of the polyamide moiety in the binding of streptavidin by biotin.
According to the PA-DNA recognition rules, KA2127 targets the DNA sequence 5’-W2GGWGW-3’, where W (Weak)
can be A or T. Large hairpin polyamides PA1 and PA25 target the DNA sequences 5’-W2GW7-3’ and 5’-
W2GW5GW4-3’, respectively. Polyamide building blocks are represented by open circles for N-methylpyrrole, filled
circles for N-methylimidazole, diamonds for β-alanine, + for the Ta tail and  for γ-aminobutyric acid. 
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1 min at 90 % B. Retention times for biotinylated polyamide conjugates were 17.6, 21.3 
and 23.1 min for KA2127-PEG4-Biotin, PA1-PEG4-Biotin and PA25-PEG4-Biotin, 
respectively. Retention times for polyamide-PB conjugates were 21.0 and 24.3 min for 
PA1-PB and PA25-PB, respectively (Chromeleon Client Version 6.80 SR10). Fractions 
were checked with an Agilent Technologies 1260 Infinity analytical HPLC using a 
Phenomenex Jupiter Proteo (C12) (4.6 x 50 mm, 4 μm, 90 Å) maintained at 40 ˚C. 
Mobile phases consisted of 0.1 % formic acid in water (A) and 100 % acetonitrile (B). 
The gradient consisted of 5 % B for 0.75 min followed by a ramp to 60 % B over 3.25 
min at 2 mL/min. Retention times for biotinylated polyamide conjugates were 2.80, 3.02 
and 3.10 min for KA2127-PEG4-Biotin, PA1-PEG4-Biotin and PA25-PEG4-Biotin, 
respectively. Retention times for polyamide-PB conjugates were 3.18 and 3.25 min for 
PA1-PB and PA25-PB, respectively (Figure 5.4). Fractions containing pure conjugates 
were pooled together and lyophilized to yield off-white solids (see Section 5.7.3 for 
detailed protocol). Chemical identity was verified with HRMS-ESI (high-resolution mass 
spectrometry electrospray ionization) by Professor B. Bythell (Table 5.2).  
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Table 5.2. Characterization of Synthesized Polyamide Conjugates by HRMS-ESI.    
Polyamide Chemical Formula Exact Mass Mass Calculated (m/z) 
Mass Observed 
(m/z) 
KA2127-B C77H109N25O17S 1687.82 [M+2Na]2+       866.90 866.93 
PA1-B C112H146N34O23S 2367.10 [M+2Na]2+     1206.54   1206.58 
PA1-PB C134H169N37O30S 2808.26 [M+H]+          2809.27 2809.23 
PA25-B C141H179N45O29S 2998.36 [M+2Na]2+     1522.17   1522.23 
PA25-PB C163H202N48O36S 3439.52 [M+2Na]2+     1742.75   1742.81 
KA2127‐PEG4‐Biotin KA2127 
PA25PA1‐PB 
PA1‐PEG4‐Biotin PA1 
PA25‐PEG4‐Biotin PA25‐PB
Figure 5.4. Analytical HPLC Traces of Synthesized Polyamide Conjugates with λ Monitored (254.8 and
300.8 nm). Analytical HPLC Traces of polyamide-PEG4-Biotin and polyamide-PB conjugates used for CSI
and COSMIC experiments. HPLC chromatograms were analysed using ChemStation for LC 3D systems Rev.
B.04.03[16]. 
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5.3.3 Cognate Site Identification (CSI) by High-Throughput SELEX 
  
 CSI experiments for KA2127-PEG4-Biotin, PA1-PEG4-Biotin, PA25-PEG4-
Biotin, PA1-PB and PA25-PB were performed at the University of Wisconsin-Madison 
as previously described.13 Briefly, polyamide conjugates at three different concentrations 
(0.01 nM, 1nM and 100 nM) were incubated at room temperature for 1 h with 100 nM of 
a DNA library containing randomized permutations of 20-bp sequences. The binding 
buffer consisted of 1X PBS [pH 7.6] with 50 ng/µL Poly(dI-dC) as a competitor to 
reduce non-specific binding interactions. Polyamide-DNA complexes were affinity 
purified with streptavidin-coated magnetic beads (Dynabeads® MyOneTM Streptavidin 
C1, Catalog # 65001). After affinity capture, the beads were washed three times with 100 
µL cold binding buffer and resuspended in a PCR master mix. PCR amplification was 
then performed for 15 cycles, followed by DNA purification with the Econospin 
Purification Kit (Epoch Life Sciences). The purified, enriched DNA was then used as the 
input DNA for a subsequent round of enrichment. Illumina sequencing adapters and a 
unique 6-bp barcode for multiplexing were separately incorporated to each enriched 
DNA sample and to the starting library by PCR amplification. High-throughput Illumina 
HiSeq 2500 sequencing on these samples was performed by the University of Wisconsin-
Madison DNA Sequencing Facility. Demultiplexing based on the 6-bp barcode was 
subsequently performed on the sequencing reads to segregate the results into separate 
data sets. The reads were truncated to 20-bp corresponding to the random region of the 
library. CSI data analysis was performed as previously described in the literature (Figure 
5.5).13 
 
 
Figure 5.5. Experimental Scheme for Cognate Site Identification (CSI) Analysis. Biotinylated polyamide
conjugates are incubated for 1 h at room temperature with a DNA library containing randomized permutations of 20-bp
sequences. Non-covalent polyamide-DNA complexes are affinity purified with streptavidin-coated magnetic beads
followed by washes to remove unbound DNA. PCR amplification and DNA purification is performed. The purified,
enriched DNA is then used as the input DNA for a subsequent round of enrichment. Illumina sequencing adapters and
a unique 6-bp barcode for multiplexing are separately incorporated to each enriched DNA sample and to the starting
library by PCR amplification. The samples are analyzed by massively parallel DNA sequencing. 
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5.3.4 Cell Culture 
 
W12E cervical keratinocytes (clonal cell line # 20850) and J2 3T3 fibroblasts were a 
kind gift of Professor Paul Lambert (University of Wisconsin-Madison). W12E 
keratinocytes maintaining HPV16 episomes (Genbank Accession No. AF125673) were 
grown as monolayer cultures in the presence of mitomycin C-treated J2 3T3 fibroblasts 
as previously described.24,33-35 Cells were grown at 37 ˚C with a 5 % CO2 atmosphere 
(NuAire NU-4750 US AutoFlow CO2 Water-Jacketed) in E media consisting of three 
parts Dulbecco’s modified Eagle medium (DMEM) and one part Ham’s F-12 media. This 
media was further supplemented with 5 % fetal bovine serum (FBS), 24 µg/mL adenine, 
5 µg/mL transferrin, 20 pM 3,3’,5-triiodo-L-thyronine (T3), 0.4 µg/mL hydrocortisone, 
10 ng/mL cholera toxin, 5 ng/mL epidermal growth factor (EGF), 5 µg/mL insulin, 100 
U/mL penicillin and 100 µg/mL streptomycin. Keratinocytes were passaged at < 70 % 
confluency by trypsin-EDTA treatment (Gibco Catalog # 25300-054) (see Section 5.7.4. 
for detailed cell culture protocols). The number of cells and viability were measured by 
trypan blue staining (Sigma, Catalog # T8157, 0.4 % solution) using a Cellometer Auto 
T4 Cell Viability Counter and SD100 cell counting chambers (Nexcelom Bioscience) 
following the manufacturer’s instructions. 
Although W12E cells are undifferentiated, differentiation can be induced upon 
confluence.24 Thus, passage of W12E keratinocytes was performed at 70 % confluence 
since differentiation leads to virion packaging, a major safety concern.  
5.3.5 Modified Hirt Method: Extraction of HPV16 Episomal DNA 
 
W12E keratinocytes (106-107 cells) were harvested and lysed in 25 mM Tris-HCl [pH 
8.0], 0.6 % SDS, 10 mM EDTA and 50 µg/mL RNase A for 5 min at room temperature. 
Denatured proteins and chromosomal DNA were then precipitated by the addition of a 
solution consisting of 3 M cesium chloride, 1 M potassium acetate and 0.67 M acetic 
acid. The samples were incubated for 15 min at 4 °C and centrifuge. Low molecular 
DNA from each sample supernatant was then purified using QIAprep 2.0 Spin Columns 
(QIAGEN) (see Section 5.7.6 for detailed protocol). 
 
5.3.6 Compound Efficacy Testing: Taqman® Real-Time PCR Antiviral Assay  
 
We verified the antiviral activities for PA1 and PA25 against HPV16 episomes using 
W12E keratinocytes maintained in the UMSL cell culture facility. Polyamide antiviral 
activities were determined by measuring the decrease of episomal HPV16 DNA as a 
function of polyamide concentration in monolayer W12E keratinocyte cultures. The 
episomal load was determined by quantitative PCR (Q-PCR) as previously described.24 
Briefly, lyophilized single-use aliquots (0.1 mg) of PA1 or PA25 were dissolved in 100 
% sterile DMSO (Sigma Life Science, Catalog # D2650) to 10 mM final concentration, 
and further diluted to 1 mM with autoclaved MilliQ H2O. Polyamide concentrations were 
verified by measuring the absorbance at λmax (~305 nm) using a Thermo Scientific 
Evolution 260 Bio UV-visible spectrophotometer, and molar extinction coefficients of 
88,235 M-1cm-1 and 147,400 M-1cm-1 for PA1 and PA25, respectively.   
HPV16-harboring W12E keratinocytes were grown at 37 °C, 5 % CO2 atmosphere on 
10-cm culture dishes in the presence of mitomycin C-treated J2 3T3 fibroblasts in 10 mL 
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of supplemented E media (complete). After removal of the spent media, cells were 
separately treated with 10 mL of E media containing PA concentrations ranging from 
0.001-3 µM with a final DMSO concentration of 0.1 %. Cells were also treated with a 
vehicle control consisting of E media (complete) with a final DMSO concentration of 0.1 
%. After 24 h incubation at 37 °C and 5 % CO2 atmosphere, viral DNA was extracted by 
a modified Hirt method.23 Episomal load for each sample was quantified by Q-PCR. 
Real-time Q-PCR was performed using a CFX96 Real-Time System/C1000 Thermal 
Cycler (Bio-Rad) as previously described.24  TaqMan® probe and primers were purchased 
from Integrated DNA Technologies. The probe consisted of a 5’ reporter 6-
carboxyfluorescein dye and a 3’ quencher 6-carboxytetramethylrhodamine dye. Primers 
and probes were designed to amplify and quantify an 84-bp region within the HPV16 L1 
gene. PCR primers and probe sequences are provided below: 
 
Sense (forward primer):  5’-TGGAGGACTGGAATTTTGGTCTA-3’ 
Antisense (reverse primer):  5’-CAATTGCCTGGGATGTTACAAA-3’ 
TaqMan® probe:  5’-56-FAM-TCCCCCAGGAGGCACACTAGAAGATACTT-TAMRA-3’ 
A standard curve was generated using known concentrations of purified 
HPV16/pUC18 plasmid DNA (total length = 10,589 bp; see Chapter 4 Section 4.3.3). 
The standard curve covered concentrations of 109 to 102 episomal molecules per 
microliter. Equation 5.2 was used to calculate total episomal molecules per microliter for 
each standard point. 
    Episomal	molecules	per	microliter	 ൌ ሺଵ.଼ଶ	௫	ଵ଴భఱሻሺஜ௚/ஜ௅	௦௧ௗ	௣௢௜௡௧ሻሺଵ଴,ହ଼ଽ	௕௣ሻሺଶሻ     (5.2) 
Q-PCR reactions contained 2 µL of template DNA, a final concentration of 1X 
Standard Taq Reaction Buffer (NEB, Catalog # B9014S), 200 µM Deoxynucleotide 
(dNTP) Solution Mix (NEB, Catalog # N0447S, 10 mM), 200 nM each primer and probe 
and 0.5 U Taq DNA Polymerase (NEB, Catalog # M0273L). The Q-PCR reactions were 
performed with the following thermal profile: 95 °C for 10 min, 39 cycles of 95 °C for 15 
s and 60 °C for 70 s, followed by fluorescence reading at the end of each cycle. Q-PCR 
reagent amounts and parameters used for the PCR reactions are summarized in Table 5.3. 
 
Table 5.3. Q-PCR Reagent Amounts and Run Parameters. The amounts given are for a 25 µL reaction.  
Program Reagent Volume (µL) PCR Step Time  
 
QPCR 
HPV16.prcl 
Autoclaved MilliQ H2O 18.4 Polymerase Activation at 95 °C 10 min 
10X Standard Taq Buffer 2.5 
Denaturation at 95 °C 15 s 
39 X 
10 mM dNTP Mix 0.5 
10 µM Forward Primer 0.5 
10 µM Reverse Primer 0.5 Annealing/Extension 
at 60 °C 70 s 10 µM TaqMan® Probe 0.5 Template DNA  2.0 
Taq DNA Polymerase 0.1 Plate Read 
Deoxynucleotide (dNTP) Solution Mix (Catalog # N0447S, 10 mM), 10X Standard Taq Reaction Buffer (Catalog # 
B9014S) and Taq DNA Polymerase (Catalog # M0273L, 5,000 U/mL) were purchased from New England Biolabs. 
 
Q-PCR results were processed and analyzed by CFX Manager 3.1 (Bio-Rad). The 
HPV16 episome number was calculated using the standard curve, and the effect of 
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polyamide on episomal load was plotted as a percent decrease compared to cells treated 
with the vehicle control. The data were fitted to the Sigmoidal equation included in 
Kaleidagraph 4.1.1 (Synergy Software) to determine the polyamide antiviral activities.  
 
5.3.7 Hydroxyl Radical (·OH) Footprinting in W12E Keratinocytes 
 
5.3.7.1 PA1 In-Cell Footprinting Using Gamma-Radiation 
 
In-cell PA-DNA interactions were interrogated by hydroxyl radical footprinting 
experiments relying on gamma-radiation to produce hydroxyl radicals20,21 in W12E cells 
treated with vehicle controls or PA1. These experiments were performed in five control 
and six PA-treated biological replicates. Briefly, a lyophilized single-use aliquot (0.1 mg) 
of PA1 was dissolved in 100 % sterile DMSO to 10 mM final concentration, and further 
diluted to 1 mM with autoclaved MilliQ H2O. Polyamide concentrations were verified by 
UV/Vis spectrophotometry.   
HPV16-harboring W12E keratinocytes were grown at 37 °C, 5 % CO2 atmosphere on 
10-cm culture dishes in the presence of mitomycin C-treated J2 3T3 fibroblasts in 10 mL 
of supplemented E media (complete). After removal of the spent media, cells were 
separately treated with 10 mL of E media containing 0.1 µM PA1 and a final DMSO 
concentration of 0.1 %. Cells were also treated with a vehicle control consisting of E 
media (complete) with a final DMSO concentration of 0.1 %. After 24 h incubation at 37 
°C and 5 % CO2 atmosphere, the media was removed and the cells were washed with 10 
mL 1X PBS. Versene treatment was then performed to selectively remove 3T3 
fibroblasts, followed by dissociation of W12E cells with trypsin. Trypsin was then 
quenched with an equal volume of E media (complete), and the W12E cells were pelleted 
by centrifugation. Harvested W12E keratinocytes (approximately 2 x 106 cells per 
sample) in 2 mL of E media (incomplete) and transferred into a 2.0 mL microcentrifuge 
tube with an internal sealing O-ring (Stockwell Scientific, Catalog # 3306S). These 
samples were placed in ice. The large volume used for these experiments increases the 
effective radiation target, thus increasing the rate of hydroxyl radicals generated in 
solution.20 W12E samples were subjected to gamma-radiation for 19.5 min (140 kRad) 
from a 60Co nuclide source (120 Rad/sec) at 37 °C at the Missouri University Research 
Reactor (MURR) (Figure 5.6). Briefly, a sample vial containing either HPV16/pUC18 
plasmid or W12E cells was place in an aluminum screw cap container (Elemental 
Container, Catalog # 0027127; 99.7 % pure aluminum, diameter = 1 inch, height = 5 
inches) with a 1” aluminum spacer on the bottom and a 2” aluminum spacer on the top of 
the sample vial. The aluminum container was then capped (Elemental Container, Catalog 
# 0027CAP) and tested for leaks. Aluminum spacers served two purposes: 1) they raised 
the sample to the appropriate height for optimum irradiation, and 2) they weighted down 
the sample to ensure it would remain submerged during irradiation. Aluminum container 
was then placed into a submerged DAGIF II aluminum holder with the 60Co gamma-ray 
source in the middle position.  
After gamma-radiation, low molecular DNA from W12E cell samples was extracted 
using a modified Hirt method23 and stored at -20 °C.  
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5.3.7.2 In-Cell Hydroxyl Radical (∙OH) Footprinting using Fenton Chemistry  
 
In-cell hydroxyl radical footprint was also performed using a method developed by 
Taylor et al. as previously described, but with minor modification.22 In this method, 
hydroxyl radicals are generated in cells by the Fenton reaction (Equation 5.1), but in 
contrast to the standard hydroxyl radical procedure used for in vitro experiments, a 50-
fold and 30-fold higher concentration of sodium ascorbate and hydrogen peroxide is 
required.22 In-cell hydroxyl radical footprint experiments were performed in five 
biological replicates for each treatment regimen. W12E monolayer cells were treated with 
polyamides exhibiting a broad range of anti-HPV16 activities: one inactive and seven 
active compounds (Table 5.1). Briefly, W12E keratinocytes were grown at 37 °C, 5 % 
CO2 atmosphere on 10-cm culture dishes in the presence of mitomycin C-treated J2 3T3 
fibroblasts in 10 mL of supplemented E media (complete). Lyophilized single-use 
aliquots (0.1 mg) of each polyamide were dissolved in 100 % sterile DMSO to 1 mM 
final concentration, and further diluted to 10 µM with 10 % sterile DMSO in autoclaved 
MilliQ H2O. After removal of the spent media, cells were separately treated with 10 mL 
of E media containing 0.1 µM PA with a final DMSO concentration of 0.1 %. Cells were 
also treated with a vehicle control consisting of E media (complete) with a final DMSO 
concentration of 0.1 %. After 24 h incubation at 37 °C and 5 % CO2 atmosphere, Versene 
(0.02 % EDTA in 1X PBS) treatment of the plates was performed to selectively remove 
3T3 fibroblasts. The attached W12E cells were washed three times with 10 mL PBS, 
followed by the addition of 10 mL 0.05 % lysolecithin permebilization solution (0.05 % 
lysolecithin in 150 mM sucrose, 80 mM KCl, 5 mM K2HPO4, 5 mM MgCl2, 0.5 mm 
CaCl2 and 35 mM NaHepes buffer [pH 7.4]) and incubated for 60 s at room temperature. 
Incubation with the 0.05 % lysolecithin permeabilization solution affords for cell 
membrane permeabilization allowing the hydroxyl radical reagents to enter the cells. A 
hydroxyl radical footprinting solution was freshly made by adding 495.5 mg sodium 
ascorbate (Sigma, Catalog # 11140-50G) to 50 mL of DMEM media (Gibco, Catalog # 
HPV16‐pUC18 in 
buffered solution 
or W12E cells in E 
media incomplete  1" aluminum spacer on the bottom and 2" aluminum spacer 
on the top of sample vial
Place microcentrifuge 
vial in aluminum 
container 
 
Place aluminum container 
in submerged DAGIF II 
aluminum holder at 
MURR  
Leak test
 
Figure 5.6. DAGIF II Gamma-Radiation Exposure Scheme. Plasmid DNA samples in microcentrifuge vials were
subjected to gamma-rays from a 60Co nuclide source (120 Rad/sec) submerged in water at 37 °C. The gamma-radiation
exposure setup consisted of placing the microcentrifuge vial in an aluminum container in between a 1” aluminum
spacer on the bottom and a 2” aluminum spacer on the top of the sample vial. These containers were leak tested prior to
placing them into a submerged DAGIF II aluminum holder containing the 60Co gamma-ray source. 
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11965-084) and mixed by vortexing. Immediately, 1 mL of freshly prepared 50X Fe(II)-
EDTA stock (500 mM EDTA and 250 mM Fe(NH4)2(SO4)2·6H2O) plus 1 mL of 30 % 
H2O2 were added to the ascorbate/DMEM media and vortexed for approximately 5 s. 
After removal of the 0.05 % lysolecithin permeabilization solution, 10 mL of the 
hydroxyl radical footprinting solution was added onto each W12E culture, followed by 
gentle swirling of the plates to evenly disperse the solution. The plates were then 
incubated for 15 minutes at room temperature. At the end of the incubation period, the 
hydroxyl radical footprinting solution was aspirated and the W12E cells were washed 
twice with 10 mL stop buffer consisting of 0.76 g of thiourea in 100 mL. The cells were 
washed with 10 mL PBS, harvested by scrapping and centrifugation (see Section 5.7.5 
for detailed protocol). Low molecular DNA from each sample was then extracted using a 
modified Hirt method.23  
 
5.3.7.3 Assessment of Fragment Size Distribution by Agilent Bioanalyzer RNA 6000 
Nanochip Kit 
 
For the assessment of ssDNA fragment size distribution produced by the cleavage 
reaction, an Agilent Bioanalyzer RNA 6000 Nanochip kit was used following the 
manufacturer’s instructions. Briefly, 4 µL of modified Hirt-extracted DNA was heat 
denatured at 95 °C for 3 min using a Mastercycler Nexus Thermal Cycler (Eppendorf) 
and immediately placed on ice until ready to load on the Nanochip. Then, 1 µL of ssDNA 
was loaded onto a sample well containing 5 µL of Agilent RNA marker solution. The 
RNA 6000 Nanochip was analyzed in an Agilent 2100 Bioanalyzer using the Eukaryote 
Total RNA Nano Series II assay conditions. The results were analyzed using Agilent 
Technologies 2100 Bioanalyzer 2100 Expert Version B.02.08.SI648 (SR3) software.  
 
5.3.7.4 Quantification of dsDNA using Qubit dsDNA BR and HS Assay Kit 
 
DNA concentration of the modified Hirt-extracted DNA from W12E cells and 
prepared libraries were quantified using Qubit dsDNA BR and HS assay kits with a Qubit 
2.0 Fluorometer (Life technologies) following the manufacturer’s instructions. Briefly, 
Qubit dsDNA BR/HS Standards #1 and #2 were prepared by separately diluting 10 µL of 
either Standard #1 (0 ng/ µL) or Standard #2 (100 ng/µL) in 190 µL of Qubit working 
solution (1:200 Qubit dsDNA BR/HS Reagent:Qubit dsDNA BR/HS buffer) in separate 
Qubit assay tubes (Life technologies, Catalog # Q32856). Unknowns were prepared by 
diluting 2 µL of cleavage reaction products or 4 µL of Illumina NGS library sample to a 
total volume of 200 µL with Qubit working solution in separate Qubit assay tubes. 
Standards and unknown solutions were vigorously vortexed and allowed to incubate at 
room temperature for at least 2 min. After the incubation period, the fluorescence signal 
of each of these solutions was quantified with a Qubit 2.0 Fluorometer (Life 
technologies). The fluorescence signal emitted by the proprietary Qubit dsDNA BR/HS 
Reagent fluorescent dye upon intercalation into dsDNA is directly proportional to the 
amount of dsDNA in the sample, which allows for the calculation of dsDNA 
concentration based on a two-point standard calibration curve. The Qubit 2.0 Fluorometer 
provides a dsDNA concentration in µg/mL of the diluted sample. Equation 5.3 was used 
to calculate dsDNA concentration of the sample. 
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ܥ݋݊ܿ݁݊ݐݎܽݐ݅݋݊	݋݂	ݑ݊݇݊݋ݓ݊ ൌ ܳݑܾ݅ݐ	2.0	ܨ݈ݑ݋ݎ݋݉݁ݐ݁ݎ	ݒ݈ܽݑ݁	ሺμg/mLሻ	x	 ଶ଴଴୶             (5.3) 
																												ݓ݄݁ݎ݁	ݔ	݅ݏ	ݐ݄݁	ݒ݋݈ݑ݉݁	݋݂	ݏܽ݉݌݈݁	ݑݏ݁݀	݅݊	݉݅ܿݎ݋݈݅ݐ݁ݎݏ 
5.3.8 Illumina Next-Generation Sequencing of Hydroxyl Radical Footprinting 
Experiments 
 
5.3.8.1 Preparation of Illumina Next-Generation Sequencing Libraries 
 
Illumina next-generation sequencing libraries were constructed using an Accel-NGS 
1S Plus DNA Library Kit (Swift Biosciences, Catalog # SI-IL1SP-12A/DI-IL1SP-48) 
following the manufacturer’s protocol (refer to Chapter 4 Section 4.7.2 for detailed 
protocol). Thermal cycling steps were performed with a Mastercycler Nexus Thermal 
Cycler. Briefly, a 15 µL (5 ng/µL) of ·OH double-hit fragments in Low EDTA TE buffer 
was heat denatured in a thermal cycler at 95 °C for 2 min and immediately placed on ice 
for 2 min before proceeding to the Adaptase step. The Adaptase step is a proprietary 
reaction that performs fragment end repair, 3’ end tailing and 3’ ligation of a truncated 
adapter. 25 µL of the Adaptase Reaction Mix was added to the 15 µL sample aliquot 
containing the denature ssDNA and cycled with the following thermal profile: 37 °C for 
15 min, 95 °C for 2 min and 4 °C hold. Following 3’ end repair and truncated adapter 
ligation, adapter-ligated DNA molecules were amplified by adding 47 µL of the 
Extension Reaction Mix and cycling with the following thermal profile: 98 °C for 30 s, 
63 °C for 15 s, 68 °C for 5 min and 4 °C hold. The newly synthesized strand allows for 
the ligation of the second truncated adapter to the 5’ end of the DNA fragment. This 
synthesized strand is not sequenced. In order to remove oligonucleotides and small 
fragments, paramagnetic SPRI-based (Solid Phase Reversible Immobilization) bead 
purification of the Extension step was performed with a SPRIselect reagent kit (Beckman 
Coulter, Catalog # B23317). Using a 1.2 ratio of SPRIselect reagent to sample, DNA 
fragments greater than or equal to 200 bp were size-selected and eluted with 20 µL of 
Low EDTA TE buffer. Addition of the second truncated adapter were achieved by adding 
20 µL of the Ligation Reaction Mix and cycled with the following thermal profile: 25 °C 
for 15 min and 4 °C hold. Clean-up of the Ligation step was then performed with a 1.0 
ratio of SPRIselect reagent:sample to size-select for dsDNA fragments of sizes > 200 bp 
using a 12-tube magnetic separation rack (NEB, Catalog # S1509S), followed by elution 
from the beads with 20 µL of Low EDTA TE buffer. Addition of the full-length indexed 
adapters was performed by adding 5 µL of Reagent R1 (index primer, SI-IL1SP-12A) 
and 25 µL of the PCR Reaction Mix. Table 5.4 and Table 5.5 provide the specific 
indexing adapters used for each sample. The reaction mixture was then amplified by 
cycling with the following thermal profile: 98 °C for 30 s, 8 cycles of 98 °C for 10 s, 60 
°C for 30 s and 68 °C for 60 s, followed by a 4 °C hold. The amplified NGS libraries 
were then size-selected with a 0.85 ratio of SPRIselect reagent:sample and eluted with 20 
µL of Low EDTA TE buffer. This was followed by a right side size selection SPRI of the 
libraries in order to remove the majority of DNA fragments > 800 bp (see Section 5.8 for 
detailed protocol). Fragment size distribution was assessed by Agilent Bioanalyzer 2100 
analysis using an Agilent DNA 1000 kit (Agilent Technologies, Catalog # 5067-1505). 
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DNA concentration was determined using a Qubit 2.0 Fluorometer with a Qubit dsDNA 
BR Assay kit. 
 
Table 5.4. PA1 In-Cell Footprinting Using Gamma-Radiation – Summary of NGS Library Preparation Parameters.  
Sample Adapter        (DI-IL1SP-48) 
Index 
Sequence 
Adapter         
(DI-IL1SP-48) 
Index 
Sequence 
Number of PCR 
Cycles 
Control-1 
(CHC4035-2SS) D501 TATAGCCT D701 ATTACTCG 8 
Control-2 
(CHC4049-3 SS) D502 ATAGAGGC D702 TCCGGAGA 8 
Control-3 
(CHC4054-1 SS) D506 TAATCTTA D706 GAATTCGT 8 
Control-4 
(CHC4054-2 SS) D507 CAGGACGT D707 CTGAAGCT 8 
Control-5 
(CHC4054-3 SS) D508 GTACTGAC D708 TAATGCGC 8 
PA1-1 (0.1 µM) 
(CHC4049-4 SS) D503 CCTATCCT D703 CGCTCATT 8 
PA1-2 (0.1 µM) 
(CHC4049-5 SS) D504 GGCTCTGA D704 GAGATTCC 8 
PA1-3 (0.1 µM) 
(CHC4049-6 SS) D505 AGGCGAAG D705 ATTCAGAA 8 
PA1-4 (0.1 µM) 
(CHC4054-4 SS) D501 TATAGCCT D709 CGGCTATG 8 
PA1-5 (0.1 µM) 
(CHC4054-5 SS) D502 ATAGAGGC D710 TCCGCGAA 8 
PA1-6 (0.1 µM) 
(CHC4054-6 SS) D503 CCTATCCT D711 TCTCGCGC 8 
Accel-NGS 1S Plus DNA Library Kit was used to prepare NGS libraries. Index sequence refers to a unique DNA 
sequence identifier in the adapter that allows for multiple libraries to be sequenced simultaneously in a sample lane. 
 
 
 
 
 
Table 5.5. In-Cell Footprinting Using Fenton Chemistry – Summary of NGS Library Preparation Parameters.  
Biological 
Replicate 
# 
Sample Adapter        DI-IL1SP-48 Sequence 
Adapter        
DI-IL1SP-48 Sequence 
Number 
of PCR 
Cycles 
1 
Control-1 
(CHC4102-1 SS) D504 GGCTCTGA D712 AGCGATAG 8 
PA11-1 (0.1 µM) 
(CHC4102-2 SS) D505 AGGCGAAG D701 ATTACTCG 8 
PA1-1 (0.1 µM) 
(CHC4102-3 SS) D506 TAATCTTA D702 TCCGGAGA 8 
PA25-1 (0.1 µM) 
CHC4102-4 SS D507 CAGGACGT D703 CGCTCATT 8 
NV1078-1 (0.1 µM) 
CHC4102-5 SS D508 GTACTGAC D704 GAGATTCC 8 
NV1087-1 (0.1 µM) 
CHC4102-6 SS D501 TATAGCCT D705 ATTCAGAA 8 
NV1111-1 (0.1 µM) 
CHC4102-7 SS D502 ATAGAGGC D706 GAATTCGT 8 
PA30-1 (0.1 µM) 
CHC4102-8 SS D503 CCTATCCT D707 CTGAAGCT 8 
PA31-1 (0.1 µM) 
CHC4102-9 SS D504 GGCTCTGA D708 TAATGCGC 8 
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2 
Control-2 
CHC4114-1 SS D505 AGGCGAAG D709 CGGCTATG 8 
PA11-2 (0.1 µM) 
CHC4114-2 SS D506 TAATCTTA D710 TCCGCGAA 8 
PA1-2 (0.1 µM) 
CHC4114-3 SS D507 CAGGACGT D711 TCTCGCGC 8 
PA25-2 (0.1 µM) 
CHC4114-4 SS D508 GTACTGAC D712 AGCGATAG 8 
NV1078-2 (0.1 µM) 
CHC4114-5 SS D501 TATAGCCT D701 ATTACTCG 8 
NV1087-2 (0.1 µM) 
CHC4114-6 SS D502 ATAGAGGC D702 TCCGGAGA 8 
NV1111-2 (0.1 µM) 
CHC4114-7 SS D503 CCTATCCT D703 CGCTCATT 8 
PA30-2 (0.1 µM) 
CHC4114-8 SS D504 GGCTCTGA D704 GAGATTCC 8 
PA31-2 (0.1 µM) 
CHC4114-9 SS D505 AGGCGAAG D705 ATTCAGAA 8 
3 
Control-3 
CHC4117-1 SS D501 TATAGCCT D706 GAATTCGT 8 
PA11-3 (0.1 µM) 
CHC4117-2 SS D502 ATAGAGGC D707 CTGAAGCT 8 
PA1-3 (0.1 µM) 
CHC4117-3 SS D503 CCTATCCT D708 TAATGCGC 8 
PA25-3 (0.1 µM) 
CHC4117-4 SS D504 GGCTCTGA D709 CGGCTATG 8 
NV1078-3 (0.1 µM) 
CHC4117-5 SS D505 AGGCGAAG D710 TCCGCGAA 8 
NV1087-3 (0.1 µM) 
CHC4117-6 SS D506 TAATCTTA D711 TCTCGCGC 8 
NV1111-3 (0.1 µM) 
CHC4117-7 SS D507 CAGGACGT D712 AGCGATAG 8 
PA30-3 (0.1 µM) 
CHC4117-8 SS D508 GTACTGAC D701 ATTACTCG 8 
PA31-3 (0.1 µM) 
CHC4117-9 SS D501 TATAGCCT D702 TCCGGAGA 8 
4 
Control-4 
CHC4133-1 SS D502 ATAGAGGC D703 CGCTCATT 8 
PA11-4 (0.1 µM) 
CHC4133-2 SS D503 CCTATCCT D704 GAGATTCC 8 
PA1-4 (0.1 µM) 
CHC4133-3 SS D504 GGCTCTGA D705 ATTCAGAA 8 
PA25-4 (0.1 µM) 
CHC4133-4 SS D505 AGGCGAAG D712 AGCGATAG 8 
NV1078-4 (0.1 µM) 
CHC4133-5 SS D506 TAATCTTA D701 ATTACTCG 8 
NV1087-4 (0.1 µM) 
CHC4133-6 SS D507 CAGGACGT D708 TAATGCGC 8 
NV1111-4 (0.1 µM) 
CHC4133-7 SS D508 GTACTGAC D709 CGGCTATG 8 
PA30-4 (0.1 µM) 
CHC4133-8 SS D507 CAGGACGT D710 TCCGCGAA 8 
PA31-4 (0.1 µM) 
CHC4133-9 SS D503 CCTATCCT D711 TCTCGCGC 8 
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Biological 
Replicate 
# 
Sample Adapter DI-IL1SP-12A Sequence 
Number 
of PCR 
Cycles 
5 
Control-5 
CHC4141-1 SS Reagent R1 (I2) CGATGT(A) 8 
PA11-5 (0.1 µM) 
CHC4141-2 SS Reagent R1 (I4) TGACCA(A) 8 
PA1-5 (0.1 µM) 
CHC4141-3 SS Reagent R1 (I5) ACAGTG(A) 8 
PA25-5 (0.1 µM) 
CHC4141-4 SS Reagent R1 (I6) GCCAAT(A) 8 
NV1078-5 (0.1 µM) 
CHC4141-5 SS Reagent R1 (I7) CAGATC(A) 8 
NV1087-5 (0.1 µM) 
CHC4141-6 SS Reagent R1 (I12) CTTGTA(A) 8 
NV1111-5 (0.1 µM) 
CHC4141-7 SS Reagent R1 (I13) AGTCAA(C) 8 
PA30-5 (0.1 µM) 
CHC4141-8 SS Reagent R1 (I14) AGTTCC(G) 8 
PA31-5 (0.1 µM) 
CHC4141-9 SS Reagent R1 (I15) ATGTCA(G) 8 
Accel-NGS 1S Plus DNA Library Kit was used to prepare NGS libraries. Index sequence refers to a unique DNA 
sequence identifier in the adapter that allows for multiple libraries to be sequenced simultaneously in a sample lane. 
 
5.3.8.2 Quality Control of NGS Libraries 
 
Prepared libraries were quantified by Qubit 2.0 Fluorometer using a Qubit dsDNA 
BR/HS assay kit and the fragment size distribution was determined by Agilent 
Bioanalyzer 2100 analysis using an Agilent DNA 1000 kit per manufacturer’s directions. 
Briefly, 1 µL of the library sample was loaded onto a sample well containing 5 µL of 
Agilent DNA marker solution. The DNA 1000 Nanochip was then analyzed in an Agilent 
2100 Bioanalyzer using the DNA 1000 Series II assay conditions. The results were 
analyzed using Agilent Technologies 2100 Bioanalyzer 2100 Expert Version 
B.02.08.SI648 (SR3) software. Equation 5.4 was used to calculate the molar 
concentration of each NGS library.  
 
											ܯ݋݈ܽݎ	ܿ݋݊ܿ݁݊ݐݎܽݐ݅݋݊	݋݂	ܰܩܵ	݈ܾ݅ݎܽݎݕ																																																																																																				(5.4)
																																		ൌ ሾ݀ݏܦܰܣሿܾݕ	ܳݑܾ݅ݐ	2.0	ሺng/μLሻ	ݔ	10଺	μL/L	ݔ ୬୫୭୪଺଺଴	୬୥ ݔ
ଵ
ே	 
ݓ݄݁ݎ݁	ܰ	݅ݏ	ݐ݄݁	ܽݒ݁ݎܽ݃݁	݂ݎܽ݃݉݁݊ݐ	ݏ݅ݖ݁	݋݂	ݐ݄݁	݈ܾ݅ݎܽݎݕ	݀݁ݐ݁ݎ݉݅݊݁݀	ܾݕ	ܣ݈݃݅݁݊ݐ	ܳݑܾ݅ݐ	1000	݇݅ݐ 
 
The molar concentration of the constructed NGS libraries was also verified by the 
DNA Core Facility at the University of Missouri using a Qubit 3.0 Fluorometer (Life 
technologies) prior to high-throughput Illumina HiSeq 2500 or NextSeq 500 sequencing. 
 
5.3.8.3 Illumina Next-Generation Sequencing  
 
High-throughput Illumina sequencing of ·OH-treated W12E samples in the presence 
or absence of polyamides were performed by the DNA Core Facility at the University of 
Missouri using single-end, 51 base pair read-length on an Illumina HiSeq 2500. The 
libraries corresponding to the hydroxyl radical footprinting (Fenton chemistry) 
experiment in the fifth biological regimen were sequenced using a single-end, 75 base 
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pair read-length on an Illumina NextSeq 500. Samples were multiplexed per lane since 
the libraries were constructed using different indexing adapters.  
 
5.3.9 Bioinformatics Analysis of NGS Results from Hydroxyl Radical Footprinting 
Experiments 
 
5.3.9.1 Sequence Alignment and Analysis of ∙OH Cleavage Intensities 
 
Demultiplexing was subsequently performed on the sequencing reads to segregate the 
sequencing results into separate data sets. Unique sequencing reads were aligned to the 
HPV16 reference genome (GenBank Accession No. AF125673) and human genome 
(hg19) using Bowtie 2 (version 2.2.9).36 The aligned, or mapped reads in the resulting 
SAM file were then processed with CountNicks.pm to determine the ·OH cleavage 
intensity at each nucleotide (see Chapter 4 Section 4.7.3 for bioinformatics instructions). 
 
5.3.10 Crosslinking of Small Molecules for Isolation of Chromatin (COSMIC) 
 
COSMIC experiments using PA1-PB and PA25-B were performed in H1 human 
embryonic stem cells (H1-hESC) at the University of Wisconsin-Madison in biological 
duplicate as previously described.13 Briefly, approximately 2.5 x 107 H1-hESC cells were 
separately treated with 400 nM of PA1-PB or PA25-PB in E8 media with a final DMSO 
concentration of 0.1 %. 
 COSMIC experiments using PA1-PB and PA25-B were also performed in W12E 
keratinocyte monolayers at The University of Missouri-St. Louis in biological duplicate 
as previously described.13 Briefly, approximately 2.5 x 107 H1-hESC cells were 
separately treated with 8 mL of E media (complete) containing 100 nM of PA1-PB or 
PA25-PB with a final DMSO concentration of 0.1 %. After 24 h incubation at 37 °C and 
5 % CO2 atmosphere, W12E cells were irradiated for 30 min at room temperature with an 
UV lamp (CalSun, Catalog # B001BH0A1A; 2.4 mW/cm2) using a glass filter. The latter 
prevents DNA thymine dimer formation by removing light with wavelengths lower than 
300 nm. After crosslinking, Versene (0.02 % EDTA in 1X PBS) treatment of the plates 
was performed to selectively remove 3T3 fibroblasts. The attached W12E cells were 
washed with 4 mL PBS, followed by dissociation of W12E cells with trypsin. Trypsin 
was then quenched with an equal volume of E media (complete), and the W12E cells 
were pelleted by centrifugation (500x g at 4 °C for 5 min). Pelleted cells were 
resuspended in COSMIC buffer (20 mM Tris-HCl [pH 8.1], 2 mM EDTA, 150 mM 
NaCl, 1 % Triton-X100, 0.1 % SDS, 1 mM PMSF, 1 mM benzamidine, 1.5 µM 
pepstatin). Cell lysates were then sonicated in a QSonica Q800R sonicator for 2 h at 4 °C 
with a cycle of 10 s on and 10 s off at 50 % power to yield DNA fragments in a range of 
100-500 bp. Samples were centrifuged at 12,000x g at 4 °C for 10 min and about 10 % of 
each sample was saved in a new microcentrifuge tube. These samples served as a 
reference of non-enriched DNA (Input DNA) and they were stored at -80 °C. The 
remaining of the chromatin samples were treated with streptavidin-coated magnetic beads 
(120 µL / sample; Dynabeads MyOne Streptavidin C1, Catalog # 65001) to capture PA-
DNA crosslinks. Briefly, the chromatin samples were incubated with streptavidin-coated 
magnetic beads, previously washed with COSMIC buffer, for 12 h at 4 °C on a 
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shaker/rotator (Barnstead/Thermolyne Labquake 400110). At the end of the incubation 
period, the samples were placed on a magnetic stand (NEB, Catalog # S1509S) and the 
immobilized streptavidin beads were washed with 1 mL of COSMIC buffer 
supplemented with 5 µM of non-functionalized PA (PA1 or PA25) once for 12 h and 
once for 4 h at 4 °C on a shaker/rotator each. Streptavidin beads were washed once with 1 
mL Wash buffer 1 (10 mM Tris-HCl [pH 8.0], 1 mM EDTA, 3 % v/v SDS, supplemented 
with 5 µM of respective non-functionalized PA) and once with 1 mL Wash buffer 2 (10 
mM Tris-HCl [pH 8.0], 1 mM EDTA, 250 mM LiCl, 0.5 % NP40, 1 % sodium 
deoxycholate, 5 µM of respective non-functionalized PA) for 7 min at room temperature 
each on a shaker/rotator. Streptavidin beads were then washed twice with Wash buffer 3 
(10 mM Tris-HCl [pH 7.5], 1 mM EDTA, 4 M urea, 0.1 % NP40, 5 µM of respective 
non-functionalized PA) for 7 min at 50 °C on a shaker/rotator. Streptavidin beads were 
washed twice with 1 mL aliquots of TE buffer (10 mM Tris-HCl buffer [pH 8.0], 1 mM 
EDTA) and resuspended in 200 µL of TE buffer. These samples of capture DNA are 
referred to as Affinity-purified (AP) DNA. Psoralen-DNA crosslinks in the Input and AP 
DNA samples were reversed by the addition of 10X crosslink reversal buffer (100 mM 
Tris-HCl [pH 8.0], 4 mM EDTA, 1M KOH) to a final concentration of 1X, followed by 
incubation for 30 min at 90 °C. Upon crosslink reversal by hot alkali treatment, DNA is 
released from the streptavidin beads onto the supernatant. Sample supernatants were 
transferred to clean amber microcentrifuge tubes and neutralized with approximately 1 
µL concentrated HCl. Samples were then treated with RNase A (Thermo Scientific, 
Catalog # EN0531)(0.2 µg/µL final concentration) for 1 h at 37 °C, followed by 
treatment with Proteinase K (Thermo Scientific, Catalog # FEREO0491)(0.2 µg/µL final 
concentration) for 1 h at 55 °C. Input and AP DNA samples were purified with a 
QIAquick PCR purification kit (QIAGEN, Catalog # 28104) (see Section 5.7.7 for 
detailed protocol). Purified DNA samples were stored -80 °C. Illumina next-generation 
sequencing libraries for input and AP DNA will be prepared with the TruSeq ChIP 
Sample Prep Kit (Illumina). High-throughput Illumina HiSeq 2500 sequencing with a 
read-length of 51 bp will be performed by the University of Wisconsin-Madison DNA 
Sequencing Facility. Demultiplexing based on the 6-bp barcode will be subsequently 
performed on the sequencing reads to segregate the results into separate data sets. 
Analysis of the COSMIC-Seq data will be performed as previously described.13 
 
5.3.10.1 Assessment of Fragment Size Distribution by 1.5 % Agarose Gel 
Electrophoresis 
 
Fragment size distributions of sheared DNA achieved for different sonication times 
were resolved by agarose gel electrophoresis. Briefly, a 20 µL aliquot of sonicated lysate 
sample was mixed with 5 µL of 6X electrophoresis loading buffer and 5 µL autoclaved 
MQH2O. Samples were loaded onto a 1.5 % agarose gel, and electrophoresis was 
performed in 1X TAE buffer at a voltage of 110 V for 1.5 h at room temperature. After 
electrophoresis, the agarose gel was stained with 0.5 µg/mL ethidium bromide for 20 min 
and washed with autoclaved MilliQ H2O for 5 min in a staining box. The fragmented 
DNA and DNA ladders (NEB, Catalog # N3232S and N3236S) were visualized with a 
FOTO/Convertible UV-light box equipped with an ethidium bromide filter (FOTODYNE 
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Incorporated). The agarose gel was imaged and analyzed with FOTO/Analyst PC Image 
version 5.00.  
 
5.4 RESULTS 
 
We relied on Cognate Site Identification (CSI) analysis of a solution-based SELEX 
(systematic evolution of ligands by exponential enrichment) method coupled to next-
generation sequencing13,28 to determine the binding preferences of PA1 and PA25 for the 
library interrogated. Furthermore, we applied multiple methodologies, including hydroxyl 
radical footprinting and COSMIC, to map the genome-wide binding sites of seven anti-
HPV polyamides and one inactive polyamide in living cells.  
 
5.4.1 Cognate Site Identification (CSI) Analysis 
 
Cognate Site Identification analysis, a SELEX-based approach developed by Ansari 
and colleagues, was used to examine the binding preferences of three hairpin polyamides 
(KA2127, PA1 and PA25). Toward this goal, we synthesized biotinylated conjugates of 
these PAs and incubated each with a DNA library containing randomized permutations of 
20-bp sequences. Affinity capture using streptavidin-coated beads allows for the 
enrichment of the bound sequences, and subsequent NGS analysis of the enriched 
sequences provides the specificity profiles of these minor groove DNA-binding ligands. 
Furthermore, CSI analysis allows for the determination of structural contributions 
afforded by the sequences flanking the binding motif.13 Ansari et al. have demonstrated 
that the binding intensities obtained from CSI analysis are directly proportional to the 
equilibrium association constant values of PA-DNA interactions.26 As a result, these data 
has been used to predict the probability of binding to specific sequences in a genome-
wide manner.29 Because binding cooperativity between nearby sites can pre-organize the 
minor groove of DNA to convert an incompatible site into a site with the appropriate 
structural features for PA-binding,19 a subset of binding sites may not be predicted by this 
analysis. Next-generation sequencing has been completed for the CSI experiments and 
bioinformatics analysis is currently in progress. 
 
5.4.2 PA1 and PA25 Antiviral Activity (IC50)   
 
Previous cell culture work and antiviral assays were performed by our collaborators at 
NanoVir. To validate our local cell culture and virology conditions with previous results, 
we verified the antiviral activities for PA1 and PA25 against HPV16 episomes using 
W12E cells maintained in the UMSL cell culture facility.  
The episomal load was determined by quantitative PCR (Q-PCR) as previously 
described.24 The standard curve generated from cloned HPV16/pUC18 plasmid DNA was 
linear over the range used (109 to 102 HPV16 copies per µL) (Figure 5.7A). Based on this 
standard curve, HPV16 episomal levels in modified Hirt23 extracts were quantified in 
monolayer W12E keratinocytes treated with vehicle controls and increasing 
concentrations of PA1 or PA25. Then, polyamide antiviral activities were determined by 
measuring the decrease of episomal HPV16 DNA as a function of polyamide 
concentration (Figure 5.7B). The apparent IC50 values for PA1 and PA25 were 0.13 and 
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0.010 µM, respectively (Figure 5.7C). These values are in agreement with the published 
IC50 values of 0.1 and 0.036 µM for PA1 and PA25.24   
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Figure 5.7. Antiviral Activities of PA1 and PA25 Determined by Taqman® Real-Time Q-PCR Assay.
(A) HPV16 episomal load was determined using a standard curved generated from known concentrations of
cloned HPV16/pUC18 DNA. The representative Q-PCR amplification curve illustrates the linear correlation
between the log of HPV16 copies and the quantification cycle (Cq) (slope = -3.529 and y-intercept = 41.795;
thus, HPV16 copies/µL = 10[(Cq-41.795)/-3.529]. (B) The effects of PA1 and PA25 on HPV16 episomal levels and
cell viability of W12E keratinocytes monolayers are plotted as a percent decrease compared to cells treated
with the vehicle control. (C) Dose-response curves for PA1 and PA25 against HPV16 in W12E keratinocytes
monolayers. Inset tables provide calculated IC50 values (m3).
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5.4.3 Hydroxyl Radical Footprinting Coupled to Massively Parallel DNA 
Sequencing (·OH-Seq)  in W12E Keratinocytes 
 
Here we have used hydroxyl radicals generated by either gamma-radiation or Fenton 
chemistry to produce short single-stranded fragments derived from two ·OH nicks in 
close proximity within the same DNA strand in W12E cells. Comparison of the relative 
cleavage intensity, as determined by Illumina next-generation sequencing, between 
vehicle control-treated cells and polyamide-treated cells should allow us to determine 
relative ligand-mediated protection within the viral and human genomes. Since oxidative 
damage to DNA by hydroxyl radicals leads to single-stranded breaks along the DNA 
molecule, we employed the Accel-NGS 1S Plus DNA Library Kit for library preparation 
due to its compatibility with denatured, single-stranded, and nicked samples (see 
Chapter 4 Section 4.2.2 for hydroxyl radical-DNA chemistry)  
 
5.4.3.1 PA1 In-Cell ∙OH Footprinting Using Gamma-Radiation – DNA Concentrations 
and Fragment Size Distribution of Low Molecular DNA Extracted from W12E 
Cells Chemistry 
 
In-cell PA1-DNA interactions were interrogated by hydroxyl radical footprinting 
experiments relying on gamma-radiation to produce hydroxyl radicals20,21 in W12E 
keratinocytes. In this technique, production of hydroxyl radicals is mediated by gamma 
radiolysis of water. These experiments were performed in five biological replicates 
consisting of vehicle control-treated cells, and six biological replicates of cells treated 
with 0.1 µM PA1 in E media (final DMSO concentration of 0.1 %) for 24 h at 37 ˚C with 
a 5 % CO2 atmosphere. HPV16-harboring W12E cells were subjected to gamma-
radiation for 19.5 min from a 60Co nuclide source (120 Rad/sec) at 37 °C at the MURR. 
The irradiation period was empirically determined. The total radiation load was 
approximately 140 kRad, which is about twice the amount (75 kRad) previously used by 
Tullius et al. to study protein-DNA complexes in bacterial cells.21 After gamma-
radiation, the low molecular fragments derived from ·OH double-hit kinetics were 
extracted using a modified Hirt method.23 DNA sample concentrations were determined 
by a Qubit dsDNA HS Assay kit (Table 5.6) and the fragment size distribution of a 
representative sample was estimated using the RNA 6000 Nanochip assay (Figure 5.8).     
 
Table 5.6. PA1 In-Cell ·OH Footprinting by Gamma-Radiation – DNA Concentrations of Samples Determined by 
Qubit dsDNA HS Assay 
Sample Qubit dsDNA Assay (ng/µL) Sample 
Qubit dsDNA Assay 
(ng/µL) 
Control-1  
(CHC4035-2) 34.7 
PA1-1 (0.1 µM) 
(CHC4049-4) 24.5 
Control-2  
(CHC4049-3) 31.3 
PA1-2 (0.1 µM) 
(CHC4049-5) 23.3 
Control-3  
(CHC4054-1) 32.5 
PA1-3 (0.1 µM) 
(CHC4049-6) 16.4 
Control-4  
(CHC4054-2) 18.5 
PA1-4 (0.1 µM) 
(CHC4054-4) 20.4 
Control-5  
(CHC4054-3) 24.8 
PA1-5 (0.1 µM) 
(CHC4054-5) 19.3 
 PA1-6 (0.1 µM) (CHC4054-6) 18.7 
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5.4.3.2 In-Cell Hydroxyl Radical (∙OH) Footprinting using Fenton Chemistry – DNA 
Concentrations and Fragment Size Distribution of Low Molecular DNA 
Extracted from W12E Cells  
 
To map the binding sites of seven anti-HPV PAs and one inactive PA to the viral and 
genomic DNA in W12E keratinocytes, we performed in-cell hydroxyl radical footprint 
experiments as previously described by Taylor et al.22 In this method, highly-reactive 
hydroxyl radicals are generated by the Fenton reaction between ferrous iron (Fe2+) and 
hydrogen peroxide (H2O2). Addition of sodium ascorbate reduces Fe(III) to regenerate 
Fe(II), affording a reaction catalytic in iron (Equation 5.1). These experiments were 
performed in five biological replicates of W12E monolayer keratinocytes treated with 
either one inactive or one of seven active compounds (Table 5.1). The cleavage reaction 
was allowed to proceed for 15 min at room temperature, as longer reaction times of 20 
and 25 min led to a significant detachment of W12E from the culture plates. After the 
cleavage reaction, the low molecular fragments derived from ·OH double-hit kinetics 
were extracted using a modified Hirt method.23 DNA sample concentrations were 
determined by Qubit dsDNA BR or HS Assay kit (Table 5.7) and the fragment size 
distribution was estimated using the RNA 6000 Nanochip assay (Figure 5.9).        
  
Table 5.7. In-Cell Footprinting by Fenton Chemistry – DNA Concentrations Determined by Qubit dsDNA HS Assay 
Biological Replicate #1 Biological Replicate #2 Biological Replicate #3 
Sample [dsDNA] (ng/µL) Sample 
[dsDNA] 
(ng/µL) Sample 
[dsDNA] 
(ng/µL) 
Control-1 
(CHC4079-1) 5.60 
Control-2 
(CHC4092-1) 45.6 
Control-3 
(CHC4097-1) 32.3 
PA11-1 (0.1 µM) 
(CHC4079-2) 13.0 
PA11-2 (0.1 µM) 
(CHC4092-2) 68.5 
PA11-3 (0.1 µM) 
(CHC4097-2) 25.9 
PA1-1 (0.1 µM) 
(CHC4079-3) 11.0 
PA1-2 (0.1 µM) 
(CHC4092-3) 36.1 
PA1-3 (0.1 µM) 
(CHC4097-3) 39.6 
PA25-1 (0.1 µM) 
(CHC4079-4) 7.98 
PA25-2 (0.1 µM) 
(CHC4092-4) 32.7 
PA25-3 (0.1 µM) 
(CHC4097-4) 28.1 
NV1078-1 (0.1 µM) 
(CHC4079-5) 5.68 
NV1078-2 (0.1 µM) 
(CHC4092-5) 22.2 
NV1078-3 (0.1 µM) 
(CHC4097-5) 23.5 
NV1087-1 (0.1 µM) 
(CHC4079-6) 5.70 
NV1087-2 (0.1 µM) 
(CHC4092-6) 27.1 
NV1087-3 (0.1 µM) 
(CHC4097-6) 23.6 
NV1111-1 (0.1 µM) 
(CHC4079-7) 7.60 
NV1111-2 (0.1 µM) 
(CHC4092-7) 29.1 
NV1111-3 (0.1 µM) 
(CHC4097-7) 20.2 
PA30-1 (0.1 µM) 
(CHC4079-8) 9.33 
PA30-2 (0.1 µM) 
(CHC4092-8) 35.5 
PA30-3 (0.1 µM) 
(CHC4097-8) 17.3 
PA31-1 (0.1 µM) 
(CHC4079-9) 16.6 
PA31-2 (0.1 µM) 
(CHC4092-9) 30.1 
PA31-3 (0.1 µM) 
(CHC4097-9) 16.5 
M
Figure 5.8. ssDNA Fragment Size Distribution of a PA1 In-Cell ·OH Footprinting Sample (Gamma-Radiation).
RNA 6000 Nanochip assay analysis of heat denatured ssDNA fragment size distribution for ·OH footprinting sample of
PA1 in W12E cells. Gamma-radiation was performed at MURR for 19.5 min at 37 °C. M: RNA marker. 
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Biological Replicate #4 Biological Replicate #5 
Sample [dsDNA] (ng/µL) Sample 
[dsDNA] 
(ng/µL) 
Control-4 
(CHC4128-1) 12.4 
Control-5 
(CHC4136-1) 34.2 
PA11-4 (0.1 µM) 
(CHC4128-2) 16.6 
PA11-5 (0.1 µM) 
(CHC4136-2) 42.7 
PA1-4 (0.1 µM) 
(CHC4128-3) 15.4 
PA1-5 (0.1 µM) 
(CHC4136-3) 38.2 
PA25-4 (0.1 µM) 
(CHC4128-4) 10.6 
PA25-5 (0.1 µM) 
(CHC4136-4) 33.5 
NV1078-4 (0.1 µM) 
(CHC4128-5) 6.4 
NV1078-5 (0.1 µM) 
(CHC4136-5) 35.4 
NV1087-4 (0.1 µM) 
(CHC4128-6) 13.3 
NV1087-5 (0.1 µM) 
(CHC4136-6) 18.7 
NV1111-4 (0.1 µM) 
(CHC4128-7) 13.3 
NV1111-5 (0.1 µM) 
(CHC4136-7) 36.9 
PA30-4 (0.1 µM) 
(CHC4128-8) 8.7 
PA30-5 (0.1 µM) 
(CHC4136-8) 13.0 
PA31-4 (0.1 µM) 
(CHC4128-9) 11.0 
PA31-5 (0.1 µM) 
(CHC4136-9) 15.5 
Accel-NGS 1S Plus DNA Library Kit was used to prepare NGS libraries. Index sequence refers to a unique DNA 
sequence identifier in the adapter that allows for multiple libraries to be sequenced simultaneously in a single sample 
lane and be identified and grouped together properly via bioinformatics processing of the sequence data. Molar 
concentrations were calculated according to Equation 5.4 using the Qubit 2.0 data. 
 
 
 
 
5.4.4 Illumina Next-Generation Sequencing of Hydroxyl Radical Footprinting 
Experiments 
 
5.4.4.1 Quality Control of NGS Libraries 
 
DNA concentration was measured by the Qubit dsDNA BR/HS assay and fragment 
size distribution was determined by the Agilent DNA 1000 assay for the constructed 
libraries. The molar concentrations of the constructed libraries were calculated according 
to Equation 5.4 using the DNA concentration measured by Qubit and the average 
fragment size of the library determined by Bioanalyzer (Tables 5.8 and 5.9). Fragment 
size distribution profiles of NGS libraries are provided in Figures 5.10 and 5.11.  
M
Figure 5.9. Single-Stranded DNA Fragment Size Distribution of a Representative In-Cell ·OH Footprinting
Sample (Fenton Chemistry). RNA 6000 Nanochip assay analysis of heat denatured ssDNA fragment size distribution
for ·OH footprinting samples in W12E cells. Cleavage reaction was performed for 15 min at room temperature in
attached cells using a footprinting solution consisting of 50 mM sodium ascorbate, 10 mM EDTA, 5 mM Fe(II) and 0.6
% H2O2. M: RNA marker. 
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Table 5.8. PA1 In-Cell ·OH Footprinting by Gamma-Radiation – Summary of NGS Library Information.  
Sample Adapter      (SI-IL1SP-48) 
Index 
Sequence 
Qubit 2.0 
(ng/µL) 
MU Qubit 
3.0 (ng/µL) 
Bioanalyzer   
Average Size 
(bp) 
Molar 
Concentration 
(nM) 
Control-1 
(CHC4035-2SS) 
D501 TATAGCCT 5.20 6.03 382 20.63 D701 ATTACTCG 
Control-2 
(CHC4049-3 SS) 
D502 ATAGAGGC 10.00 11.50 445 34.05 D702 TCCGGAGA 
Control-3 
(CHC4054-1 SS) 
D506 TAATCTTA 11.78 13.3 501 35.63 D706 GAATTCGT 
Control-4 
(CHC4054-2 SS) 
D507 CAGGACGT 5.29 5.39 493 16.26 D707 CTGAAGCT 
Control-5 
(CHC4054-3 SS) 
D508 GTACTGAC 8.14 9.08 404 30.53 D708 TAATGCGC 
PA1-1 (0.1 µM) 
(CHC4049-4 SS) 
D503 CCTATCCT 7.66 9.79 450 25.79 D703 CGCTCATT 
PA1-2 (0.1 µM) 
(CHC4049-5 SS) 
D504 GGCTCTGA 8.70 10.20 461 28.59 D704 GAGATTCC 
PA1-3 (0.1 µM) 
(CHC4049-6 SS) 
D505 AGGCGAAG 3.55 4.99 476 11.30 D705 ATTCAGAA 
PA1-4 (0.1 µM) 
(CHC4054-4 SS) 
D501 TATAGCCT 11.10 12.2 448 37.54 D709 CGGCTATG 
PA1-5 (0.1 µM) 
(CHC4054-5 SS) 
D502 ATAGAGGC 8.28 8.92 406 30.90 D710 TCCGCGAA 
PA1-6 (0.1 µM) 
(CHC4054-6 SS) 
D503 CCTATCCT 8.22 9.06 399 31.21 D711 TCTCGCGC 
Accel-NGS 1S Plus DNA Library Kit was used to prepare NGS libraries. Index sequence refers to a unique DNA 
sequence identifier in the adapter that allows for multiple libraries to be sequenced simultaneously in a single sample 
lane and be identified and grouped together properly via bioinformatics processing of the sequence data. Molar 
concentrations were calculated according to Equation 5.4 using the Qubit 2.0 data. 
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Table 5.9. In-Cell ·OH Footprinting by Fenton Chemistry – Summary of NGS Library Information.  
Biological 
Replicate #1 
Sample 
Adapter     
(SI-IL1SP-48) 
Index 
Sequence 
Qubit 2.0 
(ng/µL) 
MU Qubit 
3.0 (ng/µL) 
Bioanalyzer   
Average 
Size (bp) 
Molar 
Concentration 
(nM) 
Control-1 
(CHC4102-1 SS) 
D504 GGCTCTGA 12.2 7.29 433 42.69 D712 AGCGATAG 
PA11-1 (0.1 µM) 
(CHC4102-2 SS) 
D505 AGGCGAAG 19.9 19.9 458 65.83 D701 ATTACTCG 
PA1-1 (0.1 µM) 
(CHC4102-3 SS) 
D506 TAATCTTA 16.3 16.2 416 59.37 D702 TCCGGAGA 
PA25-1 (0.1 µM) 
CHC4102-4 SS 
D507 CAGGACGT 16.1 15.6 424 57.53 D703 CGCTCATT 
NV1078-1 (0.1 µM) 
CHC4102-5 SS 
D508 GTACTGAC 19.5 18.9 457 64.65 D704 GAGATTCC 
NV1087-1 (0.1 µM) 
CHC4102-6 SS 
D501 TATAGCCT 17.4 18.3 449 58.72 D705 ATTCAGAA 
NV1111-1 (0.1 µM) 
CHC4102-7 SS 
D502 ATAGAGGC 19.6 17.1 422 70.37 D706 GAATTCGT 
PA30-1 (0.1 µM) 
CHC4102-8 SS 
D503 CCTATCCT 15.9 16.4 427 56.42 D707 CTGAAGCT 
PA31-1 (0.1 µM) 
CHC4102-9 SS 
D504 GGCTCTGA 13.3 12.1 422 47.75 D708 TAATGCGC 
Figure 5.10. Fragment Size Distribution of Illumina NGS Libraries (Gamma-Radiation). Agilent DNA1000 assay
analysis of prepared NGS libraries from PA1 in-cell ·OH footprinting by gamma-radiation. Samples CHC4035-2 SS,
CHC4049-3 SS, CHC4054-1 SS, CHC4054-2 SS and CHC4054-3 SS correspond to W12E cells treated with vehicle
controls. Samples CHC4049-4 SS, CHC4049-5 SS, CHC4049-6 SS, CHC4054-4 SS, CHC4054-5 SS and CHC4054-6
SS correspond to W12E cells treated with 0.1 µM PA1 for 24 h. 
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Biological 
Replicate #2 
Sample 
Adapter     
(SI-IL1SP-48) 
Index 
Sequence 
Qubit 2.0 
(ng/µL) 
MU Qubit 
3.0 (ng/µL) 
Bioanalyzer   
Average 
Size (bp) 
Molar 
Concentration 
(nM) 
Control-2 
CHC4114-1 SS 
D505 AGGCGAAG 13.9 16.9 423 49.79 D709 CGGCTATG 
PA11-2 (0.1 µM) 
CHC4114-2 SS 
D506 TAATCTTA 16.2 14.0 421 58.30 D710 TCCGCGAA 
PA1-2 (0.1 µM) 
CHC4114-3 SS 
D507 CAGGACGT 14.3 15.9 424 51.10 D711 TCTCGCGC 
PA25-2 (0.1 µM) 
CHC4114-4 SS 
D508 GTACTGAC 14.7 15.2 422 52.78 D712 AGCGATAG 
NV1078-2 (0.1 µM) 
CHC4114-5 SS 
D501 TATAGCCT 15.3 15.4 415 55.86 D701 ATTACTCG 
NV1087-2 (0.1 µM) 
CHC4114-6 SS 
D502 ATAGAGGC 15.9 18.8 423 56.95 D702 TCCGGAGA 
NV1111-2 (0.1 µM) 
CHC4114-7 SS 
D503 CCTATCCT 12.1 12.8 421 43.55 D703 CGCTCATT 
PA30-2 (0.1 µM) 
CHC4114-8 SS 
D504 GGCTCTGA 13.2 15.5 429 46.62 D704 GAGATTCC 
PA31-2 (0.1 µM) 
CHC4114-9 SS 
D505 AGGCGAAG 13.0 13.7 415 47.46 D705 ATTCAGAA 
Biological 
Replicate #3 
Sample 
Adapter     
(SI-IL1SP-48) 
Index 
Sequence 
Qubit 2.0 
(ng/µL) 
MU Qubit 
3.0 (ng/µL) 
Bioanalyzer   
Average 
Size (bp) 
Molar 
Concentration 
(nM) 
Control-3 
CHC4117-1 SS 
D501 TATAGCCT 15.7 16.2 459 51.83 D706 GAATTCGT 
PA11-3 (0.1 µM) 
CHC4117-2 SS 
D502 ATAGAGGC 17.6 16.6 454 58.74 D707 CTGAAGCT 
PA1-3 (0.1 µM) 
CHC4117-3 SS 
D503 CCTATCCT 17.3 16.7 491 53.39 D708 TAATGCGC 
PA25-3 (0.1 µM) 
CHC4117-4 SS 
D504 GGCTCTGA 13.0 13.1 462 42.63 D709 CGGCTATG 
NV1078-3 (0.1 µM) 
CHC4117-5 SS 
D505 AGGCGAAG 18.4 16.2 441 63.22 D710 TCCGCGAA 
NV1087-3 (0.1 µM) 
CHC4117-6 SS 
D506 TAATCTTA 15.5 13.2 455 51.62 D711 TCTCGCGC 
NV1111-3 (0.1 µM) 
CHC4117-7 SS 
D507 CAGGACGT 13.1 11.1 457 43.43 D712 AGCGATAG 
PA30-3 (0.1 µM) 
CHC4117-8 SS 
D508 GTACTGAC 14.3 10.6 460 47.10 D701 ATTACTCG 
PA31-3 (0.1 µM) 
CHC4117-9 SS 
D501 TATAGCCT 6.4 5.57 473 20.50 D702 TCCGGAGA 
Biological 
Replicate #4 
Sample 
Adapter     
(SI-IL1SP-48) 
Index 
Sequence 
Qubit 2.0 
(ng/µL) 
MU Qubit 
3.0 (ng/µL) 
Bioanalyzer   
Average 
Size (bp) 
Molar 
Concentration 
(nM) 
Control-4 
CHC4133-1 SS 
D502 ATAGAGGC 12.5 11.2 662 28.61 D703 CGCTCATT 
PA11-4 (0.1 µM) 
CHC4133-2 SS 
D503 CCTATCCT 11.8 11.1 555 32.21 D704 GAGATTCC 
PA1-4 (0.1 µM) 
CHC4133-3 SS 
D504 GGCTCTGA 3.6 3.19 572 9.54 D705 ATTCAGAA 
PA25-4 (0.1 µM) 
CHC4133-4 SS 
D505 AGGCGAAG 11.1 9.8 517 32.53 D712 AGCGATAG 
NV1078-4 (0.1 µM) 
CHC4133-5 SS 
D506 TAATCTTA 12.3 10.8 494 37.73 D701 ATTACTCG 
NV1087-4 (0.1 µM) 
CHC4133-6 SS 
D507 CAGGACGT 8.1 7.19 514 23.88 D708 TAATGCGC 
NV1111-4 (0.1 µM) 
CHC4133-7 SS 
D508 GTACTGAC 10.5 9.37 524 30.36 D709 CGGCTATG 
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PA30-4 (0.1 µM) 
CHC4133-8 SS 
D507 CAGGACGT 11.8 10.6 523 34.19 D710 TCCGCGAA 
PA31-4 (0.1 µM) 
CHC4133-9 SS 
D503 CCTATCCT 9.2 8.28 513 27.17 D711 TCTCGCGC 
Biological 
Replicate #5 
Sample 
Adapter     
(DI-IL1SP-
12A) 
Index 
Sequence 
Qubit 2.0 
(ng/µL) 
MU Qubit 
3.0 (ng/µL) 
Bioanalyzer   
Average 
Size (bp) 
Molar 
Concentration 
(nM) 
Control-5 
CHC4141-1 SS 
Reagent R1 
(I2) CGATGT(A) 12.5 11.7 474 39.96 
PA11-5 (0.1 µM) 
CHC4141-2 SS 
Reagent R1 
(I4) TGACCA(A) 15.7 15.3 498 47.77 
PA1-5 (0.1 µM) 
CHC4141-3 SS 
Reagent R1 
(I5) ACAGTG(A) 10.3 9.56 458 34.07 
PA25-5 (0.1 µM) 
CHC4141-4 SS 
Reagent R1 
(I6) GCCAAT(A) 14.3 12.8 485 44.67 
NV1078-5 (0.1 µM) 
CHC4141-5 SS 
Reagent R1 
(I7) CAGATC(A) 13.4 12.3 468 43.38 
NV1087-5 (0.1 µM) 
CHC4141-6 SS 
Reagent R1 
(I12) CTTGTA(A) 11.9 10.4 480 37.56 
NV1111-5 (0.1 µM) 
CHC4141-7 SS 
Reagent R1 
(I13) AGTCAA(C) 13.0 12.0 489 40.28 
PA30-5 (0.1 µM) 
CHC4141-8 SS 
Reagent R1 
(I14) AGTTCC(G) 12.7 11.3 454 42.38 
PA31-5 (0.1 µM) 
CHC4141-9 SS 
Reagent R1 
(I15) ATGTCA(G) 10.2 8.85 459 33.67 
Accel-NGS 1S Plus DNA Library Kit was used to prepare NGS libraries. Index sequence refers to a unique DNA 
sequence identifier in the adapter that allows for multiple libraries to be sequenced simultaneously in a single sample 
lane and be identified and grouped together properly via bioinformatics processing of the sequence data. Molar 
concentrations were calculated according to Equation 5.4 using the Qubit 2.0 data. 
 
 
 
 
                     BIOLOGICAL REPLICATE #1        BIOLOGICAL REPLICATE #2 
 
 Figure 5.11. Caption in next page. 
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           BIOLOGICAL REPLICATE #5 
 
 
 
 
Figure 5.11. Fragment Size Distribution of Illumina NGS Libraries (Fenton Chemistry). Agilent DNA1000 
assay analysis of prepared NGS libraries from in-cell ·OH footprinting by Fenton Chemistry (grouped by biological 
replicates). W12E cells were treated for 24 h with either vehicle controls or 0.1 µM of a respective polyamide.
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5.4.4.2 Illumina HiSeq2500 and NextSeq 500 NGS  and Bioinformatics Analysis 
 
Illumina NGS libraries of ·OH footprinting samples were sequenced using single-end, 
51 base pair read-length on an Illumina HiSeq 2500 or 75 base pair read-length on an 
Illumina NextSeq 500. Bioinformatics analysis is currently underway following the 
methods provided in Chapter 4 Section 4.4.5. 
 
5.4.5 Crosslinking of Small Molecules for Isolation of Chromatin (COSMIC) with 
PA1-PB and PA25-PB in H1-hESC and W12E Cells 
 
To map the genome-wide interactions of PA1 and PA25 in the context of chromatin 
structures, we performed COSMIC-Seq experiments in H1 human embryonic stem cells 
(H1-hESC) and HPV16-bearing W12E keratinocytes. Toward this goal, we synthesized 
PA1 and PA25 derivatives (PA1-PB and PA25-PB) where the C-termini of these 
polyamides were covalently conjugated to psoralen and biotin via a flexible polyethylene 
glycol spacer (Figure 5.2). Psoralen affords the reversible photo-crosslinking of PA-
DNA interactions upon UV irradiation at 365 nm. Crosslinking is performed using a glass 
filter between the cells and the UV source to remove light with wavelengths lower than 
300 nm, significantly decreasing thymine dimer formation. Before performing this 
COSMIC on W12E keratinocytes, the transmission spectra of various glass panels were 
determined using a Thermo Scientific Evolution 260 Bio UV-visible spectrophotometer. 
With the help of Jack Harms from the O’Brien lab, the emission spectrum for the UV 
source (CalSun, Catalog # B001BH0A1A) was determined using a Hitachi U-3900 
Spectrophotometer (Figure 5.12). Based on these results, a soda-lime glass panel (3 mm 
thick) was used to filter UV light below 300 nm, while allowing approximately 87 % of 
light with 365 nm during the crosslinking step. 
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Figure 5.12. Characterization of UV Transmission for Glass Panels and Emission Spectra for UV Source. The 
transmission spectra of Borofloat (5 and 6.5 mm), Pyrex (2 mm) and soda-lime (3 mm) glass panels (Thermo 
Scientific Evolution 260 Bio UV-Vis). The emission spectrum of the UV source (power) was collected by directing
the emitted light from a CalSun UV lamp into the detector with the spectrometer lamp off (Hitachi U-3900 UV-Vis). 
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After crosslinking, the cells are lysed and the viral/genomic DNA is sonicated. The 
sonication time to yield DNA fragments in a range of 100-500 bp was optimized 
empirically. Using a QSonica Q800R sonicator at 4 °C with a cycle of 10 s on and 10 s 
off at 50 % power, the cell lysate solution (2 samples of 600 µL) was sonicated 11 times 
at 5, 10, 15, 25, 35, 45, 60, 70, 80, 90 and 120 min. A 10 µL aliquot from each solution 
was sampled at each time interval and diluted with 15 µL of Low EDTA TE buffer. The 
DNA fragment size distribution for each time interval was determined by electrophoresis 
with a 1.5 % agarose gel (Figure 5.13). The results showed that a sonication time of 2 h 
afforded DNA fragments in a range of 100-500 bp. Thus, cell lysates for COSMIC 
experiments were sonicated for 2 h (10 s on and 10 s off) at 50 % power and 4 °C using 
QSonica Q800R sonicator. 
 
 
  
After sonication, the sheared DNA is then subjected to streptavidin-coated magnetic 
beads in order to capture psoralen-DNA adducts via the biotinylated polyamide. After 
removal of non-specific DNA interactions, the psoralen-DNA crosslinks are reversed by 
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Figure 5.13. Optimization of Sonication Time of W12E Lysates. Agarose gel electrophoresis analysis of DNA
fragmentation from W12E lysates by sonication using a QSonica Q800R sonicator at 4 °C with a cycle of 10 s on and
10 s off at 50 % power. Because bromophenol blue tracking dye obscures gel images at ~300 bp, a 6X electrophoresis
buffer (25 % v/v glycerol, 1 mM EDTA and 10 mM Tris HCl [pH 7.5]) was used to load the sheared DNA. Lanes 1, 3,
15 and 22 correspond to the 50 bp DNA ladder (NEB, Catalog # N3236S; 1 µg/lane). Lanes 4, 16 and 23 correspond
to the 1 kb DNA ladder (NEB, Catalog # N3232S; 0.5 µg/lane). Lane 2 corresponds to initial sample (not subjected to
sonication). Samples were sonicated for different times (Lane 6 = 5 min, Lane 7 = 10 min, Lane 8 = 15 min, Lane 9 =
25 min, Lane 10 = 35 min, Lane 11 = 45 min, Lane 12 and 17 = 60 min, Lane 18 = 70 min, Lane 19 = 80 min, Lane 20
= 90 min and Lane 21 = 120 min). 
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hot alkali treatment and the purified, enriched sequences are analyzed by next-generation 
sequencing.13,29  
COSMIC experiments in W12E keratinocytes are ready for sequencing. On the other 
hand, next-generation sequencing has been completed for the COSMIC experiments in 
H1-hESC and bioinformatics analysis is currently in progress.  
 
5.5 CONCLUSIONS 
 
Since the ultimate goal of this project was to decipher polyamide binding across the 
viral and host genome in the context of chromatin architecture, we have employed 
hydroxyl radical footprinting (·OH) and COSMIC (crosslinking of small molecules for 
isolation of chromatin) coupled with massively parallel DNA sequencing (Seq) to assess 
the binding occupancies of anti-HPV hairpin polyamides across the viral genomes in 
keratinocytes harboring HPV episomes. These data will allow us to determine PA 
binding occupancies and whether the putative DNA-binding sites are accessible to PA in 
cells. Furthermore, PA-DNA interactions and PA-associated perturbations of viral 
chromatin-like structures will be assessed with the hydroxyl radical footprinting 
approach.20,21,37 Consequently, the effects of the antiviral hairpin polyamides in 
displacing essential viral proteins and transcription factors from the viral genome may be 
elucidated. These perturbations will be determined by comparing the chromatin 
landscape of vehicle-treated to PA-treated cells. Furthermore, comparison of the PA 
occupancies and associated perturbations on chromatin-like structures between HPV-
inactive, HPV-weakly active and HPV-potently active polyamides may provide the 
molecular foundations that underlie the ability of antiviral hairpin PAs to eliminate the 
viral load. 
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5.7 SUPPLEMENTAL INFORMATION 
5.7.1 Chemical Structures of PAs Used for In-Cell Hydroxyl Radical Experiments 
(Fenton Chemistry)  
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Figure SI5.1. Chemical Structures of PAs Used for In-Cell Hydroxyl Radical Experiments (Fenton Chemistry).
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5.7.2 Synthesis of PA1-Alexa Fluor 488 Conjugate 
 
Anti-HPV PA1 was functionalized with Alexa Fluor 488 (Figure SI5.2) for subsequent cell 
uptake studies by confocal microscopy and kinetic studies conducted by Dr. Dupureur’s group. 
Covalent conjugation of the fluorophore was accomplished by reacting of Alexa Fluor 488 
carboxylic acid, succinimidyl ester to the primary amine on the Ta tail of PA1 in the presence of 
DIEA in anhydrous NMP. 
 
Reagents 
 
Reagents Molecular Weight (g/mol) Equivalents Quantity 
PA1 (3 TFA)  
(GDH1130, 97 %) 2237.12 1 
2.32 mg 
1.04x10-6 mol 
    
Alexa Fluor 488 carboxylic acid, 
succinimidyl ester 643.41 1.5 
1.00 mg 
1.56x10-6 mol 
N,N-Diisopropylethylamine (DIEA) 129.24 (0.742 g/mL) 50 
9.03 μL 
5.19x10-5 mol 
N-Methyl-2-pyrrolidon (NMP) 99.13 Solvent 1000 μL 
 
Procedure 
1. Care must be taken through the process to keep light exposure to a minimum.  
2. Dissolve 2.32 mg of PA1 (3 TFA) in 1000 μL NMP in 1-dram vial. To this solution, add 
9.03 μL of DIEA. Cover reaction vessel with aluminum foil to protect from light. 
3. Dissolve 1 mg aliquot of Alexa Fluor 488 carboxylic acid, succinimidyl ester 
(ThermoFisher Scientific A-20000) in 150 μL.  
4. Add dye/NMP solution to the PA1/NMP solution. 
5. Allow reaction to proceed at room temperature for at least 4 h. Check for the relative 
formation of the polyamide-dye conjugate by analytical HPLC. 
a. Aliquot 10 μL of reaction mixture and dilute to 100 μL with DMSO. 
b. Filter through 0.45 μm syringe filter and inject 10 μL into reverse-phase HPLC 
(C12). 
6. Filter the reaction mixture through 0.45 μm syringe filter and transfer to appropriate 
amber Dionex vial.  
7. Rinse reaction vessel with 0.5 mL of DMSO and filter through 0.45 μm syringe filter. 
Add to solution in Step 7. 
8. Add 0.5 mL of MilliQ H2O (0.2 % formic acid) to the Dionex vial containing the reaction 
mixture. 
Figure SI5.2. Chemical Structure of PA1 Functionalized with Alexa Fluor 488 as the Formate Salt.  
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9. Purify on Dionex Ultimate 3000 prep-LC using a Macherey-Nagel Nucleodur C18 
column (2 columns in series) (21.0 mm x 50 mm each) and program Gilson M-N short.  
Mobile phase A = H2O (0.2 % formic acid); mobile phase B = methanol. 
25 % B          75 % B          90 % B          90 % B          25 % B  
10. Product eluted at 21.24 min. 
11. Check fractions for pure polyamide-dye conjugate by analytical HPLC. 
a. Aliquot 100 μL of a given fraction. 
b. Inject into reverse-phase HPLC (C12). 
12. Concentrate fractions with rotovap and transfer (~5 mL) to 20 mL vial. 
13. Rinse round bottom flask with 1:1 CH3CN / H2O (0.2 % formic acid) and add to 20 mL 
vial. 
14. Freeze solution on dry ice and lyophilize overnight.  
 
 
5.7.3 Synthesis of Biotinylated and Psoralen-Biotin PA Conjugates 
 
KA2127, PA1 and PA25 were functionalized with a PEG4-biotin affinity handle to produce 
KA2127-PEG4-Biotin, PA1-PEG4-Biotin and PA25-PEG4-Biotin (Figure 5.3) for subsequent 
Cognate Site Identification (CSI) experiments. Covalent conjugation of the affinity handle was 
accomplished by reacting biotin-PEG4-NHS ester to the primary amine on the Ta tail of each 
polyamide in the presence of DIEA in anhydrous NMP. 
 
Reagents 
 
Reagents Molecular Weight (g/mol) Equivalents Quantity 
Biotin-PEG4-NHS ester 588.67 1 1.00 mg  1.70x10-6 mol 
    
KA2127 (5 FA)  
(KA2127E) 
OR 
PA1 (3 TFA) 
(GDH1130, 97 %) 
OR 
PA25 (4 TFA) 
(KJK6006, 95 %) 
1445.46 
 
 
2237.12 
 
 
2982.79 
1.5 
3.68 mg  
2.55x10-6 mol 
 
5.70 mg  
2.55x10-6 mol  
 
7.60 mg  
2.55x10-6 mol 
N,N-Diisopropylethylamine (DIEA) 129.24  (0.742 g/mL) 50 
14.8 μL 
8.49x10-5 mol 
N-Methyl-2-pyrrolidon (NMP) 99.13 Solvent 1000 μL 
 
Procedure 
1. Dissolve either 3.68 mg KA2127 (5FA), 5.70 mg PA1 (3 TFA) or 7.60 mg PA25 (4 
TFA) in 1000 μL anhydrous NMP in 1-dram vial. To this solution, add 14.8 μL of DIEA.  
2. Stir solution for 2 minutes with magnetic stir bar. Remove 10 μL aliquot and dilute to 
100 μL DMSO, filter through 0.2 μm syringe filter and inject in analytical HPLC. 
3. Dissolve 1 mg of Biotin-PEG4-NHS ester (Conju-Probe CP-3026-100MG) in 150 μL 
anhydrous NMP.  
4. Add Biotin-PEG4/NMP solution to the polyamide/NMP solution. 
5. Allow reaction to proceed at room temperature for 3-4 h. Check for the relative formation 
of the polyamide-PEG4-Biotin conjugate by analytical HPLC. 
35 min  1 min  1 min  0.1 min 
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a. Aliquot 10 μL of reaction mixture and dilute to 100 μL with DMSO. 
b. Filter through 0.45 μm syringe filter and inject 10 μL into reverse-phase HPLC 
(C12). 
6. Filter the reaction mixture through 0.45 μm syringe filter and transfer to appropriate 
amber Dionex vial.  
7. Rinse reaction vessel with 0.5 mL of DMSO and filter through 0.45 μm syringe filter. 
Add to solution in Step 6. 
8. Add 0.5 mL of MilliQ H2O (0.2 % formic acid) to the Dionex vial containing the reaction 
mixture. 
9. Purify on Dionex Ultimate 3000 prep-LC using a Macherey-Nagel Nucleodur C18 
column (2 columns in series) (21.0 mm x 50 mm each) and program Gilson M-N short.  
Mobile phase A = H2O (0.2 % formic acid) and Mobile phase B = methanol. 
25% B          75% B          90% B          90% B          25% B  
10. Biotinylated polyamide conjugates eluted at 17.6, 21.3 and 23.1 min for KA2127-PEG4-
Biotin, PA1-PEG4-Biotin and PA25-PEG4-Biotin, respectively. 
11. Check fractions for pure polyamide-PEG4-biotin conjugate by analytical HPLC. 
a. Aliquot 100 μL of a given fraction. 
b. Inject into reverse-phase HPLC (C12). 
12. Concentrate fractions with rotovap and transfer (~5 mL) to 20 mL vial. 
13. Rinse round bottom flask with equal volume of 1:1 CH3CN / H2O (0.2 % formic acid) 
and add to 20 mL vial. 
14. Freeze solution on dry ice and lyophilize overnight.  
 
PA1 and PA25 were functionalized with a psoralen-biotin (photo-crosslinker/affinity handle) 
to produce PA1-PB and PA25-PB (Figure 5.2) for subsequent CSI (Cognate Site Identification) 
and COSMIC (crosslinking of small molecules for isolation of chromatin) experiments. Covalent 
conjugation of the psoralen-biotin moiety was accomplished by reacting the peptide acid of PB 
with HATU to generate the active ester, followed by amide bond formation between the primary 
amine on the Ta tail of each polyamide and the activated PB ester in the presence of DIEA in 
anhydrous NMP. 
 
Reagents 
Reagents Molecular Weight (g/mol) Equivalents Quantity 
PA1 (3 TFA) 
(GDH1130, 97 %)  
OR 
PA25 (4 TFA) 
(KJK6006, 95 %) 
2237.12 
 
 
2982.79 
3 
14.39 mg  
6.43x10-6 mol 
 
19.18 mg 
6.43x10-6 mol 
    
Peptide acid psoralen-biotin (PB) 933.03 1 2.00 mg 2.14x10-6 mol 
N-Methyl-2-pyrrolidon (NMP) 99.13 Solvent 150 μL 
1-[Bis(dimethylamino)methylene]-1H-
1,2,3-triazolo[4,5-b]pyridinium 3-oxid 
hexafluorophosphate (HATU) 
380.23 0.95 0.77 mg 2.04x10-6 mol 
N,N-Diisopropylethylamine (DIEA) 129.24  (0.742 g/mL) 3 
1.12 μL 
6.43x10-6 mol 
 
35 min  1 min  1 min  0.1 min 
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Procedure  
1. Care must be taken through the process to keep light exposure to a minimum.  
2. Dissolve 2.00 mg of the PB moiety and 0.77 mg of HATU in 150 μL of anhydrous 
NMP. To this solution, add 1.12 μL of DIEA. Allow reaction to proceed at room 
temperature for 5 min.  Check for the relative formation of the active ester by analytical 
HPLC. 
a. Aliquot 1 μL of reaction mixture and dilute to 100 μL with DMSO. 
b. Filter through 0.45 μm syringe filter and inject 10 μL into reverse-phase HPLC 
(C12). 
3. Dissolve 14.39 mg of PA1 (3 TFA) or 19.18 mg PA25 (4 TFA) in 300 μL of anhydrous 
NMP. Add this solution to the PB active ester and allow the reaction to proceed for 2 h at 
room temperature. Check for the relative formation of the polyamide-PB conjugate by 
analytical HPLC. 
a. Aliquot 1 μL of reaction mixture and dilute to 100 μL with DMSO. 
b. Filter through 0.45 μm syringe filter and inject 10 μL into reverse-phase HPLC 
(C12). 
4. Filter the reaction mixture through 0.45 μm syringe filter and transfer to appropriate 
amber Dionex vial.  
5. Rinse reaction vessel with 0.5 mL of DMSO and filter through 0.45 μm syringe filter. 
Add to solution in Step 4. 
6. Add 0.5 mL of MilliQ H2O (0.2 % formic acid) to the Dionex vial containing the reaction 
mixture. 
7. Purify on Dionex Ultimate 3000 prep-LC using a Macherey-Nagel Nucleodur C18 
column (2 columns in series) (21.0 mm x 50 mm each) and program Gilson M-N short.  
Mobile phase A = H2O (0.2 % formic acid); mobile phase B = methanol. 
25% B          75% B          90% B          90% B          25% B  
8. Polyamide-PB conjugates eluted at 21.0 and 24.3 min for PA1-PB and PA25-PB, 
respectively. 
9. Check fractions for pure polyamide-PB conjugate by analytical HPLC. 
a. Aliquot 100 μL of a given fraction. 
b. Filter through 0.45 μm syringe filter and inject into reverse-phase HPLC (C12). 
10. Concentrate fractions with rotovap and transfer (~5 mL) to 20 mL vial. 
11. Rinse round bottom flask with equal volume of 1:1 CH3CN / H2O (0.2 % formic acid) 
and add to 20 mL vial. 
12. Freeze solution on dry ice and lyophilize overnight.  
 
 
 
 
 
 
 
 
 
 
 
 
35 min  1 min  1 min  0.1 min 
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5.7.4 Maintenance of Cell Culture   
 
5.7.4.1 Reagents for Cell Culture Growth  
 
Adapted from Tissue Culture Techniques for the Study of Human Papillomaviruses in Stratified 
Epithelia by Meyers, et al. 
Materials 
1. Autoclaved MilliQ H2O (18.2 MΩ·cm at 25 °C) 
2. Dulbecco’s Modified Eagle’s Medium with high glucose, L-glutamine, phenol red, no 
pyruvate (Gibco, Catalog # 11965-126) 
3. Dulbecco’s Modified Eagle’s Medium with high glucose, L-glutamine, phenol red, 
sodium pyruvate (Gibco, Catalog # 11995-081) 
4. Ham’s F-12 media with L-gluramine, phenol red (Gibco, Catalog # 21127-022) 
5. 1X Phosphate Buffer Saline (Fisher, Catalog # 10010-031) 
6. 0.05 % Trypsin-EDTA with phenol red (Gibco, Catalog # 25300-054)  
7. 0.25 % Trypsin-EDTA with phenol red (Gibco, Catalog # 25200-056) 
8. Penicillin-streptomycin solution (10,000 units penicillin and 10 mg streptomycin per mL) 
(Sigma, Catalog # P4333-20ML) 
9. Epidermal growth factor powder (Invitrogen, Catalog # PHG0311) 
10. Bovine serum albumin powder (Sigma, Catalog # A4919-1G) 
11. 1 M HEPES buffer (Sigma, Catalog # 83264-100ML-F) 
12. Hydrocortisone powder (Sigma, Catalog # H0888-1G) 
13. Adenine hydrochloride hydrate (Sigma, Catalog # A9795-1G) 
14. Insulin from bovine pancreas (Sigma, Catalog # I6634-50MG) 
15. Apo-Transferrin human (Sigma, Catalog # T1147-100MG) 
16. T3 thyroid hormone, 3,3’,5-triiodo-L-thyronine sodium salt (Sigma, Catalog # T6397-
100MG) 
17. Fetal Bovine Serum (Gibco, Catalog # 16140-063) 
18. Mytomycin C powder (Fisher BioReagents, Catalog # BP2531-2) 
19. Cholera toxin powder (Sigma, Catalog # C9903-.5MG) 
20. Dimethyl sulfoxide (Sigma Life Science, Catalog # D2650) 
21. Sodium Chloride (Fisher BioReagents, Catalog # BP358-1) 
22. Potassium Chloride (Fisher BioReagents, Catalog # BP366-500) 
23. Sodium Bicarbonate (Fisher BioReagents, Catalog # BP328-1) 
24. Sodium Phosphate Monobasic Monohydrate (Fisher BioReagents, Catalog # BP330-500) 
25. Magnesium Sulfate Heptahydrate (Fisher Chemical, Catalog # M80-500) 
26. Ferric Nitrate Nonahydrate (Fisher Chemical, Catalog # I110-100) 
27. Phenol Red (Sigma Aldrich, Catalog # P3532-5G) 
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Solutions 
1. Earle’s Salts 
a. For 500 mL solution weigh and dissolve: 
i. NaCl   32 g 
ii. KCl   2 g 
iii. NaHCO3   18.5 g 
iv. NaH2PO4·H2O  0.625 g 
v. MgSO4·7H2O  1 g 
vi. Fe(NO3)3·9H2O  0.0005 g (make 1 mg/mL in autoclaved H2O) 
vii. Phenol Red  0.025 g 
b. Dilute to 500 mL with autoclaved MilliQ H2O. 
c. Filter-sterilize and store tightly capped at room temperature. 
2. HEPES Buffered Earle’s Salts (HBES) – Transfer 25 mL of 1M HEPES buffer into 
100 mL of Earle’s salts and dilute to 1 L of final volume with autoclaved MilliQ H2O. 
Filter-sterelize. 
3. 100X Adenine – Dissolve 0.169 g of adenine hydrochloride hydrate in 50 mL of MilliQ 
H2O. Filter-sterilize with a 0.22 μm filter and store at -20 °C in 5 mL aliquots.  
4. 100X Transferrin – Dissolve 50 mg of transferrin in 100 mL sterile PBS. Filter-sterilize 
with a 0.22 μm filter and store at -20 °C in 5 mL aliquots.  
5. 100X T3 thyroid hormone, 3,3’,5-triiodo-L-thyronine sodium salt – Dissolve 13.6 mg 
of T3 in 100 mL of 0.02 M NaOH (2 x 10-4 M T3). Transfer 0.1 mL of 2 x 10-4 M T3 and 
dissolve in 9.9 mL of sterile PBS (2 x 10-6 M T3). Transfer 0.5 mL of 2 x 10-6 M T3 
solution and dilute with 49.5 mL of sterile PBS (2 x 10-8 M T3).  Filter-sterilize with a 
0.22 μm filter and store at -20 °C in 5 mL aliquots.   
6. 100X Hydrocortisone – Dissolve 25 mg of hydrocortisone in 5 mL 100 % EtOH to 
generate a 5 mg/mL solution. Transfer 0.4 mL of 5 mg/mL hydrocortisone and dilute 
with 49.6 mL of HBES buffer. Filter-sterilize with a 0.22 μm filter and store at -20 °C in 5 
mL aliquots.   
7. 100X Cholera toxin – Dissolve 0.5 mg of cholera toxin (MW 85 kDa) in 0.6 mL of 
MilliQ H2O to generate a 1 x 10-5 M stock. Transfer 50 μL of 1 x 10-5 M hydrocortisone 
stock and dilute it to 50 mL of HBES buffer. Filter-sterilize with a 0.22 μm filter and 
store at 4 °C in 5 mL aliquots.  
8. 100X Epidermal Growth Factor (EGF) – Dissolve the 100 μg EGF vial in 10 mL of 
MilliQ H2O. Add 100 mg Bovine Serum Albumin dissolved in 90 mL of HBES buffer. 
Filter-sterilize with a 0.22 μm filter and store at -20oC in 5 mL aliquots.   
9. 50X Mitomycin C – (Wear gloves! DNA cross-linker) Dilute 2 mg of mitomycin C in 5 
mL of HBES. Filter-sterilize with a 0.22 μm filter and store at -20 °C in 5 mL aliquots 
(Shelf-life: 2 months).  
10. 100X Insulin – Prepare individually and do not freeze. Dissolve 5 mg of insulin in 10 
mL of 0.005 M HCl. Filter-sterilize with a 0.22 μm filter by prewetting filter with fetal 
bovine serum. 
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Cell culture media 
1. 3T3 Fibroblasts Media 
a. DMEM with high glucose, L-glutamine, phenol red, no pyruvate  445 mL 
b. Fetal Bovine Serum          50 mL 
c. Penicillin-streptomycin solution (10,000 U Pen and 10 mg Strep per mL)          5 mL 
 
2. Keratinocyte Growth Media or E Media (Incomplete) 
Use a Nalgene 500 mL carboy (Catalog # 1068672) 
a. DMEM with high glucose, L-glutamine, phenol red, sodium pyruvate 330 mL 
b. Ham’s F-12 media with L-gluramine, phenol red                  110 mL 
c. Fetal Bovine Serum          25 mL  
d. 100X Hydrocortisone           5 mL 
e. 100X Insulin            5 mL 
f. 100X Cholera toxin             5 mL 
g. 100X Adenine            5 mL 
h. 100X Transferrin                  5 mL 
i. Penicillin-streptomycin solution (10,000 U Pen and 10 mg Strep per mL)        5 mL 
j. 100X T3 thyroid hormone                5 mL 
 
3. E Media (Complete) 
a. Keratinocyte Growth Medium or E Medium (Incomplete)   495 mL 
b. 100X Epidermal Growth Factor (EGF)         5 mL 
 
4. Freezing Media for 3T3 Fibroblasts (5 % DMSO) 
a. 3T3 Fibroblasts Media                              47.5 mL 
b. Dimethyl sulfoxide         2.5 mL 
 
5. Freezing Media for Keratinocytes (10 % DMSO) 
a. Keratinocyte Growth Medium or E Medium (Incomplete)      45 mL 
b. Dimethyl sulfoxide               5 mL 
 
 
5.7.4.2 Thawing of 3T3 Fibroblasts (Feeder Cells) from N2 Chamber 
 
Materials 
1. 3T3 fibroblasts received from the laboratory of Paul Lambert and stored in liquid N2 
chamber. 
2. 3T3 Fibroblasts Media (DMEM with high glucose, L-glutamine, phenol red, no pyruvate 
supplemented with 10 % fetal bovine serum and 1 % penicillin-streptomycin). 
 
Procedure 
1. Place 3T3 Fibroblasts Media in 37 °C water bath (American Scientific Products S/P 
Water bath). 
2. Obtain 3T3 fibroblast aliquot from the liquid N2 chamber.  
3. Quickly thaw the container by hand in approximately 2 min. Immerse closed contained in 
70 % ethanol and wipe with Kimwipes (make sure to wipe neck of container well). 
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4. Transfer cell suspension to a 15 mL disposable centrifuge tube and add 3T3 Fibroblasts 
Media to a final volume of 10 mL. 
5. Mix suspension well by gently pipetting up and down. 
6. Immediately, pipette a 20 μL aliquot from this suspension and add to cellometer slide. 
Count cells in Cellometer Auto T4 Cell Viability Counter using 3T3 setting. 
7. Pellet 3T3 fibroblasts using an Eppendorf Centrifuge 5702 at 500 rcf (relative centrifugal 
force) for 10 min. 
8. Aspirate the media being careful not to disturb the cell pellet. 
9. Add the appropriate volume of 3T3 Fibroblasts Media to obtain 4.00 x 105 cells/mL 
(given in step 6). Resuspend the 3T3 cell pellet by gently pipetting up and down. 
10. Transfer 1 mL of cell suspension into a 100 mm x 20 mm culture dish (Sigma SIAL0167) 
and add 9 mL of 3T3 Fibroblasts Media. 
11. Place cell culture dish in an incubator at 37 °C with a 5 % CO2 atmosphere (NuAire NU-
4750 US AutoFlow CO2 Water-Jacketed).  
12. Change 3T3 Fibroblasts Media every other day. Passage 3T3 fibroblasts at 80-90 % 
confluence. Do not allow cells to reach 100 % confluence. 
 
5.7.4.3 3T3 Fibroblasts (Feeder Cells) 
 
Materials 
 
1. 3T3 fibroblasts in cell culture dish/flask. 
2. 3T3 Fibroblasts Media (DMEM with high glucose, L-glutamine, phenol red, no pyruvate 
supplemented with 10 % fetal bovine serum and 1 % penicillin-streptomycin). 
3. 1X Phosphate Buffer Saline. 
4. 0.05 % trypsin / 0.53 mM EDTA solution. 
 
Procedure 
1. Place 3T3 Fibroblasts Media in 37 °C water bath (American Scientific Products S/P 
Water bath). 
2. Aspirate the media from 3T3 fibroblasts culture and wash cells with 10 mL of 1X PBS. 
Repeat once.  
3. Add 2 mL of 0.05 % trypsin/EDTA and incubate for approximately 5 min. in an 
incubator at 37 °C with a 5 % CO2 atmosphere (NuAire NU-4750 US AutoFlow CO2 
Water-Jacketed) (longer incubation times might be necessary, check dish/flask under 
microscope). 
4. After most of the 3T3 fibroblasts have been detached from the surface, add 2 mL of 3T3 
Fibroblasts Media to the plate transfer cell suspension to a 15 mL disposable centrifuge 
tube. Rinse plate with 6 mL of 3T3 Fibroblasts Media and transfer to the same 15 mL 
disposable centrifuge tube containing the bulk of the cells. 
5. Mix suspension well by gently pipetting up and down. 
6. Pellet 3T3 fibroblasts using an Eppendorf Centrifuge 5702 at 500 rcf (relative centrifugal 
force) for 5 min. 
7. Aspirate the media being careful not to disturb the cell pellet. 
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8. Add 10 mL of 3T3 Fibroblasts Media and resuspend the 3T3 cell pellet by gently 
pipetting up and down. 
9. Transfer 1 mL of cell suspension into a 100 mm x 20 mm culture dish (Sigma SIAL0167) 
and add 9 mL of 3T3 Fibroblasts Media. This corresponds to a 1:10 split ratio. 
10. Place cell culture dish in an incubator at 37 °C with a 5 % CO2 atmosphere (NuAire NU-
4750 US AutoFlow CO2 Water-Jacketed). 
11. Change 3T3 Fibroblasts Media every other day. Passage 3T3 fibroblasts at 80-90 % 
confluence. Do not allow cells to reach 100 % confluence. 
 
5.7.4.4 Mitomycin C Treatment of 3T3 Fibroblasts (Feeder Cells) 
 
Materials 
1. 3T3 fibroblasts in cell culture dish/flask at 80-90 % confluency. 
2. 3T3 Fibroblasts Media (DMEM with high glucose, L-glutamine, phenol red, no pyruvate 
supplemented with 10 % fetal bovine serum and 1 % penicillin-streptomycin). 
3. E Media (incomplete). 
4. 1X Phosphate Buffer Saline. 
5. 50X Mitomycin C (Make sure to wear gloves; inhibitor of cell division). 
6. 0.05 % trypsin / 0.53 mM EDTA solution. 
7. Cellometer Auto T4 Cell Viability Counter slide. 
Procedure 
1. Place 3T3 Fibroblasts Media and E Media (incomplete) & thaw 50X Mitomycin C in 37 
°C water bath (American Scientific Products S/P Water bath). 
2. Aspirate the media from 3T3 fibroblasts culture and wash cells with 10 mL of 1X PBS. 
Repeat once.  
3. Add 200 μL of 50X Mitomycin C solution to 10 mL of 3T3 Fibroblasts Media on 3T3 
fibroblasts. Swirl gently and incubate for 2-4 hr at 37°C with a 5 % CO2 atmosphere 
(NuAire NU-4750 US AutoFlow CO2 Water-Jacketed). 
4. Aspirate the media from 3T3 fibroblasts culture and wash cells with 10 mL of 1X PBS. 
Repeat once.  
5. Add 3 mL of 0.05 % trypsin/EDTA and incubate for approximately 5 min in an incubator 
at 37 °C with a 5 % CO2 atmosphere (NuAire NU-4750 US AutoFlow CO2 Water-
Jacketed) (longer incubation times might be necessary, check dish/flask under 
microscope). 
6. After most of the mitomycin C-treated 3T3 fibroblasts have been detached from the 
surface, add E Media (incomplete) to a final volume of 10 mL and transfer cell 
suspension to a 15 mL disposable centrifuge tube. 
7. Mix suspension well by gently pipetting up and down. 
8. Immediately, pipette a 20 μL aliquot from this suspension and add to cellometer slide. 
Count cells in Cellometer Auto T4 Cell Viability Counter using 3T3 setting. 
9. Pellet 3T3 fibroblasts using an Eppendorf Centrifuge 5702 at 500 rcf (relative centrifugal 
force) for 5 min. 
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10. Aspirate the media being careful not to disturb the cell pellet. 
11. Add the appropriate volume of E Media (incomplete) or 3T3 Fibroblasts Media to 
obtain 4.00 x 105 cells/mL (given in step 8). If fibroblasts are to be used within 24 h, 
resuspend in E Media (incomplete), otherwise resuspend in 3T3 Fibroblasts Media. Use 
fibroblasts within 48 h after Mitomycin C treatment. Resuspend the 3T3 cell pellet by 
gently pipetting up and down. 
12. Transfer 1 mL of cell suspension into a 100 mm x 20 mm culture dish (Sigma SIAL0167) 
and add 9 mL of 3T3 Fibroblasts Media (1:10). Need at least two plates: one for W12E 
maintenance and one for experiment. 
13. Place cell culture dish in an incubator at 37 °C with a 5 % CO2 atmosphere (NuAire NU-
4750 US AutoFlow CO2 Water-Jacketed). 
 
5.7.4.5 Thawing of W12E Keratinocytes from N2 Chamber 
 
Materials 
1. W12E keratinocytes received from the laboratory of Paul Lambert and stored in liquid N2 
chamber. 
2. E Media (incomplete). 
3. Mitomycin C-treated 3T3 fibroblasts in E Media (incomplete). 
4. E Media (complete). 
5. Cellometer Auto T4 Cell Viability Counter slide. 
 
Procedure 
1. Obtain W12E keratinocytes aliquot from the liquid N2 chamber.  
2. Quickly thaw the container by hand in approximately 2 min. Immerse closed contained in 
70 % ethanol and wipe with Kimwipes (make sure to wipe neck of container well). 
3. Transfer cell suspension to a 15 mL disposable centrifuge tube and add cold E Media 
(incomplete) to a final volume of 10 mL. 
4. Mix suspension well by gently pipetting up and down. 
5. Immediately, pipette a 20 μL aliquot from this suspension and add to cellometer slide. 
Count cells in Cellometer Auto T4 Cell Viability Counter using small cell setting. 
6. Pellet W12E keratinocytes using an Eppendorf Centrifuge 5702 at 800 rcf (relative 
centrifugal force) for 5 min. 
7. Aspirate the media being careful not to disturb the cell pellet. 
8. Add the appropriate volume of E Media (incomplete) to obtain 4.00 x 105 cells/mL 
(given in step 5). Resuspend the W12E cell pellet by gently pipetting up and down. 
9. Check under the microscope the dish with the Mitomycin C-treated 3T3 fibroblasts in E 
Media to ensure cells are attached to the surface. Aspirate the media from 3T3 fibroblasts 
culture. 
10. Add 9 mL of E Media (incomplete) to the 100 mm x 20 mm culture dish (Sigma 
SIAL0167) containing the mitomycin C-treated 3T3 fibroblasts and transfer 1 mL of the 
W12E keratinocyte suspension on top of the 3T3 fibroblasts. 
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11. Incubate cells for 24 h in incubator at 37 °C with a 5 % CO2 atmosphere (NuAire NU-
4750 US AutoFlow CO2 Water-Jacketed).  
12. After the 24 h incubation period, replace the media with 10 mL of E Media (complete). 
13. Change E Media (complete) every other day. Passage W12E keratinocytes at 70 % 
confluence. Do not allow cells to reach 100 % confluence. 
 
5.7.4.6 W12E Keratinocytes 
 
Materials 
1. W12E keratinocytes (70 % confluent) in cell culture dish/flask on top of mitomycin C-
treated 3T3 fibroblasts. 
2. E Media (incomplete). 
3. 1X Phosphate Buffer Saline. 
4. 0.02 % EDTA / PBS. 
5. 0.05 % trypsin / 0.53 mM EDTA solution. 
6. Cellometer Auto T4 Cell Viability Counter slide.  
7. E Media (complete). 
Procedure 
1. Place E Media (incomplete) in 37 °C water bath (American Scientific Products S/P Water 
bath). 
2. Aspirate the media from sub-confluent culture.  
3. Add 3 mL of 0.02 % EDTA / PBS and incubate for 1 min. After incubation, use a wide-
bore tip to spray the plate vigorously with the 0.02 % EDTA / PBS solution. Aspirate 
solution and wash cells with 10 mL of 1X PBS.  
4. Add 3 mL of 0.05 % trypsin/EDTA and incubate for approximately 5 min in an incubator 
at 37 °C with a 5 % CO2 atmosphere (NuAire NU-4750 US AutoFlow CO2 Water-
Jacketed) (longer incubation times might be necessary, check dish/flask under 
microscope). 
5. After most of the W12E keratinocytes have been detached, add E Media (incomplete) to 
a final volume of 10 mL and transfer cell suspension to a 15 mL disposable centrifuge 
tube. 
6. Mix suspension well by gently pipetting up and down. 
7. Immediately, pipette a 20 μL aliquot from this suspension and add to cellometer slide. 
Count cells in Cellometer Auto T4 Cell Viability Counter using HeLa setting. 
8. Pellet W12E cells using an Eppendorf Centrifuge 5702 at 500 rcf (relative centrifugal 
force) for 5 min. 
9. Aspirate the media being careful not to disturb the cell pellet. 
10. Add the appropriate volume of E Media (incomplete) to obtain 2.00 x 105 cells/mL 
(given in step 7). Resuspend the W12E cell pellet by gently pipetting up and down. 
11. Transfer 1 mL of cell suspension into a 100 mm x 20 mm culture dish (Sigma SIAL0167) 
containing Mitomycin C-treated 3T3 cells and add 9 mL of E Media (incomplete). 
Incubate cells for 24 h in incubator at 37 °C with a 5 % CO2 atmosphere (NuAire NU-
4750 US AutoFlow CO2 Water-Jacketed).  
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12. After the 24 h incubation period, replace media with 10 mL of E Media (complete). 
13. Change E Media (complete) every other day. Passage W12E keratinocytes at 70 % 
confluence. Do not allow cells to reach 100 % confluence. 
 
5.7.4.7 Cryopreservation of 3T3 Fibroblasts (Feeder Cells) 
 
Materials 
1. 3T3 fibroblasts in cell culture dish/flask at 80-90 % confluency. 
2. 3T3 Fibroblasts Media (DMEM with high glucose, L-glutamine, phenol red, no pyruvate 
supplemented with 10 % fetal bovine serum and 1 % penicillin-streptomycin). 
3. Freezing Media for 3T3 Fibroblasts (5 % DMSO). 
Procedure 
1. Trypsin-treated cells are resuspended in fresh Freezing Media for 3T3 Fibroblasts at 
approximately 1 x 106 cells / mL. 
2. Transfer approximately 1 x 106 cells into a sterile storage vial that has been wiped with 
70 % ethanol. 
3. Place vial into an isopropanol holder and transfer them to a -80 °C chamber to allow 
gradual cooling of the cells for 24 h.  
4. After the 24 h period, place vial into a liquid N2 chamber. 
 
5.7.4.8 Cryopreservation of W12E Keratinocytes 
 
Materials 
1. W12E keratinocytes (70 % confluent) in cell culture dish/flask on top of mitomycin C-
treated 3T3 fibroblasts. 
2. Freezing Media for Keratinocytes (10 % DMSO). 
Procedure 
1. Trypsin-treated cells are resuspended in fresh Freezing Media for Keratinocytes at 
approximately 1 x 106 cells / mL. 
2. Transfer approximately 1 x 106 cells into a sterile storage vial that has been wiped with 
70 % ethanol. 
3. Place vial into an isopropanol holder and transfer them to a -80 °C chamber to allow 
gradual cooling of the cells for 24 h.  
4. After the 24 h period, place vial into a liquid N2 chamber. 
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5.7.5 Fenton Chemistry: ·OH Radical Cleavage of Viral and Host DNA in W12E 
(HPV16-harboring) Keratinocytes 
 
MATERIALS 
1. W12E keratinocytes (70 % confluent) in cell culture dish/flask with mitomycin C-
treated 3T3 fibroblasts. 
2. 1 M NaOH (Store at 4 °C) 
Dissolve 2.00 g of NaOH pellets (Fisher Scientific, Catalog # BP359-500) in 50 mL 
of autoclaved MilliQ H2O. 
3. 1X Phosphate Buffer Saline (Fisher Scientific, Catalog # 10010-031) 
4. 500 mM Sucrose Stock (Store at 4 °C) 
Dissolve 34.23 g of sucrose (Fluka, Catalog # 84097; MW 342.30 g/mol) in 200 mL 
of autoclaved MilliQ H2O. Filter-sterilize using a 0.22 μm MILLEX-GP filter. 
5. 1,600 mM KCl Stock 
Dissolve 5.96 g of potassium chloride (Sigma-Aldrich, Catalog # P9333-500G; MW 
74.55 g/mol) in 50 mL of autoclaved MilliQ H2O. Filter-sterilize using a 0.22 μm 
MILLEX-GP filter. 
6. 100 mM K2HPO4 Stock 
Dissolve 1.14 g of potassium phosphate dibasic trihydrate (Sigma-Aldrich, Catalog 
# P5504-100G; MW 228.22 g/mol) in 50 mL of autoclaved MilliQ H2O. Filter-
sterilize using a 0.22 μm MILLEX-GP filter. 
7. 100 mM MgCl2 Stock 
Dissolve 476 mg of magnesium chloride (Sigma-Aldrich, Catalog # M8266-100G; 
MW 95.21 g/mol) in 50 mL of autoclaved MilliQ H2O. Filter-sterilize using a 0.22 
μm MILLEX-GP filter. 
8. 10 mM CaCl2 Stock 
Dissolve 55.5 mg of calcium chloride (Sigma-Aldrich, Catalog # C1016-100G; MW 
110.98 g/mol) in 50 mL of autoclaved MilliQ H2O. Filter-sterilize using a 0.22 μm 
MILLEX-GP filter. 
9. 100 mM NaHepes buffer, pH 7.4 
Dissolve 11.92 g of 4-(2-hydroxyethyl)piperazine-1-ethanesulfonic acid (Sigma-
Aldrich, Catalog # H3375-100G; MW 238.30 g/mol) in 400 mL of autoclaved 
MilliQ H2O. Adjust pH to 7.4 using 1M NaOH (~25 mL). Adjust total volume to 
500 mL with autoclaved MilliQ H2O. Filter-sterilize using a 0.2 μm aPES 
membrane Nalgene filter unit. 
10. Incomplete Permeabilization Solution (Store at 4 °C) 
Combine 180 mL of 500 mM sucrose stock, 30 mL of 1,600 mM KCl stock, 30 mL 
of 100 mM K2HPO4 stock, 30 mL of 100 mM MgCl2, 30 mL of 10 mM CaCl2, 210 
mL of 100 mM NaHepes buffer (pH 7.4) and 90 mL of autoclaved MilliQ H2O. 
Filter-sterilize using a 0.2 μm aPES membrane Nalgene filter unit. 
11. 0.05 % Lysolecithin Permeabilization Solution (prepare immediately before use) 
Dissolve 0.5 mg of lysolecithin Type I (Sigma-Aldrich, Catalog # L4129-100MG) 
per 1 mL of Incomplete Permeabilization Solution. Filter-sterilize using a 0.22 μm 
MILLEX-GP filter. 
12. Stop Buffer (Store at 4 °C) 
Dissolve 7.6 g of thiourea (Sigma-Aldrich, Catalog # 88810-100G) in 1000 mL of 
1X PBS buffer. Filter-sterilize using a 0.2 μm aPES membrane Nalgene filter unit. 
13. 500 mM EDTA disodium Stock (Store at 4 °C) 
Dissolve 7.44 g of ethylenediaminetetraacetic acid disodium salt dehydrate, EDTA 
disodium salt dehydrate (Sigma-Aldrich, Catalog # E5134-100G; MW 372.24 
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g/mol) in 20 mL of autoclaved MilliQ H2O. Adjust pH to 7.4-8.0 using 1 M NaOH. 
Adjust total volume to 40 mL with autoclaved MilliQ H2O. Filter-sterilize using a 
0.22 μm MILLEX-GP filter. 
14. 50X Fe(II)-EDTA Stock (prepare immediately before use) 
Dissolve 196 mg of ammonium iron(II) sulfate hexahydrate, Fe(NH4)2(SO4)2·6 H2O 
(Sigma-Aldrich, Catalog # 203505-25G; MW 392.14 g/mol) in 2 mL of 500 mM 
EDTA disodium stock.  
15. DMEM (high glucose, L-glutamine, phenol red, no pyruvate) (Gibco 11965-084) 
16. 30 % wt/vol H2O2 Solution (Fisher Scientific, Catalog # H325-500) 
PROCEDURE 
1. Aliquot 100 mL of Incomplete Permeabilization Solution and allow to equilibrate to 
room temperature. 
2. Aliquot 100 mL DMEM Media and allow to equilibrate to room temperature. Bring 30 
% H2O2 to cell culture lab. 
3. Aspirate the media from sub-confluent culture. 
4. Add 5 mL of 0.02 % EDTA / PBS, wait 60 s (shake dish to aid in the Versene treatment). 
After incubation, use a wide-bore tip to spray the plate vigorously with the 0.02 % EDTA 
/ PBS solution. Aspirate solution and wash cells three times with 10 mL of 1X PBS.  
5. During the Versene treatment incubation period, prepare 0.05 % Lysolecithin 
Permeabilization Solution by dissolving lysolecithin (0.5 mg/mL; 50 mg for 100 mL) in 
Incomplete Permeabilization solution. Also, prepare 50X Fe(II)-EDTA Stock and 
weigh sodium ascorbate. Set aside for Step 9. 
6. Add 10 mL of 0.05 % Lysolecithin Permeabilization Solution to each cell culture dish 
and incubate for 60 seconds at room temperature. 
7. Aspirate the permeabilization solution. 
8. Add 991 mg of (+)-Sodium L-ascorbate (Sigma-Aldrich, Catalog # 11140-50G; MW 
198.11 g/mol) to 100 mL of DMEM Media and mix well. Add 2 mL of 50X Fe(II)-
EDTA Stock followed by 2 mL of 30 % H2O2. Immediately mix for 5 seconds by 
vortexing. 
9. Add 10 mL of the solution prepare in Step 9 onto each cell culture plate. Gently swirl the 
plates and incubate at room temperature for 15 minutes. Check each plate under 
microscope for cell detachment.  
10. Aspirate the footprinting solution from the dishes and wash cells twice with 10 mL of 
Stop Buffer. 
11. Wash cells with 1X PBS. 
12. Add 3 mL of 0.05 % trypsin/EDTA and incubate for approximately 5 min in an incubator 
at 37 °C with a 5 % CO2 atmosphere (NuAire NU-4750 US AutoFlow CO2 Water-
Jacketed) (longer incubation times might be necessary, check dish/flask under 
microscope). 
13. After most of the W12E keratinocytes have been detached, add DMEM Media to a final 
volume of 5 mL and transfer cell suspension to a 15 mL disposable centrifuge tube. 
14. Pellet W12E cells using an Eppendorf Centrifuge 5702 at 500 rcf (relative centrifugal 
force) for 5 min. 
15. Aspirate the media being careful not to disturb the cell pellet. 
16. Place tubes in ice and perform modified Hirt DNA extraction as soon as possible. 
 
Reference: Cannistraro, V.J.; Pondugula, S.; Song, Q.; Taylor, J.-S. Rapid Deamination of 
Cyclobutane Pyrimidine Dimer Photoproducts at TCG Sites in a Translationally and Rotationally 
Positioned Nucleosome in Vivo. Journal of Biological Chemistry 209, 26597-26609 (2015) 
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5.7.6 Modified Hirt Extraction of HPV Episomes from W12E (HPV16-harboring) 
Keratinocytes 
 
Materials 
1. W12E keratinocytes (106-107 cells). 
2. MilliQ H2O (18.2 MΩ·cm at 25°C). 
3. Cell wash buffer – Ca2+ / Mg2+-free Phosphate-buffered saline (PBS). 
4. Resuspension buffer (Buffer P1) – 50 mM Tris-HCl, pH 8.0, 10 mM EDTA, 100 
µg/mL RNase A. 
5. Lysis solution – 1.2 % sodium dodecyl sulfate (SDS); 10 mM EDTA. 
Dissolve 1.2 g SDS (MW = 288.37 g/mol) in 80 mL MilliQ H2O. Add 2 mL of 0.5 M 
EDTA. Add MilliQ H2O to a total volume of 100 mL. 
6. Precipitation solution – 3M cesium chloride, 1 M potassium acetate, 0.67 M acetic acid. 
Dissolve 25.25 g CsCl (MW = 168.36 g/mol), 4.91 g potassium acetate (98.14 
g/mol) and 1.93 mL glacial acetic acid (17.4 M) in 40 mL MilliQ H2O. Add MilliQ 
H2O to a total volume of 50 mL. 
7. Ice bath. 
8. Centrifuge (14,000x g). 
9. QIAprep Miniprep Kit with 2.0 Spin Columns (up to 20 μg episomal DNA). 
10. Column wash buffer – 80 mM potassium acetate, 10 mM Tris-HCl, pH 7.5, 40 µM 
EDTA, 60 % ethanol. 
Dissolve 3.93 g potassium acetate (98.14 g/mol), 5 mL 1M Tris (pH 7.5), 40 μL 0.5 
M EDTA in 100 mL MilliQ H2O. Add 300 mL 100 % ethanol and MilliQ H2O to a 
total volume 500 mL.  
11. Elution buffer – EB Buffer (10 mM Tris-HCl, pH 8.5) or Low EDTA TE. 
 
Procedure 
1. Centrifuge cells (106-107) at 500x g, 10 min and wash pellet with cold cell wash buffer. 
2. Resuspend cells in 250 µL of resuspension buffer (Buffer P1). 
3. Lyse cells with 250 µL of lysis solution. 
4. Gently mix the solution by inverting the microcentrifuge tube (do not vortex). Allow 
solution to incubate for 5 min at room temperature. 
5. Add 350 µL of precipitation solution to precipitate denatured proteins and chromosomal 
DNA. 
6. Immediately mix solution by inverting the tube (do not vortex). Place tube into an ice 
bath for 15 min. 
7. Centrifuge at 16,000x g at 4 °C for 30 min. 
8. Carefully transfer the supernatant to a QIAprep Spin Column. 
9. Centrifuge for 60 s at 14,000x g and discard the flow-through. 
10. Wash the column by adding 750 µL of column wash buffer.  
11. Centrifuge for 60 s at 14,000x g and discard the flow-through. 
12. Centrifuge the column an additional minute at 14,000x g to remove the residual column 
wash buffer.  
13. Place the inner column into a clean 1.5 mL Eppendorf microcentrifuge tube and elute the 
DNA by adding 50 µL of elution buffer onto the center of the column.   
14. Allow the column to stand for 60 s and centrifuge at 14,000x g for 60 s.   
Reference: Arad, U. Modified Hirt Procedure for Rapid Purification of Extrachromosomal DNA 
from Mammalian Cells. BioTechniques 24, 760-762 (1998).  
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5.7.7 Crosslinking of Small Molecules to Isolate Chromatin (COSMIC) 
 
Materials 
1. W12E keratinocytes (~2.5 x 107 cells) (70 % confluent) in cell culture dish/flask with 
mitomycin C-treated 3T3 fibroblasts. 
2. NuAire NU-4750 US AutoFlow CO2 Water-Jacketed 
3. Polyamide-psoralen/biotin (PB)  
4. E Media (complete) and E Media (incomplete) 
5. 1X Phosphate Buffer Saline (PBS) (HyClone, Catalog # SH30256.02) 
6. CalSun Facial Tanning Sun Lamp / Face Tanner 110V (CalSun, Catalog # 
B001BH0A1A) 
7. Glass filter (23 cm x 40 cm x 3 mm) 
8. 0.05 % trypsin / 0.53 mM EDTA solution (ThermoFisher, Catalog # 25300-062) 
9. 0.02 % EDTA / PBS (Store at room temperature) 
Combine 1.325 mL of 100 mM EDTA disodium solution with 248.675 mL 
autoclaved MilliQ H2O. Filter-sterilize using a 0.22 μm MILLEX-GP filter. 
10. Thermo Scientific Sorvall ST16R centrifuge 
11. Benchtop shaker/rotator (Barnstead/Thermolyne Labquake shaker/rotator 400110) 
12. Streptavidin-coated magnetic beads (Dynabeads® MyOneTM Streptavidin C1, Catalog 
# 65001) 
13. QIAquick PCR purification kit (QIAGEN, Catalog # 28104) 
14. 1 M Tris-HCl (pH 8.1) (Store at 4 °C) 
Dissolve 121.14 g of Tris (Trizma base; Sigma-Aldrich, Catalog # T1503-1KG; 
MW = 121.14 g/ mol) in 800 mL of autoclave MilliQ H2O. Adjust pH to 8.1 using 
concentrated HCl. Adjust total volume to 1000 mL with autoclaved MilliQ H2O. 
Filter-sterilize using a 0.2 μm aPES membrane Nalgene filter unit. 
15. 5 M NaCl (Store at 4 °C) 
Dissolve 29.22 g NaCl (Fisher Bioreagents, Catalog # BP358-1; MW = 58.44 
g/mol) in 90 mL autoclaved MilliQ H2O. Add autoclaved MilliQ H2O to a total 
volume of 100 mL. 
16. 500 mM EDTA disodium (Store at 4 °C) 
Dissolve 7.44 g of ethylenediaminetetraacetic acid disodium salt dehydrate, EDTA 
disodium salt dehydrate (Sigma-Aldrich, Catalog # E5134-100G; MW 372.24 
g/mol) in 20 mL of autoclaved MilliQ H2O. Adjust pH to 8.0 using 1M NaOH. 
Adjust total volume to 40 mL with autoclaved MilliQ H2O. Filter-sterilize using a 
0.22 μm MILLEX-GP filter. 
17. 10 % Sodium dodecyl sulfate (SDS) (Store at room temperature) 
Dissolve 5 g SDS powder (Sigma-Aldrich, Catalog # L4509-100G; MW = 288.37 
g/mol) in 40 mL autoclaved MilliQ H2O. Add autoclaved MilliQ H2O to a total 
volume of 50 mL. 
18. 10 % Triton X-100 (Store at room temperature) 
Dissolve 5 mL Triton X-100 (Sigma-Aldrich, Catalog # X100-100ML) in 40 mL 
autoclaved MilliQ H2O. Add autoclaved MilliQ H2O to a total volume of 50 mL. 
19. COSMIC buffer (20 mM Tris-HCl [pH 8.1], 2 mM EDTA, 150 mM NaCl, 1 % Triton-
X100, 0.1 % SDS) (Store at 4 °C) 
Combine 1 mL of 1 M Tris-HCl (pH 8.1), 0.2 mL of 500 mM EDTA, 1.5 mL of 5 M 
NaCl, 5 mL of 10 % Triton X-100 (Sigma-Aldrich, Catalog # X100-100ML), 0.5 
mL of 10 % SDS and 41.8 mL of autoclaved MilliQ H2O. Filter-sterilize using a 
0.22 μm MILLEX-GP filter. 
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20. 100 mM Phenylmethylsulfonyl fluoride (PMSF) (Store at -20 °C) 
Dissolve 17.5 mg of PMSF powder (G-Biosciences, Catalog # 786-055; MW = 
174.19 g/mol) in 1 mL of anhydrous ethanol 200 proof (Decon Labs, Inc. Catalog # 
DSP-MD.43) 
21. 100 mM Benzamidine HCl (prepare fresh each time) 
Dissolve 15.7 mg of benzamidine HCl (Fisher BioReagents, Catalog # BP435-25; 
MW = 156.61 g/mol) in 1 mL of autoclaved MilliQ H2O. 
22. 150 μM Pepstatin A (Store at -20 °C) 
Dissolve 0.1543 mg of pepstatin A (Alfa Aesar, Catalog # J60237-LB0; MW = 
685.90 g/mol) in 1.5 mL of sterile DMSO. Hydrolysis leads to a more yellow 
solution. 
23. Wash Buffer 1 (10 mM Tris-HCl [pH 8.0], 1 mM EDTA, 3 % v/v SDS) (Store at 4 °C) 
Add 100 μL of 1 M Tris-HCl buffer pH 8.0 (Invitrogen UltraPure, Catalog # 15-
568-025), 20 μL of 500 mM EDTA disodium, 3 mL of 10 % SDS and 6.88 μL of 
autoclaved MilliQ H2O. Filter-sterilize using a 0.22 μm MILLEX-GP filter. 
24. Wash Buffer 2 (10 mM Tris-HCl [pH 8.0], 1 mM EDTA, 250 mM LiCl, 0.5 % NP40, 1 
% sodium deoxycholate) (Store at 4 °C) 
Add 100 μL of 1 M Tris-HCl buffer pH 8.0 (Invitrogen UltraPure, Catalog # 15-
568-025), 20 μL of 500 mM EDTA disodium, 105.95 mg of LiCl powder (Acros 
Organics, Catalog # 199880050; MW = 42.38 g/mol), 50 μL of NP40 (MP 
Biomedicals IGEPAL CA-630, Catalog # 198596) and 100 mg of deoxycholate acid 
sodium salt (Sigma-Aldrich, Catalog # D6750-10G, MW = 414.55 g/mol). Add 
autoclaved MilliQ H2O to a total volume of 10 mL and filter-sterilize using a 0.22 
μm MILLEX-GP filter. 
25. Wash Buffer 3 (10 mM Tris-HCl [pH 7.5], 1 mM EDTA, 4 M urea, 0.1 % NP40) 
(prepare fresh each time) 
Add 100 μL of 1 M Tris-HCl buffer pH 7.5 (Invitrogen, Catalog # 15567-027), 20 
μL of 500 mM EDTA disodium, 2.4024 g of urea crystals (Sigma-Aldrich U5128-
100G, MW = 60.06 g/mol) and 10 μL of NP40 (MP Biomedicals IGEPAL CA-630, 
Catalog # 198596). Add autoclaved MilliQ H2O to a total volume of 10 mL and 
filter-sterilize using a 0.22 μm MILLEX-GP filter. 
26. Tris EDTA (TE) Buffer (10 mM Tris-HCl buffer [pH 8.0], 1 mM EDTA) (Store at room 
temperature) 
Add 500 μL of 1 M Tris-HCl buffer pH 8.0 (Invitrogen UltraPure 15-568-025) and 
100 μL of 500 mM EDTA disodium. Add autoclaved MilliQ H2O to a total volume 
of 50 mL and filter-sterilize using a 0.22 μm MILLEX-GP filter. 
27. 10X Crosslink Reversal Buffer (100 mM Tris-HCl [pH 8.0], 4 mM EDTA, 1M KOH) 
(Store at RT) 
Add 1.5 mL of 1 M Tris-HCl buffer pH 8.0 (Invitrogen UltraPure 15-568-025), 120 
μL of 500 mM EDTA disodium and 0.84 g of KOH powder (Asfa Aesar A16199-
0E, MW = 56.11 g/mol). Add autoclaved MilliQ H2O to a total volume of 15 mL 
and filter-sterilize using a 0.22 μm MILLEX-GP filter. 
28. 6N HCl (Store at room temperature) 
Dilute 5 mL of concentrated HCl (Fisher Scientific A144C-212) with 5 mL of 
autoclaved MilliQ H2O. filter-sterilize using a 0.22 μm MILLEX-GP filter. 
29. pH indicator paper (Whatman Type CF 2613991) 
30. RNase A (Thermo Scientific EN0531, 10 mg/mL) (Store at -20 °C) 
31. Proteinase K (Thermo Scientific FEREO0491, 20 mg/mL) (Store at -20 °C) 
32. Water, nuclease-free (ThermoFisher Scientific R0581) 
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Procedure 
I. Crosslinking in Live Cells 
1. Cell culture media and PBS are always added to the side of culture dishes to prevent 
disrupting the attached cells. 
2. Start with ~2.5 x 107 W12E keratinocytes (this corresponds to approximately ten 10-cm 
culture dishes). 
3. Grow W12E keratinocytes in E Media (complete) on 10-cm culture dishes in an 
incubator at 37 °C with a 5 % CO2 atmosphere (NuAire NU-4750 US AutoFlow CO2 
Water-Jacketed). 
4. From this step forward, care must be taken to keep light exposure to a minimum in order 
to avoid premature photo-crosslinking. 
5. Prepare at least 80 μL of 100 μM polyamide-psoralen/biotin (PB) conjugate in sterile 
DMSO (each 10-cm culture dish requires 8 μL). Determine PA-PB concentration using 
an UV-Vis spectrophotometer. 
6. Aspirate the spent E Media (complete) from the sub-confluent culture and add 8 mL of 
fresh E Media (complete). 
7. Add 8 μL of 100 μM polyamide-PB conjugate (100 nM final concentration in culture 
media) directly to the culture media of each 10-cm culture dish. Gently swirl the dish to 
evenly disperse the polyamide-PB conjugate into the media. 
8. Incubate W12E keratinocytes for 24 hours in an incubator at 37 °C with a 5 % CO2 
atmosphere (NuAire NU-4750 US AutoFlow CO2 Water-Jacketed). Ensure to protect 
dishes from light. 
9. Aspirate media and wash cells with 4 mL of 1X PBS. 
10. Aspirate PBS and add 3 mL of E Media (incomplete). 
11. Dim the lights and remove the lid of five dishes. Set the dishes containing W12E 
keratinocytes on a flat surface and place a Glass filter (23 cm x 40 cm x 3 mm) over the 
five culture dishes to filter out UV-light with λ < 300 nm. Set the UV source (CalSun 
Facial Tanning Sun Lamp / Face Tanner 110V) on top of Glass filter and crosslink cells 
for 30 minutes with 365 nm UV irradiation (2.4 mW/cm2). Repeat for remaining dishes. 
Proceed with protocol while crosslinking is performed for the second set of dishes.  
12. Aspirate media and wash cells with 4 mL of 1X PBS.  
13. Add 3 mL of 0.02 % EDTA / PBS and incubate for 1 min. After incubation, use a wide-
bore tip to spray the plate vigorously with the 0.02 % EDTA / PBS solution. Aspirate 
solution and wash cells with 4 mL of 1X PBS.  
14. Aspirate 1X PBS and add 3 mL of 0.05 % trypsin / 0.53 mM EDTA solution per 10-cm 
dish. Incubate for 5 min in an incubator at 37 °C with a 5 % CO2 atmosphere (NuAire 
NU-4750 US AutoFlow CO2 Water-Jacketed). 
15. Quench trypsin by adding 3 mL of E Media (incomplete) per dish and transfer cell 
suspension to one 50 mL disposable conical tube. Place W12E keratinocytes on ice from 
this step forward. 
16. Pellet W12E keratinocytes using a Thermo Scientific Sorvall ST16R centrifuge at 500 
rcf (relative centrifugal force), 4 °C for 5 minutes. Aspirate supernatant.  
17. Wash pellet with 3 mL cold 1X PBS and centrifuge at 500 rcf, 4 °C for 5 minutes. 
Aspirate supernatant.  
 
Protocol can be stopped at this point.  Flash-freeze W12E keratinocytes in 
liquid nitrogen and store samples at -80 °C until ready to continue.   
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II. Isolation of Chromatin 
1. Add 1.2 mL COSMIC buffer and resuspend cells by pipetting up and down several 
times. 
2. To this suspension, add 13.3 μL each of fresh 100 mM PMSF, 100 mM benzamidine and 
150 μM pepstatin protease inhibitors to a final concentration of 1 mM PMSF, 1 mM 
benzamidine and 1.5 μM pepstatin. 
3. Split cell lysate solution into two amber microcentrifuge tubes. 
4. Sonicate cell lysate solutions with sonicator (QSonica Q800R) for 2 hours (10 seconds 
on, 10 seconds off, 50 % power) at 4 °C to fragment host and viral genomes to a range of 
100-500 bp. Ensure level of water in reservoir is parallel to the level of chromatin 
solution.  
5. Place samples in ice. 
6. Centrifuge the samples at 12,000x g, 4 °C for 10 minutes.  
7. Carefully transfer supernatant containing soluble chromatin into a new amber 
microcentrifuge tube. Discard the pellet. 
8. Save 10 % of sample in a new microcentrifuge tube and label it as Input DNA. Store at -
80 °C. 
9. Place the remaining chromatin sample in ice for the next steps of protocol. 
 
Protocol can be stopped at this point.  Store samples at -80 °C until ready to 
continue.   
 
III. Capture of Ligand-DNA Crosslinks 
1. Resuspend the streptavidin-coated magnetic beads (Dynabeads® MyOneTM 
Streptavidin C1 65001) by vortexing for >30 seconds. 
2. Transfer 120 μL of streptavidin-coated magnetic beads in an amber microcentrifuge tube. 
3. Add 1 mL of COSMIC buffer and mix for 5 minutes at room temperature on a 
shaker/rotator (Barnstead/Thermolyne Labquake shaker/rotator 400110). 
4. Place the sample of streptavidin-coated magnetic beads on a magnetic stand until the 
beads settle and a clear solution is observed (~ 2 minutes). 
5. Carefully remove and discard the clear supernatant. 
6. Immediately, add chromatin sample (~1 mL) to streptavidin-coated magnetic beads (120 
μL) and resuspend the beads by pipetting up and down several times. 
7. Incubate the sample suspension for at least 4 hours (or overnight) at 4 °C on a 
shaker/rotator.  
 
IV. Isolation of Affinity-purified DNA 
1. Prepare Wash Buffers 1-3. Wash Buffers 1 and 2 can be stored at 4 °C for several months. 
Wash Buffer 3 must be prepared fresh each day. 
2. Add non-functionalized polyamide to Wash Buffers 1-3 to a final concentration 5 μM. 
 
Add 4.75 μL of 10 mM non-functionalized polyamide in sterile DMSO to 9.50 mL of 
Wash Buffer 1.    
Add 2.13 μL of 10 mM non-functionalized polyamide in sterile DMSO to 4.25 mL of 
Wash Buffer 2.  
Add 2.25 μL of 10 mM non-functionalized polyamide in sterile DMSO to 4.50 mL of 
Wash Buffer 1. 
 
3. At the end of the incubation period, place the sample suspension on a magnetic stand 
until the beads settle and a clear solution is observed (~ 2 minutes). Carefully remove and 
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discard the clear supernatant. Do not disturb the bead pellet, as the DNA—PA-PB is 
associated with the beads. 
4. Add 1 mL of COSMIC buffer and mix for 12 hours at 4 °C on a shaker/rotator. Repeat 
wash and incubate for 4 hours. 
5. Add 1 mL of Wash Buffer 1 to the sample and resuspend the streptavidin-coated 
magnetic beads. Incubate the sample suspension for 7 minutes at room temperature on a 
shaker/rotator. Place the sample suspension on a magnetic stand until the beads settle and 
a clear solution is observed (~ 2 minutes). Carefully remove and discard the clear 
supernatant. 
6. Add 1 mL of Wash Buffer 2 to the sample and resuspend the streptavidin-coated 
magnetic beads. Incubate the sample suspension for 7 minutes at room temperature on a 
shaker/rotator. Place the sample suspension on a magnetic stand until the beads settle and 
a clear solution is observed (~ 2 minutes). Carefully remove and discard the clear 
supernatant. 
7. Add 1 mL of Wash Buffer 3 to the sample and resuspend the streptavidin-coated 
magnetic beads. Incubate the sample suspension for 7 minutes at 50 °C on a 
shaker/rotator. Place the sample suspension on a magnetic stand until the beads settle and 
a clear solution is observed (~ 2 minutes). Carefully remove and discard the clear 
supernatant. 
8. Repeat step 7. 
9. Add 1 mL of TE Buffer to the sample and resuspend the streptavidin-coated magnetic 
beads. Place the sample suspension on a magnetic stand until the beads settle and a clear 
solution is observed (~ 2 minutes). Carefully remove and discard the clear supernatant. 
10. Repeat step 9. 
11. Resuspend the streptavidin-coated magnetic beads in 200 μL of TE Buffer. This sample 
of capture DNA is referred to as Affinity-purified DNA. 
12. Reverse the psoralen-DNA crosslinks by adding 10X Crosslink Reversal Buffer to 
Input DNA and Affinity-purified DNA aliquots to a final concentration of 1X. Incubate 
samples for 30 minutes at 90 °C. 
13. For the Affinity-purified DNA, place the sample suspension on a magnetic stand until the 
beads settle and a clear solution is observed (~ 2 minutes). Transfer the entire eluate 
supernatant to a clean amber microcentrifuge tube, ensuring not to pipette any magnetic 
beads. 
14. Neutralize the Input and Affinity-purified DNA samples to pH 7 by adding ~1 μL 6 N 
HCl per 100 μL sample. Confirm samples have been neutralized by adding a drop (~0.5 
μL) onto pH indicator paper. 
15. Add RNase A (Thermo Scientific EN0531, 10 mg/mL) to the Input DNA and Affinity-
purified DNA (0.2 μg/μL final RNase A concentration). Incubate for 1 hour at 37 °C. 
16. Add Proteinase K (Thermo Scientific FEREO0491, 20 mg/mL) to the Input DNA and 
Affinity-purified DNA (0.2 μg/μL final Proteinase K concentration). Incubate for 1 hour 
at 55 °C. 
17. Purify each DNA sample with a QIAquick PCR purification kit (QIAGEN 28104). 
Elute DNA in 58 μL of Water, nuclease-free (ThermoFisher Scientific R0581). Store 
Input and Affinity-purified DNA samples at -20 or -80 °C. 
18. Analyze samples by Next-generation sequencing. 
 
 
Reference: Erwin, G.S.; Grieshop, M.P.; Bhimsaria, D.; Eguchi, A.; Rodríguez-Martinez, J.A.; 
Ansari, A.Z. Genome-wide Mapping of Drug-DNA Interactions in Cells with COSMIC 
(Crosslinking of Small Molecules to Isolate Chromatin). Journal of Visualized Experiments 107, 
e53510 (2016) 
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5.7.8 Right Side Size Selection with SPRI of NGS Libraries 
 
Purpose: To remove DNA fragments > 800 bp in prepared Illumina NGS libraries. 
 
1. Homogenize the SPRIselect beads by gently vortexing the solution. 
2. Transfer each Sample volume to a clean 1.5 mL Eppendorf microcentrifuge vial and 
dilute to a final volume of 50 μL with Low TE buffer. Add the appropriate SPRI volume 
to each sample. 
Sample volume * 0.6 (ratio) = SPRI volume 
3. Homogenize the sample by vortexing or pipetting 10 times.  Briefly spin down the 
samples to collect droplets (no bead-sample droplets on the sides of the tube). 
4. Incubate the sample suspensions for 1 min at room temperature. 
5. Place the sample suspension on a magnetic stand until the beads settle and a clear 
solution is observed (~ 2 minutes). 
6. Carefully remove and transfer the clear supernatant to a clean vial. Do not disturb the 
bead pellet, as the large DNA fragments are associated with the beads. 
7. Add the appropriate SPRI volume to each transferred supernatant sample. 
Sample (initial) volume * (1.8x – 0.6) = SPRI volume 
8. Homogenize the sample by vortexing or pipetting 10 times.  Briefly spin down the 
samples to collect droplets (no bead-sample droplets on the sides of the tube). 
9. Incubate the sample suspensions for 1 min at room temperature. 
10. Place the sample suspension on a magnetic stand until the beads settle and a clear 
solution is observed (~ 2 minutes). 
11. Carefully remove and discard the clear supernatant. Do not disturb the bead pellet, as the 
DNA is associated with the beads. 
12. While on the magnet stand, add 180 μL of the freshly prepared 85 % ethanol solution to 
the vial without disturbing the bead pellet.  Incubate for 30 s, and carefully remove and 
discard the ethanol solution. Do not disturb the bead pellet, as the DNA is associated with 
the beads. 
13. Briefly spin down the sample.  Place back on the magnetic stand and remove any residual 
ethanol from the bottom of the vial. 
14. Air-dry the bead pellet. 
15. Resuspend the pellet by adding Elution volume (20 μL) of Low EDTA TE.  Homogenize 
the suspension by pipetting up and down.  Briefly spin down the samples to collect 
droplets (no bead-sample droplets on the sides of the tube). 
16. Incubate suspension for 1 minute and place the tube on the magnetic stand. 
17. Transfer the entire eluate supernatant to a clean 0.2 mL PCR vial, ensuring not to pipette 
any magnetic beads.  If magnetic beads are present in the eluate, transfer eluate to a new 
0.2 mL PCR vial, place on magnetic stand and collect eluate again 
 
